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SUMMARY 
Ten overlapping fragments covering the entire Clostridium difficile toxin A gene were 
cloned and expressed in Escherichia coli. Eight fragments (a', a2, b, c, d, e, f and g) 
represented the first 5.55kb of the gene whereas two fragments (hl and h2) each spanned 
the entire C-terminal repeat region of the molecule. 
All activities relating to binding to carbohydrates (i. e. cold haemagglutination of rabbit 
erythrocytes), binding to bovine thyroglobulin and non-specific binding to a murine 
monoclonal antibody were restricted solely to peptides H1 (amino acids [aa] 1834-2683) 
and H2 (aa 1832-2683). Peptide H2 alone also displayed the ability to bind to cells and to 
be internalised into endosome-like compartments within the cells. Taken together with 
the observation that peptide H2 caused a cytopathic effect on Vero cells which was 
atypical of the holotoxin, these results may indicate that the repeat region of toxin A 
stimulates intracellular signalling pathways prior to Rho glucosylation. 
Peptide A2 (aa 1-536) glucosylated recombinant RhoA (rRhoA) in vitro, whereas 
peptides A'(aa 1-205), B (aa 542-859), C (aa 114-859), D (aa 869-1330), E (aa 542- 
1161), G (aa 869-1830) and H2 (aa 1832-2683) did not. The results obtained for peptides 
A', A2 and C indicate that the first 536 as encompass the catalytic domain for this 
activity, that more than the first 205 as alone are needed for expression of enzymic 
activity, and that for a peptide to be active it must not lack the first 113 aa. The first 113 
as of the holotoxin are probably essential for the correct folding of the catalytic domain 
and expression of its activity. 
These studies were also the first to locate the toxin A ATP binding site to a peptide 
spanning as 542-859 (peptide B) of the holotoxin. Antibody reaction profiles of 
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antiserum to holotoxin A against toxin A peptides and of antiserum to the peptides 
against holotoxin A indicate that this region is unexposed in the native state. Also of 
interest was the observation that the only peptides, which contained the nucleotide- 
binding site (B and E), lacked the ability to glucosylate rRhoA. Further peptide A2, 
which possessed glucosyltransferase activity, lacked the nucleotide-binding site. These 
studies therefore, suggest that a nucleotide-binding site is not required for in vitro 
glucosylation of rRhoA by toxin A, and fail to identify a role for the toxin A nucleotide 
binding site. 
An engineered truncated form of toxin A, consisting of the first 539 as of the holotoxin 
(encompassing glucosyltransferase activity) fused to the 852 as C-terminal peptide H2 
(repeat end binding portion) caused a conventional cytopathic effect (CPE), but was 
1,400 fold less cytotoxic to Vero cells than the holotoxin. Peptide A2 (aa 1-536) alone 
had no effect on Vero cells or in rabbit ileal loops suggesting that peptide H2 aided 
delivery of the glucosyltransferase molecule into cells leading to a CPE. The truncated 
toxin lacked the nucleotide binding site and the putative membrane-translocating domain 
(internal hydrophobic region). The reduced activity of the truncated toxin suggests that 
although not essential for cytotoxic activity, the nucleotide-binding site and the internal 
hydrophobic region are important for stability and/or efficient translocation of the 
holotoxin into the cytosol. 
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SECTION-1 
INTRODUCTION 
1.1 Pathogenicity 
Pathogenicity is the ability to cause disease while a pathogen is any microorganism with 
that ability. Over 250 bacterial genera are listed in Bergey's Manual of Determinative 
Bacteriology with only about 10% included as pathogenic species of man or animals. 
Within a bacterial genus not every species is pathogenic and not every strain of each 
pathogen is virulent. The percentage of the total microbial biomass capable of causing 
disease is, therefore, very small (Stephen and Pietrowski, 1986). 
To cause a disease a bacterium must be able to attach to and infect broken skin or mucous 
surfaces before entry into uninfected sites. The organism must be able to proliferate in the 
host environment then invade and damage the host (Sperling P. F. 1983). The ability to 
damage the host distinguishes an organism from being pathogenic as opposed to 
infective. Bacteria adopt two main mechanisms for damaging a host. Firstly, they 
stimulate self-damaging activities, which lead to hypersensitivity or immunopathological 
damage in the host. Secondly, some organisms possess the ability to produce toxic 
substances, which interact directly with specific host cells. 
1.2 Toxins 
A toxin is a protein or conjugated protein produced by some higher plants, animal, fungi 
and pathogenic bacteria, that is highly poisonous to other living organisms. Robert Koch, 
who first described Vibrio cholerae as the causative agent of cholera, suggested that 
cholera was a toxin-mediated disease (Koch R. 1884, cited from van Heyningen W. E. 
1970). Later, it was recognised that toxins were also responsible for death from 
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diphtheria (Roux and Yersin, 1888), tetanus (von Behring and Kitasoto, 1890) and 
botulism (van Erniengen, 1896) (all cited from Smith H. 1995). 
Toxins can be simply divided into two main types, endotoxins and exotoxins. Endotoxins 
are found in the outer membrane of gram-negative bacteria and are released when cell 
integrity is disrupted. The endotoxins are antigen complexes of protein, polysaccharide 
and lipid. It is believed that the protein determines the antigenicity of the toxin, the 
polysaccharide the immunological specificity and the lipid possibly the toxicity. The 
endotoxins do not appear to be neutralised by toxin antiserum because antibodies are 
directed against the non-toxic protein and polysaccharide regions. 
Exotoxins are released by bacterial cells into the body tissues enabling bacteria to 
produce disease without extensive spread or multiplication. Organs and tissue, therefore, 
can be affected at a distance from the site of infection. Exotoxins are protein toxins and 
are therefore antigenic. They can be neutralised by toxin antiserum and are considerably 
more toxic than endotoxins. Some exotoxins exhibit specificity for particular tissues or 
cell types. For example, neurotoxins (e. g. tetanus toxin) affect cells of the central nervous 
system while enterotoxins (e. g. Cholera toxin) affect cells of the intestinal mucosa often 
producing severe diarrhoea. Cholera toxin is a cytotonic enterotoxin because it induces a 
net fluid secretion by interfering with biochemical regulatory mechanisms without 
causing histological damage. A cytotoxic enterotoxin, however, induces actual damage to 
intestinal cells as a necessary prelude to fluid secretion (Stephen and Pietrowski, 1986). 
Of particular interest in this thesis are Clostridium species which contain one of the most 
potent collections of toxigenic bacteria in existence. 
32 
1.3 Clostridia 
Clostridia are widely distributed in nature, present in soil and the intestinal tract of 
humans and animals. The bacteria are gram-positive, spore forming anaerobic bacilli. The 
clostridial genus includes organisms that produce organic solvents such as acetone and 
butanol (e. g. Clostridium acetobutylicum). Some convert nitrogen to ammonia by 
nitrogen fixation (e. g. Clostridium pasteurianum) while others are medically important 
because they are pathogenic to humans and animals. The pathogenic species produce a 
variety of soluble toxins, some of which are extremely potent. Of more than 85 species of 
clostridia described in Bergey's Manual of Determinative Bacteriology, at least 20 
produce toxins (Lyerly and Allen, 1997). 
The important human clostridial diseases include gas gangrene (C. perfringens, C. novyi, 
C. septicum, C. sordellii and C. histolyticum), tetanus (C. tetani), botulism (C. 
botulinum), pseudomembranous colitis and antibiotic-associated diarrhoea (C. docile), 
C. perfringens type A-induced food poisoning and C. perfringens type C necrotising 
jejunitis (pig-bel). The C. botulinum and C. tetani neurotoxins are zinc proteases 
(Schiavo et al, 1992a, b, c) and are amongst the most lethal toxins with less than l OOng of 
either being sufficient to kill an adult (Stephen and Pietrowski, 1986). 
In the last twenty years C. docile has been identified as the cause of pseudomembranous 
colitis (PMC) and antibiotic-associated diarrhoea (George RH et al, 1978, Larson et al 
1978). C. docile is also the most identifiable bacterial cause of nosocomial diarrhoea 
and is second only to C. perfringens as the most common identifiable anaerobe to cause 
diarrhoea (Borriello, 1995). 
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1.4 Classes of clostridial toxins 
There are currently three characterised classes of clostridial toxins. The first is 
represented by the clostridial neurotoxins (tetanus and botulinum). These toxins are 
single polypeptide chains, which are cleaved by an intrinsic protease to produce a heavy 
and light chain fragment held together by a disulphide bond. Once in the circulation the 
carboxyl terminal part of the heavy chain fragment binds to the neuronal cells enabling 
the toxin to be internalised into acidic compartments by receptor mediated endocytosis 
(RME). The amino terminal 50kDa domain of the heavy chain is then believed to 
translocate the membrane releasing the catalytic light chain fragment into the cytoplasm 
where it has its effect. The neurotoxins act to inhibit neurotransmitter release (Schiavo 
and Montecucco, 1997). 
The second, relatively small group of clostridial toxins, is called the `Binary Toxins'. 
Examples include the iota toxins of C. perfringens and C. spiroforme and the C. 
botulinum toxin C2. Binary toxins are composed of two separate and independent protein 
components, which possess little or no toxicity alone but in combination can cause 
serious, even fatal effects. The binding component (heavy chain) facilitates uptake of the 
enzymatic portion (light chain) into the cell. The light chain is an ADP-ribosyltransferase 
and transfers an ADP-ribosyl group from NAD onto monomeric actin. The modified 
actin inhibits polymerisation of actin filaments at the barbed end leading to rounding up 
of cultured mammalian cells. Clostridial binary toxins can also induce fluid accumulation 
in ligated intestinal loops (Lyerly and Allen, 1997). 
The third class is the ` large clostridial cytotoxins'. This group contains cytotoxins of high 
molecular weight (Mr> 200,000) with an AB"-type of molecular architecture (" indicating 
that the molecules are multivalent with respect to receptor binding) which enter cells by 
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RME (von Eichel-Streiber et al, 1996). This group includes toxins A and B of C. difcile, 
alpha toxin of C. novyi plus the haemorrhagic (HT) and lethal (LT) toxins of C. sordellii. 
These single polypeptide toxins bind to cells and are internalised by RME. Following 
endosomal processing and possible activation, the toxins enter the cytoplasm where they 
have an effect on the cytoskeletal system resulting in cell rounding and eventual cell 
death (Lyerl y and Allen, 1997). The largest of the clostridial cytotoxins is C. docile 
toxin A. The remainder of this thesis will concentrate on C. dif cile, its toxins and the 
role they play in antibiotic associated PMC. 
1.5Cdjußle 
C. docile is an enterotoxigenic clostridial species which is an anaerobic opportunistic 
human gut pathogen. The organism is a gram-positive spore former but can stain gram 
variable in older stationary cultures. It produces two large protein toxins, A (enterotoxin) 
and B (cytotoxin) which are closely related to the HT and LT toxins of C. sordellii 
(Martinez and Wilkins, 1992). C. docile is the most common identifiable cause of 
nosocomial diarrhoea and is now established as the aetiological agent of PMC in humans 
(George et al 1978a, b, Larson et al, 1978). The spores shed by C. dif cile infected 
patients can persist in the environment for long periods of time and care has to be taken 
by health care workers to avoid transferring them to other patients. 
1.5.1 Historical background of C. diJcile and PMC 
One of the earliest descriptions of PMC related to a young woman who presented with 
pseudomembranous lesions of the intestinal tract and haemorrhagic diarrhoea following 
surgery (Finney, 1893). C. docile was first identified in the stools of healthy infants and 
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was originally called Bacillus dif lcilis due to the difficulty in isolating the organism 
(Hall and O'Toole, 1935). Early experiments on guinea pigs suggested that the organism 
was toxigenic (Hall and O'Toole, 1935, ýSnyder, 1937). Observations that C. difficile was 
often isolated from patients who presented with no unusual clinical features led 
investigators to initially believe that the C. dilcile toxin, lethal to animals, played no role 
in clinical disease in humans (Smith and King, 1962). The massive increase in the 
incidence of PMC in the 1950's was finally associated with antibiotic therapy (Reiner et 
al 1952, Hummel et al, 1964, Tedesco et al, 1974). At this time PMC was attributed to 
Staphylococcus aureus because the organism was commonly isolated from the stools of 
diseased experimental animals (Hummel et al, 1964). 
In 1969 came the first description of C. difficile causing intestinal disease in rats 
(Hammerstrom et al, 1969). From this time onwards work to establish the relationship 
between the lesion, the toxin and the organism evolved rapidly. In 1977 Larson and co- 
workers identified a cytopathic protein toxin in the stools of patients suffering from PMC. 
At the same time the observation that the cytotoxic factor present in the caecal contents 
of diseased animals could be neutralised by polyvalent gas gangrene anti-toxin (Bartlett 
et al, 1977) led to further work which implicated c. sordellii as the causative agent of 
PMC in animals (Rifkin et al, 1977). This hypothesis was soon disregarded as it became 
apparent that C. sordellii was not a component of the cecal microbiota of diseased 
hamsters. C. docile was soon identified as the dominant clostridial species in the caecal 
contents of diseased hamsters and was shown to produce a cytopathic toxin (Bartlett et al, 
1977,1978a) which was neutralised by C. sordellii anti-toxin (Bartlett et al, 1978b). 
Evidence that C. difcile was also the causative agent of PMC in humans, and that the 
organism was readily isolated from the faeces of diseased patients was soon to follow 
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(Bartlett et al, 1978c, George RH et al, 1978, George W. L et al, 1978, Larson et al, 
1978). 
Until 1980 it was believed that the cytotoxic factor was the only toxin produced by C. 
difficile (Taylor and Bartlett, 1979, Rolfe and Finegold, 1979). Shortly after, however, 
purification of this cytotoxin resulted in the detection of an additional cytotoxic activity 
(Humphrey et al, 1979, Banno et al, 1981, Taylor et al, 1981, Sullivan et al, 1982) 
suggesting that C. docile produces at least two distinct toxins. These were initially 
designated DI and D2 (Banno et al, 1981) but were renamed toxins A (enterotoxin) and 
B (cytotoxin) respectively due to their different elution patterns on anion exchange resins 
(Sullivan et al, 1982). 
1.5.2 C. dif cile gastrointestinal disease 
C. difficile organisms are present in the normal colonic flora of 2-5% of the general adult 
population. Thirty to 75% of healthy neonates are also colonised with toxigenic C. 
difficile but are asymptomatic. In an adult the normal bacterial flora in the gut serves as a 
major barrier against colonisation by pathogens. When the flora is disturbed the host 
becomes susceptible to colonisation or overgrowth of the pathogen. The prevalence of 
disease, therefore, is increased when a person is hospitalised or exposed to antibiotics. 
C. docile infection can range from mild diarrhoea to the life threatening condition PMC 
depending on several factors including the virulence of the infecting strain. In adults C 
difficile accounts for 15-20% of all cases of antibiotic associated diarrhoea (AAD), 50- 
70% of all cases of antibiotic associated colitis (AAC) and 90-100% of cases of PMC 
(Bartlett, 1990). Patients always present with profuse watery or bloody diarrhoea often 
containing mucus. AAD is defined as diarrhoea associated with recent antibiotic use with 
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no evidence of colitis. AAC is defined as diarrhoea associated with recent antibiotic use 
with evidence of non-specific inflammatory reaction but no pseudomembranes. The 
extreme disease PMC is characterised by the presence of cream to yellow/ green plaques 
on the colonic mucosa. These are 1-2 mm in diameter in the early stages but increase in 
size as the disease progresses. Upon closer examination the pseudomembrane consisting 
of sloughed epithelial cells, fibrin, mucus and polymorphonuclear leukocytes appears to 
be erupting from the surface of the colonic mucosa (Dodson and Borriello, 1996). The 
underlying mucosal surface often reveals well-defined lesions and ulcerations consisting 
of epithelial necrosis and a marked leukocyte infiltration of the lamina propria (Abrams 
et al, 1980, Totten et al, 1978). 
Antibiotics frequently associated with C. docile diarrhoea include clindamycin, 
ampicillin and cephalosporins (Trnka and LaMont, 1984, Bartlett, 1984, George et al, 
1982). However, virtually every antibiotic has been implicated with the disease at some 
time. The first line of treatment of C. docile disease is to remove the antibiotic. In 
instances where the symptoms of the disease are more severe, the most common 
treatment is the oral administration of vancomycin or metranidazole. If treatment of PMC 
is delayed, life threatening complications can occur such as protein losing enteropathy, 
toxic megacolon, colonic perforations, severe fluid loss and electrolyte imbalances. 
1.5.3 Animal models 
C. dicile causes antibiotic-associated pseudomembranous colitis in a number of animal 
species including hamsters, guinea-pigs, rats and rabbits. The hamster, however, has 
proved to be the best animal model for the disease. As with PMC in humans, the hamster 
disease can be initiated with a whole range of antibiotics (Chang et al, 1978, Fekety et al, 
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1979, Price et al, 1979). The disease in hamsters is localised in the proximal colon and 
the ileum, whereas PMC in humans occurs primarily in the distal colon. The coverings of 
inflammatory debris present in the caeca of diseased hamsters, however, are very similar 
to the pseudomembranes observed in the colon of many PMC patients (Price and Davies, 
1977). The hamster became routinely used as a model for studying PMC in the late 
1970s. Larson and co-workers isolated cytotoxic C. dfýcile strains from patients with 
PMC and showed that they induced fatal enterocolitis when inoculated orally into 
hamsters pre-treated with vancomycin. The organism was re-isolated from the caecal 
contents of the hamsters and was shown to cause the same cytotoxic effect as the initial 
inoculum (Larson et al, 1978). Another interesting observation is that like human infants, 
infant hamsters seem to have high numbers of toxigenic C. dilcile and toxins A and B in 
their stools whilst remaining asymptomatic for the disease (Griffin et al, 1984, Rolfe and 
Iaconis, 1983). 
Other animal models have been used such as clindamycin pre-treated guinea pigs (Rehg, 
1980) and lincomycin pre-treated rabbits (Rehg and Pakes, 1982) but they proved less 
successful than the hamster model. Germ free rats (Czuprynski et al, 1983) and mice 
(Onderdonk et al, 1980, Corthier et al, 1985, Sugiyama et al, 1985) have also been used 
as animal models for PMC. These animals, however, are considerably more expensive to 
use than hamsters. Also these gnotobiotic animals are free from other organisms and so 
do not satisfactorily reflect the in vivo situation in humans, whereas the hamster model 
better approximates to the human conditions. 
1.5.4 Colonisation resistance 
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Colonisation of the gut is important in the development of normal intestinal morphology. 
The gut flora is extremely complex (i. e. 1012 viable organisms/gram of gut content, with 
400-500 different species) and acts as a barrier preventing non-resident and other 
pathogenic bacteria from becoming established (Borriello, 1990). This phenomenon, 
termed colonisation resistance, is dependent to a large extent on the `crowding out' effect 
by the indigenous gut flora. The flora forms an impenetrable layer over the mucosa, and 
any bacteria that shed from this layer, into the lumen of the tract, multiply and 
successfully compete with potential pathogens for nutrients. The resident bacteria are also 
capable of producing antibacterial substances such as colicine (Branche et al, 1963), and 
release short chain fatty-acids which have anti-microbial activity (Meynell, 1963). 
Disruption of the normal flora, for example by antibiotic therapy, allows the 
establishment of opportunistic organisms. Many in vivo and in vitro studies have shown 
that disruption of the normal flora is a pre-requisite for C. difficile infection of the gut 
(Rolfe et al, 1981, Corthier et al, 1985, Barclay and Borriello, 1982, Malamou-Ladas and 
Tabaqchali, 1982). The role of colonisation resistance in C. dfricile infection has been 
demonstrated using faecal emulsion (Borriello and Barclay, 1986, Borriello et al, 1988). 
A study showed that C. docile growth and cytotoxin production were inhibited in faecal 
emulsions from healthy adults but not in sterilised emulsions. This confirmed the 
importance of viable bacteria in the inhibitory system (Barclay and Borriello, 1986). 
Caecal emulsions from the hamster, pre-treated with clindamycin or ampicillin, were also 
found to support C. docile growth and cytotoxin production, whereas caecal emulsions 
from untreated animals did not (Borriello et al, 1988a). 
Attempts have been made to reconstitute colonisation resistance to C. docile infection in 
patient's following antibiotic therapy. Faecal enemas have been used to successfully 
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reintroduce a complete gut flora (Schwan et al, 1984). Micro-organisms, known to have 
an inhibitory effect on C. docile growth, e. g. human source strain Lactobacillus GG 
(Gorbach et al, 1987) and Sacchromyces boulardii (Elmer et al, 1989), have also been 
used to treat relapsing C. docile colitis. The protective effects of S. boulardii on C. 
difficile-induced inflammatory diarrhea in humans have been shown to be due, in part, to 
proteolytic digestion of toxins A and B by a secreted protease (Castagliuolo et al, 1999). 
Feeding S. boulardii to mice during oral immunisation with C. docile toxin A, has also 
been shown to stimulate a 19-fold increase in specific intestinal IgA anti-toxin A levels 
(Qamar et al, 1999). Non-toxigenic avirulent strains of C. docile have been shown to be 
protective against subsequent colonisation with toxigenic virulent strains of C. docile 
(Borriello and Barclay, 1985, Seal et al, 1987). 
All of these models were successful in demonstrating the importance of the normal gut 
flora and certain probiotics as barriers to colonisation by C. dff cile. 
1.6 Factors influencing the outcome of infection with G difilcile 
1.6.1 Age of the host 
Antibiotic-associated susceptibility to C. docile infection appears to increase with age. 
The elderly who receive antibiotic therapy in a hospital setting comprise the population at 
highest risk. It has been suggested that age-related changes in the gut flora of the elderly 
(Ellis-Pegler et al, 1975, Yamagishi et al, 1976) cause a reduction in the amount of 
disruption of colonisation resistance required for C. docile to colonise (Borriello and 
Barclay, 1986). It has also been shown that toxin A causes an increased chemotactic 
response of leukocytes, in elderly subjects compared to young subjects, explaining the 
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more severe inflammatory response seen in the elderly with C. docile disease 
(Triadafilopoulos et al, 1991). 
Another interesting aspect of PMC is that new-borns and young infants often harbour C. 
difficile and its toxins in their intestines without developing disease (Donta and Mayers, 
1982). This is also true in the hamster model (Borriello et al 1985). This can be explained 
to some extent by the fact that neonates have a developing and incomplete intestinal flora 
that is unable to exclude C. docile (Borriello, 1990). It is possible that infants lack the 
receptors for toxin A in their intestines, or that the receptors exist in an immature form 
that are not recognised by toxin A (Lyerly et al, 1988). Another possible explanation is 
that the mucin layer covering the receptors on infant intestinal cells is much thicker than 
in adults thus preventing toxin A from binding (Lyerly et al, 1988). 
1.6.2 Disruption of colonisation resistance 
Most antibiotics, but particularly clindamycin, ampicillin and cephalosporins, kill or 
suppress the normal flora to such an extent that C. docile is free to colonise and cause 
toxinogenic diarrhoea. Other procedures that may disrupt the normal gut flora and 
predispose patients to C. difficile infection include the use of medications that decrease 
intestinal motility (Trinka and LaMont, 1984), gastrointestinal tract surgery (McFarland 
et al, 1991) and cancer chemotherapy treatment (Fainstein et al, 1981). 
1.6.3 Virulence factors 
The outcome of infection with C. docile is dependent primarily on the virulence 
potential of the infecting strain and on the extent to which the virulence determinants are 
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allowed to be expressed. Many virulence factors or potential factors have now been 
identified for C. docile. 
1.6.3.1 Adherence to host mucosal cells and fimbrae 
C. docile is regularly isolated from areas of the gut that are continually washed by 
intestinal fluids, suggesting that the bacterium produces specific factors that mediate 
adherence to host cells. C. docile has been found in association with the intestinal 
mucosa of man (Borriello, 1979) and hamsters (Borriello et al, 1988b). Highly virulent 
toxigenic strains of C. df/cile have been found to adhere and colonise much more 
efficiently than poorly virulent toxigenic or avirulent non-toxigenic strains (Borriello et 
al, 1988b). It has been suggested that the toxins damage the host cells exposing masked 
receptor sites for C. docile or that they affect the ability of the gut cells to produce 
mucosal secretions (Laboisse, 1995). 
Trefoil peptides and mucin glycoproteins have been shown to protect T84 monolayers 
from C. dilcile toxin A injury in vitro (Kindon et al, 1995). It has been suggested that 
cells of the intestinal mucosa must be poorly covered by the visoelastic gel produced by 
trefoil peptides and mucin glycoproteins to enable virulent toxigenic C. dif cile strains to 
adhere to and colonise the gastrointestinal tract. 
Heat shocking of C. docile at 60°C appears to greatly enhance its ability to adhere to 
CaCo-2 and HT29-MTX cells (Eveillard et al, 1993). The adhesion factors involved are 
believed to be two surface proteins, which, although scarcely expressed by C. docile, 
become over-expressed following induction by antibiotic therapy, or some other stimuli, 
allowing the bacteria to adhere to the mucus (Eveillard et al, 1993). One of these 
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adhesins is believed to be a lectin because glucose and galactose partially block 
attachment of C. docile to tissue culture cells (Karjalainen et al, 1994). 
Typing of C. diJcile strains has proved successful in revealing a consistent correlation 
between certain protein types and virulent strains (Pantosti, et al, 1988, Tabaqchali, 
1990). A 36 kDa protein has been identified (Pantosti et al, 1988) and purified (Cerquetti 
et al, 1992) and appears to be specifically expressed by highly virulent toxigenic C. 
docile strains isolated from hospitalised patients with PMC. Its role in C. docile 
virulence remains unclear, although it has been suggested that it may be a promoter for 
cell adhesion (Mastrantonio et al, 1995). 
Some strains of C. docile have been shown to possess fimbrae that are 4-9nm in 
diameter and which originate from the pole of the cell (Borriello et al, 1988c). To date, 
no direct correlation has been made between the presence of the fimbrae and the ability 
of C. docile to adhere to the gut mucosa of hamsters or to cause disease. The role of the 
fimbrae in C. docile disease, therefore, remains unclear. 
1.6.3.2 Capsule 
For many bacteria the presence of a capsule is an important virulence factor that protects 
against phagocytosis (Duerden et al, 1994). C. docile appears to be resistant to 
phagocytosis by polymorphonuclear leukocytes (PMNs) even though there is a great 
infiltration of PMNs during disease. It was concluded, therefore, that there must be an 
anti-phagocytic factor, such as a capsule, present on the surface of the bacterium. In 
support of this hypothesis, recent studies have demonstrated that some strains of C. 
di(cile produce capsule-like material in vitro (Davies and Borriello, 1990, Baldassari et 
al, 1991) that has apparent phenotypic similarities to the small capsule associated with 
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Bacteroides fragilis (Borriello et al, 1990). Although these studies were unable to 
demonstrate a correlation between possession of a capsule and virulence status of the C. 
d ff cile strain in vitro, it remains a possibility that the possession of a capsule by C. 
difficile confers resistance to phagocytosis. 
1.6.3.3 Enzymes 
C. docile produces a variety of hydrolytic and proteolytic enzymes (Seddon et al, 1990, 
Seddon and Borriello, 1992, Hafiz, 1974). Different c. docile strains have been shown 
to be positive for hyaluronidase, chondroitin-4-sulphatase, collagenase, heparinase and 
general protease activity (Seddon et al, 1990). Toxigenic C. di(cile strains produce more 
collagenase than non-toxigenic strains and the most virulent strains in the hamster model, 
are the most proteolytic (Karjalainen et al, 1995). 
Hydrolytic and proteolytic enzymes, as well as permitting tissue degradation of the 
intestinal wall, break down host polymers into smaller components, thus providing the 
bacteria with energy sources. For example, C. docile requires N-acetylglucosamine but 
lacks the enzyme necessary for cleaving this monosaccharide from oligosaccharide side 
chains (Wilson and Perini, 1988). To compensate, C docile is able to produce 
hyaluronidase and obtain N-acetylglucosamine from hyaluronic acid. 
1.6.3.4 Toxin production 
At least five toxic factors have been described for C. docile but only two of these, toxins 
A and B (which possess an overall homology of 69% at the amino acid level) have been 
implicated in disease and studied in detail. The molecules are single polypeptides of 
303kDa (toxin A) and 269kDa (toxin B), making toxin A the largest protein known to 
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date (Lyerly and Allen, 1997). In order to differentiate between the two toxins, toxin A is 
described as an enterotoxin and toxin B as a cytotoxin. This description is not strictly 
correct because both toxins are potent cytotoxins, although toxin B is at least 1000 times 
more cytotoxic for most cell lines. Unlike toxin A, toxin B does not appear to be able to 
affect the undisturbed mucosa of the hamster gut (Lyerly et al, 1985a, Mitchell et al, 
1986, Triadafilapoulous et al, 1987). It has been suggested that toxin B acts 
synergistically with toxin A, which is required for initial tissue damage and escape of 
toxin B from the gut (Lyerly et al, 1985a). 
A cytotoxigenic strain of C. dif cile has been isolated that fails to haemagglutinate rabbit 
red blood cells, or to react in toxin A specific enzyme immunoassays (Haslam et al, 
1986). This strain, 8864, was initially believed to be toxin A negative, toxin B positive. 
The interest shown in this isolate was due to the prior assumption that all strains were 
either non-toxigenic or produced both toxins (Lyerly et al, 1988). Interestingly, this strain 
was shown to cause haemorrhage and diarrhoea in hamsters (Borriello et al, 1992), 
initially thought to be due to the effects of toxin B or an additional enterotoxic factor. 
Further characterisation revealed that strain 8864 produced a modified form of toxin B 
(Borriello et al, 1992, Torres, 1991), and that the lack of the toxin A protein was not due 
to a silent copy of the gene, but to the absence of the 3' end of the gene (Borriello et al, 
1992). It was later shown that the front portion of the toxin A gene was present in strain 
8864 (Lyerly et al, 1992) but was not being expressed due to rearrangements in the 
pathogenicity locus resulting in altered transcription (Soehn et al, 1998). It was 
concluded that the effects seen in the hamster model were due to the altered activity of 
the modified toxin B gene. Both toxins A and B will be discussed in more detail in later 
sections. 
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1.6.3.5 Other toxic factors 
Several investigators have described an additional non haemorrhagic enterotoxic activity 
expressed by C. dif cile (Banno et al, 1984, Mitchell et al, 1987, Guiliano et al, 1988, 
Torres and Lonnroth, 1989). In 1989 Torres and co-workers described an enterotoxin 
designated toxin C which caused a clear haemorrhagic fluid secretion similar to that 
caused by cholera toxin. It was concluded that toxin C was antigenically and biologically 
distinct from toxins A and B. 
A motility 
- 
altering factor has also been described in culture filtrates of C. docile 
which is believed to cause altered motor activity in the intestine, but does not cause tissue 
damage or fluid secretion (Justus et al, 1982). 
In an isolated study, one C. docile strain (CD196) out of fifteen isolated from patients 
with PMC produced a 43 kDa actin specific ADP-ribosyltransferase (Popoff et al, 1988) 
homologous to the enzymatic component of other clostridial binary toxins (Popoff and 
Boquet, 1988). It has recently been reported that this strain produces both the enzymatic 
and binding components forming a complete binary toxin which is cytotoxic for cells 
(Perelle et al, 1997). This toxin is unlikely to be an essential virulence factor for C. 
dif cile because it is not produced by all pathogenic strains. 
The production of toxins A and B by C. docile is thought to be the most important 
virulence factor because, irrespective of the presence or absence of any other factors, 
non-toxigenic strains are avirulent in the hamster model of the disease (Borriello, 1990, 
Fluit et al, 1991, ). 
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1.7 Characteristics of toxins A and B 
One of the most unusual features of both toxins is their extremely large size. There has 
been much controversy over the actual molecular weights and sub-unit composition of 
the toxins. Past studies have estimated native toxin A to have a Mr of between 400,000 
and 600,000 and native toxin B to have a Mr of between 360,000 and 500,000. Under 
denaturing conditions both toxins were found to have a Mr in excess of 250,000 and did 
not dissociate into subunits (Banno et al, 1984, Lyerly et al, 1986a). Other investigators 
have reported sizes of 50 kDa (Pothoulakis et al, 1986, Rihn et al, 1988, Meador and 
Tweten, 1988) and 43 kDa (Torres and Lonnroth, 1988a) for toxin B. In an isolated 
study, toxin A was reported to have an Mr of 52,000 and a sub-unit composition of Al 
(Mr 41,500) and A2 (Mr 16,000) (Rihn et al, 1984). 
Others have observed minor protein bands following SDS-PAGE of toxins A and B 
which were smaller than the major toxin band and which reacted with toxin specific 
antibodies. It was suggested that the toxin exists as aggregates of small sub-units that 
were dissociated under denaturing conditions (Lyerly et al, 1986b). 
The molecular masses of 303,103 Da for toxin A and 269,696 Da for toxin B were finally 
deduced from the published DNA sequence data (Dove et al, 1990, Barroso et al, 1990). 
These sizes are in agreement with other estimations (Bann et al, 1984, Lyerly et al, 
1986a) but contradict others (Pothoulakis et al, 1986, Rihn et al, 1984,1988). The native 
Mr values of 600 kDa (toxin A) and 500 kDa (toxin B) suggest that both toxins exist as 
dimers, either in the native state, or as a result of purification procedures. There is 
evidence to suggest that toxin A is produced as a `pro-toxin' form that lacks 
haemagglutinating activity but retains cytotoxicity and is activated within the bacterial 
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cell to the fully active form Pro- toxin A has been shown to contain twice as many a- 
helices as toxin A (Borriello et al, 1990, Kamiya and Borriello, 1992). 
The coding DNA of both toxin genes is extremely AT rich (toxin A gene has an AT 
content of 73.1 mol%). Both proteins contain high concentrations of the amino acids 
glycine, aspartic acid, and glutamic acid and low concentrations of histidine and 
methionine (Banno et al, 1984, Lyerly et al, 1986a, b). Both toxins appear to be acidic 
molecules with pI values reported as 5.31 for toxin A (Sauerborn and von Eichel- 
Streiber, 1990) and 4.24 for toxin B (Barroso et al, 1990). 
Toxins A and B are susceptible to a variety of proteases and extremes of pH and 
temperature, with toxin B being more susceptible and less stable than toxin A (Lyerly et 
al, 1986a, Banno et al, 1984, Sullivan et al, 1982, Taylor et al, 1981). Proteases shown to 
inactivate both toxins include amylase, pronase and chymotrypsin (Rolfe and Finegold, 
1979) whilst trypsin inactivates only toxin B (Rolfe and Finegold, 1979, Lyerly et al, 
1989a, Torres and Lonnroth, 1988b). Both toxins are inactivated by oxidising agents such 
as H202 and 02 but can be protected by the addition of a reducing agent such as 
dithiothreitol. The toxins are not sensitive to reducing agents or sulphydryl-inactivating 
agents, suggesting that these groups are not involved in binding or enzymatic action of 
the toxins (Lyerly et al, 1986a). 
1.7.1 Immunochemical properties 
Studies have shown that toxins A and B are immunologically distinct molecules which do 
not cross react significantly in immunoassays (Lyerly et al, 1983, Laughan et al, 1984). 
Polyclonal toxin A antibodies do not neutralise cytotoxic activity of toxin B and toxin B 
polyclonal antibodies do not neutralise cytotoxic or enterotoxic activity of toxin A (Libby 
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and Wilkins, 1982, Taylor et al, 1981, Banno et al, 1984). Interestingly, the C. sordellii 
HT cross reacts antigenically and is highly related genetically and biologically to toxin A. 
Similarly, the C. sordelli LT is similar in biological activity and antigenic structure to 
toxin B (Martinez and Wilkins, 1992). Although highly related neither toxin A nor B 
cross-react antigenically with C. novyi a-toxin (Hofmann et al, 1995). Toxin A has, 
however, been shown to be antigenically cross-reactive with the glucan binding protein 
from Streptococcus mutans (Wren et al, 1991). 
Some mouse monoclonal antibodies (Mats) have been isolated that cross-react with both 
toxins A and B (Lyerly et al, 1986b, von Eichel-Streiber et al, 1987, Rothman et al, 
1988) initially suggesting that the toxins share some immunodeterminants. It was later 
discovered that these cross-reacting antibodies were able to bind to the toxins in a non- 
immune fashion with non-specific binding being greater to toxin A than B (Lyerly et al, 
1989b). Several specific Mabs have also been raised to toxin A but only two of these 
appear to block any biological activity of the toxin. The first, PCG-4 (Lyerly et al, 1985b) 
neutralises the enterotoxic and haemagglutinating activities of toxin A but not the 
cytotoxic activity. As the PCG-4 Mab precipitates toxin A, it was concluded that it was 
recognising a repeating unit in the molecule (Lyerly et al, 1986b). It was later confirmed 
that this antibody recognises epitopes in amino acid residues 2,097 through 2,141 and 
2,355 through 2,398, both of which are within the C-terminal repeat region (Frey and 
Wilkins, 1992). As the PCG-4 Mab blocks toxin A induced haemagglutination of rabbit 
red blood cells, it was concluded that enterotoxicity was prevented by blocking binding 
of the toxin to its receptor on the target cell (Frey and Wilkins, 1992). The failure of the 
antibody to neutralise cytotoxicity suggests that the enterotoxic and cytotoxic activities of 
toxin A are distinct (Lyerly et al, 1986b). 
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In contrast, the second Mab 37B5 (Kamiya et al, 1991) was shown to neutralise the 
enterotoxic activity of toxin A but not the haemagghrtinating or cytotoxic activities. It 
was concluded that the antibody was blocking an active site for enterotoxicity not 
associated with receptor binding (Kamiya et al, 1991). The binding site for this antibody 
in the toxin A molecule has not yet been identified. 
In toxin A the C-terminal region is immundominant (Frey, and Wilkins, 1992). Pre- 
treatment with PCG-4 reduces the binding of polyclonal toxin A antiserum to native toxin 
A by about 75%, suggesting that the PCG-4 binding sites are particularly 
immundominant (Lyerly and Wilkins, 1995). In contrast, immundominant epitopes are 
located along the entire length of the toxin B molecule (Sauerborn et al, 1994). Some of 
these epitopes in the C-terminal repeat region also elicit protective antibodies (Torres and 
Month, 1996). 
1.7.2 Biological activity 
Although toxins A and B are extremely homologous at the amino acid level, they differ in 
their biological activities. Unlike toxin B, toxin A is referred to as a potent enterotoxin 
(Mitchell et al, 1986) because in the rabbit ligated intestinal loop model (Riflcin et al, 
1978a) toxin A causes the accumulation of proteinaceous, haemorrhagic fluid (Banno et 
al, 1984). Toxin A differs from classically studied enterotoxins (e. g. cholera toxin, which 
produces a clear rice-water fluid in the loop assay and so is often referred to as a 
`histotoxin') by causing extensive tissue damage which results in an increased 
permeability of the gut mucosa and eventual vessel leakage (Mitchell et al, 1986, Lima et 
al, 1988). Toxin B, however, appears to lack enterotoxic activity in rabbit intestinal loops 
but it does cause some haemorrhaging. 
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A study has shown that when toxin A was given intragastrically to hamsters it caused 
haemorrhagic fluid secretions, severe inflammation and death, whereas intragastric 
administration of toxin B had no effect on the hamster caecum or small intestine. When 
toxin B was administered with sub-lethal amounts of toxin A, however, the animals died 
(Lyerly et al, 1985a). This suggests that toxins A and B act synergistically with the tissue 
damage caused by toxin A facilitating action of toxin B. The inability of toxin B to affect 
intestinal cells may be due to the lack of a receptor for toxin B on these cell types. 
The effects of toxins A and B on human colonic epithelium in Ussing chambers has also 
been studied (Riegler et al, 1995). The results of this in vitro assay suggested that the 
human colon is approximately ten times more sensitive to the damaging effects of toxin B 
than A. Although this is the first observation of toxin B having activity on undisturbed 
intestinal mucosa, it is possible that manipulation during surgery may have damaged the 
tissue enabling toxin B access to the deeper layers of the colonic mucosa. Both toxins A 
and B are lethal when injected intraperitoneally or subcutaneously in mice, hamsters, rats 
and rhesus monkeys (Amon et al, 1984, Banno et al, 1984, Lyerly et al, 1986a, Sullivan 
et al, 1982, Taylor et al, 1981). 
Toxin B is generally 1000 fold more cytotoxic than toxin A for most cell lines (Sullivan 
et al 1982). Results have indicated that cell lines which express high levels of the 
trisaccharide residue Galal-3Galß1-4 G1cNAc are 100 to 1000 times more sensitive to 
toxin A than other cell lines (Tucker and Wilkins, 1989). The morphological effect 
elicited by both toxins has been termed `actinomorphic' (Chang et at, 1978) and is 
characterised by cell rounding (Chang et al, 1979, Donta et al, 1982). Approximately 3- 
200 ng/ml of toxin A is required to cause complete cell rounding as opposed to only 1.5-5 
pg/ml of toxin B (McFarland, 1995). A variety of mammalian cells are affected by toxins 
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A and B (Pothoulakis et al, 1986, Donta et al, 1982, Wedel et al, 1983, Fiorentini and 
Thelestam, 1991, Sullivan et al, 1982, Borriello and Welch, 1984) suggesting that the 
receptors involved in the intoxication process are ubiquitous. 
It is assumed that the toxins affect the microfilament system of the cell because early 
investigators observed disorganisation of the actin filaments in toxin infected cells 
(Pothoulakis et al, 1986, Thelestam and Bronnegard, 1980). Both toxins have been shown 
to cause accumulation of F-actin and a-actin in an irregularly organised form opposite to 
the nucleus of the cell. Other components such as filamen and vinculin also showed 
abnormal distribution. The effect on the cytoskeleton causes the cell to retract and round, 
accompanied by marginalisation of the nucleus which is localised at one pole of the cell 
(Ahlgren et al, 1983, Fiorentini et al, 1990, Aktortes and Just, 1995). Further data has 
shown that toxin A causes surface blebbing with apoptosis-like cell death and that these 
changes are achieved without any measurable effect on the cellular calcium homeostasis 
(Fiorentini et al, 1993). Due to the change in F-actin organisation, the toxins were 
suspected to affect Rho proteins, the small GTPase proteins involved in regulation of the 
microfilament system. It has been shown that toxins A and B monoglucosylate Rho 
proteins using UDP-glucose as a substrate (Dillon et al, 1995, Just et al, 1995b, c). This 
modification inactivates Rho and its ability to induce polymerisation of actin filaments 
therefore causing cell retraction. 
Toxin A is also described as a lectin due to its ability to haemagglutinate rabbit red blood 
cells (rRBCs) via the high numbers of branched Gala 1-3 Galß 1-4 G1cNAc trisaccharide 
residues present on the surface of the erythrocyte (Krivan et al, 1986). This activity is 
greater at 4°C than at 37°C. Sequencing of the toxin A gene revealed a series of repeats at 
the carboxy-terminus of the molecule (Dove et al, 1990) which are thought to be 
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responsible for the lectin properties of toxin A (Price et al, 1987). Bovine thyroglobulin 
also contains high numbers of the Gala 1-3Ga1ß 14 G1cNAc residues and has been shown 
to bind toxin A at 4°C (Krivan et al, 1986). Thermal thyroglobulin affinity 
chromatography (Krivan and Wilkins, 1987, Kamiya et al, 1988), followed by anion- 
exchange and fast protein liquid chromatography (Kamiya et al, 1989) is now effectively 
used to purify toxin A to homogeneity. Toxin B lacks the ability to agglutinate rRBCs or 
bind bovine thyroglobulin. 
1.7.3 Toxin receptors 
The repeat region at the carboxy terminus of toxin A has long been identified as the 
receptor binding portion of the molecule (Price et al, 1987, Dove et al, 1990). Binding of 
toxin A to rabbit erythrocytes and hamster brush border membranes at 4°C, and to a 
lesser extent at physiological temperatures, led to the identification of the trisaccharide 
residue Gala1-3G41-4 G1cNAc as a possible receptor for toxin A (Krivan et al, 1986). 
Many observations support this theory. Firstly, it was shown that pretreatment of hamster 
brush borders with a-galactosidase (which cleaves terminal a-galactose residues), or with 
the lectin from Bandeirea simplificolia, reduces binding to toxin A (Krivan et al, 1986). 
Secondly, toxin A is 1000 times more cytotoxic for the mouse carcinoma F9 cell line 
which expresses high levels of the Gala1-3Ga1ßl-4 G1cNAc trisaccharide on its cell 
surface than other cell lines (Tucker and Wilkins, 1989). Finally, a further study has 
shown that a human anti-galactose antibody (which recognises Gala 1-3Galß1-4 G1cNAc) 
not only inhibits binding of toxin A to its receptor in the rat colon, but also mimics the 
effects of the toxin by causing fluid secretion and increased vascular permeability 
(Pothoulakis et al, 1996a). An earlier study reported that the membrane receptor for toxin 
54 
A in rabbit ileum is a galactose and N-acetyl glucosamine containing glycoprotein that 
appears to be coupled to a G-protein. The report concluded that binding of toxin A to its 
receptor stimulates a G-protein dependant signal transduction pathway which activates 
the cell prior to internalisation of the toxin or expression of the enzymatic activity 
(Pothoulakis et al, 1991). 
More recently, the rabbit small intestine brush border membrane enzyme, 
sucrase/isomaltase, has been identified as a receptor for toxin A (Pothoulakis et al, 
1996b). Chinese hamster ovary cells transfected with sucrase/isomaltase cDNA showed 
increased intracellular calcium release in response to both holotoxin and recombinant 
repeat end peptide. Anti- sucrase/isomaltase IgG also inhibited toxin A induced secretion 
in rabbit ileum suggesting that binding alone stimulates signal transduction pathways 
across the membrane (Pothoulakis et al, 1996b). 
Although the Galal-3Galß1-4 G1cNAc trisaccharide appears to be a receptor for toxin A 
in hamsters, it cannot be the receptor in the human intestine because the a- 
galactosyltransferase required for its formation is absent in humans (Thall et al, Galili et 
al, 1988). Current work on the toxins has therefore concentrated on identifying a receptor 
for toxin A in human intestinal epithelium. Three additional blood group carbohydrate 
antigens, designated Lewis X, Y and I, were identified as possible intestinal epithelial cell 
receptors for toxin A (Tucker and Wilkins, 1991). Their data indicates that toxin A binds 
the X and I antigens only at 4°C, but binds the Y antigen with greater affinity at both 4°C 
and 37°C. A common feature of these three carbohydrates is that they contain a Galß1-4 
G1cNAc residue (type 2 core) with a branch either on, or adjacent to, the core. It has been 
suggested that this branch holds the carbohydrate in a conformation that favours binding 
to toxin A (Tucker and Wilkins, 1991). It has been shown that N-acetylglucosamine 
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inhibits binding of toxin A to the Lewis Y antigen suggesting that the disaccharide 
Gulp 1-4 G1cNAc is the minimum structure required for binding to toxin A (Tucker and 
Wilkins, 1991). Interestingly, human neonates appear to be resistant to toxin A damage 
although they express the Y antigen on their intestinal epithelium (Kapadia et al, 1981, 
Karlsson and Larson, 1981). A possible explanation is that the receptor coupled G-protein 
system has not been fully developed in the neonates. 
The direct binding of toxin A to human intestinal epithelial cells has been demonstrated 
recently (Smith et al, 1997). Pre-treatment of the cells with ß-galactosidase (which 
cleaves terminal ß-galactose residues) reduced toxin A binding, supporting the idea that 
the Lewis X, Y and I antigens may be receptors for toxin A on human intestinal epithelial 
cells. As a-galactosidase treatment also reduced toxin A binding, however, it has been 
suggested that more than one receptor type may be involved (Smith et al, 1997). 
Cell receptors for toxin B have not yet been fully characterised. Recent results however, 
have shown that oligosaccharides containing sialic acid and n 
-acetyl glucosamine 
mediate toxin B binding and biological effects in human colonic mucosa (Castagliuolo et 
al 1998a). The toxin receptor(s) involved in the cytotoxic activity are likely to be fairly 
ubiquitous molecules because both toxins are active against a wide variety of cell types. 
1.7.4 Molecular characterisation 
Prior to sequencing of the toxin A and B genes, several investigators isolated fragments 
of the toxins from C. docile genomic libraries using polyclonal anti-toxin sera. A 0.3kb 
DNA fragment of the toxin A gene was isolated and found to hybridise to a 4.5 kb PstI 
generated fragment of C. docile DNA (Muldrow et al, 1987) An immunoreactive toxin 
A peptide coded for by a 4.7kb Pstl digested DNA fragment was also isolated from a 
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genomic library (Price et al, 1987). This DNA fragment was believed to code for a non- 
toxic binding portion of toxin A because it haemagglutinated rabbit erythrocytes but 
lacked cytotoxic and enterotoxic activity (Price et al, 1987). Further, a 14.3Kb DNA 
fragment was isolated from a XEMBL3 C. docile genomic library using polyclonal 
toxin A antiserum. This fragment encoded a 235 kDa protein that haemagglutinated 
rabbit erythrocytes and caused a cytotoxic effect on tissue culture cells, properties which 
are characteristic of native toxin A (Wren et al 1987). 
DNA sequencing has revealed that the coding region of the toxin A gene is 8.133Kb in 
length (Dove et al, 1990, Sauerborn and von Eichel Streiber, 1990). This encodes a single 
chain protein of 308 kDa (2,710 amino acids). One third of the gene (2,499bp) at the 3' 
end, consists of 38 contiguous repeating units which have been classified into two main 
groups dependant on length and sequence similarities (Dove et al, 1990). The 3' end of 
the toxin B gene lies 1,350bp upstream of the toxin A translational start with the two 
genes being separated by a small ORF encoding a 16-19 kDa polypeptide (Dove et al, 
1990). The coding region of the toxin B gene was shown to be 7.098 kb in length 
encoding a single chain protein of 269.696 kDa (2,366 amino acids) (Barroso et al 1990, 
Johnson et al, 1990). Toxin B also possesses repeating units at the carboxyl terminus but 
it is unclear whether these function as the binding portion of the molecule. 
Other proteins that cross-react antigenically with toxin A have been reported to contain 
C-terminal repeat sequences including four glycosyltransferases and a glucan binding 
protein from Streptococcus mutans (Wren, 1991, Wren et al, 1991, von Eichel-Streiber 
and Sauerborn, 1990). 
The amino acid sequences of the toxin A and B genes show 49% identity and 63% 
similarity, suggesting that the toxins arose by duplication. The greatest homology (64%) 
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appears between the N-terminal two-thirds of the molecules (von Eichel-Streiber et al, 
1992). C. docile toxin B has also been shown to be 75.7% identical and 90.3% similar 
to the C. sordellii LT at the amino acid level. Similar homologies are expected between 
C. sordellii HT and C docile toxin A (Green et al, 1995). C. docile toxins A and B, C. 
sordellii LT and HT, and the C. novyi a-toxin, all contain repeat sequences at the C- 
terminal end of their molecules. These toxins have been classified as large clostridial 
cytotoxins (LCT's) (Bette et al, 1991) with reference to their high molecular weights, 
their close structural and fimctional relationships and their similar in vivo and in vitro 
biological activities. Based on acquired knowledge and sequence similarities, a structural 
and functional domain map was postulated for both toxins (Barrosso et al, 1994) (see 
figure 1.1). Although no direct evidence was presented, the N-terminus of the toxins was 
believed to encode the cytotoxic activity. A 50 amino acid hydrophobic region near the 
centre of the toxin was tentatively assumed to be involved in membrane translocation 
while the repetitive C-terminal domain was known to be involved in binding to 
glycoconjugates (Barroso et al, 1994). The development of a series of toxin B mutants 
also highlighted the importance of four conserved cysteine residues (Cys597, Cys700, 
CyS1169, Cys1623) and a putative nucleotide binding site (aa's 651-683) for full expression 
of biological activity (Barroso et al, 1994). 
A sequence comparison between toxin B and a variant form (ToxB-1470), which is far 
less potent to endothelial cells, revealed that the majority of the changes in the variant 
sequence resided between amino acids 1-868 (von Eichel-Streiber et al, 1995). This 
provides further evidence to suggest that the N-terminal third of the toxin B gene encodes 
the cytotoxic activity. 
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Using PCR, the C. difficile toxigenic element was found to be chromosomal, 19.6Kb in 
length, and comprising of five ORFs including the toxin A and B genes. Non-toxigenic 
strains were shown to lack this entire element but possess a unique 127 bp DNA fragment 
in its place (Hammond and Johnson, 1995). The toxigenic element has also been 
described as a pathogenicity locus (PaLoc) because its very existence is a prerequisite for 
the pathogenicity of a strain (Braun et al, 1996). The locus is a distinct genetic element 
integrated at a single site (running in one direction) in the C. docile genome. The five 
ORFs were named TcdA- TcdE inclusive, with TcdA and TcdB being the original toxin 
A and B genes. TcdA, TcdB, TcdD and TcdE were shown to be transcribed in the same 
direction whilst TcdC is transcribed in the opposite direction (see figure 1.2) (Braun et al, 
1996). 
Transcriptional analysis of the TcdA- TcdE genes showed that they are all transcribed 
(Hundsberger et al, 1997). Interestingly, in the early exponential phase, high levels of 
TcdC and low levels of TcdA, B, D and E transcripts were detected, but in the stationary 
phase this was reversed. It has been suggested that TcdC may have a negative effect on 
transcription of the other genes (Hundsberger et al, 1997). TcdD contains a helix-turn- 
helix motif typical of DNA binding proteins (Hundsberger et al, 1997) and is believed to 
be a positive regulator that activates expression of C. difcile toxins A and B (Moncrief et 
al, 1997). Eight additional ORFs have been identified outside of the PaLoc, which also 
appear to be present in non-toxigenic strains (Braun et al, 1996) (see figure 1.2). The 
function of these small ORFs still remains unclear. 
1.7.5 Functions of toxins A and B 
1.7.5.1 Phosphate and nucleoside binding 
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Studies have indicated that toxin B has a phosphate binding site(s) which, when 
occupied, delays cytotoxicity but does not prevent it. Toxin B also binds nucleoside 
triphosphates, nuclear, di-, tri-, and tetraphosphates, inorganic polyphosphates and 
polyphosphorylated sugars (Florin and Thelestan, 1984). The polyphosphate-binding site 
in toxin B shares characteristics with the site in the diptheria toxin. Both bind all 
nucleoside triphosphates as well as di-and tetrphosphates, but bind ATP with a greater 
affinity than other nucleotides. Also, binding of ATP to both molecules caused a dose 
dependant inhibition of the cytopathic effect in the 1-5mM range (Florin and Thelestam, 
1984). In one study, approximately 7-20% of a toxin B preparation was shown to bind 
ATP (Florin and Thelestam, 1984). ATP was protective to cells even upon addition 10 
minutes, after the toxin B binding step, suggesting that the ATP binding site and the 
receptor binding site are separate in this molecule. It has been suggested that the ATP 
binding site may be involved in the interaction of toxin B with the cell shortly after the 
binding step (Florin and Thelestam, 1984). A putative ATP binding site has been located 
in toxin B between amino acids 651-683 and shows high levels of homology with 
conserved ATP binding sites (Barroso et al, 1994). 
More recently, the change in intrinsic fluorescence of tryptophan residues has been used 
to demonstrate that toxin A also binds nucleotides and tetraphosphates. The binding 
affinity was greatest for tetraphosphates, adenosine triphosphate then guanosine 
triphosphate respectively (Lobban and Borriello, 1992). Both toxins A and B bind to 
ATP-agarose columns although a greater proportion of toxin A (35%) than toxin B (20%) 
appeared to be retained on the column (Lobban and Borriello, 1992, Florin and 
Thelestam, 1984). The phosphate-binding site in toxin A appears to be analogous to the 
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`P' site of fragment B of diptheria toxin (Lory and Collier, 1980, Boquet and Duflot, 
1981). 
Toxin A also binds to NAD+ suggesting that it contains a nucleoside-binding site 
(Lobban and Borriello, 1992). In diptheria toxin, the phosphate and nucleoside binding 
sites are distinct but appear to come together in the tertiary structure of the molecule to 
contribute to the nucleotide-binding site (Boquet and Duflot, 1981). It is not known if this 
is also true of toxin A or if toxin B has a nucleoside-binding site. The function of the 
phosphate binding site and, for toxin A at least the nucleoside binding site, are unknown 
for both toxins A and B. 
1.7.5.2 Interaction with nucleic acid 
Several investigators have reported that both DNA and RNA co-purify with toxin B but 
not toxin A (Meador and Tweten, 1988, Bisseret et al, 1989, Borriello, 1991). The DNA 
fragments recovered ranged from 20MDa (Meador and Tweten, 1988) to 20 nucleotides 
(Bisseret et al, 1989). Contradictory observations were made by these investigators. The 
first authors found that the presence of nucleic acid decreased toxin B induced 
cytotoxicity, while the latter implied that removal of the nucleic acids with DNAase had a 
detrimental effect on toxin B induced cytotoxicity. Further investigation (in agreement 
with Bisseret and co-workers) found that treatment of toxin B with DNAase reduced 
cytotoxic activity but treatment with RNAase had no effect (Borriello et al, 1991). 
However, it was also shown that the effect of the DNAase was due to contamination with 
proteases (Borriello et al, 1991), DNAase treated with protease inhibitors no longer 
caused a reduction in toxin B cytotoxicity. Purification of the DNAase showed the 
presence of a protease which was active against toxin B but not toxin A, and which was 
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sensitive to the effects of the serine protease inhibitor PMSF. It would appear, therefore, 
that the reduced cytotoxic activity observed by Bisseret and co-workers was due to a 
contaminating serine protease. 
The relevance of the interaction of toxin B with nucleic acid, if any, is unknown. It is 
unlikely that toxin B binds directly to host cell DNA switching off an essential gene 
involved in cytoskeletal control, as Vero DNA does not inhibit toxin B induced 
cytotoxicity for Vero cells (Borriello, 1991). 
1.7.5.3 Stimulation of increased inositol triphosphate (IP3) production 
Binding of toxins A and B to cells has been shown to subvert host phosphatidyl inositol 
signal transduction mechanisms. A study revealed that the toxins caused a net stimulation 
of increased IP3 production of 25.5% in duodenal membrane preparations (Smith et al, 
1995). Incubation of toxin A with membrane preparations for 10 minutes at 37°C 
increased the accumulation of IP3 by 42%, whereas incubation of toxin B in the same 
conditions reduced the accumulation of IP3 by 16.5%. The stimulation of IP3 was greater 
at 4°C than 37°C, which is consistent with the known thermal binding characteristics of 
toxin A to its receptor (Krivan et al, 1986, Smith et al, 1995). Stimulation of IP3 
production may be involved in the toxin A induced secretory response. 
1.7.5.4 Carbohydrate binding properties 
The observation that toxin A haemagglutinates rabbit erythrocytes at 4°C led to the 
identification of a trisaccharide residue Galal-3Galpl-4G1cNAc, as a receptor for toxin 
A. This trisaccharide is present on hamster brush border membranes, bovine 
thyroglobulin and rabbit erythrocytes (Krivan et al, 1986, Clark et al, 1987), but is not 
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present on human cells. Human tissues, however, express the Gal(1-4G1cNAc structure, 
e. g. Lewis X, Y, and I blood group antigens, which also bind toxin A (Tucker and 
Wilkins, 1991). The Galß 1-4G1cNAc disaccharide appears to be the minimum structure 
required for binding, and probably forms a receptor for toxin A in human intestinal tissue. 
The toxin B receptor is also believed to be carbohydrate based but no particular structure 
has yet been identified (Thelestam and Bronnegard, 1980). 
1.7.5.5 Non-specific binding to monoclonal antibodies (Mabs) 
Both toxins A and B bind non-specifically to many murine Mabs raised against antigens 
other than toxin A, although this is a feature more of toxin A than B (Lyerly et al, 
1989b). None of the cross-reacting Mabs neutralised biological activity of either toxin 
leading investigators to conclude that the antibody binding does not occur via a true 
immune response (Lyerly et al, 1989b). Toxin A also appears to bind to human 
paraproteins in a manner believed to be non-specific (Borriello, 1991). 
Many other bacterial proteins have been shown to bind non-immunologically to 
antibodies e. g. Protein A from Staphylococcus aureus (Forsgren and Sjoquest, 1966). 
These proteins, along with several others from gram-negative organisms, appear to bind 
non-specifically to the Fc domain of the antibody molecule (Forsgren and Grubb, 1979, 
Labbe and Grenier, 1995, Yarnall et al, 1988). Recently, however, it has been shown that 
non-specific binding of C. docile toxin A to an IgG3?. murine Mab was mediated 
through the Fab domain of the immunoglobulin (Cooke and Borriello, 1998). This 
represents the first observation of a bacterial antigen binding to the Fab component of 
antibodies. 
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Pre-treatment of the Fab fragment with a-galactosidase reduced binding to toxin A 
suggesting that the non-specific binding was mediated through a carbohydrate moiety on 
the Fab domain (Cooke and Borriello, 1998). The Lewis X antigen, also present on the 
secretory component of immunoglobulins, is unlikely to be involved in the non-specific 
interaction because it was unable to compete with the antibody for binding to toxin A 
(Cooke and Borriello, 1998). The region of the toxin A molecule responsible for binding 
to the Fab region of Mabs has not yet been determined. It has been suggested that the 
ability of toxin A to bind to carbohydrate residues on the Fab fragment of secretory IgA 
antibodies may promote interaction with mucus (Cooke and Borriello, 1998). 
1.7.5.6 Covalent modification of Rho proteins 
Several clostridial species produce toxins that disrupt the actin cytoskeleton by ADP- 
ribosylation of either actin, such as the C2-toxin of C. botulinum (Aktories et al, 1986), 
or the small GTPase Rho, such as C. botulinum exoenzyme C3 (Aktories et al, 1987, 
Chardin et al, 1989). Early observations showed that micro-injection of C. docile toxins 
A and B into cells caused disruption of the actin cytoskeleton suggesting that the target 
for the toxins was cytosolic (Meuller et al, 1992). Due to changes in F-actin organisation 
induced by C. docile toxins A and B, Rho proteins were also suspected to be cellular 
targets for these proteins. For many years, however, investigators failed to demonstrate 
that the C. docile toxins possessed ADP-ribosyltransferase activity (Florin and 
Thelestam, 1991, Popoff et al, 1988). 
Finally it was shown that despite their different in vivo biological activities, both toxins A 
(Just et al, 1995a) and B (Just et al, 1994) covaleatly modify Rho proteins in such a way 
that subsequent ADP-ribosylation by exoenzyme C3 was prevented. Also shown was that 
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the modification was dependent on an unknown heat stable cytosolic factor with a 
molecular mass between 500 and 3,000 Da (Just et al, 1995a). Further investigation 
revealed that the molecular mass of toxin A modified recombinant Rho was 162 Da 
higher than unmodified Rho. As this difference corresponded to the molecular mass of a 
hexose, but the estimated size of the required cytosolic factor was >500 Da, the authors 
tested a number of sugar nucleotides for their ability to act as a co-factor for toxin A (Just 
et al, 1995b). It was finally shown that toxins A and B monoglucosylate Rho at the amino 
acid position Thr-37 using UDP-glucose as the substrate (Just et al, 1995b and 1995c). It 
was further shown that the three subtypes of small G-proteins within the Rho family (Rho 
A, Rad 1 and Cdc 42) were all substrates for the toxins but that other subtypes of the Ras 
superfamily (H-Ras, Rab 5 and Arf 1) were not (Just et al, 1995b). 
The observation that a mutant cell line, which produces low levels of UDP-Glucose was 
resistant to both C. docile toxin B and to C. sordellii LT suggested that both toxins 
require UDP-glucose as a co-factor (Chaves-Olarte et al, 1996). It was later confirmed 
that the C. sordellfi LT is also a glucosyltransferase which uses UDP-glucose as a co- 
substrate, but that this toxin modifies Rac and Ras proteins but not Rho or Cdc 42 
proteins (Just et al, 1996). The C. novyi a-toxin, however, is an N-acetyl- 
glucosaminyltransferase that utilises UDP-N-acetyl-glucosamine as a co-substrate to 
modify Rho subfamily proteins (Rho, Rac, Cdc 42, RhoG) (Selzer et al, 1996). All of the 
large clostridial cytotoxins appear to modify the threonine in the effector region (Thr-37 
in Rho, Thr-35 in Rac) of the GTP-binding protein (Just et al, 1995c, 1996, Selzer et al, 
1996). The interaction of C. docile toxins A and B with Rho proteins will be discussed 
in more detail in Section 6. 
65 
The Rho GTPases form a subgroup of the Ras superfamily of low molecular mass GTP- 
binding proteins comprising RhoA, RhoB, RhoC, Racl, Rac2, Cdc 42 and RhoG. They 
are primarily involved in the organisation of the actin cytoskeleton but have also been 
associated with protein phosphorylation, phospholipid synthesis, formation of protein- 
protein complexes and regulation of transcription factors (Machesky and Hall, 1996). 
Rho has been shown to control the formation of stress fibres and focal adhesins as well as 
being involved in growth regulation. Rac is involved in lamellipodia ruffling and Cdc 42 
induces filapodia. (Machesky and Hall, 1996). 
Cellular actin rapidly turns over between the monomeric (G-actin) and the polymeric (F- 
actin) forms. The turnover rate is controlled by two classes of actin binding proteins 
called sequestering proteins and capping proteins (Symons, 1996). Sequestering proteins 
bind to G-actin and inhibit actin polymerisation whereas capping proteins inhibit 
polymerisation by binding to the barbed (fast polymerising) ends of filaments. Activated 
Rho GTPases are believed to be involved in the mechanism of filament uncapping thus 
allowing further actin polymerisation (Hartwig et al, 1995). Rho GTPases function as 
molecular switches shuttling between the active GTP-bound state and the inactive GDP- 
bound state. The cycling between the two states of Rho is controlled by three additional 
factors, GTPase activating proteins, GTPase exchange factors and GDP dissociation 
inhibitors (Symons, 1996). 
Figure 1.3 illustrates the transition between the active and inactive states of Rho and the 
conformational changes that allow modification by C. docile toxins. Tbr-37 is part of the 
switch region involved in the transition between the active and inactive states of the GTP- 
binding proteins. In the inactive state the OH groups of Thr-3 7 of Rho is made accessible 
for modification by C. docile toxins A and B (von Eichel-Streiber et al, 1996). The 
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toxins glucosylate Rho at Thr-3i, disrupting the normal switch mechanism rendering the 
molecule permanently inactive. This leads to a breakdown of the actin filament network 
of cells. A consequence of the depolymerisation of F-actin to G-actin is that the tight 
junctions between cells is destroyed (von Eichel-Streiber et al, 1996). 
Toxins A and B have become powerful tools for delineating the signal transduction 
pathways mediated by the small GTP-bindmg proteins. They have been used to study 
Rho protein-dependent phospholipase D (PLD) activity in human embryonic kidney cells 
(Schmidt et al, 1996) and in human promyelocytic leukaemia HL60 cells (Ohguchi et al, 
1996). Inactivation of Rho by toxins A and B caused a marked inhibition of membrane 
associated PLD activity. PLD hydrolyses membrane phospholipids but has also been 
shown to act as a mediator of actin reorganisation downstream of Rho proteins (Steed et 
al, 1996). Blockage of PLD activation may, therefore, lead to cytoskeletal 
rearrangements. It has been suggested that C. docile toxins may mediate their cytotoxic 
and enterotoxic effects, in part, by inhibiting the Rho-PLD pathway (Ohguchi et al, 
1996). 
1.7.5.7 Interaction with cells of the immune system 
Toxins A and B are potent activators of human monocytes, with toxin A also being a 
potent chemoattractant of granulocytes (Pothoulakis et al, 1988, Flegel et al, 1991, 
Linevsky et al, 1997). Toxin A has a direct effect on mast cells, stimulating them to 
release small amounts of TNF-a. Longer exposure to toxin A however, affects the release 
of inflammatory mediators from mast cells, possibly due to the alteration of the 
cytoskeleton and induction of apoptosis (Calderon et al, 1998). Toxin B has been shown 
to stimulate monocytes to produce the inflammatory products interleukin-1 (IL-1), IL-6 
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and tumour necrosis factor (TNF) which contribute to epithelial damage, mucus release 
and membrane permeability. Toxin B is extremely toxic to monocytes and eventually 
eliminates them thus preventing phagocytosis of bacteria (Flegel et al, 1991). Toxin A 
causes a rapid dose dependent increase in the concentration of free cytosolic calcium in 
human granulocytes which stimulates a chemotactic response by granulocytes to toxin A 
(Pothoulakis et al, 1988). The increased cytosolic calcium is thought to initiate an 
infiltration of the intestinal lamina propria with granulocytes, which are activated to 
release inflammatory mediators and cause epithelial damage. Toxin A also stimulates the 
release of macrophage inflammatory protein-2 (MIP-2) from macrophages and intestinal 
epithelial cells in vitro (Castagliuolo et al, 1996). MIP-2 has chemotactic properties on 
polymorphonuclear cells (PMNs). By blocking the effects of MIP-2 in the rat ileal loop 
model with MEP-2 antiserum, investigators were able to inhibit toxin A induced 
inflammatory diarrhoea (Castagliuolo eta!, 1996). 
More recently came the demonstration that toxin A induces the release of neutrophil 
chemotactic factors, including TNFa and IL-1B, from rat peritoneal macrophages (Rocha 
et al, 1997). Toxin A stimulated macrophages have also been shown to release an 
additional factor capable of inducing intestinal secretions in vitro (Rocha et al, 1998). 
The release of this intestinal secretory factor (ISF) was significantly reduced by platelet 
activating factor (PAF), TNFa inhibitors, cyclo-oxygenase inhibitors and pertussis toxin. 
Both monoclonal anti-IL-1B and recombinant human IL-1 receptor agonist completely 
blocked the activity of the ISF. The investigators determined that cyclo-oxygenase 
products, PAF and TNFa are involved in the release of the ISF. From their data they 
concluded that the ISF was IL-1B and that its regulation was dependent on the activation 
of a G-protein (Rocha et al, 1998). 
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A recent study has shown that T84 and HT29 cells produce IL-8 in response to toxin A 
exposure (Mahida et al, 1996). In this study, toxin A induced epithelial cell rounding, 
detachment and apoptosis in human colonic biopsy specimens. Others have reported that 
IL-8 is induced in intestinal epithelial cell lines in response to cytokines such as IL-I and 
TNFa (Eckmann et al, 1993). Loss of adherence between intestinal epithelial cells and 
of cells to the extracellular matrix component of the basement membrane has also been 
shown to induce apoptosis (Bates et al, 1994, Ruoslahti and Reed, 1994). It was therefore 
concluded that intestinal epithelial cell IL-8 production and apoptosis most likely 
occurred as a consequence of cell injury and detachment rather than as a direct effect of 
the toxin (Mahida et al, 1996). As IL-8 is a potent chemoattractant of PMNs, however, it 
is likely that its production is essential for the induction of the intestinal inflammation 
seen in PMC. The effect of toxin A on lamina propria T-cells, macrophages, and 
eosinophils was also studied (Mahida et al, 1998). None of these cells require adherence- 
dependent signalling from components of the extracellular matrix for survival and 
therefore any induction of apoptosis would most likely be due to a direct effect of the 
toxin on the cells. The results showed that toxin A induced an early rapid loss of colonic 
lamina propria macrophages followed by apoptotic death of T-cells and eosinophils 
(Mahida et al, 1998). Toxin A also induced the release of TNFa from lamina propria 
cells, however, neutralisation of this cytokine did not influence toxin induced apoptosis 
of T-lymphocytes. The investigators were able to demonstrate toxin A induced apoptosis 
of purified T-lymphocytes implying that toxin A induces cell death following a direct 
interaction with the cells (Mahida et al, 1998). Toxin A also increased the proportion of 
T-cells expressing the IL-2 receptor (CD25) suggesting that toxin A induces activation of 
T-cells prior to their death by apoptosis. These studies demonstrate that C. docile toxin 
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A is capable of suppressing human colonic mucosal immune responses by inducing early 
loss of macrophages followed by T-cell apoptosis. It is possible that toxin A induces cell 
death by apoptosis by inactivating the cytosolic Rho GTPases (Mahida et al, 1998). 
C. docile toxin B has also been shown to potently activate monocytes to release IL-8 
(Linevsky et al, 1997) and to induce apoptosis of intestinal cells (Fiorentini et al, 1998). 
1.8 Structure-function relationships of the C. docile toxins 
When the research for this PhD was initiated, the only structure-function relationship that 
had been made for either toxin A or B was the observation that toxin A binds to 
carbohydrate residues via repeating sub-units at the C-terminal end of its molecule. 
The trisaccharide residue Gala 1-3Galß 1-4G1cNac was identified as a receptor for toxin A 
on the rabbit erythrocyte (Krivan et al, 1986). There are 38 contiguous repeating units at 
the C-terminal end of toxin A, which were identified as a binding site for this 
trisaccharide (Price et al, 1987). Although this trisaccharide residue is not expressed on 
human cells, it led to the identification of the Lewis X, Y and I antigens as possible 
receptors for toxin A on intestinal cells (Tucker and Wilkins, 1991). A putative ATP 
binding site had also been located in the toxin B molecule between amino acids 651-683 
(Barroso et at, 1994) although no direct evidence has been provided to confirm this 
location. 
1.9 Mechanisms of action of toxins A and B 
Due to their high molecular weight and typical cytopathic action on cells in culture, 
toxins A and B have been classified as `large clostridial cytotoxins' (LCTs). The LCTs 
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have an N-terminal catalytic domain and a C-terminal receptor binding domain composed 
of repeating units (von Eichel-Streiber et al, 1996). The advantage of encoding several 
binding epitopes within one chain is that it allows the toxins to interact with more than 
one cell receptor thus increasing the affinity of the toxins for the cells. 
The C-terminal repeat regions of toxins A and B are the least homologous (von Eichel- 
Streiber et al, 1992) probably suggesting that they use different receptor structures for 
their cellular uptake. The fact that toxin B is not a potent enterotoxin may be explained 
by the lack of a receptor for the toxin on intestinal cells. 
Following receptor binding, the toxins are internalised by receptor mediated endocytosis 
(Henriques et al, 1987 Florin and Thelestam, 1983) via coated pits (Kushnaryov and 
Sedmak, 1989). Cells pre-treated with compounds that raise the pH of endosomes and 
lysosomes were reported to be protected from the cytopathic effect (CPE) suggesting that 
the toxins require passage through an acidic compartment for activation (Henriques et al, 
1987, Florin and Thelestam, 1983). In addition, intracellular processing of the toxin 
appears to be required in post endosomal compartments. The nature of the putative 
enzymatic processing has not yet been clarified although it has been suggested that 
activation of the toxins can only take place following partial unfolding of the proteins at 
low pH (Henriques et al, 1987). 
Experiments have shown that LCTs are active upon microinjection into the cytosol 
(Meuller et al, 1992). Induction of the CPE by microinjection, however, requires several 
fold higher amounts of the toxins than intoxication by the normal route. It is reasonable to 
suggest that the required processing conditions for the toxins are also present in the 
cytosol, although the natural route via endosomal compartments appears to provide a 
more efficient activation of the toxins. All LCTs share a central hydrophobic region 
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which is believed to be involved in membrane translocation (Barroso et al, 1994, 
Hofmann et al, 1995, von Eichel-Streiber et al, 1992). Following activation, this putative 
transmembrane-spanning region is thought to allow the toxins access into the cytosol 
where they have their effect. 
Once inside the cytosol the C. docile toxins glucosylate GTP-binding proteins of the 
Ras-related Rho subfamily using UDP-glucose as a substrate (Just et al, 1995a, b, c). This 
leads to actin depolymerisation, general cytoskeletal breakdown and cell rounding. The 
rounding of the cells, especially at the perijunctional ring, increases tight junction 
permeability between the cells, allowing for the leakage of fluids and soluble components 
into the colonic lumen. Another hypothetical model was suggested following the 
observation that toxin A stimulates intracellular calcium release which also alters 
epithelial permeability (Pothoulakis et al, 1988). This model states that binding of toxin 
A to its intestinal cell receptor stimulates transmembrane signals that result in the release 
of a mediator on the basolateral side of the epithelium. This mediator, of unknown nature, 
is thought to activate neurons that trigger fluid secretion and immune cells prior to Rho 
glucosylation (Castagliuolo et al, 1994). In this model, toxin B is unable to stimulate 
these transmembrane signalling events and thus unable to trigger fluid secretion. 
Following toxin A induced damage to the intestinal epithelium, both toxins access deeper 
cell layers of the gut where the damage continues. Interaction of toxins A and B with 
cells of the immune system (See Section 1.7.5.7) results in the release of inflammatory 
mediators which cause additional cellular damage and increased permeability of the 
lamina propria. 
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1.10 Research aims and objectives 
When this research was initiated a very limited amount of information was available on 
the structure-function relationships of either toxin A or B. In order to control C. docile 
associated disease, it is essential to understand the mechanism of action of these toxins 
and the part they play in the disease process. The aim of this PhD is to increase the 
understanding of the structure-function relationship of toxin A, the most important 
virulence factor of C. docile. 
It is proposed to PCR amplify, clone and express overlapping DNA fragments covering 
the entire toxin A molecule. The recombinant toxin A peptides will be purified then used 
to raise polyclonal monospecific antisera in rabbits in order to provide important 
information of the tertiary structure of toxin A. In addition, the peptides will be used to 
localise a full range of biological activities of toxin A, including glucosyltransferase 
activity, nucleotide binding, haemagglutination, cytotoxicity, non-specific binding to 
monoclonal antibodies and receptor ligand binding. The identification of regions of the 
enterotoxin molecule that are important for toxicity will be essential for the future 
development of preventative therapy. 
The overlapping peptides covering the entire toxin A molecule will also prove to be an 
invaluable and unique tool for future research into many other aspects of C. docile 
disease. 
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SECTION-2 
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Section 
-2 
General Materials and Methods 
2.1 Bacterial strains, plasmids and growth conditions. 
2.1.1 Source and culture of Escherichia coli strains. 
The genotypes and sources of E. coli strains used in this study were BL21 (DE3) [F ompT 
hsdSB(rB mB) gal dcm(DE3)] (Novagen Inc), JM109 [endAl, recAl, gyrA96, thi, hsdR17, 
(rI, mK+), relAl, supE44, ?, A(lac-proAB), [F', traD36, proAB, lacI9ZAM15]] (Stratagene) 
and TB1 [araA(lac proAB) rpsL ($80 lacZAM15) hsdR ] (New England Biolabs). 
The E. coli strains stored at 
-70°C in Luria-Bertani broth (LBB) plus 30% glycerol were 
inoculated onto Luria-Bertani agar (LBA) plates (containing antibiotics where necessary) 
and incubated at 37°C overnight to isolate single colonies. Overnight cultures of the 
bacterial strains were produced by inoculating a single bacterial colony into 10 mis of LBB 
(plus antibiotics where necessary) and incubating for 15 hrs at 37°C aerobically with 
shaking (250 rpm). 
2.1.2 Source and culture of Clostridium di/cile strains. 
The virulent C. docile strains used in this study were clinical isolates from the stools of 
patients who presented with C. docile infection. The avirulent strain was a clinical isolate 
from a patient who presented with diarrhoea due to Shigella sonnei. The strains used 
included strain VPI 10463 [highely virulent and toxigenic] (Krivan et al, 1986), M-1 
[avirulent and non-toxigenic] (Borriello et al, 1987) and 8864 [toxin B positive, toxin A 
negative, poorly virulent] (Haslam et al, 1986; Torres, 1991; Borriello et al, 1992). 
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The C. docile strains stored in Robertsons Cooked Meat Medium (Southern Group 
Laboratories, U. K) were inoculated onto blood agar plates and incubated anaerobically 
(MK3 Anaerobic Work Station; Don Whitley Scientific Ltd, England) for 2 days at 37°C to 
isolate single colonies. 
To produce overnight cultures of the C. docile strains, a single bacterial colony was 
inoculated into 10 mis of Modified Brain Heart Infusion (MBHI) broth (3.7% BHI, 0.5% 
yeast extract, 0.05% cysteine hydrochloride and 0.03% sodium formaldehyde 
sulphoxylate, pH 7.3) and incubated anaerobically at 370C for 2 days. 
2.1.3 Plasmids and antibiotic resistance. 
The T-tailing vector pCRII (Invitrogen) confers on E. cola strains resistance to ampicillin 
(l00µgm1'1). The expression vectors pMalc2, pMalp2 (New England Biolabs) pET3a and 
pET3d (Novagen) confers on E. coli strains resistance to ampicillin (100µgm1"'). The 
expression vector pET30a (Novagen) confers on E. coli strains resistance to kanamycin 
(30µgm"). 
E. coli transformants containing these plasmids were grown as described in section 2.1.1 
with the exception that the relevant antibiotic described above was included in the LBB 
and LBA media. 
2.1.4 Preparation of calcium chloride competent E. coli cells. 
Calcium chloride (CaC12) competent JM109 and XL2-Blue cells were purchased from 
Stratagene Ltd while BL21 DE3 cells were obtained from Novagen Inc. CaC12 competent 
TB1 cells were purchased from New England Biolabs Ltd. Cells were also prepared `in 
house' by the method described by Ausubel et al, 1992. 
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A single colony of E. coli BL21 DE3, TBI or JM109 was inoculated into 50 mis of LBB 
and grown overnight at 37°C with shaking. Four mis of the overnight culture were 
inoculated into 400mls of LBB in a2 litre flask and grown at 37°C, with shaking (250 
rpm), to an OD600 of 0.4. The culture was aliquoted into eight 50m1 pre-chilled 
polypropylene tubes and incubated on ice for 5-10 mins. The cells were gently pelleted at 
1,600 xg for 7 mies at 4°C, then each was resuspended in 10 mis of ice-cold calcium 
chloride (CaC12) solution (60mM CaC12,15% glycerol, 10mM piperazine N, N'-bis 2- 
ethane-sulphonic acid [PIPES]). The cells were pelleted at 1,100 xg for 5 mins at 4°C, then 
each resuspended in 10 mis of fresh ice-cold CaC12 solution. The cells were incubated on 
ice for 30 minn and then centrifuged at 1,100 xg for 5 mies at 4°C. Each pellet was 
resuspended in 2 mis of ice-cold CaC12 solution. Aliquots (250gl) of CaC12 competent cells 
were placed into pre-chilled eppendorf tubes and stored at -70°C. 
2.1.5 Preparation of electroconipetent E. coli cells. 
Electrocompetent E. coli BL21 DE3 cells were purchased from Novagen Inc., USA. 
Electrocompetent E. coli BL21 DE3 or JM109 cells were also prepared using the method 
described by Ausubel et al, 1992. 
A single colony of E. coil cells was inoculated into 5 mis of LBB and grown overnight at 
37°C with shaking, then 2.5 mis of the overnight culture were inoculated into 500 mis of 
LBB and grown at 37°C with shaking to an OD6w of 0.5-0.6. 
The cells were chilled in an ice-water bath for 10-15 mins, then centrifuged at 5,000 xg for 
20 mins at 4°C. The cells were resuspended gently in 5 mis of ice-cold sterile distilled 
water (SDW) before adding a further 500 mis of ice-cold SDW. The cells were mixed and 
centrifuged at 5,000 xg for 20 mins at 4°C. Again the pellet was resuspended in ice-cold 
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SDW, mixed and centrifuged as described above. The supernatant was gently poured off 
and the pellet was resuspended by swirling in the remaining liquid. The cells were mixed 
with 40 mis of ice-cold 10% glycerol and then centrifuged at 5,000 xg for 20 mins at 4°C. 
The cells were resuspended in an equal volume of ice-cold l0% glycerol and 100µl 
aliquots were placed into pre-chilled eppendorf tubes then stored at 
-70°C. 
2.2 DNA Manipulations. 
2.2.1 C. docile chromosomal DNA extractions. 
Toxigenic C. docile VPI 10463 was grown in dialysis tubing suspended in Brain Heart 
Infusion Broth (BHIB) (see section 2.1.2). The culture ( 100mis) was centrifuged at 
10,179xg for 1 hr at 4°C (High Speed 18 Refrigerator Centrifuge; MSE). The cell pellet 
was washed with 20 mis of SDW and the cells harvested at 9,000xg for 10 mins. The pellet 
was resuspended in 15 mis of 1M sucrose and 15 mis of lysozyme solution (10 mg/ml in 
SDW) then incubated at 37°C for 1 hr. 
Following centrifugation at 9,000xg for 5 wins, the pellet was resuspended in 7.5 mis 
50mM Tris-HC1 pH 8.0,2.5mis 0.25 M EDTA pH 8.0 and 600 µd pronase (20 mg/ml) then 
incubated at 37°C for 30 minn. 
The cells were lysed by firstly incubating with 2.5 mis N- lauroylsarcosine for 20 mies at 
37°C, then with 2 mis 10% SDS for 10 mins at 65°C. RNA was removed by incubating 
with 12.5 mis SDW and 250µ1 of 10 mg/ml RNase for 30 mins at 37°C. The DNA 
preparation was purified by adding an equal volume of phenol: chloroform: IAA (6: 4: 1), 
(Sigma) mixing gently and then centrifuged at 9,000 xg for 5 mies. The upper layer was 
removed to a clean tube and extracted twice more with phenoUchloroform/IAA as 
described. To remove contaminating phenol two successive chloroform extractions were 
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performed. In each case the upper layer was mixed with an equal volume of chloroform 
and then centrifuged at 9,000 xg for 5 mins. To precipitate the DNA, the upper layer was 
gently mixed with an equal volume of isopropanol and 0.05 volumes of 7.5M NH4Ac. The 
DNA was spooled out of solution using a glass rod and placed in a clean eppendorf tube. 
The DNA was washed in 5x 1 ml of 80% ethanol, then air dried and resuspended in 500µ1 
of SDW. 
2.2.1.1 Calculation of DNA concentration: 
To calculate DNA concentration, 5µl of DNA was mixed thoroughly with 495µl of SDW 
then transferred to a 0.5 cm UV glass cuvette. Spectrophotometer readings were taken at 
260 nm and 280 nm using 500µ1 of SDW in an identical cuvette as a blank reference. The 
following equation was used to calculate the concentration of double stranded DNA: 
A260 value x 2* x 100** x 50*** = DNA concentration (µg/ml) 
* Pathlength: cuvettes are 0.5 ml thick but the equation relies on 1 cm cuvettes. 
** Dilution factor of DNA. 
*** When A260 = 1, the double stranded DNA concentration is 50µg/ml or the single 
stranded DNA concentration is 37µg/ml. The 50*** value is replaced with 37 for single 
stranded DNA. 
2.2.1.2 Calculation of DNA purity: 
For pure DNA: 
A6 = 1.9 
Azso 
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A value lower than this suggests contamination with phenol or protein and requires further 
purification. 
2.2.2 Isolation of plasmid DNA. 
2.2.2.1 Small scale preparation: 
Plasmid DNA (1-5µg) was isolated from an overnight bacterial culture using the Wizard 
Minipreps DNA Purification System (Promega), as outlined by manufacturers instructions. 
The Wizard DNA Purification protocol is based on a modified alkaline lysis procedure. 
Briefly, 3ml of an overnight bacterial culture was harvested by centrifugation at 11,600xg 
for 2 min. Bacterial pellets were resuspended in 0.2ml of cell resuspension buffer (50mM 
Tris-HCI, pH 7.5,10mM EDTA, 100µg/ml RNase A), and then lysed by the addition of 
0.2ml of cell lysis buffer (0.2M NaOH, 1% SDS). The cell lysate was neutralised by the 
addition of 0.2m1 of cell neutralisation buffer (1.32M Potassium acetate, pH 4.8), and the 
precipitate that formed was pelleted by centrifugation at 11,600xg for 5 min. I ml of 
Wizard Minipreps DNA Purification Resin was added to the supernatant before the 
Resin/DNA mix was passed through a Wizard purification column. The DNA bound to the 
column was washed by the addition of 2m1 of column wash solution (200mM NaCl, 
20mM Tris-HCI, pH 7.5,5mM EDTA, 55% ethanol), followed by centrifugation at 
11,600xg for 30 sec. Plasmid DNA was eluted from the column by the addition of 50µl of 
SDW (heated to 65°C), followed by centrifugation at 11,600xg for 30 sec. Plasmid DNA 
stocks were stored at 4°C. 
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2.2.2.2 Large scale preparation: 
Plasmid DNA (100-50Oµg) was isolated from an overnight bacterial culture using the 
Qiagen Maxi Plasmid Purification Kit (Qiagen Inc. ), as outlined by the manufacturers 
instructions. The Qiagen plasmid purification protocols are based on a modified alkaline 
lysis procedure. 
Briefly, 100ml of an overnight culture containing high copy number plasmid, or 500m1 of 
a culture containing low copy number plasmid was harvested at 6000xg for 15min at 4°C. 
The bacterial pellet was resuspended in 10ml of buffer PI (50mM Tris-HCI, pH 8.0; 
10mM EDTA; 100µg/ml RNase A), and then lysed by the addition of 10ml of buffer P2 
(200mM NaOH; 1% SDS). The cell lysate was neutralised by the addition of 10ml of ice 
cold buffer P3 (3. OM Potassium acetate, pH 5.5), and the precipitate that formed was 
pelleted by centrifugation at 10,000 xg for 30min. A Qiagen-tip 500 was equilibrated by 
applying 10ml of buffer QBT (750mM NaCl; 50mM MOPS, pH 7.0; 15% ethanol; 0.15% 
Triton X-100) and allowing the column to empty by gravity. The centrifugation 
supernatant was allowed to drip through the purification column, and the plasmid DNA 
that bound to the membrane was washed with 2x 30m1 of buffer QC (1. OM NaCl; 50mM 
MOPS, pH 7.0; 15% ethanol). Plasmid DNA was eluted from the purification column by 
the addition of 15m1 of buffer QF (1.25M NaCl; 50mM Tris-HCI, pH 8.5; 15% ethanol), 
and was then precipitated by the addition of 0.7 volumes of isopropanol followed by 
centrifugation at 10,000 xg for 30min. DNA pellets were washed with 70% ethanol, air 
dried and then resuspended in 200µl of SDW. Plasmid DNA stocks were stored at 4°C. 
2.2.3 Agarose gel electrophoresis 
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DNA was analysed by agarose gel electrophoresis as outlined by Maniatis et al, 1982. Two 
horizontal agarose gel electrophoresis systems were used throughout this project. The 
Anachem mini gel tank (model H2-SET) was used to run gels with dimensions 10cm x 
5.8cm x 0.5cm, and the Northumbria Biologicals Ltd. System (model SPH2O100) was used 
to run gels with dimensions 15cm x 13cm x 1cm. 
Unless otherwise stated, electrophoresis grade agarose (Boehringer Mannheim) was 
dissolved in 1x TBE buffer (90mM Tris Base, 90mM Boric acid, 2mM EDTA) to a final 
concentration of 0.8%. Linear DNA has an efficient range of separation that is related to 
the percentage of agarose in the gel (see table 2.1). DNA samples were diluted with 0.16 
volumes of 6x bromophenol blue loading buffer (0.25% bromophenol blue, 4(r(w/v) 
sucrose in water) before being applied to the wells of the agarose gel. A 1Kb DNA ladder 
(Boehringer Mannheim) was included on all gels for DNA size estimations. Gels were 
resolved in 1x TBE buffer containing 0.5µg/ml ethidium bromide at 80 Volts for 1-3hr. 
Following electrophoresis, DNA fiagments were visualised by Ultra-violet illumination 
(Transilluminator model TM40, Ultra Violet Products Inc). 
2.2.4 Purification of DNA from agarose gels using spinbind columns. 
DNA was purified from agarose gels using the `Spinbind® DNA Recovery System' (FMC 
Bioproducts, Denmark). A brief outline of the methodology is provided below. 
Following agarose gel electrophoresis (see section 2.2.3) the DNA fragment of interest was 
excised from the gel minimising the amount of agarose. The agarose was removed from 
the slice by centrifugation through glass beads (Sigma) at 11,600xg for 10 mins. The 
supernatant containing the DNA was collected, mixed with 1.5 volumes of sodium iodide 
(Nal) solution (reagent A), applied to a Spinbine unit, and then incubated for I min to 
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allow the solution to wet the MPS® membrane uniformly. The unit was centrifuged at 
11,600xg for 10secs then the supernatant was reapplied to the unit and spun for a further 
10secs. The supernatant was discarded and the unit transferred to a clean eppendorf tube. 
The DNA was washed by applying l00gl of ice-cold ethanol wash buffer (Reagent E) to 
the Spinbindd unit and spinning at 11,600xg for 10secs. The buffer was discarded and the 
wash stage repeated twice to remove Nat. The empty unit was centrifuged at 11,600xg for 
30secs to remove any remaining ethanol wash buffer, and subsequently transferred to a 
clean eppendorf. The DNA was eluted from the unit by applying 5Oµ1 SDW followed by 
centrifugation for 10secs at 11,600xg. The purified DNA was analysed by agarose gel 
electrophoresis (see section 2.2.3). 
2.2.5 Ethanol precipitation of DNA. 
Two volumes of 100% ethanol and 0.1% volume of 3M sodium acetate pH 5.2 were added 
to the DNA solution, mixed and incubated at 20°C for lhr. The mixture was centrifuged 
at 11,600xg for 30mins and the supernatant was removed. The DNA pellet was washed 
with 0.5ml of 70% ethanol and recentrifuged at 11,600xg for 10mins. The supernatant was 
removed and the DNA pellet was air dried then resuspended in 10-200µl of SDW (volume 
dependant on the amount of DNA expected). 
2.2.6 Restriction digestion of DNA. 
DNA was digested with DNA restriction enzymes as outlined by the manufacturers 
instructions (Boehringer Mannheim). 
Approximately 5µg (1-lOµ1) of DNA were digested with lµ1 of the relevant restriction 
enzyme (4-10 Units; Boehringer Mannheim) and 2µl of its respective 10 x buffer 
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(Boehringer Mannheim) in a 20µ1 reaction volume made up with SDW. Digests were 
incubated at 37°C or 30°C (as outlined by manufacturers instructions) for 2 hrs. Restriction 
digest profiles were analysed by agarose gel electrophoresis (see section 2.2.3). Where it 
was necessary to perform a double digest, the DNA was precipitated using ethanol (see 
section 2.2.5) following the first digestion before proceeding with the second digest. 
2.2.7 DNA Ligation. 
The compatible `sticky ends' of the digested vector and insert DNA were ligated in a 1: 1 or 
1: 3 ratio of vector to insert. To calculate a 1: 1 molar ratio of vector ends to insert ends, the 
following equation was used: 
Xng DNA insert = (Ybp DNA insert) (550 g, vector) 
(size in bp of vector) 
Ligations were performed in a 20µl volume reaction containing Xµl digested insert, Yµ1 
digested vector, 2. t1 10 x ligase buffer (Gibco BRL), 1 µl T4 DNA ligase (4U/µl, Gibco 
BRL), and were made up to 2Oµ1 with SDW. The reactions were incubated at 4°C 
overnight. 
2.2.8 Transformation of calcium chloride competent E. coli cells 
Approximately 50ng of plasmid DNA or 10µl of a ligation reaction (see section 2.2.7) 
were incubated with l00µ1 of ice-cold CaC12 competent E. coli cells (see section 2.1.4) on 
ice for 30mins. The cells were heat shocked in a 42°C water bath for 2mins then quickly 
placed on ice for a further 2mins. Nine hundred µl of LBB (pre-warmed to 37°C) was 
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added and each transformation reaction was incubated at 37°C with shaking (225rpm) for 
Ihr. The cells were pelleted by centrifugation at 11,600xg for 30secs then resuspended in 
20Oµ1 of LBB. The cell suspension was spread on the surface of LBA plates containing the 
appropriate antibiotics and selective reagents (outlined in the relevant sections). The plates 
were incubated at 37°C for 16hrs then stored at 4°C. 
2.2.9 Transformation of electrocompetent E. coli cells 
Approximately lOng of plasmid DNA or 51il of a ligation reaction (see section 2.2.7) were 
dialysed to remove salt prior to electroporation. The samples were placed on a filter (vs 
O. 025µ ; Millipore) and floated on the surface of SDW for 30mins at RT. One hundred µl 
of electrocompetent E. coli cells (see section 2.1.5) were thawed on ice then incubated with 
the dialysed DNA sample for 2mins on ice. The cells were added to a Gene PulsefTm 
cuvette (0.2cm Electrode Gap; Biorad) which was subsequently placed in the Gene 
pulserTM (Biorad). The electroporator was set at a resistance of 200 Ohms then 2.5Volts 
were passed through the cuvette. The transformation reaction was diluted immediately with 
9O0µ1 of LBB then incubated at 37°C with shaking (250rpm) for l hr. The cells were 
pelleted by centrifugation at 11,600xg for 30secs then resuspended in 300µl of LBB. The 
cells were spread on the surface of LBA plates containing the appropriate antibiotics and 
selective reagents (outlined in the relevant sections) then incubated at 37°C for 16hrs. 
2.3 PCR amplification of regions of the toxin A gene. 
Fragments of the toxin A gene were amplified from C. dilcile strain VPI 10463 
chromosomal DNA (see section 2.2.1) on a Techne Thermocycler (PHC-1) by the 
polymerase chain reaction (PCR). Oligonucleotide primers were designed based on the 
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published toxin A sequence data (Dove et al. 1990; see appendix 1). Forward primers read 
5' to 3' on the positive strand of the DNA helix, and reverse primers read 5' to 3' on the 
negative complementary DNA strand. Restriction endonuclease recognition sites were 
engineered into the primers for efficient cloning into plasmid vectors. 
One hundred ng of chromosomal DNA was amplified in a l00µ1 volume reaction 
containing 10mM Tris-HCI (pH. 8.3), 50mM KCI, 2mM MgC12,0.01% gelatin, 0.005% 
Tween-20,0.2mM dNTP's (Pharmacia) with Taq DNA polymerase (5U, Boehringer 
Mannheim U. K) and 1µg of each primer (outlined in the relevant sections). Controls 
containing only one of the two primers, and a control lacking template DNA were included 
in each amplification reaction. Each reaction mixture was overlayed with 50µ1 of mineral 
oil (Sigma). Various thermocycling conditions (outlined in the relevant sections) were used 
to denature, anneal and extend the template DNA for a total of 35 cycles, with a final 
extension cycle of 72°C for 10 min. Amplified DNA was analysed by agarose gel 
electrophoresis (see section 2.2.3), and stored at 4°C. 
2.4 Cloning of PCR products using the Original TA Cloning Kit. 
PCR products were first cloned into a T-tailing vector as outlined by the manufacturers 
instructions (Invitrogen). A brief outline of the procedures is given below. 
2.4.1 Ligation to the pCR11 plasmid vector. 
A 1: 1 or 1: 3 ratio of vector DNA to PCR product DNA was used for ligation reactions (see 
section 2.2.7) which were performed in a l0111 volume reaction containing 5µd SDW 
(TAl), I gl 10 x ligation buffer (TA2), 2 i1 pCRI I vector (TA3,25ng/gl), 1 µl of purified 
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PCR product (Xng), and 1 µl of T4 DNA ligase (TAS). The ligation reactions were 
incubated at 4°C for a minimum of 4br but usually overnight. 
2.4.2 Transformation of constructs into Inv aF competent cells. 
One vial of One Shot Inv aF competent cells per ligation reaction was defrosted on ice. 
Two µl of 0.5M ß-mercaptoethanol (TA! 1) followed by I µl of the ligation reaction was 
added to the competent cells, which were mixed by gentle stirring. The cells were 
incubated on ice for 30 min, heat shocked at 42°C for 30 sec then immediately cooled on 
ice for 2 min. The transformed bacteria were supplemented with 4500 of the supplied 
SOC medium and allowed to grow with shaking (225 rpm) at 37°C for lhr. One hundred µl 
of each reaction was spread onto the surface of an LBA plate containing 100µgml' of 
ampicillin (LB Amp) that had been pre-spread with 501l of 20mgmr' 5-bromo-4-chloro-3- 
indoyl-ß-D-galactosidase (X-gal) Ihr previously. The plates were inverted and incubated at 
37°C overnight. 
White colonies indicated transformation of recombinant plasmids. Ten such colonies were 
selected and the plasmids isolated using the Qiagen Plasmid Mini kit (see section 2.2.2.1). 
Each plasmid was digested with the relevant restriction endonucleases (see section 2.2.6) 
to excise the cloned DNA fragment. The DNA profiles were examined by agarose gel 
electrophoresis (see section 2.2.3) to identify clones with the correct size insert. Positive 
clones were stored in glycerol at -70°C (see section 2.1.1). 
2.5 Automated DNA sequencing 
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A detailed account of the methodology can be found in the ABI PRISM Dye Termination 
Cycle sequencing Ready Reaction Kit protocol ( Perkin Elmer). A brief outline is provided 
below. 
Recombinant plasmids were purified (see section 2.2.2.2) and resolved on a 0.8% agarose 
gel (see section 2.2.3) with a DNA mass ladder (Gibco) to establish the plasmid DNA 
concentration. The plasmid insert DNA was sequenced in the DNA sequencing laboratory, 
Queens Medical Centre, Nottingham. The plasmid was used as a template in a 
thermocycling reaction to incorporate a fluorescent dye termination. The plasmid was 
precipitated, washed in ethanol and dried under vacuum (Speed Vac Plus SC21OA; 
Saivant). The dried plasmid was resuspended in formamide EDTA and resolved on a 
sequencing gel (Applied Biosystems 373A DNA Sequencer) for 14hrs before signal 
analysis. 
2.6 Toxin A production. 
Highly purified toxin A was obtained from crude culture filtrate using bovine- 
thyroglobulin affinity chromatography followed by two step anion-exchange 
chromatography on Q Sepharose Fast Flow (QSFF) and Mono Q columns. Cytotoxicity 
and haemagglutination (H/A) assays were used to test fractions collected at each stage of 
purification, such that fractions containing toxin A (positive in both assays) could be 
identified and pooled for further purification. Polyacrylamide gel electrophoresis (see 
section 2.7.1) was used to check the homogeneity of the final product eluted off the Mono 
Q column. Full details are given below. 
2.6.1 Growth of C docile in dialysis bags. 
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Toxigenic C. docile VPI 10463 was grown in dialysis tubing (size 2,14.3mm; Medicell 
International Ltd., England), suspended in Bill broth (BHI [3.7%], yeast extract [0.5%], 
cysteine hydrochloride [0.05%] and sodium formaldehyde sulphoxylate [0.03%], pH 7.3) 
and incubated anaerobically at 37°C for 3 d. Dialysis tubing was cut to length and secured 
with string to the tubing in a rubber bung, so that the tubing was able to hang freely in an 
11 side-arm flask containing Bill broth. A small amount of sterile phosphate buffered 
saline (PBSA) was added to the tubing before the bung was wrapped in foil and autoclaved 
at 121°C for 15 mins. Following autoclaving, 50 ails of PBSA was added to the dialysis 
tubing and the system incubated aerobically at 37°C overnight, to allow equilibration of 
micronutrients between the dialysis bag contents and the Bill broth. The following day, 
the dialysis tubing was inoculated with 1 ml of an 18 h 10 ml C dif cile VPI 10463 
suspension, followed by enough sterile PBSA to make the tubing taut. The top of the flask 
was covered with autoclaved foil and the system was incubated anaerobically at 37°C for 3 
d. The contents of the dialysis tubing were harvested and centrifuged at 10179 xg at 4°C 
for 1h (High Speed 18 Refrigerator Centrifuge; MSE). The culture supernatant containing 
the toxin A protein was filtered (0.45 µm; Acrodisc) and stored at 4°C until purification 
could be carried out as outlined below. 
2.6.2 Thyroglobulin affinity chromatography. 
The method used was that of Krivan and Wilkins (1987). Two hundred and fifty mg of 
bovine thyroglobulin (Sigma Chemical Co, St Louis, USA) was dissolved in 50mis of 0.1 
M MOPS buffer. The thyroglobulin solution was then reacted with 10mis of activated 
affinity gel 15 (Bio-Rad Laboratories), overnight at 4°C on a shaker. Any remaining 
active sites on the gel were then blocked by treatment with 100 µl of 0.1M ethanolamine 
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for 3mins at 4°C. The coupled beads were packed into a glass column (Pharmacia, 
Uppsala, Sweden: column C10/10,10 x 100 mm) and washed at 37°C, firstly with 20 
column volumes of a basic buffer (0.1 M glycine 0.5 M NaCl pH 10) then 20 column 
volumes of an acidic buffer (0.1 M glycine, 0.5 M NaCl pH 2.0). These stringent washes 
ensured that free thyroglobulin did not remain ionically bound to the gel. Finally the gel 
was equilibrated with 20 column volumes of TBS (0.05 M Tris buffer containing 0.15 M 
NaCl pH 7.0) at 4°C. Approximately 100 mis of crude C. dicile culture filtrate (see 
section 2.6.1) was applied to the column at 4°C. The column was washed with 100mis of 
TBS at 4°C to remove all proteins other than toxin A, which remained bound to the 
column. The column was then warmed to 37°C for 30 mins before toxin A was eluted by 
washing with 50mis of TBS at 37°C. The thermal eluate was collected in 5ml fractions, 
and each fraction was monitored for absorbency at 280nm, for cytotoxicity (see section 
2.6.5) and H/A (see section 2.6.4). 
2.6.3 Anion-exchange chromatography. 
Two types of anion-exchange chromatography were used as part of a Fast Protein Liquid 
Chromatography (FPLC) apparatus to analyse the toxins of C. docile (as described in 
Borriello et al, 1987) 
The thyroglobulin eluted fractions containing toxin A were pooled and filtered (0.2µm; 
Acrodisc). The sample was first applied to a QSFF column (Pharmacia) via a 10ml super 
- 
loop (pharmacia) and then eluted by a0-1. OM sodium chloride gradient in 20mM Tris- 
HCI, pH. 7.5. For each fraction collected, the absorbance at 280nm, H/A (section 2.6.4) 
and cytotoxicity (section 2.6.5) were measured. Following QSFF chromatography, the 
fractions containing toxin A were desalted by dialysis against 20mM Tris-HC1, pH 7.5, 
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overnight at 4°C. The toxin A sample was then further purified by mono Q 
chromatography. The sample was applied to, and eluted from the mono Q column 
(Pharmacia) in the same way as for QSFF chromatography, with the exception that a 
plateau was added to the salt gradient just before the toxin A elution point to remove a 
known closely eluting contaminant (Kamiya et al, 1988). 
2.6.4 Haemagglutination assay. 
This assay is based on a method described by Krivan et al (1986) with the slight 
modification that a 1% rabbit red blood cell (RRBC) suspension was used (Kamiya et al, 
1988), instead of a 2.5% suspension. Two-fold serial dilutions of the samples (50µ1) were 
prepared with Tris Buffered Saline (isotonic buffer) in the wells of a v-bottom 
microtitration plate (Seto-well). Fifty t1 of a 1% RRBC suspension was added to each well 
and left to incubate for at least 3h at 4°C. H/A titres were expressed as the reciprocal of 
the highest dilution giving a positive H/A when viewed by eye. 
2.6.5 Cytotoxicity assay. 
This assay makes use of African Green Monkey Kidney (Vero) cells, as described by 
Kamiya et al (1988). Vero cells were grown in culture flasks in Medium 199 (Sigma, St 
Louis, USA) containing 5% newborn calf serum, 1% penicillin and 1% glutamine (Growth 
medium). When confluent, the cells were recovered from the flask by incubating with 3 
mis of trypsin / EDTA solution (Sigma U. K. ) at 37°C for 2mins. The cells were loosened 
from the flask by gentle tapping and were resuspended in 20mis of growth medium. Two 
hundred µl aliquots of the cell suspension were added to each well of a 96 well sterile 
microtitre plate (Falcon). The cells were incubated overnight at 37°C to reach confluency 
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before the medium was replaced with 10091 of maintenance medium (Medium 199 
containing 2% newborn calf serum, 1% penicillin and 1% glutamine). Ten-fold serial 
dilutions of the toxin A samples were prepared in PBSA, and l00µ1 of each sample was 
added to the Vero cells in the microtitre plate. Following an incubation of 24 hat 37°C, 
cells were monitored for a cytopathic effect (CPE), commonly seen as cell rounding. The 
cytotoxicity titre (cytotoxic unit [CU]/100 µl) was expressed as the highest dilution that 
induced more than 50% CPE after an incubation of 24 h. 
2.7 Protein Manipulations. 
2.7.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
Protein samples were analysed by separating on linear SDS-PAGE gels using the method 
of Laemmli (1970). The larger the size of the protein to be analysed, the higher the 
percentage of acrylamide that was included in the gel. 
Polyacrylamide gels were poured using the solutions and volumes outlined in table 2.2. 
The Protean II electrophoresis system (Biorad) was assembled as outlined by 
manufacturers instructions and used to run gels with dimensions 20 cm x 16 cm. The 
Protean II mini electrophoresis system (Biorad), on the other hand, was used to run gels 
with dimensions 7cm x 9cm. 
The separating gel was poured then overlaid with a small layer of propan-2-ol to hasten the 
setting time. The propan-2-ol was washed from the surface of the separating gel with SDW 
before the stacking gel was applied. A comb (Biorad) was inserted into the stacking gel 
prior to its setting to form wells for protein sample loading. Once the stacking gel was set, 
the comb was removed and the gel was placed into the Protean electrophoresis tank 
containing three litres of running buffer (25mM Tris base, 250 mM glycine pH 8.3,0.1% 
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SDS). Protein samples were mixed with an equal volume of 2x SDS loading buffer 
(100mM Tris-HC1 pH 6.8,2% SDS, 20% glycerol, 0.2% bromophenol blue, 5% ß- 
mercaptoethanol), heated to 100°C for 5 minn then loaded into the wells in the stacking gel. 
Ten µl of either high or low molecular weight markers (Pharmacia) were also included on 
the gel to allow protein size estimations to be made. Protein samples were resolved on 
large gels at a constant current of 35 mA for 4 hrs or 8 mA for 16 hrs. Small gels were run 
at 200 Volts for 40 mins. 
protein profiles were visualised by incubating in coomassie blue solution (60mis SDW, 30 
mis propan-2-ol, 10 mis glacial acetic acid, 0.5g coomassie brilliant blue [Biorad]) for 1 hr 
with shaking then in destain solution (SDW: propan-2-ol : glacial acetic acid in a 6: 3: 1 
ratio) for 4x2 hrs. Alternatively the protein profiles on the gel were transferred to 
nitrocellulose by western blotting (see section 2.7.3). 
2.7.2 Silver staining of SDS-PAGE gels. 
Protein samples were resolved on an 8% SDS-PAGE gel (see section 2.7.1). The apparatus 
was dismantled and the gel placed in fixative (30% ethanol, 10% acetic acid) for 30mins at 
RT. The gel was transferred to sensitiser solution (0.28M NaAc, 30% ethanol, 0.1% 
sodium thiosulphate, 0.5% glutaraldehyde) for lhr at RT then washed for 4x 15mins in 
SDW. The gel was placed in 200mls of stain solution (0.1% AgNO3,0.005% 
formaldehyde) for lhr and the proteins visualised by incubating in developing solution 
(2.5% Na2CO3,0.016% formaldehyde) for 30mins at RT. The gel was rinsed in SDW to 
remove excess stain and the reaction stopped by placing in 10% acetic acid. 
2.7.3 Westen blotting and immunological detection. 
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The SDS-PAGE gel (see section 2.7.1) was incubated in transfer buffer (39mM glycine, 
48mM Tris base pH 8.3) for 2mins with shaking to remove SDS. One sheet of 
nitrocellulose (Schleider and Schull BA85,0.45µm), two sheets of 3MM blotting paper 
(Whatmann) and two transfer pads (Biorad) were pre-soaked in transfer buffer for 5mins. 
The sheet of nitrocellulose was placed on top of the gel and together they were sandwiched 
between the sheets of 3MM blotting paper. A transfer pad was placed either side and the 
sandwich was clamped then placed in the western transfer tank containing 31 of transfer 
buffer. One Biorad Transblot system was used for blotting gels with dimensions 20 cm x 
16 cm at a constant current of 220mA for 2hrs. A second Biorad Transblot system was 
used for blotting gels with dimensions 7cm x 9cm and was also set at 220mA for 2 hrs. 
Following protein transfer from the SDS-PAGE gel to the nitrocellulose, the apparatus was 
dismantled and the nitrocellulose placed protein side up in a plastic container. The proteins 
were stained red with Ponceau stain (Sigma) for 30s and the bands corresponding to the 
molecular weight markers were drawn onto the nitrocellulose. The ponceau stain was 
removed from the blot by rinsing in tap water. The western blot was blocked by incubating 
in 1% gelatin/PBSA/0.05% Tween 20 for 1 hr at RT with shaking. The nitrocellulose was 
washed briefly in PBSA/0.05% Tween 20 (PBST) and was then incubated with a primary 
antiserum to the protein of interest (diluted in 0.1% gelatin/PBST) for 2hrs at RT with 
shaking. The details of specific antisera and their corresponding dilution factors are 
provided in the appropriate sections. 
The filter was washed in PBST for 5x 5mins at RT with shaking. The protein of interest 
was localised by incubating with a 1: 1000 dilution of an alkaline phosphatase conjugated 
whole molecule IgG anti-rabbit or anti-mouse conjugate (Sigma) for 1 hr at RT with 
shaking. The blot was washed for 5x 5mins with PBST and then for 5mins with SDW. 
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The immune complex was detected by developing with BCIP/NBT alkaline phosphatase 
substrate solution (Sigma). Once the colour had developed, the reaction was stopped by 
rinsing in tap water and the nitrocellulose was air dried. 
2.7.4 Dot blotting of proteins. 
Two d of each test solution was spotted onto a small strip of nitrocellulose (Schleicher and 
Schuell, 0.2µm), and allowed to air dry. Blots were blocked with 1% gelatin (Biorad) in 
PBSA for ihr at RT, and then incubated with 3mis of primary antibody (diluted 1: 1000 or 
1: 10000 in 0.1% gelatin/ PBSA) for 2hr at RT. The blots were washed five times in PBSA 
/ 0.05% Tween 20 (Sigma) and then incubated with 3m1 of a 1: 1000 dilution of either goat 
anti-rabbit alkaline phosphatase conjugate (Sigma) or goat anti-mouse alkaline 
phosphatase conjugate (Sigma) for ihr at RT. Blots were washed five times with 
PBSA/Tween 20 and binding was visualised by incubating with 3m1 of BCIP/NBT 
substrate solution (Sigma). 
2.8 Expression and purification of recombinant peptides. 
2.8.1 Induction of expression of recombinant fusion protein. 
Cells containing the fusion plasmid were incubated overnight in LBB containing ampicillin 
(100µg/ml) at 37°C with shaking. LBB (9.9m1) containing ampicillin (100µg/ml) was 
inoculated with 0. lml of the overnight culture and the cells were incubated at 37°C with 
good aeration to 2x108 cells/m! (O. D. 6w of approx. 0.5). One ml of cells was removed, 
pelleted at 11,600 xg for 2min and resuspended in l00µ1 of 2x SDS-PAGE sample buffer 
(see section 2.7.1). This sample represented the uninduced control cells. Expression was 
induced in the remaining culture by the addition of isopropyl-ß-D-thiogalactosidase 
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(IPTG) to the final concentration of 0.3mM (for pMal vectors), 0.4mM (for pET3d 
vectors) or 0.1mM (for pET30a vectors), with continued incubation at 37°C for 2hrs or 
ihrs, for pMal vectors (New England Biolabs) or pET vectors (Novagen) respectively. 
Five hundred pl of cells was removed, pelleted at 11,600 xg for 2min and resuspended in 
100µl 2x SDS-PAGE sample buffer. This sample represented the induced cells. The 
uninduced and induced cells were boiled for 5min and the proteins resolved by 8% SDS- 
PAGE (section 2.7.1). The proteins were transferred to nitrocellulose by western blotting 
(section 2.7.3), and the presence of recombinant fusion protein was determined by 
immunological detection (see section 2.7.3). 
2.8.2 Purification of maltose binding protein (MBP) fusion products. 
The MBP fusion products were purified by amylose affinity chromatography as outlined 
by the manufacturers instructions ( New England Biolabs). 
One litre of LBB containing ampicillin (100µg/m1) was inoculated with 10m1 of an 
overnight culture of bacterial cells (section 2.1.1) containing the MBP fusion plasmid. The 
cells were incubated at 37°C with good aeration to 2x 108 cells/ml (O. D. 6m of approx. 
0.5). Expression was induced by the addition of IPTG to the final concentration of 0.3mM 
and the cells were incubated for a further 2hr. The bacteria were harvested by 
centrifugation at 4,000 xg for 20min, resuspended in 50mis amylose column buffer 
(20mM Tris-HCI, 200mM sodium chloride [NaCl], 1mM EDTA) and incubated at 
-20°C 
overnight. The cells were thawed in cold water and disrupted by l5sec bursts of sonication 
(Soniprep 150; MSE) at an amplitude of 8 microns, in an ice-water bath. Cell debris and 
insoluble proteins were pelleted by centrifugation at 9,000 xg for 30min and discarded. 
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The supernatant (crude extract) was diluted 1: 5 with amylose column buffer and stored at 
4°C before being loaded onto the amylose column. 
Amylose resin (New England Biolabs) was poured into a 2.5 x 10cm column (Biorad) and 
allowed to settle by gravity flow. The resin was washed with 8 column volumes of 
amylose column buffer before the diluted crude extract was applied at a flow rate of 
approximately lml / min. The resin was washed with 10-12 column volumes of amylose 
column buffer, before being sealed and stored at 4°C overnight. The fusion protein was 
eluted from the resin with amylose column buffer containing 10mM maltose, and was 
collected in 10 fractions of 3m1 each. The three fractions containing the highest 
concentration of fusion product were pooled, diluted in 50mis amylose column buffer then 
passed through an amylose column a second time. Each eluted fraction was analysed for 
the presence of fusion protein by 8% SDS-PAGE (section 2.7.1). 
2.8.3 Cleavage of the MBP fusion products with factor Xa. 
The MBP was cleaved from fusion products by treatment with Factor Xa as outlined by the 
manufacturers instructions (New England Biolabs). 
Factor Xa cleavage was carried out at a w/w ratio of I% the amount of fusion protein. The 
reaction mixture was incubated for 3hr to overnight at 4°C. Protein profiles were analysed 
by SDS-PAGE (section 2.7.1). Depending on the particular fusion protein, the amount of 
Factor Xa was adjusted within the range of 0.1-5.0% to get an acceptable rate of cleavage. 
2.8.4 Determination of the solubility of recombinant toxin A peptides. 
One hundred ml cultures of bacterial cells containing a plasmid with a toxin A DNA insert 
and a plasmid lacking a DNA insert were incubated at 37°C with shaking to an OD6W of 
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0.5. Half of each culture was removed and the cells pelleted at 5,000xg for 20mins at 4°C 
(uninduced cells). Expression of recombinant protein was induced in the remaining culture 
by the addition of IPTG (for concentrations see section 2.8.1) with continued incubation at 
37°C. The uninduced cell pellets were resuspended in 10mis of PBSA then sonicated in an 
ice-water bath for bursts of 15secs at an amplitude of 10 microns. The insoluble proteins 
and cellular debris were pelleted from the sonicate at 10,000xg for 20mins at 4°C. The 
10ml supernatants (uninduced soluble fractions) were stored at 4°C until further analysis. 
The pellets were resuspended with the aid of sonication into 10mis of PBSA (uninduced 
insoluble fractions) then stored at 4°C until further analysis. 
Following the 2 or 3hr incubation of the second half of each culture, the induced cells were 
pelleted, sonicated and processed as already described for the uninduced samples to 
produce induced soluble and induced insoluble fractions. 
Each fraction was mixed 1: 1 with 2x SDS-PAGE sample buffer and resolved on two 8% 
SDS-PAGE gels (see section 2.7.1). One gel was stained with coomassie blue (see section 
2.7.1) and the remaining gel was western blotted (see section 2.7.3). The peptide of interest 
was detected on the blot using the method outlined in section 2.7.3. The primary antibodies 
used are outlined in the relevant sections. 
2.8.5 Purification of proteins from inclusion bodies present within E. coli cells. 
Based on a method for purifying proteins from inclusion bodies present within E. coli cells 
(Ausubel, F. M. et al, 1992). 
Briefly, IL of LBB containing 100pg/ml of ampicillin was inoculated with 10ml of an 
overnight culture of bacterial cells (section 2.1.1) containing the recombinant plasmid. The 
cells were incubated at 37°C with good aeration to 2x 108 cellslml (O. D. 6w of approx. 
103 
0.5). Expression was induced by the addition of IPTG to the final concentration of 0.4mM 
and the cells were incubated for a further 3hr. The cells were pelleted by centrifugation at 
5,655 xg for 10min and resuspended in 10ml of HEMGN buffer (100mM KCI, 25mM 
HEPES pH 7.6,0.1mM EDTA pH 8.0,12.5mM MgC12,10% glycerol, 0.1% Nonidet P. 40) 
containing protease inhibitors (1 mM dithriothreitol, 1 gg/ml leupeptin, 1 gg/ml pepstatin, 
0.1 mM PMSF and 0.1 mM sodium meta bisulphite). Cells were disrupted by incubating at 
4°C for 30min with 500ggIml of lysozyme (Sigma), followed by two 15sec bursts of 
sonication (Soniprep 150; MSE) at an amplitude of 8 microns. The inclusion bodies were 
pelleted at 27,000 xg for 15min, and then solubilised by rotating for 30min in 10ml of 
HEMGN buffer containing 4M guanidine HCl (Sigma) at 4°C. Following centrifugation at 
27,000 xg for 30min the supernatant was dialysed for periods of 4hr to overnight against 
IL of HEMGN buffer containing 1M guanidine HCI, 2x 1L of HEMGN buffer alone and 
against 2x 5L of Tris-buffered saline pH. 7 (TBS). Samples were collected prior to 
guanidine hydrochloride treatment and following final dialysis. The samples were resolved 
on an 8% SDS-PAGE gel (see section 2.7.1) and transferred to nitrocellulose by western 
blotting (see section 2.7.3). The antibodies used in detection are outlined in the relevant 
sections. 
2.9 Protein concentration determinations. 
2.9.1 Coomassie® plus protein assay reagent kit. 
Unknown protein concentration determinations were made by directly comparing an 
unknown absorbance value to the absorbance values of a set of albumin standards of 
known concentrations using the Coomassie® Plus Protein Assay Reagent Kit (Pierce, 
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U. K). Two procedures were adopted dependant on the approximate protein concentration 
expected: 
2.9.1.1 Standard assay procedure. 
The standard assay was used for determining protein concentrations in the range of 
75µgm1'' to 1,500µgmt'. A known protein concentration series was produced by diluting 
the stock albumin standard (Pierce, U. K) in the same diluent as the protein sample whose 
concentration was to be determined. The standard data points selected were 50,100,250, 
400,500,1,000 and 1,500µgm14. Ten µl of each dilute standard, of the unknown protein 
sample and of the sample diluent (to be used as a blank reference) were placed, in 
duplicate, into the wells of a microtitre plate (EIA; Biorad). Two hundred and ninety µl of 
Protein Assay Reagent (Pierce, U. K) was applied to each sample and mixed by gentle 
tapping. The absorbance values at 595nm of the protein/dye mixtures were recorded 
immediately. The absorbance at 595nm of the blank was subtracted from each standard or 
unknown protein sample absorbance. A standard curve was prepared by plotting the 
average net absorbance at 595nm for each dilute albumin standard. The standard curve was 
used to determine the protein concentration for each unknown protein sample. 
2.9.1.2 Micro assay procedure. 
The micro assay was used for determining protein concentrations in the range I to 25µgml 
1. This assay was performed as outlined in section 2.9.1.1 with the exception that the 
standard albumin data points were 1,5,10,15 and 25µgm i. Each sample was mixed with 
Protein Assay Reagent (Pierce, U. K) in a 1: 1 ratio before reading the absorbance values at 
595nm. 
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2.9.2 Estimation of the concentration of a protein within a mixed population. 
A stock albumin solution (Pierce, U. K) was diluted to 1 µgµ1' and 100ngµ1' in 2x SDS- 
PAGE sample buffer (see section 2.7.1). One hundred ng to 1µg, in 100ng incremental 
rises, plus 2µg and 31Lg of albumin were added to the wells of a 10% SDS-PAGE gel (see 
section 2.7.1). Five µg to 50µg, in 5µg incremental rises of albumin, were added to the 
wells of a second 10% SDS-PAGE gel. An aliquot of the sample containing the protein of 
interest was included on each gel, as was an aliquot of high molecular weight markers 
(Pharmacia). 
The two gels were resolved at a constant current of 70mA for 3-4hrs. The gels were stained 
in coomassie blue to visualise the protein bands (see section 2.7.1). Protein concentrations 
were estimated by visually comparing the band intensity of the protein of interest to the 
band intensities of the albumin standards. 
2.10 Optimisation of expression of recombinant peptides. 
2.10.1 Varying the IPTG concentration and the length of induction time. 
To optimise the expression of toxin A peptides, the method outlined in section 2.8.1 was 
adapted in the following ways. 
Aliquots of the recombinant toxin A bacterial culture were grown to an ODD of 0.4,0.5, 
0.6,0.7,0.8,0.9 and 1.0. Expression was induced in each of the aliquots by the addition of 
IPTG to final concentrations of 0.1mM, 0.2mM, 0.3mM and 0.4mM with continued 
incubation at 37°C. For each different sample, expression was stopped after 30mins, 
60mins, 90mins, 120mins, 150mins and 180mins by pelleting then resuspending in 2x 
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SDS sample buffer. Each sample was run on an 8% SDS-PAGE gel, stained with 
coomassie blue and western blotted (see section 2.7.1 and 2.7.3). 
2.10.2 Varying the host E. coli strain. 
Each recombinant plasmid containing a toxin A insert was transformed into 
electrocompetent BL21 DE3, JM109 and TB1 E. coli cells (see section 2.1.5) by 
electroporation (see section 2.2.9). 
Each clone was incubated at 37°C before expression of the toxin A peptide was induced 
(see section 2.8.1). Prior to addition of IPTG, lml of the cells was removed, pelleted at 
11,600 xg for 2mins then resuspended in 0.5ml PBSA (uninduced cells). After incubation 
with IPTG lml of cells was removed, pelleted and resuspended in 0.5m1 PBSA (induced 
cells). Both samples were sonicated in an ice-water bath for bursts of 15secs at amplitude 
of 8 microns. Two µl of the uninduced and induced samples were spotted onto 
nitrocellulose (Schleicher and Schull BA85,0.45µm). The sonicated induced sample was 
pelleted at 11,600 xg for 2mins and 2µl of the supernatant (induced supernatant fraction) 
was spotted onto the nitrocellulose. The nitrocellulose was left to air dry and the dot blot 
was performed (see section 2.7.4). Primary antibodies used are outlined in the relevant 
sections. 
2.11 N-Terminal sequencing of proteins. 
The toxin A peptides were cleaved where necessary from the MBP fusion using factor Xa 
at 4°C overnight as described above (see section 2.8.3). The protein mixture was resolved 
on a 10% SDS-PAGE mini gel (see section 2.7.1) then incubated for 5mins in 10mM 
CAPS (3-[cyclohexylamino]-1-propanesulphonic acid) buffer pH 11. The proteins were 
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transferred in CAPS buffer onto Hybond PVDF membrane (Amersham International) by 
western blotting (see section 2.7.3). The PVDF membrane blot was rinsed in SDW and the 
proteins stained for a few seconds in amido black solution (0.1% napthol black in 5% 
acetic acid). Excess stain was removed by rinsing in SDW and the protein band of interest 
was excised from the membrane using a sterile scalpel blade. The protein on the membrane 
strip was sequenced `in house' (Dept. of Biochemistry, Queens Medical Centre). 
2.12 Electro-elution of proteins from SDS-PAGE gels. 
Approximately 500µg of the MBP fusion product purified by amylose affinity 
chromatography (see section 2.8.2) was cleaved with factor Xa at 4°C overnight (see 
section 2.8.3). 
The protein mixture was resolved on a 10% SDS-PAGE mini gel alongside a sample of 
low molecular weight markers (see section 2.7.1). The gel was fixed in 20% methanol for 
15 mins. The proteins were stained in 20% methanol, 0.1% coomassie blue for 15mins 
then destained in 20% methanol for 15mins. Using a sterile scalpel blade and a clean 
surface, the protein band corresponding to the toxin A peptide of interest was cut from the 
gel and placed in 3mls of elution buffer (50mM Tris, 50mM glycine, 0.1% SDS) for 
15mins. 
A small circular disc (14 KDa cut off; Biorad) was softened by incubating in elution buffer 
at 65°C for 1 hr. The electroelution tank, glass capillary tube and filter holder (Biorad) 
were cleaned thoroughly in SDW then equilibrated in elution buffer for 10mins. The 
electroelution equipment was assembled making sure not to trap air bubbles between the 
fritt and the membrane. One litre of elution buffer was poured into the assembled tank and 
the buffer was kept circulating using a magnetic stirrer. 
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The protein/gel slice was given extra weight by dissolving lg of sucrose powder into the 
buffer. The entire sample including the gel slice was loaded into the glass capillary in the 
electroelution tank. The protein sample was eluted at a constant current of l OmA (per tube 
to be eluted) for 16 hrs. To dislodge proteins stuck to the membrane, the direction of the 
current was reversed for 10secs. The equipment was dismantled and the protein-containing 
fraction under the fritt was pipetted into an eppendorf. The eluted protein sample was 
analysed by 10% SDS-PAGE (see section 2.7.1). 
2.13 Determination of the pI value of proteins by isoelectric focusing (IEF). 
The Phastsystem equipment (Pharmacia) was used to determine the pi value of proteins. 
Two Broad Range IEF gels (Phastgel pH 3-9; Pharmacia) were pre-run for 75 Vlus to 
equilibrate. Two µl droplets of each protein sample were placed in the wells formed in a 
strip of Parafilm (Alpha Laboratories Ltd.; England). Two µl of Broad Range IEF Markers 
(Pharmacia) were placed into one of the wells to allow pI determinations to be made. An 
eight well comb (Pharmacia) was dipped into the protein samples and the comb then gently 
lowered to touch the surface of the centre of the gel. The same procedure was repeated to 
produce an identical second gel. The separation and control unit was set to run the gels for 
a further 425 Vhrs. 
At the end of the programme one of the gels was transferred to the development unit. 
Tubes attached to the equipment (1-9) were submerged into the following buffers 
respectively: 
- 
20% trichloroacetic acid (100mis); 50% ethanol, 10% glacial acetic acid 
(500mls); 10% ethanol, 5% glacial acetic acid (500mls); 8.3% glutaraldehyde (100mis); 
0.5% silver nitrate (100mis); 12.5% sodium carbonate (40mis), SDW (160mis), 
formaldehyde (100µ1); 5% glacial acetic acid (loon-is); 10% glacial acetic acid, 5% 
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glycerol (100mis); SDW (1,000mis). The chamber was set for developing a silver stain gel 
and the pre-set programme allowed to proceed. 
The second gel was western blotted onto nitrocellulose. The gel loading assembly was 
removed from the equipment and was replaced with the development unit. Six pieces of 
3MM paper (Whatmann), one piece of cellulose acetate (Whatmann) and one piece of 
nitrocellulose (Schleicher and Schull BA85; 0.45µm) were cut to the size of the gel and 
pre-soaked in transfer buffer (39mM glycine, 48mM Tris pH 8.3,5% methanol). Three of 
the sheets of 3MM and the nitrocellulose were placed onto the western blot platform. 
Using a cheese wire the gel was loosened from its plastic backing, transferred onto the pre- 
soaked sheet of cellulose acetate and placed cellulose acetate side down on top of the 
nitrocellulose on the blotting platform The three remaining sheets of 3MM were placed on 
top of the gel. Transfer buffer was applied to the electrode and the equipment was run for 5 
Vhrs. The blot was then developed (see section 2.7.3) to locate the protein of interest. 
2.14 Ion-exchange chromatography. 
When performing ion-exchange chromatography it is important to consider the pI of the 
protein of interest, the charge of the purification column and the pH of the ion exchange 
buffer. A generalised outline of the methodology is provided below. 
The protein sample was dialysed (Slide-A-Lyzer Cassette, IOKda cut off; Pierce) against 51 
of 20mM Tris pH 7.5 (for anion-exchange chromatography) or 5L of 50mM phosphate 
buffer (25mM disodium hydrogen phosphate, 25mM potassium dihydrogen phosphate) pH 
7.5 (for cation-exchange chromatography) overnight at 4°C. The sample was recovered, 
filtered (0.21im filters; Acrodisc) and applied to the ion-exchange column via a 10 ml 
super-loop (Pharmacia). A positively charged anion-exchange column (Mono Q; 
110 
Pharmacia) was used for purifying negatively charged proteins and a negatively charged 
cation-exchange column (Mono-S; Pharmacia) was used for purifying positively charged 
proteins. The proteins were eluted with a 0-1. OM sodium chloride gradient (made up in the 
relevant ion-exchange buffer). For each fraction collected, the absorbance at 280nm was 
determined. Fractions containing protein were analysed by SDS-PAGE (see section 2.7.1). 
2.15 Enzyme-! inked immunosorbent assay (ELISA). 
Protein samples were diluted in 0.05M carbonate buffer pH 9.6 to the final concentration 
of 5 or lOµgml"'. The wells of a 96 well Enzyme Immunoassay plate (EIA; Biorad) were 
coated in multiples of six with 50pl of the protein samples and incubated at 4°C overnight. 
The protein samples were removed and the wells blocked with 200µl of blocking buffer 
(1% gelatin/PBSA/0.05% Tween-20 [Sigma]) for lhr at RT. Fifty µl of primary antibody 
(specific details outlined in the relevant sections) diluted in 0.1% gelatin/PBSA/0.05% 
Tween-20 (diluent) were applied to three of the six wells coated with each protein sample. 
The remaining three wells for each sample were coated with 5Oµ1 of diluent (conjugate 
control samples) and all of the wells were incubated for 2 hrs at RT. The plate was washed 
with 4x 2001il of PBSA/Tween-20 (PBST) and the wells incubated with 50µl of a 1: 1,000 
dilution of either goat anti-mouse or goat anti-rabbit (specified in the relevant sections) 
alkaline phosphatase conjugate (Sigma) for 1 hr at RT. The plate was washed with 4x 
200µl of PBST then 2x 200µl of SDW before the reaction was developed by applying 
50µl of p-nitrophenyl phosphate substrate solution (pNpp; Sigma) to each well. When 
sufficient colour had developed the absorbency at a wavelength of 405nm was determined 
using an ELISA plate reader (Labsystems iEMS Reader N[F). 
III 
Amount of Agarose 
in Gel % w/v 
Efficient range of Separation of 
Linear DNA Molecules (kb) 
0.3 5-60 
0.6 1-20 
0.7 0.8-10 
0.9 0.5-7 
1.2 0.4-6 
1.5 0.2-3 
2.0 0.1-2 
Table 2.1 
Range of separation of DNA in gels containing different amounts of agarose (taken from 
Maniatis et ad, 1982). 
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Reagents Percentage Separating Gel 
5% 8% 10% 11% 12% Stacking Gel 
Acrylamide 7.5 ml 12 ml 15 ml 16.5 ml 18 ml 1.3 ml 
(National 
Diagnostics) 
Separating ** 11.25 ml 11.25 ml 11.25 ml 11.25 ml 11.25 ml 
Buffer 
Stacking Buffer * 2.5 ml 
Sterile Water 26.25 ml 21.75 ml 18.75 ml 16.25 ml 15.75 ml 6.1 ml 
10% Ammonium 150µl 1501I 150µl 150µI 150µl 100µI 
persulphate 
TEMED* l00µ1 100µI 100µl 100µl 100µI 50µl 
** 3M Tris-HC1 pH 8.8,0.4% SDS 
0.5M Tris-HCI pH 6.8,0.4% SDS 
Table 2.2 
Reagent volumes required for the preparation of SDS-PAGE gels. 
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Toxin A Constructs 
3.1 SUMMARY 
To study the structure-function relationships of Clostridium difficile toxin A it was 
necessary to produce overlapping peptides spanning the entire toxin A molecule. This 
section was successful in the PCR amplification of eight N-terminal (al, a2, b, c, d, e, f 
and g) and two C-terminal (hl and h2) overlapping fragments covering the entire toxin A 
gene. Both fragments hl and h2 spanned the complete C-terminal repeat end-binding 
portion of the toxin. Fragments al, a2, b, c, d, e, f, g and hl were cloned into the pMal 
vectors and were shown to be `in frame' with the mal E gene encoding the N-terminal 
maltose binding protein (MBP) fusion. The C-terminal repeat end fragment, h2, was 
cloned into the NcoI site of the pET 3d vector which bypasses the T7 purification tag. 
All of the toxin A fragments, except al, were successfully expressed in E. coli and named 
peptides A2-H2 respectively. With the exception of peptide E, the size of each 
recombinant peptide compared to the size estimated from the length of the insert DNA. 
Peptide E was estimated to be 125.85 kDa but was truncated at 108 kDa. Peptides A2, B, 
C, D, E, F, G and H1 were purified by amylose affinity chromatography. The purified 
peptides B, D, E and G were cleaved to completion with 1% factor Xa, whereas peptides 
A2, C and F were only partially cleaved. Peptide H1 was resistant to factor Xa cleavage 
and was subsequently replaced by unfused peptide H2 for studies involving the C- 
terminal repeat region of toxin k The expression of peptide H2 within inclusion bodies 
in the E. coif cell made purification by thyroglobulin affinity chromatography difficult. 
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The peptide was successfully purified from inclusion bodies, however, and was found to 
retain biological activity. 
This section was successful in the expression and purification of nine overlapping toxin 
A peptides. Of these, seven N-terminal peptides (A2, B, C, D, E, F and G) and one C- 
terminal peptide (H2) were studied throughout the remainder of this thesis. These eight 
overlapping peptides covered the entire toxin A protein. For a more detailed description 
of the location of these peptides in the toxin A molecule see appendices 4 and 5. 
3.2 INTRODUCTION 
Many functions have been attributed to both toxins A and B and have been discussed in 
full in section 1. Very few structure-function relationships, however, have been made for 
either toxin, particularly toxin A. For eventual vaccine development, it is essential to 
understand the way in which these toxins are contributing to C. difcile disease. This is 
where understanding the relationships between the structure and function of toxin A is 
important. 
There are many approaches to studying the structure-function relationships of toxin A. It 
is possible to cleave the toxin into smaller peptides using proteases such as trypsin or 
chymotrypsin. These proteases would cleave toxin A into more than thirty peptides by 
cleaving at arginine or lysine residues (Lyerly, D. M and Wilkins, T. D, 1988). It is also 
possible to disrupt regions of the toxin A molecule by site-directed mutagenesis then look 
for a loss of function of the mutated toxin. The method adopted in this thesis for 
structure-function analysis however was to PCR amplify and clone overlapping 
fragments of the toxin A gene. These fragments would be expressed in the pMal vectors 
and purified from E. coli making use of the MBP fused to the N-terminus of the 
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recombinant peptide. This fusion would later be removed by factor Xa cleavage. As the 
entire toxin A gene has been sequenced (Dove et al, 1990), this approach would make it 
possible to control the exact boundaries of each toxin A peptide. The limitation of these 
studies is that it cannot be guaranteed that the recombinant peptides will fold in the same 
way as their complementary regions in the native toxin A molecule. It is also possible 
that cloning the gene in small sections may result in the disruption of an active site 
causing the loss of a function. In a given assay, therefore, a positive result is a good 
indication that a particular peptide is responsible for a function, however a negative result 
does not rule out the involvement of that region of the toxin in the function in question. 
The aim of this section was to produce overlapping toxin A peptides representing the 
entire toxin A molecule. It was hoped that each peptide would later be assessed for its 
ability to contribute to particular functions displayed by the native toxin. 
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3.3 MATERIALS AND METHODS 
3.3.1 Polymerase chain reaction (PCR) amplification of regions of the toxin A gene. 
Throughout the next few sections, regions of the PCR primers in bold represent an 
engineered restriction endonuclease site, whereas underlined regions of the PCR primers 
represent an engineered translational stop codon. For all fragments amplified, I Oµ1 of the 
product was analysed by 0.8% agarose gel electrophoresis (see section 2.2.3). 
3.3.1.1 PCR amplification of fragment al. 
The forward primer 5' TATTGCTCTTGGATCCATAAAACAA 3' (1) and the reverse 
primer 5' CAGAAAGAGGTCGACCAGTCTAATC 3' (2) (see appendix 2) were used 
in a PCR reaction (see section 2.3) to amplify a 1.306 Kb fragment (al) of the toxin A 
gene covering base pairs (bps) 324 - 1,630. The thermocycling conditions were 
denaturation at 96°C for 1min, annealing at 57°C for 1min and extension at 72°C for 
2mins. 
3.3.1.2 PCR amplification of fragment a2. 
Due to the failure of expression of peptide Al (see section 3.4.6.1), this region of the 
toxin A gene was reamplified using a different forward primer to produce fragment a2. 
The forward primer 5' GGATCCATGTCTTTAATATCTAAAGAAG 3' (3) and the 
reverse primer (2) (see appendix 2) were used in a PCR reaction (see section 2.3) to 
amplify a 1.630 Kb DNA fragment (a2) of the toxin A gene covering bps 1-1,630. The 
thermocycling conditions were denaturation at 96°C for 1min, annealing at 51°C for 1 
min and extension at 72°C for 2mins. 
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3.3.1.3 PCR amplification of fragment b. 
The forward primer 5' TATACTGGTGGATCCCTTTCTGAAG 3' (4) and the reverse 
primer 5' CATTTTCAAGTCGACTGAACTAATC 3' (5) (see appendix 2) were used in 
a PCR reaction (see section 2.3) to amplify a 0.99Kb DNA fragment (b) of the toxin A 
gene covering bps 1,609 
- 
2,599. The thermocycling conditions were denaturation at 
97°C forl min, annealing at 50°C forl min and extension at 72°C for 1.5mins. 
3.3.1.4 PCR amplification of fragment c. 
The forward primer (1) and the reverse primer (5) (see appendix 2) were used in a PCR 
reaction (see section 2.3) to amplify a 2.275Kb DNA fragment (c) of the toxin A gene 
covering bps 324 
- 
2,599. The thermocycling conditions were denaturation at 97°C for 1 
min, annealing at 50°C for 1min and extension at 72°C for 3mins. 
3.3.1.5 PCR amplification of fragment d. 
The forward primer 5' ACTTGAAAATGGATCCGATGAATTA 3' (6) and the reverse 
primer 5' TTTATATTCGTCGACATTGGCTATG 3' (7) (see appendix 2) were used in 
a PCR reaction (see section 2.3) to amplify a 1.424Kb DNA fragment (d) of the toxin A 
gene covering bps 2,589 
- 
4,013. The thermocycling conditions were denaturation at 
96°C for lmin, annealing at 54°C for 1min and extension at 72°C for 2mins. 
3.3.1.6 PCR amplification of fragment e. 
The forward primer (4) and the reverse primer (7) (see appendix 2) were used in a PCR 
reaction (see section 2.3) to amplify a 2.404Kb DNA fragment (e) of the toxin A gene 
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covering bps 1,609 
- 
4,013. The thermocycling conditions were denaturation at 97°C for 
lmin, annealing at 52°C for lmin and extension at 72°C for 3mins. 
3.3.1.7 PCR amplification of fragment f. 
The forward primer 5' GGAGCAGGAGGATCCTACTCTTTAT 3' (8) and the reverse 
primer 5' TATATTGATTAAGCTTTAAACTAAT 3' (9) (see appendix 2) were used in 
a PCR reaction (see section 2.3) to amplify a 1.553Kb DNA fragment (1) of the toxin A 
gene covering bps 3,955 
- 
5,508. The thermocycling conditions were denaturation at 
97°C for 1 min, annealing at 44°C for 1 min and extension at 72°C for 2mins. 
3.3.1.8 PCR amplification of fragment g. 
The forward primer (6) and the reverse primer (9) (see appendix 2) were used in a PCR 
reaction (see section 2.3) to amplify a 2.919Kb DNA fragment (g) of the toxin A gene 
covering bps 2,589 
- 
5,508. The thermocycling conditions were denaturation at 96°C for 
Imin, annealing at 44°C for Imin and extension at 72°C for 3.5mins. 
3.3.1.9 PCR amplification of fragment hl. 
The forward primer 5' AATTAGTTAAAGGATCCATCAATAT 3' (10) and the reverse 
primer 5' CTCGAAAAGTCGACCAGCTTAAGCC 3' (11) (see appendix 2) were used 
in a PCR reaction (see section 2.3) to amplify a 2.587Kb DNA fragment (hi) of the toxin 
A gene covering bps 5,483 - 8,070. The thermocycling conditions were denaturation at 
96°C for 1min, annealing at 51°C for lmin and extension at 72°C for 3mins. Ten d of the 
amplified product was analysed by 0.8% agarose gel electrophoresis (see section 2.2.3). 
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3.3.1.10 PCR amplification of fragment h2. 
Due to failure of Factor Xa cleavage of peptide HI (see section 3.4.11.5), fragment h2 
was amplified for cloning into an alternative expression vector. The forward primer 5' 
CCATGGGATTAATCAATATAAATAATTCA 3' (12) and the reverse primer (11) (see 
appendix 2) were used in a PCR reaction (see section 2.3) to amplify a 2.576Kb DNA 
fragment (h2) of the toxin A gene covering bps 5,495 
- 
8,070. The thermocycling 
conditions were denaturation at 96°C for lmin, annealing at 50°C for lmin and extension 
at 72°C for 3mins. 
3.3.2 Cloning of toxin A PCR products into a T-tailing vector. 
The PCR products amplified in section 3.3.1 were purified from agarose gels (see section 
2.2.4), ligated into the pCRII T-tailing vector (Invitrogen; see section 2.4.1) then 
transformed into Inv aF competent cells (Invitrogen; see section 2.4.2). Recombinant 
plasmid DNA was isolated (see section 2.2.2.1) from selected white colonies, and the 
purity checked by agarose gel electrophoresis (see section 2.2.3). 
Plasmids thought to contain toxin A fragments al, a2, b, c, d, e and hi were digested with 
the restriction enzymes BamHI and Sall (see section 2.2.6) and the DNA profiles were 
analysed by 0.8% agarose gel electrophoresis (see section 2.2.3) to identify clones with 
the correct sized inserts. Similarly plasmids thought to contain toxin A fragments f and g 
were analysed following digestion with BamHI and Hind. 1II (see section 2.2.6) whereas 
the plasmid thought to contain fragment h2 was analysed following digestion with Ncol 
(see section 2.2.6). Digestion of a plasmid containing an inverted h2 insert would produce 
two bands of 1.586 Kb and 5.177Kb, whereas a correct orientation would produce two 
bands of 4.154 Kb and 2.609 Kb. Overnight cultures (see section 2.1.1) of the host cells 
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containing plasmids with the desired inserts were mixed 1: 1 with 60% sterile glycerol 
and stored at 
-70°C. 
3.3.3 Sub-cloning of toxin A fragments into expression vectors. 
3.3.3.1 Sub-cloning of the N-terminal toxin A fragments. 
The pCRII plasmids containing toxin A fragments al, a2, b, c, d, e, f and g were isolated 
from their host E. colt cells (see section 2.2.2.2). 
Plasmids containing fragments al, a2, b, c, d and e were digested at 37°C for 2 hrs with 
the restriction enzymes BamHI and Sall (see section 2.2.6) and the DNA profiles were 
analysed by 0.8% agarose gel electrophoresis (see section 2.2.3). The 1.281Kb, 1.616Kb, 
0.967Kb, 2.25Kb, 1.4Kb and 2.382Kb DNA fragments corresponding to toxin A inserts 
al, a2, b, c, d and e respectively, were purified from the agarose gels (see section 2.2.4). 
The pMa1TM- p2 and pMa1TM- c2 MBP fusion vectors (New England Biolabs Ltd. U. K; 
see appendix 3) were digested with BamHI and Sall (see section 2.2.6), analysed by 0.8% 
agarose gel electrophoresis (see section 2.2.3) then purified from the agarose gel (see 
section 2.2.4). The purified BamHI, Sall digested toxin A fragments were ligated (see 
section 2.2.7) into the BamHI, Sall digested pMal-p2 and pMal-c2 expression vectors. 
The pCRII plasmids containing toxin A fragments f and g were treated as described with 
the following exceptions. The 1.528Kb and 2.893Kb DNA fragments corresponding to 
toxin A inserts f and g were excised from the pCRII vector by digestion, at 37°C for 2 
hrs, with the restriction enzymes BamHI and Hindill (see section 2.2.6). These DNA 
inserts were ligated (see section 2.2.7) into the BamHI, Hindf digested pMal-p2 and 
pMal-c2 expression vectors (New England Biolabs Ltd. U. K). 
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The ligation reactions containing fragments al, b and f were transformed (see section 
2.2.8) into CaC12 competent TB l E. coil host cells (New England Biolabs Ltd.; see 
section 2.1.1). Ligation reactions containing fragments a2, c, d, e and g were transformed 
(see section 2.2.8) into CaC12 competent JM109 E. coli host cells (see sections 2.1.1 and 
2.1.4). Two hundred µl aliquots of the transformation reactions were spread onto the 
surface of LB agar plates containing 100µgml"1 of ampicillin (LB Amp). Following 
incubation at 37°C overnight, colonies were selected and restreaked onto both a master 
LB Amp plate and an LB Amp plate containing 80ggm1't X-gal and 0.1 mM IPTG. 
Following incubation at 37°C for 8-16 hrs the lac phenotype of each clone was 
determined on the X-gal plate. White colonies were recovered from the master plate and 
the recombinant plasmid DNA was isolated (see section 2.2.2.1). Plasmids containing 
toxin A inserts were identified by digesting with the restriction enzymes (see section 
2.2.6) BamHI and Sall (fragments al, a2, b, c, d and e) or BamHI and HindlII (fragments 
f and g) then analysing the DNA profiles on 0.8% agarose gels (see section 2.2.3). 
Toxin A fragment a2 was also sub-cloned as a BamHI fragment into a BamHI digested 
(see section 2.2.6) pET3a vector (Novagen Inc. ). The recombinant plasmid was 
transformed (see section 2.2.8) into CaC12 competent BL21 DE3 cells (see section 2.1.4), 
plated onto LB Amp plates then incubated at 37°C overnight. Plasmid DNA was isolated 
from ten colonies (see section 2.2.2.1). Digesting with BamHI (see section 2.2.6) then 
analysing the DNA profiles by 0.8% agarose gel electrophoresis (see section 2.2.3) 
identified plasmids with an insert. Overnight cultures (see section 2.1.1) of the cells 
containing plasmids with the desired inserts were mixed 1: 1 with 60% sterile glycerol 
and stored at 
-70°C. 
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3.3.3.2 Sub-cloning of the C-terminal toxin A fragments. 
The pCRH plasmid containing toxin A fragment hi was isolated using the method 
outlined in section 3.3.2. The recombinant plasmid and the pMal-p2 expression vector 
were digested at 37°C for 2 hrs with the restriction enzymes BamHl and Sall (see section 
2.2.6) before analysing the DNA profiles by 0.8% agarose gel electrophoresis (see 
section 2.2.3). The 2.562Kb and 6.721Kb DNA fragments, corresponding to the BamHI, 
Sall digested toxin A fragment hl and pMal-p2 vector respectively, were purified from 
the agarose gel as outlined in section 2.2.4. The two DNA fragments were ligated 
together (see section 2.2.7) then transformed (see section 2.2.8) into CaC12 competent 
TB 1 host cells (New England Biolabs; see section 2.1.4). Two hundred W aliquots of the 
transformation reaction were spread onto the surface of LB Amp plates and incubated at 
37°C overnight. Colonies were selected and re-streaked onto a master LB Amp plate and 
a LB Amp plate containing 80µgm1'1 X-gal and 0.1mM IPTG. Following incubation at 
37°C for 8-16 hrs the lac phenotype of each clone was determined on the X-gal plate. 
White colonies were recovered from the master plate and the recombinant plasmid 
isolated (see section 2.2.2.2). A plasmid containing toxin A fragment hl was identified 
by digesting with the restriction enzymes BamHI and Sall (see section 2.2.6) then 
analysing 10µl of the DNA profile by 0.8% agarose gel electrophoresis (see section 
2.2.3). 
Due to insufficient factor Xa cleavage of the peptide H1 fusion protein (see section 
3.4.11.5), fragment h was re-amplified using a second set of PCR primers to produce 
fragment h2 (see section 3.3.1.10). Following cloning of fragment h2 into the pCRII T- 
tailing vector (see section 3.3.2), the recombinant plasmid containing an inverted insert 
was isolated (section 2.2.2.2). The pCRII plasmid containing fragment h2 and the pET3d 
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expression vector (Novagen Inc; see appendix 3) were digested with the restriction 
enzymes Ncol and BamHI (see section 2.2.6) at 37°C for 2 hrs. The DNA profiles were 
analysed by 0.8% agarose gel electrophoresis (see section 2.2.3). The 2.568Kb and 4.5Kb 
DNA fragments, corresponding to the Ncol, BamHI digested fragment h2 and pET3d 
vector respectively, were purified from the agarose gel (see section 2.2.4). The two DNA 
fragments were ligated (see section 2.2.7) then transformed (see section 2.2.9) into 
electrocompetent E. coli BL21 DE3 cells (see sections 2.1.1 and 2.1.5). Two hundred µl 
aliquots of the transformation reaction were plated onto LB Amp plates and incubated at 
37°C overnight. Plasmid DNA was isolated from ten selected colonies as outlined in 
section 2.2.2.1. Plasmids with the h2 insert were identified by digesting with the 
restriction enzymes NcoI and BamHI (see section 2.2.6) then analysing the DNA profiles 
by 0.8% agarose gel electrophoresis (see section 2.2.3). 
Overnight cultures (see section 2.1.1) of host cells containing a plasmid with either 
fragment hl or h2 were mixed 1: 1 with 60% sterile glycerol and stored at 
-70°C. 
3.3.4 DNA sequencing of the cloned toxin A fragments. 
The toxin A DNA fragments cloned in sections 3.3.3.1 and 3.3.3.2 were sequenced (see 
section 2.5). DNA fragments cloned into the pMal vectors were sequenced using the 
forward Mal E primer (New England Biolabs) and the reverse M13 primer (New England 
Biolabs). Toxin A fragments cloned into pET vectors (Novagen Inc. ) were sequenced 
using the forward primer 5' CGACTCACTATAGGGAGA 3' and the reverse primer 5' 
TAGTTATTGCTCAGCGGT 3'. The additional primers 5' 
ATGTCATTATCTATAGCTGC 3' (elntl; bps 3217-3236) and 5' 
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AATAATTCGATAAAACTAGG 3'(elnt2; bps 3480-3499) were also used to sequence 
further into the toxin A fragment e insert. 
The sequence profiles obtained were compared to the known toxin A sequence data 
(Dove et al, 1990). 
3.3.5 Induction of expression of recombinant toxin A peptides. 
1PTG was used to induce expression of the toxin A peptides in their host E. coli strains 
(see section 2.8.1) with the same strains containing plasmids without inserts included as 
negative controls. The protein profiles were analysed by 8% SDS-PAGE (see section 
2.7.1) and western blotting (see section 2.7.3). Western blots containing potential toxin A 
peptides Al, A2, B, C, D, E, F and G (resulting from the induction of plasmids 
containing toxin A fragments al, a2, b, c, d, e, f and g respectively) were probed with a 
1: 10,000 dilution of anti-MBP antiserum (New England Biolabs) followed by a 1: 1,000 
dilution of goat anti-mouse alkaline phosphatase conjugate (Sigma). Western blots 
containing toxin A peptides H1 and H2 (resulting from the induction of plasmids 
containing toxin A fragments hl and h2 respectively) were probed with 3µgm1"1 of the 
monoclonal antibody PCG-4 followed by a 1: 1,000 dilution of goat anti-mouse alkaline 
phosphatase conjugate (Sigma). 
3.3.6 Optimisation of expression of toxin A peptides. 
3.3.6.1 Transforming with rare tRNA encoding plasmids. 
3.3.6.1.1 Introductory comment. 
For the successful expression of recombinant genes it is essential that the codon usage of 
the foreign protein is compatible with that of the host strain. A characteristic feature of 
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clostridial DNA is its low G and C base content (Hill et al, 1966), which in the coding 
region of the C. docile toxin A gene is only 26.9 mol% (Dove et al, 1990). The codon 
usage of clostridial genes is therefore, biased towards codons in which A and U 
predominate. Certain codons (e. g. AGA for arginine) preferentially used in C. docile 
genes are extremely rare in E. coli gene expression (see appendix 6). Problems with 
premature termination of translation of these AT rich recombinant peptides can occur due 
to the low levels of the cognate tRNAs that recognise these rare codons in E. coll. 
A pBR322 based plasmid carrying the genes encoding the tRNAs that recognise the AGA 
and AGG arginine codons was made available from SmithKline Beecham. By 
introducing this plasmid, and thus these rare tRNAs, into the host E. coil cell it was 
hoped that the expression of the toxin A peptides would be improved. 
3.3.6.1.2 Materials and methods. 
In an attempt to improve the expression of toxin A peptides A2, C, D, E and HI from the 
pMalp2 vector and H2 from the pET3d vector, each was expressed in the presence of the 
plasmid pDC952. This plasmid contains the argU gene encoding the rare tRNAs for the 
AGA/AGG codons. Dr. Shatzman from SmithKline Beecham Pharmaceuticals kindly 
supplied the pBR322 based plasmid pDC952. 
The recombinant plasmids containing toxin A inserts and the pDC952 plasmid were 
isolated from their host E. coil strains (see section 2.2.2.1) and the DNA concentrations 
were determined (see section 2.2.1.1). 
For each toxin A fragment, electrocompetent E. coil BL21 DE3 (see section 2.1.5) were 
transformed by electroporation (see section 2.2.9) with 100ng of the recombinant toxin A 
plasmid plus 100ng of pDC952 or 100ng of the toxin A plasmid only. Transformants 
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containing both plasmids were selected for on LBA plates containing lOOggml' of 
ampicillin and 35ggml"1 of chloramphenicol. Transformants containing the recombinant 
toxin A plasmids were selected for on LBA plates containing only ampicillin. 
Expression of the toxin A peptide from each clone was induced as described in section 
2.8.1, with the exception that clones containing plasmid pDC952 were grown in the 
presence of ampicillin and 35ggm1"1 of chloramphenicol. Levels of expression of the 
toxin A peptides with and without the presence of the rare arginine encoding tRNAs were 
compared by 8% SDS-PAGE (see section 2.7.1) and western blotting (see section 2.7.3). 
Blots containing peptides A2, C, D and E were probed with a 1: 10,000 dilution of anti- 
MBP antiserum (New England Biolabs) followed by a 1: 1,000 dilution of goat anti-rabbit 
alkaline phosphatase conjugate (Sigma). Blots containing peptides HI and H2 were 
probed with 3 µgml ' of the monoclonal antibody PCG-4 followed by a 1: 1,000 dilution 
of goat anti-mouse alkaline phosphatase conjugate (Sigma). 
3.3.6.2 Varying the host E. coil strain. 
In an attempt to increase the expression of toxin A peptides A, C, E, HI and H2, each 
was transformed into different E. coli hosts (see section 2.10.2). 
Blots containing peptides A, C and E were probed with a 1: 10,000 dilution of anti-MBP 
antiserum (New England Biolabs) followed by a 1: 1,000 dilution of goat anti-rabbit 
alkaline phosphatase conjugate (Sigma). Blots containing peptides HI and H2 were 
probed with 3µgml"' of the monoclonal antibody PCG-4 followed by a 1: 1,000 dilution 
of goat anti-mouse alkaline phosphatase conjugate (Sigma). 
3.3.6.3 Varying the IPTG concentration and length of induction time 
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In an attempt to increase the expression of toxin A peptides A, C, H1 and H2, the IPTG 
concentration and length of induction time were varied for each peptide (see section 
2.10.1). Samples were resolved on 8% SDS-PAGE gels (see section 2.7.1) and western 
blotted (see section 2.7.3). 
Blots containing peptides A and C were probed with a 1: 10,000 dilution of anti-MBP 
antiserum (New England Biolabs) followed by a 1: 1,000 dilution of goat anti-rabbit 
alkaline phosphatase conjugate (Sigma). Blots containing peptides HI and H2 were 
probed with 3p. gm1"' of the monoclonal antibody PCG-4 followed by a 1: 1,000 dilution 
of goat anti-mouse alkaline phosphatase conjugate (Sigma). 
3.3.7 Purification and cleavage of recombinant toxin A peptides. 
3.3.7.1 Purification of MBP fusion peptides. 
Recombinant toxin A fusion peptides A2, B, C, D, E, F, G and HI were purified by 
amylose affinity chromatography (see section 2.8.2) and the concentrations of the 
peptides in the 3ml eluted fractions determined (see section 2.9.1.1). The fractions 
collected were resolved on an 8% SDS-PAGE gel (see section 2.7.1) and western blotted 
(see section 2.7.3). Blots were probed with a 1: 10,000 dilution of anti-MBP antiserum 
(New England Biolabs) followed by a 1: 1,000 dilution of goat anti-rabbit alkaline 
phosphatase conjugate (Sigma). Bacterial cells containing the pMal vector without an 
insert were treated in the same way and the MBP purified was used as a negative control 
in all experiments. 
3.3.7.2 Thyroglobulin affinity chromatography. 
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Recombinant toxin A peptides H1 and H2 were purified by thyroglobulin affinity 
chromatography (see section 2.6.2) with the following modifications. One litre of induced 
cells containing toxin A peptide H1 or H2 was prepared (see section 2.8.2). Expression of 
peptide HI was induced by the addition of 1PTG to the final concentration of 0.3mM 
whereas peptide H2 was induced with 0.4mM IPTG. The bacteria were harvested by 
centrifugation at 4,000 xg for 20mins, re-suspended in 50mis of ice-cold TBS then re- 
centrifuged as above. The pellet was re-suspended in 50mls of ice-cold TBS then stored 
at 
-20°C overnight. The cells were thawed in cold water then disrupted by sonication (see 
section 2.8.2). The sonicate containing toxin A peptide H1 or H2 was then applied to, and 
eluted from the thyroglobulin column (see section 2.6.2). The concentration of protein in 
the eluted fractions was determined (see section 2.9.1.2) along with the ability of the 
protein to haemagglutinate rabbit red blood cells (see section 2.6.4). The protein in the 
fractions collected was resolved by 8% SDS-PAGE (see section 2.7.1) and transferred to 
nitrocellulose by western blotting (see section 2.7.3). The blots were probed with 3µgml"' 
of the monoclonal antibody PCG-4 followed by a 1: 1,000 dilution of goat anti-mouse 
alkaline phosphatase conjugate (Sigma). 
3.3.7.3 Concentration of toxin A peptide H1 by evaporation. 
Toxin A peptide H1 was purified by thyroglobulin affinity chromatography (see section 
3.3.7.2). Two 5m1 fractions containing peptide H1 were pooled and a 1000 aliquot was 
removed for further analysis. The remaining 10mis of the protein sample was 
concentrated by bringing the volume down from l Omis to I ml, by evaporation at 60°C 
(Speed Vac Plus SC21OA; Saivant). 
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The ability of the protein to haemagglutinate rabbit red blood cells, prior to and after 
evaporation, was determined (see section 2.6.4). Two µl of each sample was spotted onto 
nitrocellulose for dot blot analysis (see section 2.7.4) and subsequently probed with 
3µgml4 of the monoclonal antibody PCG-4 followed by a 1: 1,000 dilution of goat anti- 
mouse alkaline phosphatase conjugate (Sigma). 
3.3.7.4 Factor Xa cleavage of toxin A/ MBP fusion products. 
Toxin A fusion peptides B, D, E, F, and G were cleaved with 1% factor Xa whereas toxin 
A fusion peptides A, C and Hl were cleaved with both 1% and 2% factor Xa (see section 
2.8.3). The cleaved and uncleaved products were resolved in adjacent lanes on 8% SDS- 
PAGE gels (see section 2.7.1). One gel containing peptides A, B, C, D, E, F and G was 
stained with coomassie blue (see section 2.7.1) whereas one gel containing peptide H1 
was silver stained (see section 2.7.2). A second gel containing peptides A, B, C, D, E, F 
and G was western blotted (see section 2.7.3) and probed with a 1: 10,000 dilution of anti- 
MBP antiserum (New England Biolabs) followed by a 1: 1,000 dilution of goat anti-rabbit 
alkaline phosphatase conjugate (Sigma). A second gel containing peptide HI was western 
blotted and probed with 3µgml-' of the monoclonal antibody PCG-4 followed by a 
1: 1,000 dilution of goat anti-mouse alkaline phosphatase conjugate (Sigma). 
3.3.7.5 Purification of proteins from inclusion bodies present within E. coil cells. 
The method outlined in section 2.8.4 was used to determine the solubility of toxin A 
peptides F, HI and H2. 
The method outlined in section 2.8.5 was then used to purify peptides F, H1 and H2 from 
inclusion bodies present within E. coli cells. Forty µl samples, of the soluble sonicate 
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prior to and the solubilised pellet after guanidine hydrochloride treatment, were resolved 
on an 8% SDS-PAGE gel (see section 2.7.1) and western blotted (see section 2.7.3). 
Blots containing peptide F were probed with a 1: 10,000 dilution of anti-MBP antiserum 
(New England Biolabs) followed by a 1: 1,000 dilution of goat anti-rabbit alkaline 
phosphatase conjugate (Sigma). Blots containing peptides H1 and H2 were probed with 
3ggml"1 of the monoclonal antibody PCG-4 followed by a 1: 1,000 dilution of goat anti- 
mouse alkaline phosphatase conjugate (Sigma). Bacterial cells containing the expression 
vector without an insert were also treated as described and the E. coil proteins purified 
were used as a negative control in all experiments. 
3.3.7.6 Effect on the formation of inclusion bodies by inducing the expression of peptide 
H1 at 30°C or 37°C. 
An attempt was made to prevent toxin A peptide HI being placed into inclusion bodies 
within the E. colt host cell. BL21 DE3 cells containing pMal-p2 with the fragment hl 
insert were treated as described in section 2.8.4 with the exception that one aliquot was 
incubated and induced at 37°C whilst a second aliquot was incubated and induced at 
30°C. Induced soluble and insoluble fractions from each temperature were resolved on 
8% SDS-PAGE gels (see section 2.7.1) and western blotted (see section 2.7.3). The blot 
was probed with 3ggml" of the monoclonal antibody PCG-4 followed by a 1: 1,000 
dilution of goat anti-mouse alkaline phosphatase conjugate (Sigma). 
3.3.8 Concentration determinations of the recombinant toxin A peptides. 
3.3.8.1 Concentration of toxin A peptide / MBP fusion products. 
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The concentration of the full-length peptide A2, B, C, D, E, F, G and H1 / MBP fusion 
products were determined (see sections 2.9.1.1 and 2.9.1.2. The toxin A peptide fusion 
products were cleaved with factor Xa (see section 3.3.7.4). Fifty 41 of the cleavage 
reaction was resolved on an 8% SDS-PAGE gel (see section 2.7.1) alongside 50µl of the 
uncleaved product and the gel was stained with coomassie blue (see section 2.7.1). The 
concentration of the toxin A peptide present within the cleavage mixture was estimated as 
a percentage of the calculated concentration of total fusion protein. 
3.3.8.2 Concentration of peptide H2 purified from inclusion bodies 
The concentration of full-length peptide H2 was determined (see section 2.9.2). Forty µi 
of the peptide H2 protein preparation purified in section 3.3.7.5 was resolved on an 8% 
SDS-PAGE gel (see section 2.7.1) alongside the albumin standards of known 
concentration. The gel was stained with coomassie blue and the concentration of full- 
length peptide H2 was estimated by visual comparison to the albumin standards. 
3.3.9 Further purification of toxin A peptide H2. 
3.3.9.1 Introductory comment. 
When toxin A peptide H2 was isolated from inclusion bodies (see section 3.3.7.5), a few 
E. colf proteins were co-purified. The following procedures were performed in an attempt 
to further purify peptide H2. 
3.3.9.2 Thyroglobulin slurry. 
A1 ml sample of the peptide H2 preparation (see section 3.3.7.5) was dialysed (Slide-A- 
Lyzer Cassette, 10,000Da cut off; Pierce) against 2x1 litre of TBS. A 0.5ml fraction of 
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the dialysed protein sample was incubated with 2mls of activated bovine thyroglobulin 
(see section 2.6.2) on a rotator at 4°C overnight. The excess protein sample was removed 
and stored at 4°C (unbound protein). The thyroglobulin was washed at 4°C with 6x 2mls 
of TBS with intermittent centrifugation steps at 6,500 xg for 1 min (wash). 
Bound peptide H2 was eluted from the thyroglobulin by applying 0.5m1 of TBS (pre- 
incubated at 37°C) and incubating rotating at 37°C for 2.5 hrs. The slurry was centrifuged 
at 6,500 xg for 30 secs and the supernatant containing peptide H2 was aspirated 
(thyroglobulin eluted protein). 
Aliquots of the unbound protein, the wash and the thyroglobulin eluted protein were 
tested for their abilities to haemagglutinate rabbit red blood cells (see section 2.6.4) and 
were compared to the H/A titre of the original peptide H2 preparation. 
3.3.9.3 Isoelectric focusing (IEF) of peptide H2. 
The isoelectric point (pI value) of peptide H2 was determined by applying aI µl sample 
of the peptide (see section 3.3.7.5) to the centre of two Broad Range EEF gels (Biorad). 
The gels were processed (see section 2.13) and the resulting western blot was probed 
with 3µgm1"1 of the monoclonal antibody PCG-4 followed by a 1: 1,000 dilution of a goat 
anti-mouse alkaline phosphatase conjugate (Sigma) (see section 2.7.3). 
3.3.9.4 Ion-exchange chromatography. 
3.3.9.4.1 Introductory comment. 
Separation in ion-exchange chromatography depends upon the reversible adsorption of 
charged solute molecules to an immobilised ion-exchange group of opposite charge. 
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Separation is obtained since different substances have different degrees of interaction 
with the ion exchanger due to differences in their charges and charge densities. 
Positively charged exchangers (e. g. Mono Q columns) have negatively charged counter 
ions (anions) available for exchange and so are termed anion exchangers. Proteins with a 
net negative charge (i. e. a low pI value) are therefore, preferentially purified on these 
positively charged exchangers. Negatively charged exchangers (e. g. Mono S columns) on 
the other hand, have positively charged counter ions (cations) and are termed cation 
exchangers. Proteins with a net positive charge (i. e. a high pI value) are therefore, more 
easily purified by cation exchange chromatography. When the pH of the buffer system is 
the same as the pI of a protein, the protein has no net charge (amphoteric molecule) and 
will not bind to either column. In these circumstances it is necessary to alter the pH of the 
buffer to give the protein a net charge. At a pH below its isoelectric point (pI) a protein 
has a net positive charge and will adsorb to cation exchangers. When the pH is above the 
pi therefore, a protein has a net negative charge and will adsorb to anion exchangers. 
3.3.9.4.2 Methodology. 
Taking the pI value of peptide H2 to be approximately 9.0 (see section 3.4.13.2), attempts 
were made to purify peptide H2 by cation-exchange chromatography (see section 2.14). 
In separate runs the buffer systems applied were 50mM phosphate buffer pH 7.5 and 6.0. 
Taking the pl value of peptide H2 to be approximately 6.5 (see section 3.4.13.2), attempts 
were made to purify peptide H2 by anion-exchange chromatography (see section 2.14). In 
separate runs the buffers systems applied were 20mM Tris-HCl pH 7.5 and 8.5. After 
each run the samples eluted with the 0-1M salt gradient were screened for the presence of 
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peptide H2 using the H/A assay (see section 2.6.4). Fractions showing a positive H/A 
titre were analysed on silver stained 8% SDS-PAGE gels (see section 2.7.2). 
3.3.10 Further purification of Toxin A peptide B. 
3.3.10.1 Introductory comment. 
Following factor Xa cleavage of the maltose binding protein (MBP) fusion products (see 
section 3.3.7.4), the toxin A peptide preparations were contaminated with the 43 kDa 
MBP. The following procedures were undertaken to remove the MBP from the toxin A 
peptide preparations. The toxin A peptide B fusion protein has been used as an example. 
3.3.10.2 Electro-elution from a SDS-PAGE gel. 
Approximately 500µg of the toxin A peptide B/ MBP fusion product was cleaved with 
factor Xa at 4°C overnight (see section 3.3.7.4). Ten µl of the protein mixture were 
resolved on a 10% SDS-PAGE mini gel (see section 2.7.1) alongside an aliquot of low 
molecular weight (LWT) markers (Pharmacia). The 35 kDa protein corresponding to 
toxin A peptide B was electro-eluted from the gel (see section 2.12). A 40µl aliquot of 
the eluted peptide was analysed by 10% SDS-PAGE (see section 2.7.1) and the 
remainder was stored at -20°C. 
3.3.10.3 Isoelectric focusing (IEF) of toxin A peptide B. 
The toxin A peptide B/ MBP fusion product was cleaved using factor Xa (see section 
3.3.7.4) and an attempt was made to determine the PI value of peptide B (see section 
2.13). One pl samples of the cleavage mixture and of MBP alone were applied to the 
centre of the Broad Range IEF gel (Biorad) (see section 2.13). The protein band in the 
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cleavage mixture that did not correspond to the MBP was taken to be the pI value of 
toxin A peptide B. 
3.3.10.4 Anion Exchange chromatography. 
One ml of aI mgml"1 solution of the toxin A peptide B fusion product was cleaved with 
1% factor Xa (see section 3.3.7.4). To separate peptide B from the MBP, the cleaved 
mixture was applied to a Mono-Q anion exchange column (Pharmacia) (see section 2.14). 
In separate runs the buffer systems used were 20mM Tris-HC1 pH 6.0,7.5 and 8.0. After 
each run, 40µl aliquots of the samples eluted with the salt gradient that corresponded to a 
protein absorbance peak on the printout were analysed by 10% SDS-PAGE (see section 
2.7.1). 
3.3.10.5 Direct cleavage of the peptide B fusion product on the amylose column. 
The toxin A peptide B/ MBP fusion product produced from one litre of induced cells was 
applied to an amylose affinity column (see section 2.8.2). The column was washed with 
200mls of column buffer (20mM Tris-HCI, 200mM NaCl, 1mM EDTA), saturated with 
12mis of column buffer containing 150µg of factor Xa, then sealed and incubated at 4°C 
overnight. Toxin A peptide B was eluted in 20 xI ml fractions of column buffer. The 
bound MBP was eluted in 9x1 ml fractions of column buffer containing 10mM maltose. 
Forty µl aliquots of the eluted fractions were analysed for protein content by 8% SDS- 
PAGE (see section 2.7.1) and western blotting (see section 2.7.3). Blots were probed with 
a 1: 10,000 dilution of anti-MBP antiserum (New England Biolabs) followed by a 1: 1,000 
dilution of a goat anti-rabbit alkaline phosphatase conjugate (Sigma). 
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3.3.10.6 N-terminal sequencing of the toxin A peptides. 
One mgml-l solutions of the toxin A peptide B, D and E fusion products, purified by 
amylose affinity chromatography (see section 3.3.7.1), were cleaved with 1% factor Xa 
(see section 3.3.7.4). Each cleaved peptide was applied in IOW aliquots across the wells 
of a 10% SDS-PAGE mini-gel (see section 2.7.1). The protein bands were transferred 
onto Hybond PVDF membrane and stained with amido black (see section 2.11). 
Membrane strips containing the 35 kDa, 49 kDa and 65 kDa proteins, corresponding to 
peptides B, D and E respectively, were excised from the PVDF membrane and air-dried. 
The N-terminal sequences of the proteins on the strips were determined (see section 2.11) 
and were compared to the known toxin A amino acid sequence data (Dove et al, 1990). 
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3.4 RESULTS 
3.4.1 Introductory comment 
Due to the large number of toxin A fragments that were cloned, expressed and purified, it 
was impractical to include the controls for every experiment in the figures although they 
were included at the time the experiments were performed. The figures for toxin A 
fragment b, however, show all the controls and have been included as a representation. 
3.4.2 PCR amplification of the overlapping toxin A fragments 
Using the primers and thermocycling conditions outlined in section 3.3.1, eight N- 
terminal (al, a2, b, c, d, e, f and g) and two C-terminal (hl and h2) fragments of the toxin 
A gene were successfully amplified using the polymerase chain reaction (PCR). 
A PCR reaction using primers 4 and 5 (see appendix 2) at a concentration of 10ng/gl was 
successful in amplifying a 0.99 Kb DNA product (bps 1,609-2,599 of the toxin A gene; 
see appendix 1) corresponding to toxin A fragment b (see figure 3.1, lane 2). At a 
concentration of 5ngIVl, however, the primers failed to amplify this product (figure 3.1 
lane 3). The reactions containing either only primer 4 or primer 5 showed no 
amplification suggesting that the 0.99Kb fragment was the result of an amplification 
using both primers (figure 3.1 lanes 4 and 5). When VPI template DNA was omitted from 
the reaction there was no amplification of a DNA fragment (figure 3.1 lane 6). 
Primers 1 and 2 (see appendix 2) were successfully used to amplify a 1.306Kb DNA 
product (bps 324-1,630 of the toxin A gene; see appendix 1) corresponding to toxin A 
fragment al (figure 3.2 lanes 1 and 2). 
Due to failure of expression of toxin A fragment al (see section 3.4.6.1), primers 3 and 2 
(see appendix 2) were used to successfully amplify a 1.630Kb DNA product (bps 1-1,630 
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of the toxin A gene; see appendix 1) corresponding to toxin A fragment a2 (figure 3.2 
lanes 3 and 4). 
A PCR reaction using primers 1 and 5 (see appendix 2) resulted in the amplification of a 
2.275Kb DNA product (bps 324-2,599 of the toxin A gene; see appendix 1) 
corresponding to toxin A fragment c (see figure 3.2 lanes 5 and 6). 
Primers 6 and 7 (see appendix 2) were successfully used to amplify a 1.424Kb DNA 
product (bps 2,589-4,013 of the toxin A gene; see appendix 1) corresponding to toxin A 
fragment d (figure 3.3 lanes 1 and 2). 
A PCR reaction containing primers 4 and 7 (see appendix 2) was successful in amplifying 
a 2.404Kb DNA product (bps 1,609-4,013 of the toxin A gene; see appendix 1) 
corresponding to toxin A fragment e (figure 3.3 lanes 3 and 4). 
Primers 8 and 9 (see appendix 2) were successfully used to amplify a 1.553Kb DNA 
product (bps 3,955- 5,508 of the toxin A gene; see appendix 1) corresponding to toxin A 
fragment f (figure 3.3 lanes 5 and 6). The 2.919Kb product corresponding to toxin A 
fragment g (bps 2,589-5,508 of the toxin A gene; see appendix 1) was successfully 
amplified (figure 3.3 lanes 7 and 8) using primers 6 and 9 (see appendix 2). 
The 2.587Kb DNA product corresponding to the C-terminal toxin A fragment hl (bps 
5,483-8,070 of the toxin A gene; see appendix 1) was successfully amplified (figure 3.3 
lanes 9 and 10) using primers 10 and 11 (see appendix 2). Due to low levels of expression 
of fragment hl (see section 3.4.6.2) and poor factor Xa cleavage of the resultant peptide 
(see section 3.4.11.5) this region of the toxin A gene was reamplified using primers 12 
and 11 (see appendix 2). The resultant 2.576Kb DNA product (bps 5,495-8,070 of the 
toxin A gene; see appendix 1) corresponded to toxin A fragment h2 (figure 3.3 lanes 11 
and 12). 
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A summary of the amplified and subsequently cloned toxin A fragments can be seen in 
figure 3.4. 
3.4.3 T-tailing of the toxin A fragment PCR products 
Each of the PCR products amplified in section 3.4.2 was cloned successfully into the 
pCRII T-tailing vector as outlined in section 3.3.2. (results not shown). 
3.4.4 Sub-cloning into expression vectors 
The toxin A fragments cloned into the T-tailing vector (see section 3.4.3) were removed 
and sub-cloned into expression vectors (see sections 3.3.3.1 and 3.3.3.2). 
3.4.4.1 N-terminal fragments 
Toxin A fragments b and f were successfully sub-cloned into the pMal-p2 expression 
vector. Digestion of fragment b clones with BamHI and Sall produced a 0.967Kb 
fragment corresponding to fragment b and a 6.721Kb fragment corresponding to the 
linear vector (figure 3.5). Digestion of fragment f clones with BamHI and Hind1Il 
produced the vector band plus a 1.528Kb fragment corresponding to fragment f (figure 
3.7 lanes 3 and 4). 
Toxin A fragments al, a2, c, d, e and g were sub-cloned into both the pMal-p2 and 
pMalc2 vectors although only the results for pMal-c2 are shown. Successful cloning of 
the 1.281Kb (figure 3.6 lanes 1 and 2), 1.616Kb (Figure 3.6, lanes 4 and 5), 2.25Kb 
(Figure 3.6, lanes I and 3), 1.4Kb (Figure 3.7, lanes I and 2) and 2.382Kb (Figure 3.6, 
lanes 4 and 6) DNA bands corresponding to fragments al, a2, c, d and e respectively was 
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verified by digestion with BamHI and Sall. In each case a linear vector band of 6.646Kb 
was present. 
Digestion of fragment g clones with BamHI and Hindill produced the vector band and a 
2.893Kb band corresponding to toxin A fragment g (see Figure 3.6, lanes 7 and 8). Toxin 
A fragment a2 was also successfully sub-cloned as a BamHI fragment from the pCRII 
vector into the pET3a expression vector. Digestion of positive clones with BamHI 
produced a 4.5Kb linear vector band and a 1.616Kb band corresponding to toxin A 
fragment al (results not shown). 
3.4.4.2 C 
-terminal fragments 
Toxin A fragment hl was successfully sub-cloned into the pMal-p2 expression vector. 
Digestion with BamHI and Sall produced a 6.721Kb vector band and a 2.562Kb band 
corresponding to fragment hl (Figure 3.6, lanes 9 and 10). Toxin A fragment h2 was sub- 
cloned as an Ncol, BamHI fragment from the pCRH vector into the pET3d expression 
vector. Digestion of positive clones with Ncol and BamHI produced a 4.5Kb vector 
band and a 2.568Kb band corresponding to fragment h2 (see Figure 3.7, lanes 5 and 6). 
3.4.5. DNA Sequencing from the expression vectors 
The cloned toxin A fragments were sequenced as outlined in section 3.3.4. In all cases the 
sequence data obtained was compared to the known toxin A sequence data (Dove et al, 
1990) and was shown to be the correct fragment (data not shown). The data showed the 
engineered restriction sites in both primers and the engineered stop codon in the reverse 
primer. Each cloned fragment was shown to be in the correct reading frame for over- 
expression from the vector's own promotor. 
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3.4.6 Induction and expression of toxin A peptides 
Expression was induced from the pMal and pET vectors (see appendix 3) using IPTG. In 
the pMal vectors the cloned DNA was inserted downstream from the malE gene which 
encodes a 43 kDa maltose binding protein. IPTG induction resulted in the expression of a 
toxin A peptide / MBP fusion product. In the pET3a vector the cloned DNA was inserted 
downstream from an 11 amino acid T7 tag peptide. 
The size of the recombinant peptide was estimated by taking 1 Kb of cloned DNA to be 
equivalent to a peptide of 35 kDa. Peptides expressed from the pMal vectors were then 
expected to be 43 kDa larger than the estimated size due to the N-terminal MBP fusion. 
3.4.6.1 N-terminal peptides 
IPTG induction of fragment b in the pMalp2 vector resulted in high levels of expression 
of a MBP fusion product of approximately 80 kDa which was clearly visible on a 
coomassie gel (see Figure 3.8, lane 6). This compared well to the estimated size of 
peptide B of 76.85 kDa. The peptide B fusion product reacted with anti-MBP antiserum 
on a western blot (see Figure 3.8, lane 7) and was clearly larger than the control product 
obtained by inducing expression from the pMalp2 vector in the absence of an insert (see 
Figure 3.8, lane 9). 
Induction of expression of fragment al from the pMalp2 vector failed to produce a MBP 
fusion product (see Figure 3.9, lanes 1-6). This was also the case when inducing 
expression from the pMalc2 vector (results not shown). 
Due to the failed expression of fragment al 
, 
fragment a2 was amplified and cloned (see 
sections 3.4.2,3.4.3 and 3.4.4.1) into both the pMalp2 and pMalc2 vectors. Induction of 
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expression of fragment a2 from the pMalp2 vector again failed to produce a fusion 
product (results not shown). IPTG induction from the pMalc2 vector, however, did result 
in the expression of a fusion product of approximately 100 kDa which was visible on a 
coomassie gel (see Figure 3.9, lanes 7 and 8). This compared well to the estimated size of 
A2 of 99.28 kDa. Western blot analysis revealed that as well as the full length product 
there was high levels of expression of a series of truncated products the most 
predominant of which were approximately 65 kDa in size (see Figure 3.9, lanes 9 and 
10). As the first 43 kDa of this product is the MBP it would appear that there is some 
termination of translation approximately 22 kDa into peptide A2. In an attempt to 
overcome this problem, fragment a2 was cloned into the pET3a expression vector (see 
section 3.4.4.1). Unfortunately, induction of expression of fragment a2 from this vector 
failed to produce a fusion product (results not shown). 
IPTG induction of fragment c from the pMal-p2 vector resulted in very low levels of 
expression of fusion product (peptide Q. The product was smaller than the estimated 
121.33 kDa and many truncations were observed (results not shown). In the pMal-c2 
vector the number of truncations was reduced and a product of the correct size was 
observed. The levels of expression of peptide C was still low but was detectable on a 
western blot and a coomassie gel (see Figure 3.10, lanes 4 and 9). 
Induction of expression of fragments d and e from the pMal-p2 vector failed to produce 
fusion products (results not shown). Induction from the pMal-c2 vector, however, 
produced high levels of expression of the peptide D/MBP fusion product of 
approximately 90 kDa which was visible on both a coomassie gel and a western blot (see 
Figure 3.10, lanes 3 and 8). This compared to the estimated size of peptide D of 91.51 
kDa. Induction of expression of fragment e from the pMalc2 vector produced a product 
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of approximately 108 kDa which was visible on both a coomassie gel and a western blot 
(see Figure 3.10, lanes 5 and 10). This protein was smaller than the estimated size of 
peptide E of 125.85 kDa. It would appear that translation was being terminated 65 kDa 
into peptide E. This may have been due to a change in the reading frame of the DNA 
between the region 1641 bp to 2237 bp generating a stop codon. The additional 
sequencing primers outlined in section 3.3.4 were used to sequence this region of the 
insert DNA. The eIntl primer was used to sequence the region 1641 bp to 1991 bp in the 
fragment e insert. The eInt2 primer was used to sequence the region 1938 bp to 2237 bp 
in the fragment e insert. These results proved that there was no change in the reading 
frame of the DNA in the region covering 57 to 70 kDa of the peptide E product (results 
not shown). 
IPTG induction of fragment f from the pMal-p2 vector resulted in high levels of 
expression of a MBP fusion product of approximately 95kDa which was clearly visible 
on an SDS-PAGE gel (figure 3.11 lanes 1-3) This compared well to the estimated size of 
peptide F of 96.24kDa. On the western blot there appears to be some smearing of the 
antibody reaction possibly due to the protein not entering the separating gel efficiently 
(figure 3.11 lane 5). 
Induction of expression of fragment g from the pMal-p2 vector resulted in very low 
levels of expression of a fusion protein of approximately 145kDa (results not shown). 
Expressing from the pMal-c2 vector increased the amount of fusion protein produced. 
The size of the recombinant peptide compared well to the estimated size of peptide G of 
144.01 kDa. Levels of expression were still low but the protein was clearly visible on 
both a coomassie gel (figure 3.11 lanes 7-9) and a western blot (figure 3.11 lanes 10-12). 
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3.4.6.2 C-terminal peptides 
IPTG induction of fragment hl in the pMal-p2 vector resulted in low levels of expression 
of a MBP fusion product of approximately 130 kDa. This compared to the estimated size 
of peptide H1 of 132.67 kDa. The protein reacted on a western blot with PCG-4 (see 
Figure 3.12, lanes 3 and 4) but due to low levels of expression the peptide was barely 
visible on a coomassie gel (see Figure 3.12, lanes 1 and 2). Further, this protein cleaved 
insufficiently with factor Xa. (see section 3.4.11.5) and was, therefore, re-amplified as 
fragment h2 for cloning into an alternative vector (see sections 3.4.2,3.4.3 and 3.4.4.2). 
By cloning the repeat region of toxin A into the Ncol site of the pET3d vector (see 
appendix 3) it was possible to bypass the T7 tag and produce an unfused recombinant 
peptide. Due to low levels of expression the peptide was not clearly visible on a 
coomassie gel (see Figure 3.13, lane 4). A peptide of approximately 90 kDa did react 
with PCG-4 on a western blot (see Figure 3.13, lane 10). This compared to the estimated 
size of peptide H2 of 89.46 kDa. E. coli cells containing pET3d without an insert were 
also induced with IPTG but showed no reaction with the PCG-4 monoclonal antibody 
(see Figure 3.13, lanes 11 and 12). 
3.4.7 Optimisation of expression of toxin A peptides 
3.4.7.1 Transforming with rare tRNA encoding plasmids 
In an attempt to improve the expression of toxin A fragments a2, c, d, e and hI from the 
pMal-p2 vector, and h2 from the pET3d vector, each was induced in the presence of a 
plasmid encoding the rare tRNAs for the AGA / AGG codons (see section 3.3.6.1). The 
results showed that no more peptide was expressed in the presence of these tRNAs than 
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when the pDC952 plasmid was excluded from the reaction. The results for peptides A2, 
C, D and E are shown in Figure 3.14. 
3.4.7.2 Varying the host E. coli strain 
Toxin A peptides A2, C, E, H1 and H2 were transformed into different E. coil strains in 
an attempt to improve the levels of expression (see section 3.3.6.2). Levels of expression 
of peptides A2, C and E were unaffected by varying the E. coli strain (results not shown). 
The level of expression of peptide HI, however, was greater in the E. coil strain BL21 
DE3 (see Figure 3.15, lanes 4a to 4c) than in the E. coif strains TB 1 (see Figure 3.15, 
lanes 2a to 2c) or JM109 (see Figure 3.15, lanes 6a to 6c). The concentration of peptide 
H1 in the induced sonicated whole cell preparation (figure 3.15, lane 4b), was far greater 
than in the sonicated supernatant fraction suggesting that a high percentage of the peptide 
was being lost in the insoluble fraction. When the pMal-p2 plasmid lacking the insert was 
induced in the different cell lines, the resultant proteins did not react with the PCG-4 
monoclonal antibody (see Figure 3.15, lanes 3,5 and 7). The results of peptide H2 were 
as shown for peptide H1. For future work the yields of peptides H1 and H2 were 
maximised by inducing and purifying the peptides from the E. coli strain BL21 DE3. 
3.4.7.3 Varying IPTG concentration and induction time 
The experiment outlined in section 3.3.6.3 was used in an attempt to increase the 
expression of peptides A2, C, Hl and H2. For each peptide the level of expression was 
constant when sampling at an O. D6oo of 0.4 or above, and an IPTG concentration of 0.3 
mM or above. Below these values the levels of expression was reduced (results not 
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shown). By using the IPTG concentrations and length of induction times outlined in 
section 2.8.1, the level of expression for each peptide was therefore maximised. 
3.4.8 Purification and cleavage of N-terminal toxin A peptides 
The toxin A peptide fusion products were purified by amylose affinity chromatography as 
outlined in section 3.3.7.1. The concentration of protein in each fraction was determined 
as outlined in section 2.9.1.1. 
The protein concentration in the 3ml aliquot containing the highest concentration of the 
peptide A2 fusion product was typically in the range of 400 - 500 Factor Xa, at a 
concentration of 1%, was insufficient for complete cleavage of the 99.28 lcDa peptide A2 
fusion product, although the amount of full length peptide was significantly reduced (see 
Figure 3.16, lanes 3 to 4 and Figure 3.17, lanes 3 to 4). Cleavage with 2% and 3% factor 
Xa was more successful but was still incomplete (results not shown). 
The highest protein concentration for the peptide B fusion product was typically in the 
range of 1.0 - 1.5 mg/ml-'. One percent factor Xa successfully cleaved the 76.85 kDa 
peptide B fusion product resulting in the 43 kDa MBP and the 33.85 kDa toxin A peptide 
B product (see Figure 3.16, lanes 5 and 6). On a western blot the 33.85 kDa peptide B did 
not react with anti-MBP antiserum (see Figure 3.16, lane 6 and Figure 3.17, lane 6). 
The protein concentration in the aliquot containing the highest concentration of the 
peptide C fusion product was typically in the range of 400-500 ggml"'. Factor Xa failed 
to cleave the 121.33 kDa peptide C fusion product into the 43 kDa MBP and the 78.33 
kDa peptide C product (figure 3.16 lanes 7-8 and figure 3.17 lanes 7-8). 
The typical concentrations of the purified peptide D and E fusion products were 0.8 
- 
1.0 
mgml"' and 1.0 - 1.5 mgml"1 respectively. One percent factor Xa successfully cleaved the 
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91.51 kDa peptide D fusion product into the 43 kDa MBP and the 48.41 kDa peptide D 
product (see figure 3.16 lanes 12 and 13). On a western blot the 49 kDa peptide D did not 
react with the anti-MBP antiserum (see figure 3.16 lane 13 and 3.17 lane 13). One 
percent factor Xa cleaved the 108 kDa peptide E fusion product into the 43 kDa MBP and 
the 65 kDa truncated peptide E (see figure 3.16 lanes 9 and 10). Again on a western blot 
the 65 kDa truncated peptide E did not react with the anti-MBP antiserum (see figure 
3.16 lane 10 and 3.17 lane 10). After an overnight incubation with factor Xa there did 
appear to be some uncleaved full-length protein in the two samples (D and E), but 
increasing the incubation time to 24 hrs completed the cleavage. 
The typical concentration of the purified peptide G fusion product was 300 
- 
400 µgml'1. 
One percent factor Xa cleaved the 144.01 kDa peptide G fusion product into the 43 kDa 
MBP and the 101.01 kDa peptide G product (see figure 3.16 lanes 14 and 15). On a 
western blot, although the anti-MBP antiserum reacted with a small amount of uncleaved 
peptide, the 101.01 kDa peptide G did not react (see figure 3.16 and 3.17 lanes 14-15). 
The average concentration of the purified peptide F fusion product was 200 
- 
300 p. gml"1 
(see figure 3.18). This concentration appeared to be low and did not reflect the over- 
expression seen in figure 3.11 A and B. Factor Xa failed to cleave the 96.24 kDa fusion 
product into the 43 kDa MBP and the 53.24 kDa peptide F product (see figure 3.18 lanes 
7,15,16 and 24). 
A summary of the expressed and purified toxin A peptides can be seen in appendices 4 
and 5. 
3.4.9 Determination of the solubility of the peptide F fusion product 
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As the concentration of the peptide F fusion product purified by amylose affinity 
chromatography was lower than expected, the method outlined in section 3.3.7.5 was 
used to determine the solubility of the peptide. Only a small percentage of the peptide 
was purified by amylose affinity chromatography (see figure 3.19 lanes 3 and 8). 
Following purification from inclusion bodies only a small percentage of the original 
peptide was located in the soluble fraction (see figure 3.19 lanes 4 and 9). At the end of 
this procedure it is expected that approximately 50% of a soluble recombinant protein 
will remain in solution whilst the remainder forms a precipitate. In the case of the toxin A 
peptide F fusion product the majority of the peptide precipitated following renaturation 
(see figure 3.19 lanes 5 and 10). These results implied that the peptide F fusion product 
was highly insoluble. 
3.4.10 Further purification of toxin A peptide B 
3.4.10.1 Introductory comment 
The following results were obtained when trying to remove the MBP from the toxin A 
peptide B/ MBP cleavage mixture. Peptide B has been included as an example although 
attempts were also made to further purify other toxin A peptides. 
3.4.10.2 Electro-elution from an SDS-PAGE gel. 
Following factor Xa cleavage the 33.85 kDa toxin A peptide B (see figure 3.20 lane 3) 
was successfully eluted from a SDS-PAGE gel (see figure 3.20 lane 5). There was no 
trace of the 43 kDa MBP (seen in figure 3.20 lane 4) in the electro-eluted sample. After 
one freeze / thaw reaction the eluted peptide B showed a degree of degradation on an 
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SDS-PAGE gel, even with the addition of the protease inhibitors PMSF and pepstatin 
(results not shown). 
3.4.10.3 Iso-electric focusing of toxin A peptide B. 
Iso-electric focusing was used to determine the PI value of peptide B as outlined in 
section 3.3.10.3. The results were inconclusive, as only one band was visible on the gel 
from the cleavage mixture running at a pI value of 4. Unfortunately this band also lined 
up with the control band corresponding to the MBP alone (results not shown). 
3.4.10.4 Anion exchange chromatography 
Although the pI determination for peptide B was inconclusive (see section 3.4.10.3) an 
attempt was made to purify the peptide by anion exchange chromatography. The buffer 
systems attempted for purification were 20mM Tris-HC1 pH 7.5, pH 6.0 and pH 8.0. 
Prior to injection onto the column both peptide B and the MBP were present in the 
sample. An aliquot of each eluted fraction that corresponded to a protein absorbance peak 
on the printout was resolved on the SDS-PAGE gel. In each case where protein was 
present it corresponded to the 43 kDa MBP and not peptide B (results not shown). In 
summary anion-exchange chromatography failed to purify peptide B from the cleavage 
mixture. 
3.4.10.5 Cleavage of the peptide B fusion product on an amylose column 
The method outlined in section 3.3.10.5 was used to purify peptide B. Following factor 
Xa cleavage of the fusion product whilst bound to the column, it was hoped that peptide 
B would be released leaving the MBP still attached to the column. Each of the eleven 
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fractions eluted with amylose column buffer (see figure 3.21, lanes 4-13) contained both 
the MBP and peptide B. Both of these proteins were clearly visible in the original 
cleavage mixture (see figure 3.21, lane 14). Some of the later fractions also contained the 
uncleaved 76.85 kDa product (see figure 3.21 lanes 11-13). The fractions eluted with 
1QmM maltose were also mixed containing the MBP, the uncleaved fusion product and 
peptide B (see figure 3.21 lane 15). 
3.4.10.6 N 
-terminal sequencing of the toxin A peptides 
Following factor Xa cleavage, the 33.85 kDa peptide band corresponding to toxin A 
peptide B was sequenced (see section 3.3.10.6). The first ten amino acids of the peptide 
were ISEFGSLSED. The `ISEF' motif corresponds to the last four amino acids of the 
MBP to one side of the factor Xa cleavage site. The `GSLSED' motif was as expected 
and corresponds to the first six amino acids of peptide B (amino acids 540-545 of the 
toxin A protein). The sequence data was 100% accurate. 
The sequence data obtained for the 65 kDa peptide E was also ISEFGSLSED because the 
initiation sites for expression of both peptides B and E are at the same point in the toxin 
A gene. 
The sequence data obtained for the 49 kDa peptide D was ISEFGSDELY. The expected 
sequence data for this region of the toxin A protein was GSDELK giving an accuracy of 
83.3%. 
3.4.11 Purification and cleavage of toxin A peptide Hl 
3.4.11.1 Thyroglobulin affinity chromatography 
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Toxin A peptide H1 was purified by thyroglobulin affinity chromatography as outlined in 
section 3.3.7.2. A 40µl aliquot of the fraction containing the highest concentration of 
peptide H1 was just visible on a coomassie gel (see figure 3.22 lane 5). The fusion 
peptide reacted strongly on a western blot with the monoclonal antibody PCG-4 (see 
figure 3.22 lanes 7-9) whereas the MBP alone did not (see figure 3.22 lane 11). The full- 
length product was approximately 130 kDa, which compared to the estimated size of the 
fusion product of 132.67 kDa. The PCG-4 monoclonal antibody also reacted with a large 
number of breakdown products of peptide Hi, because the antibody is directed against a 
repeated unit, which is found at intervals throughout the C-terminal region of toxin A. 
Three millilitre aliquots of peptide H1 at a concentration of 104gml"1 were routinely 
purified by thyroglobulin affinity chromatography. A similar result was obtained when 
peptide H1 was purified by amylose affinity chromatography (result not shown). 
A summary of peptide Hl can be found in appendices 4 and 5. 
3.4.11.2 Concentration of peptide HI by evaporation 
Prior to concentration, peptide H1 was at a concentration of 10µgm1"1, had a H/A titre of 
1: 32 and reacted strongly with PCG-4 on a dot blot. Following evaporation the peptide 
concentration had increased to 25µgm1"' but the H/A titre had dropped to 1: 8 and the 
peptide reacted more weakly with PCG-4 (results not shown). This implied that heating 
to 60°C had reduced both the biological activity and antigenicity of peptide H1. 
3.4.11.3 Determination of the solubility of peptide HI 
As the yield of peptide HI purified from the soluble fraction was poor (see section 
3.4.11.1), it was assumed that a large proportion of the peptide was being lost in the 
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insoluble fraction. The method outlined in section 2.8.4 was, therefore, used to determine 
the solubility status of peptide H1. 
The results showed that only a small percentage of the total peptide was soluble and 
available for purification by amylose affinity chromatography (see figure 3.23 lanes 2 
and 5). The majority of the peptide was insoluble (see figure 3.23 lanes 3 and 4) and was 
being lost prior to purification by affinity chromatography. The method outlined in 
section 3.3.7.5 showed that peptide H1 was being placed into inclusion bodies within the 
E. coli cell (result not shown). 
3.4.11.4 Effect on the formation of inclusion bodies by inducing expression of peptide H1 
at 30°C or 37°C. 
Inducing the expression of recombinant peptides at 30°C as opposed to 37°C has been 
shown to reduce the formation of inclusion bodies within E. coli cells (Ausubel et al, 
1992). The method outlined in section 3.3.7.6 was used to determine whether or not 
reducing the temperature would increase the proportion of soluble peptide H1. The 
results showed that lowering the temperature to 30°C only reduced the overall expression 
of peptide H1 but did not effect the ratio of soluble: insoluble protein (result not shown). 
3.4.11.5 Factor Xa cleavage of the peptide H1 fusion product 
The peptide H1 fusion product was treated with both 1% and 2% factor Xa in an attempt 
to remove the MBP (see section 3.3.7.4). Neither concentration was successful in 
cleaving the full-length fusion protein (see figure 3.24 lanes 4 and 9) into the 43 kDa 
MBP and the 89.67 kDa peptide HI (see figure 3.24 lanes 5 and 10,6 and 11). 
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3.4.12 Purification of toxin A peptide H2 
3.4.12.1 Introductory comment 
Due to poor levels of expression (see section 3.4.11.1), insufficient factor Xa cleavage 
(see section 3.4.11.5) and insolubility of fusion peptide H1, it was decided to re-clone the 
C-terminal repeat region of toxin A into a vector that would express an unfused peptide 
(see section 3.4.6.2). This would overcome the problem of removing a fusion protein 
whilst still allowing purification by thyroglobulin affinity chromatography. The resultant 
peptide was named H2. 
3.4.12.2 Thyroglobulin affinity chromatography 
Toxin A peptide H2 was purified by thyroglobulin affinity chromatography as outlined in 
section 3.3.7.2. The purified recombinant peptide was not visible on a coomassie gel but 
did react with the PCG-4 monoclonal antibody on a western blot (results not shown). 
The size of the full-length peptide was approximately 90 kDa, which compared to the 
estimated size of 89.46 kDa. The typical concentration of a batch of peptide H2 purified 
by thyroglobulin affinity chromatography was 5.5p. gm1"1. The H/A titre corresponding to 
this concentration was only 1: 8. A summary of peptide H2 can be found in appendices 4 
and 5. 
3.4.12.3 Purification of peptide H2 from inclusion bodies 
Due to the poor recovery of peptide H2 by thyroglobulin affinity chromatography, it was 
assumed that peptide H2, like HI (see section 3.4.11.3), was being placed into inclusion 
bodies within the host cell. The method outlined in section 3.3.7.5 was, therefore, used to 
purify peptide H2 from inclusion bodies. A small proportion of the recombinant peptide 
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was present in the soluble sonicate fraction (see figure 3.25, lanes 5 and 11) but the 
majority was found in the insoluble fraction (see figure 3.25, lanes 6 and 12). Following 
solubilisation of the inclusion bodies and renaturation of the proteins, peptide H2 still 
reacted on a western blot with the PCG-4 monoclonal antibody (see figure 3.26 lane 8). 
Although some E. coil proteins were isolated during the purification procedure, the full 
length peptide H2 was clearly visible on a coomassie gel running at 89.46 kDa (see figure 
3.26 lane 4). The negative control E. coil proteins showed a similar banding pattern to 
that of the peptide H2 preparation, but did not react with the PCG.. 4 monoclonal antibody 
on a western blot (see figure 3.26 lanes 3 and 7). 
This purification procedure typically yielded 25mis of recombinant peptide H2. When 
compared to a series of BSA standards on a coomassie gel it was estimated that 40µ1 of 
the preparation contained 1µg of full length peptide H2 (see figure 3.27 lanes 11 and 14). 
The total concentration of peptide H2 was, therefore, 25ggm1"1. 
3.4.13 Further purification of toxin A peptide H2 
3.4.13.1 Thyroglobulin slurry 
Bovine thyroglobulin was used as outlined in section 3.3.9.2 to remove unwanted E. coli 
proteins from the peptide H2 preparation purified in section 3.4.12.3. Prior to 
thyroglobulin purification, peptide H2 was visible on a coomassie gel running at 89.46 
kDa and gave a H/A titre of 1: 128. Following thyroglobulin purification, peptide H2 was 
barely visible on a coomassie gel and the H/A titre had dropped to 1: 8 (results not 
shown). 
The peptide H2 preparation isolated in section 3.4.12.3 was also further purified by 
thyroglobulin affinity chromatography as outlined in section 3.3.7.2. Again, an 
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unsatisfactory amount of peptide H2 was recovered with a low H/A titre (results not 
shown). 
3.4.13.2 Isoelectric focusing (IEF) of toxin A peptide H2 
Isoelectric focusing was used to determine the pI value of peptide H2 (see section 
3.3.9.3). The presence of the contaminating E. coil proteins made it difficult to determine 
which band corresponded to peptide H2 on a silver stain gel (see figure 3.28 lane 2). The 
toxin A band lined up with the markers at a pI value of approximately 5.5 (see figure 3.28 
lane 4). The IEF gel was western blotted and probed with the PCG-4 monoclonal 
antibody. Two main bands from the peptide H2 preparation reacted with antibody. These 
protein bands lined up with the markers at pI values of approximately 6.5 and 9.0 (see 
figure 3.28 lane 5). It is possible that the band at a pI value of 6.5 was due to residual 
protein in the loading well, because the sample was loaded in the centre of the gel. From 
these results it was difficult to conclude whether the pI value of peptide H2 was 6.5 or 
9.0. 
3.4.13.3 Ion-exchange chromatography 
The method outlined in section 3.3.9.4.2 was used to purify peptide H2 by both anion and 
cation-exchange chromatography. Taking the pi value of peptide H2 to be 6.5 (see 
section 3.4.13.2) it was decided to use a positively charged anion-exchange column for 
purification. Prior to application to the column, the peptide H2 preparation purified in 
section 3.4.12.3 gave a WA titre of 1: 128 (see figure 3.29 lanes 3 and 11). Using a 20mM 
Tris-HCl pH 8.5 buffer system, the fractions eluted that corresponded to protein 
absorbance peaks on the printout gave H/A titres between 1: 2 and 1: 4 (see figure 3.29 
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lanes 12-16). Each fraction, therefore, contained a small amount of peptide H2. On a 
silver stain gel however, it was evident that the purification was unsatisfactory because 
other proteins were still present in the peptide H2 fractions (see figure 3.29 lanes 4-8). A 
similar result was obtained using a buffer system at a pH of 7.5 (results not shown). 
Taking the pI value of peptide H2 to be 9.0 (see section 3.4.13.2), a negatively charged 
cation-exchange column was selected for purification. None of the buffer systems 
outlined in section 3.3.9.4.2 resulted in the satisfactory purification of peptide H2. In each 
case the H/A titres of the eluted fractions were low and the samples were still 
contaminated with other proteins (results not shown). 
161 
123456 
0.99 kb 
Figure 3.1 
0.8% agarose gel showing the PCR amplification of toxin A fragment b from C. difficile 
VPI 10463 chromosomal DNA using primers 4 and 5. 
Lane 1,1 Kb ladder; lane 2,1 Ong/µl of both primers; lane 3,5ng/µl of both primers; lane 
4,1 Ong/µl of primer 5 only; lane 5,1 Ong/µl of primer 4 only; lane 6, no template DNA. 
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Figure 3.2 
0.8% agarose gels showing toxin A fragment PCR products amplified from C. difficile 
VPI 10463 chromosomal DNA. 
Lanes 1,3 and 5,1 Kb ladder; lane 2, fragment al; lane 4, fragment a2; lane 6, fragment 
C. 
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Figure 3.3 
0.8% agarose gels showing toxin A fragment PCR products amplified from C. difrcfle 
VPI 10463 chromosomal DNA. 
Lanes 1,3,5,7,10 and 11,1 Kb ladder; lane 2, fragment d; lane 4, fragment e; lane 6, 
fragment f; lane 8, fragment g; lane 9, fragment hl; lane 12, fragment h2. 
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Figure 3.5 
0.8% agarose gel showing the sub-cloning of toxin A fragment b into the pMal-p2 
expression vector. 
Lane 1, l Kb ladder; lane 2, pMal-p2 plus fragment b (uncut); lane 3, pMal-p2 plus 
fragment b (BamHI and Sall digest). 
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Figure 3.6 
0.8% agarose gels showing the sub-cloning of the toxin A fragments into the pMal 
expression vectors (digested with BamHI and Sall unless otherwise stated). 
Lanes 1,4,8 and 9, ]Kb ladder; lane 2, pMal-c2 plus fragment al; lane 3, pMal-c2 plus 
fragment c; lane 5, pMal-c2 plus fragment a2; lane 6, pMal-c2 plus fragment e; lane 7, 
pMal-c2 plus fragment g (BamHI and Hindill digest); lane 10, pMal-p2 plus fragment h 1. 
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Figure 3.7 
0.8% agarose gels showing the sub-cloning of toxin A fragments into the pMal or pET 
vectors. 
Lanes 1,3 and 5,1 Kb ladder; lane 2, pMal-c2 plus fragment d (BamHI and Sall digest); 
lane 4, pMal-p2 plus fragment f (BamHI and Hindu ! digest); lane 6, pET3d plus 
fragment h2 (BamHI and Ncol digest). 
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Figure 3.8 
8% SDS-PAGE gel (A) and respective western blot (B) probed with MBP antiserum 
showing the induction of expression of toxin A peptide B. 
Lanes I and 12, high molecular weight (MWT) markers; lanes 2 and 11, MBP; lanes 3 
and 10, uninduced TBI cells containing pMal-p2 only; lanes 4 and 9, induced TBI cells 
containing pMal-p2 only; lanes 5 and 8, uninduced TBI cells containing pMal-p2 plus 
fragment b; lanes 6 and 7, induced TBI cells containing pMal-p2 plus fragment b. 
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Figure 3.9 
8% SDS-PAGE gels and their respective western blots probed with MBP antiserum 
showing induction of expression of toxin A peptides. 
Coomassie blue stain (A) and western blot (B) of lanes I and 4, high MWT markers; 
lanes 2 and 5, induced TB 1 cells containing pMal-p2; lanes 3 and 6, induced TB 1 cells 
containing pMal-p2 plus fragment al. 
Coomassie blue stain (C) and western blot (D) of lanes 7 and 9, high MWT markers; 
lanes 8 and 10, induced JM109 cells containing pMal-c2 plus fragment a2. 
170 
A 
KDa 
12345 
212+w 
170 
116 
WSW WAWW 
76 
53, 
low 
B 
KDa 
6789 10 
212 
-- 170 
- 
116 
76 
A 
53 
-l 
ý rr 
ýw tý 
Figure 3.10 
8% SDS-PAGE gel stained with coomassie blue (A) and respective western blot (B) 
probed with MBP antiserum showing the induction of expression of toxin A peptides. 
Lanes 1 and 6, high MWT markers; lanes 2 and 7, induced JM109 cells containing pMal- 
c2; lanes 3 and 8, induced JM 109 cells containing pMal-c2 plus fragment d; lanes 4 and 
9, induced JM 109 cells containing pMal-c2 plus fragment c; lanes 5 and 10, induced 
JM 109 cells containing pMal-c2 plus fragment e. 
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Figure 3.11 
8% SDS-PAGE gels and their respective western blots probed with MBP antiserum 
showing the induction of expression of toxin A peptides. 
Coomassie blue stain (A) and western blot (B) of lanes I and 4, high MWT markers; 
lanes 2 and 5, induced TBI cells containing pMal-p2 plus fragment f; lanes 3 and 6, 
induced TB 1 cells containing pMal-p2 only. 
Coomassie blue stain (C) and western blot (D) of lanes 7 and 10, high MWT markers; 
lanes 8 and 11, induced JM109 cells containing pMal-c2 only; lanes 9 and 12, induced 
JM109 cells containing pMal-c2 plus fragment g. 
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Coomassie blue stain (A) and western blot (B) of lanes 1 and 3, induced BL21 DE3 cells 
containing pMal-p2 plus fragment hl; lanes 2 and 4, high MWT markers. 
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Figure 3.13 
8% SDS-PAGE gel (A) and its respective western blot (B) probed with the monoclonal 
antibody PCG-4 showing the induction of expression of toxin A peptide H2. 
Lanes I and 7, high MWT markers; lanes 2 and 8, toxin A; lanes 3 and 9, uninduced 
BL21 DE3 cells containing pET3d plus fragment h2; lanes 4 and 10, induced BL21 DE3 
cells containing pET3d plus fragment h2; lanes 5 and 11, uninduced BL21 DE3 cells 
containing pET3d only; lanes 6 and 12, induced BL21 DE3 cells containing pET3d only. 
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8% SDS-PAGE gel and its respective western blot of E. coli BL21 DE3 cells showing the 
induced expression of toxin A fragments in the presence of plasmid pDC952 encoding 
rare tRNA's. 
(A) Coomassie blue stain of lane 1, high MWT markers; lane 2, pMal-p2 only; lane 3, 
pMal-p2 plus fragment a2; lane 4, as lane 3 containing plasmid pDC952; lane 5, pMal-p2 
plus fragment d; lane 6, as lane 5 containing plasmid pDC952; lane 7, pMal-p2 plus 
fragment c; lane 8, as lane 7 containing plasmid pDC952; lane 9, pMal-p2 plus fragment 
e; lane 10, as lane 9 containing plasmid pDC952. 
(B) western blot of (A) probed with MBP antiserum; Lanes 11-20 as lanes 1-10. 
175 
1 2a 2b 3a 3b 4a 4b 5a 5b 6a 6b 7a 7b 
0 
2c 3c 4c 5c 6c 7c 
'E ý*ý. ý`ý i, k. ,ý ý+t x 9f ýý F xä, dýy"f ý,,. ý, ý ý} ýý ý? ax r ýý qý 
,f.,,,, ýi c ýY ýa ký yx, ý 
ýýr P 
Figure 3.15 
Optimisation of expression of toxin A peptide H1 by transforming into different E. coli 
cell lines. 
Lane 1, toxin A; lane 2a, uninduced pMal-p2 plus fragment hl in E. coli TB1; lane 2b, as 
lane 2a but induced; lane 2c, as 2b but supernatant fraction only; lane 3a, uninduced 
pMal-p2 only in E. coli TBI; lane 3b, as lane 3a but induced; lane 3c, as lane 3b but 
supernatant fraction only; lanes 4a-4c, as lanes 2a-2c but in E. coli BL21 DE3; lanes 5a- 
5c, as lanes 3a-3c but in E. coli BL21 DE3; lanes 6a-6c, as lanes 2a-2c but in E. coli 
JM109; lanes 7a-7c, as lanes 3a-3c but in E. coli JM109. 
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Figure 3.16 
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8% SDS-PAGE gels showing the amylose affinity purification and factor Xa cleavage 
(I%) of the toxin A peptide fusion products. 
Lanes I and 11, Low MWT markers; lanes 2 and 16, MBP; lane 3, uncleaved fusion 
peptide A2; lane 4, cleaved fusion peptide A2; lane 5, uncleaved fusion peptide B; lane 6, 
cleaved fusion peptide B; lane 7, uncleaved fusion peptide C; lane 8, cleaved fusion 
peptide C; lane 9, uncleaved fusion peptide E; lane 10, cleaved fusion peptide E; lane 12, 
uncleaved fusion peptide D; lane 13, cleaved fusion peptide D; lane 14, uncleaved fusion 
peptide G; lane 15, cleaved fusion peptide G. 
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Western blots of the gels shown in figure 3.16 probed with MBP antiserum. 
Lanes 1-16 as figure 3.16 lanes 1-16. 
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Figure 3.18 
8% SDS-PAGE gel (A) and western blot (B) probed with MBP antiserum showing 
amylose affinity purification and factor Xa cleavage of the peptide F fusion product. 
Lanes I and 30, High MWT markers; lanes 2 and 29, MBP; lanes 3-14, uncleaved fusion 
peptide F (fractions 1-12); lane 15, cleaved fusion peptide (fraction 5); lane 16, as lane 
15; lanes 28-17, as lanes 3-14. 
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Figure 3.19 
10% SDS-PAGE gel (A) and western blot (B) probed with MBP antiserum to determine 
the solubility of the toxin A peptide F fusion product. 
Lanes I and 6, High MWT markers; lanes 2 and 7, MBP; lanes 3 and 8, peptide F fusion 
product purified by amylose affinity chromatography; lanes 4 and 9, peptide F fusion 
product purified from inclusion bodies (supernatant fraction); lanes 5 and 10, as lanes 4 
and 9 (pellet fraction). 
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Figure 3.20 
8% SDS-PAGE gel showing electro-eluted toxin A peptide B. 
Lane 1, Low MWT markers; lane 2, uncleaved toxin A peptide B fusion product; lane 3, 
cleaved toxin A peptide B fusion product; lane 4, MBP; lane 5, electro-eluted toxin A 
peptide B. 
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Figure 3.21 
8% SDS-PAGE gel showing the fractions eluted following factor Xa cleavage of the 
toxin A peptide B fusion product on an amylose affinity column. 
Lane 1, Low MWT markers; lane 2, MBP; lanes 3-13, amylose column buffer wash 
fractions (1-11) following overnight cleavage; lane 14, cleaved toxin A peptide B fusion 
product; lane 15,1 0mM maltose eluted fraction following wash. 
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Figure 3.22 
8% SDS-PAGE gel (A) and subsequent western blot (B) probed with the monoclonal 
antibody PCG-4 showing the peptide HI fusion product purified by thyroglobulin affinity 
chromatography. 
Lanes I and 12, High MWT markers; lanes 2 and 11, MBP; lanes 3 and 10, toxin A; 
lanes 4 and 9, purified peptide HI fusion product (fraction 4); lanes 5 and 8, as lanes 4 
and 9 (fraction 5); lanes 6 and 7, as lanes 4 and 9 (fraction 6). 
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8% SDS-PAGE gel (A) and subsequent western blot (B) probed with the monoclonal 
antibody PCG-4 to determine the solubility of the toxin 
A peptide H1 fusion product. 
Lanes I and 6, High MWT markers; lanes 2 and 5, induced BL21 DE3 cells containing 
pMal-p2 plus toxin A fragment 
hl (supernatant fraction); lanes 3 and 4, as lanes 2 and 5 
(pellet fraction). 
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Figure 3.24 
8% silver stained SDS-PAGE gel (A) and western blot (B) probed with the monoclonal 
antibody PCG-4 showing the factor Xa cleavage of the peptide 1-11 fusion product 
purified by amylose affinity chromatography. 
Lanes I and 7, High MWT markers; lanes 2 and 8, MAP; lanes 4 and 9, uncleaved 
peptide HI fusion product; lanes 5 and 10, peptide Hl fusion product cleaved with 1% 
factor Xa; lanes 6 and 11, as lanes 5 and 10 cleaved with 2% factor Xa. 
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Figure 3.25 
8% SDS-PAGE gel (A) and western blot (B) probed with the monoclonal antibody PCG- 
4 showing the location of peptide H2 at different stages of purification 
from inclusion 
bodies within BL21 DE3 cells. 
Lanes I and 7, High MWT markers; lane 2 and 8, toxin A; lanes 3 and 9, induced whole 
cells containing the pET3d plasmid only; 
lanes 4 and 10, induced cells containing pET3d 
plus toxin A fragment h2 (supernatant fraction following PBS wash); lanes 5 and 11, as 
lanes 4 and 10, (soluble sonicate supernatant); lanes 6 and 12, as lanes 4 and 10 
(insoluble sonicate fraction following solubilisation with guanidine hydrochloride). 
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Figure 3.26 
8% SDS-PAGE gel (A) and western blot (B) probed with monoclonal antibody PCG-4 
showing toxin A peptide H2 and its respective E. coli negative control purified from 
insoluble inclusion bodies within the E. coli BL21 DE3 cells. 
Lanes I and 5, High MWT markers; lanes 2 and 6, toxin A; lanes 3 and 7, E. coli 
negative control purified from BL21 DE3 cells containing plasmid pET3d only; lanes 4 
and 8, toxin A peptide H2 (*) purified from BL21 DE3 cells containing pET3d plus toxin 
A fragment h2. 
187 
kDa 
170 
116 
76 
53 
123456789 10 11 12 13 14 15 
ein 
44 
r 
y'`S'; ý',: fiiý' i, 
i 
Figure 3.27 
8% SDS-PAGE gel showing Bovine Serum Albumin (BSA) concentration standards for 
the estimation of the concentration of peptide H2 in the protein mixture purified from 
inclusion bodies. 
Lane 1, High MWT markers; lane 2,100ng BSA; lane 3,200ng BSA; lane 4,300ng 
BSA; lane 5,400ng BSA; lane 6,500ng BSA; lane 7,600ng BSA; lane 8,700ng BSA; 
lane 9,800ng BSA; lane 10,900ng BSA; lane 11,1µg BSA; lane 12,2µg BSA; lane 13, 
3µg BSA; lane 14, full length toxin A peptide H2 (*) in protein mixture purified from 
inclusion bodies; lane 15, E. coli negative control proteins purified from inclusion bodies. 
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Figure 3.28 
Determination of the pI values of the toxin A peptides H1 and H2 by isoelectric focusing. 
A) Silver stained pH. 3-9 Broad Range Phastgel of lane 1, broad range markers; lane 2, 
toxin A peptide H2 purified from inclusion bodies; lane 3, toxin A peptide Hl purified 
from inclusion bodies; lane 4, toxin A. 
B) Western blot of (A) probed with the monoclonal antibody PCG-4. Lanes 5-7, as lanes 
2-4. 
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Figure 3.29 
A) 10% silver stained gels showing the fractions eluted after the peptide H2 / E. coli 
protein mixture was applied to a Mono Q anion-exchange column at pH. 8.5. 
Lanes l and 9, High MWT markers; lanes 2 and 10, toxin A; lanes 3 and 11, peptide H2 
preparation purified from inclusion bodies; lane 4, eluted fraction 12; lanes 5-8, eluted 
fractions 20-23; lanes 12-16, eluted fractions 24-28. 
B) A table to show the H/A titres of the fractions (shown in A) eluted from the anion- 
exchange column. 
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3.5 DISCUSSION 
The PCR reactions discussed were optimised by adjusting the annealing temperatures and 
the positions of the primers to avoid DNA secondary structure loops interfering with the 
amplification cycles. The study was successful in amplifying eight N-terminal and two C- 
terminal overlapping fragments of the toxin A gene. These fragments represented the 
entire coding region of the toxin gene. An attempt was made to clone the PCR products 
directly into the expression vectors, however, the close proximity of the engineered 
restriction endonuclease sites to the ends of the primers made this task difficult. To 
overcome this problem the PCR products were first cloned into a T-tailing vector by 
taking advantage of the poly A tail, which is added by Taq polymerase. Once in the 
expression vectors, the toxin A fragments were sequenced to confirm the relative position 
of each fragment in the toxin A gene. The sequence data also confirmed that each 
fragment was in the correct reading frame for expression from each host plasmid. 
Of the ten toxin A fragments cloned, nine resulted in the expression of a recombinant 
fusion protein upon IPTG induction. The tenth, toxin A fragment al, would not express 
in either the pMal-p2 or pMal-c2 vectors. It has been suggested that the second codon in 
a gene could affect its expression by as much as 15-fold. Codons such as AAA, AAU and 
ACC in the second position after the initiation colon have been shown to enhance 
expression in E. coil (Komine, Y et al, 1990). Although this is an important 
consideration, recombinant peptides expressed from the pMal vectors have an N-terminal 
MBP fusion and this protein alone is expressed in high levels in E. coll. 
A new forward PCR primer was designed 335bp upstream from the primer used to 
produce fragment al in the hope of amplifying the first 1.6Kb of the toxin A gene. The 
PCR product amplified (fragment a2) was successfully expressed in E. coil from the 
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pMal-c2 vector. A large proportion of the expressed protein (A2) however, was 
truncated. In an attempt to overcome this problem, fragment a2 was also cloned into the 
pET3a vector. This vector allows expression of a peptide with a six amino acid histidine 
fusion on its N-terminus. Unfortunately, expression from this vector failed to produce a 
recombinant peptide. These results suggested that the presence of a large N-terminal 
fusion such as the MBP, as opposed to a small fusion, was favourable and facilitated 
translation to proceed into the toxin A fragment. 
The toxin A fragments a2, c, d, e and g expressed fusion products from the pMal-c2 
vector but not the pMal-p2 vector. In the pMal-p2 vector the signal sequence of the mal E 
gene is intact, which potentially allows fusion proteins to be exported to the periplasm. 
The lack of expression of these fragments from the pMal-p2 vector suggested that they 
were not exported to the periplasm, possibly due to secondary structure that is 
incompatible with passage through the membrane. These peptides were more stable from 
the pMal-c2 vector, which allows cytoplasmic expression. Peptides B, F and HI were 
satisfactorily expressed from the pMal-p2 vector. As passage of a protein through the 
membrane allows disulphide bond formation, it cannot be assumed that the peptides 
expressed in the cytoplasm (A2, C, D, E and G) were folded correctly. Indeed it is 
unlikely that all of the peptides produced `in vitro' were folded in the same way as their 
corresponding regions in the native holotoxin. With the exception of peptide E, the sizes 
of the expressed toxin A peptides matched the estimated sizes. Peptide E was 
approximately 108 kDa as opposed to the estimated 125 kDa. DNA sequencing failed to 
reveal a premature stop codon or a change in the reading frame of the cloned fragment e 
DNA. Although the reason for the premature termination of translation was unknown, N- 
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terminal sequencing confirmed that the correct peptide (albeit shorter) was being 
expressed. 
The levels of expression in E. coil varied between peptides. Generally expression was 
better for peptides B, D, E and F than for peptides A2, C, G and H. Where expression 
was poor, there appeared to be a large number of truncated products that reacted with the 
antiserum as well as the full length peptide. Other workers have also encountered 
difficulties with expression of C. docile toxin A in E. coli (von Eichel-Streiber et al, 
1989; Johnson et al, 1988) both at the level of transcription / translation and product 
stability. Similarly problems have also been encountered with expression of tetanus and 
botulinum toxin genes (Eisel et al, 1986; Fairweather et al, 1986). 
There are several possible explanations for the poor expression of C. dificile toxin A in 
E. coll. Firstly, a characteristic feature of clostridial DNA is its low G and C base content 
(Hill L. R, 1966). The coding region of the C. di/`icile toxin A gene has an extremely low 
G+C content of 26.9 mol% (Dove et al, 1990). When expressing A+T rich genes, such as 
toxin A (A+T content of 73.1 mol%) in E. coil there can be a problem with reinitiation of 
translation and / or transcription giving rise to the expression of additional smaller 
peptides. E. coli promoter sequences (comprising the -10 and -35 TATA boxes) are also 
characteristically A+T rich (Young et at, 1989), therefore it is likely that regions within 
the toxin A coding sequence may resemble additional E. coil promoter sequences. In this 
situation, E. coil RNA polymerase could bind to these additional sites and transcribe 
shorter mRNAs. These shorter mRNAs would be more abundant because they would be 
transcribed more quickly, and the RNA polymerase transcribing them would stall other 
RNA polymerase running behind them. The shorter mRNAs would not be translated 
however, unless there was a recognised ribosome-binding site (RBS) the correct distance 
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downstream from the pseudo promoter. Even with translation occurring there would only 
be a 1: 3 chance that the DNA would be in the correct reading frame. Finally any peptides 
produced by these means would not contain a MBP fusion and would, therefore, not react 
with the anti-MBP antiserum. 
Like the promoter sequences, some E. coil RBSs are also A+T rich (Young et al, 1989). 
It is also possible, therefore, that the A+T rich toxin A DNA contains internal sequences 
that resemble E. coil RBSs (Shine-Dalgarno sequences). If present, the ribosome would 
bind to these additional sites and reinitiate translation resulting in the production of 
shorter peptides. The efficiency of ribosome binding is dependent on the spacing between 
the Shine-Dalgarno sequence and the translational start codon. The optimal spacing 
between these sites in E. coli is 7 +/- 2 nucleotides (Young et al, 1989). Successful 
translation of these truncated peptides would therefore be dependent on the presence of 
start codons (most frequently AUG) 7 +/- 2 nucleotides downstream from the pseudo 
RBSs. Should this coincidence occur there would be a 1: 3 chance that the peptides would 
be expressed in the correct reading frame. Again, the peptides that were successfully 
expressed would not be fused to the MBP and would not react with the anti-MBP 
antiserum. It is unlikely therefore, that the two processes already discussed were the main 
contributors to the poor expression of the toxin A peptides, because a large number of the 
truncated products reacted with the anti-MBP antiserum on western blots. 
It is much more likely that the problem was with premature termination of translation 
rather than re-initiation of transcription / translation. The poor expression of clostridial 
genes in E. coil is most likely due to incompatible codon usage. The inefficient 
production of tetanus toxin in E. co/i has been attributed to conflicting codon usage (Eisel 
et al, 1986). The extremely low G+C content of clostridial DNA has a marked effect on 
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codon usage, which is strongly biased towards codons in which A and U predominate. 
The biased codon usage is most common for amino acids with six synonymous codons 
(see appendix 6). It is evident from the codon usage table that the amino acid arginine is 
of particular concern. The codons AGA and AGG are used for an arginine amino acid in 
C. dificile genes at frequencies of 75.7% and 7.4% respectively, and in E. coil genes at 
frequencies of 4.5% and 2.7% respectively. Unfortunately these two codons are the rarest 
in global gene expression in E. coil (Chet et al, 1994). On average only 2.5 AGA codons 
and 1.5 AGG codons exist in every 1,000 codons in the E. coil chromosome (taken from 
Netscape site: htt I/a, %wv. dna. affrc. go. ip/-nakamura/). Genes such as toxin A that contain a 
significant proportion of these rare codons may cause translational problems in 
expression systems in E. coll. The problems would result from a combination of high 
levels of expression coupled with low levels of the cognate tRNAs that recognise these 
rare codons (Rosenberg et al, 1993. During translation where a cognate tRNA is not 
readily available, the acceptor region on the ribosome is left vacant with nothing to 
transfer to the growing polypeptide chain. This stalling or idling of the ribosome causes 
premature chain termination. Toxin A peptides produced by this process would be 
truncated within the toxin A coding sequence and would therefore contain the MBP and 
react with anti-MBP antiserum. 
Expression of toxin A fragment a2 in E. coil resulted in the expression of several 
additional truncated products, the most predominant of which were in the range of 61-68 
kDa. These truncated species also reacted with the anti-MBP antiserum (see figure 3.9). It 
was calculated that these premature terminations occurred approximately 18-25 kDa into 
the peptide. This region of the toxin A gene contains seven AGA or AGG codons 
representing arginine amino acids (see appendix 7). It is likely, therefore, that the lack of 
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the cognate tRNAs for these codons was responsible for the poor expression of peptide 
A2. In an attempt to resolve this problem the toxin A peptides were expressed in the 
presence of a pBR322 plasmid containing the tRNA genes for recognition of the 
AGA/AGG codons (plasmid pDC952 supplied by SmithKline Beecham 
Pharmaceuticals). A potential problem with this experiment was that like the pDC952 
plasmid, the pMal vectors are also based on pBR322. As both plasmids have a colEl 
origin of replication it was considered unlikely that both would function to full efficiency 
within the same cell. It was hoped however, that although the overall levels of expression 
may be lower, the proportion of full-length protein would be increased. Unfortunately, 
the results showed that there was no improvement in expression with these tRNAs 
possibly due to the fact that C. dffcile also shows a strong preference towards other 
codons (e. g. UUA for leucine). 
Other possible contributory reasons for the presence of additional bands in the purified 
peptide preparations may include denaturation of the products on SDS-PAGE gels or host 
proteases recognising and cleaving the foreign proteins. 
Expression of peptides HI and H2 were improved by re-transforming into the host strain 
F coli BL21 DE3 every 2-3 months. This strain lacks the Ion protease and the ompT outer 
membrane protease and so reduces proteolytic degradation within the host cell (Furlong 
et al, 1992). It is possible that expression could have been further improved in a different 
host-vector system such as the baculovirus system, but unfortunately time did not allow 
for these studies. Having considered all of the potential problems in expressing C. 
dificile genes in E. coli however, it is both surprising and satisfying that peptides 
representing the entire toxin A molecule were finally produced. 
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All of the peptides containing MBP were successfully purified by amylose affinity 
chromatography. It became evident however, that peptide F was highly insoluble and was 
resistant to factor Xa cleavage. As this region of the toxin A molecule was also covered 
in peptide G, peptide F was omitted from several studies. Peptide C was purified at a late 
stage in this thesis and so was included in some, but not all, of the following functional 
assays. 
As with peptide F, peptide HI was also resistant to factor Xa cleavage. Other workers 
have reported that when screening a C. docile genomic library with anti-toxin A 
antiserum, only clones containing the C-terminal repeat region of toxin A (equivalent to 
peptides Hi and H2) were detected (von Eichel-Streiber et al 1989, Muldrow et al 1987, 
Dove et a11990 and Wren et a! 1987). This may suggest that the C-terminal repeat region 
of toxin A is wrapped around the rest of the molecule in the native state. It is possible 
therefore, that peptide H1 was wrapping itself around the MBP in the fusion product 
making the factor Xa site inaccessible to cleavage. Peptide H2, covering the same region 
of the toxin as peptide HI, was expressed without a fusion tag and therefore did not 
require cleavage. This peptide was used in all functional studies in place of peptide HI 
. 
Unfortunately attempts to further purify the toxin A peptides were unsatisfactory. 
Thyroglobulin affinity chromatography did result in low levels of purified peptide H2, 
but these levels were too low to allow for the necessary dilution factors required for 
analysis. Despite the problems of purification it was decided to proceed with the planned 
functional assays with appropriate E. coli negative controls. Toxin A peptides A2, B, D, 
E, G and H2 covering the entire toxin A molecule were included in all of the functional 
assays. These peptides were cleaved where necessary and included in the experiments 
alongside the relevant controls outlined in section 3.3.7.1 and 3.3.7.5. It became apparent 
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that some of the peptides were more stable at 4°C as MBP fusion products than following 
factor Xa cleavage. It may be that the peptides were more soluble or less susceptible to 
degradation as MBP fusions. The fusion proteins were, therefore, routinely cleaved the 
night before inclusion in an experiment. 
A summary of the purified toxin A peptides can be found in appendices 4 and 5. 
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Section 4 
Immunological Properties of Holotoxin A and the Toxin A Constructs 
4.1 SUMMARY 
Monospecific polyclonal antisera were raised in rabbits to formalised holotoxin A and to 
the peptides A2, B, D, E, G and H2. All of the toxin A peptides were antigenic eliciting a 
specific antibody response. The polyclonal antiserum to formalised holotoxin A also 
recognised peptides A2, C, D, G and H2 but not peptides B, F or truncated E. Polyclonal 
monospecific antisera to peptides A2, D, G and H2 recognised formalised holotoxin A, 
whereas antisera to peptides B and truncated E did not. All of the antisera recognised 
non-formalised holotoxin A and the crude culture filtrate from the toxigenic C. difcile 
strain VPI 10463. None of the antisera to peptides A2, B, D, E, and G, representing the 
N-terminal part of toxin A, bound non-specifically to the C-terminal peptide H2. These 
results suggest that peptides B, F and truncated E are unexposed in the native toxin 
molecule. 
The monoclonal antibodies (blabs) PCG-4 and 37B5 bound to the repeat end peptide, H2, 
but not to the N-terminal peptides A2, B, C, D, E, F and G. These results suggest that 
both Mabs block toxin A induced enterotoxicity by blocking binding of the holotoxin to 
its target cell. 
The C-terminal `repeat end' peptide, H2, bound non-specifically to the murine Mab 
IgG3X, whereas the N-terminal peptides A2, E and G did not. The binding was 
significantly reduced by prior treatment of the antibody with a-galactosidase suggesting 
that the C-terminal repeat region of toxin A binds non-specifically to Mabs via galactose 
residues on the Fab domain of the molecule. 
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4.2 INTRODUCTION 
The tertiary structure of the C. difficile toxin A molecule has yet to be solved by X-ray 
crystallography. Results to date have shown that only clones that express part, or all, of 
the C 
-terminal repeat region of toxin A are isolated from C. dif cile genomic libraries by 
screening with polyclonal antiserum to toxin A (Price et al 1987, von Eichel-Streiber et 
al 1989, Muldrow et al 1987, Wren et al 1987). These results suggest that either the N- 
terminal portion of toxin A is not antigenic or that it is hidden inside the molecule with 
the C 
-terminal repeat region wrapped around it and surface exposed. 
Many Mabs have been raised to toxin A (von Eichel-streiber et al 1987, Rothman et al 
1988, Lyerly et al 1985b, Kamiya et al 1991) but only PCG-4 (Lyerly et al, 1985b) and 
37B5 (Kamiya et at, 1991) have been shown to neutralise biological activity of toxin A. 
The Mab PCG-4 has been reported to neutralise toxin A induced H/A and enterotoxicity 
but not cytotoxic activity (Lyerly et al, 1986b). The binding site for this Mab has been 
localised to the repeat region of toxin A between amino acid residues 2,097 through 
2,141 and 2,355 through 2,389. It was concluded that PCG-4 was neutralising 
enterotoxicity by blocking binding of the toxin to its target cell (Frey et al, 1992). The 
Mab 37B5 blocks toxin A induced enterotoxicity but not H/A and the binding site for this 
antibody has not yet been identified. As this antibody did not neutralise H/A it was 
concluded that it was not preventing binding of the toxin to its target cell but was 
blocking an additional active site for enterotoxicity in the N-terminus of the molecule 
(Kamiya et al, 1991). These predictions make this antibody invaluable and very 
interesting to study. As these two Mabs neutralise biological activity of toxin A it is 
believed that they react with the toxin by a true immune reaction. 
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Other Mabs raised to toxin A have been shown to cross-react with both toxins A and B 
(von Eichel-Streiber et al 1987, Rothman et al 1988, Kamiya et al 1991, Lyerly et al 
1985b, Lyerly et al 1986b). Although it has been suggested that these cross-reacting 
antibodies are recognising an epitope that is shared between toxin A and B, it has been 
shown that both toxins react non-specifically with murine monoclonal antibodies (IgM, 
IgG, and IgA) (Lyerly et al, 1989). It was suggested, therefore, that these cross-reacting 
Mabs were binding non-specifically to the toxins and not by a true immune reaction. It 
has recently been shown that toxin A binds non-specifically to the Fab domain of IgG 
Mabs (Cooke et al, 1998). It is important to have an effective screening assay for 
detection of these non-specific Mabs to prevent misleading results. 
The initial aim of this section was to raise polyclonal monospecific antisera to holotoxin 
A and to the toxin A peptides. These antisera would be used to generate reaction profiles 
of antiserum to holotoxin A against toxin A peptides and of antiserum to the peptides 
against holotoxin A. The results would be used to predict which regions of holotoxin A 
are surface exposed in the molecule's native state. Another aim of this section was to 
locate an active site for enterotoxicity by pinpointing the binding site for the 37B5 Mab 
in the toxin A molecule. Finally, an attempt would be made to determine which region of 
the toxin A molecule is responsible for binding non-specifically to the Fab of an IgG3X 
murine Mab. 
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4.3 MATERIALS AND METHODS 
4.3.1 Production of polyclonal monospecific antisera to toxin A and toxin A 
peptides. 
Toxin A peptides A2, B, D, E, G and H2 (100µgm1"') were used to raise polyclonal 
monospecific antisera in rabbits. The peptides were purified by amylose affinity 
chromatography as outlined in section 2.8.2. Prior to injection, peptides A2, B, D, E and 
G were cleaved from the maltose binding protein by incubating in a final concentration of 
10µgmt' of Factor Xa (New England Biolabs) at 4°C overnight. Toxoid was prepared by 
incubating toxin A (100ggml') in a final concentration of 0.4% formaldehyde for 36hr at 
37°C. Prior to injection a 10ml pre-bleed blood sample was taken from seven 5Kg New 
Zealand White female rabbits (Shrubacre Rabbits, Ltd. ). Six of these rabbits were given 4 
x 0.25m1 subcutaneous injections of 1: 1 v/v toxin A peptide with Freund Complete 
Adjuvant (FCA). The seventh rabbit was given 4x0.25m1 subcutaneous injections of 1: 1 
v/v toxoid with FCA. Two weeks later fresh antigen was prepared and mixed 1: 1 v/v with 
Freund Incomplete Adjuvant (FIA) and injected as already described. The rabbits were 
boosted fortnightly with antigen: FIA for a further two injections, after which they were 
terminated and bled. The blood was left to clot at room temperature and the serum 
decanted off. Each polyclonal monospecific antiserum was adsorbed against whole E. coli 
cells four times as follows. Three millilitres of an overnight culture of E, coli cells were 
pelleted at 13,000xg for 2min and the supernatant removed. The pellet was resuspended 
in Iml of antiserum and the mixture incubated, rotating overnight, at room temperature. 
The adsorbed antiserum was retained following centrifugation at 13,000xg for 2min. 
Following the final adsorption the antiserum was aliquoted and stored at 
-20°C. 
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The titre of each antiserum was determined using an ELISA based assay (see section 
2.15). Each protein used to raise antiserum was diluted to a final concentration of 5µg/ml 
and applied to 32 wells of an ELISA plate. Each antiserum was diluted two-fold from a 
1: 5 dilution down to a 1: 163,840 dilution. Each dilution of the relevant antiserum was 
applied in duplicate to the wells containing the corresponding antigen. The remaining 16 
wells coated with each antigen were incubated with the same dilutions of the relevant pre- 
bleed serum. The binding of each antiserum to each antigen was detected using a 1: 1000 
dilution of goat anti-rabbit alkaline phosphatase conjugate. The absorbance (405nm) for 
the pre-bleed serum was deducted from the corresponding absorbance, using the peptide 
antiserum, and the difference subsequently plotted on a graph. 
4.3.2 Cross-reactivity of polydonal monospecific toxin A antiserum. 
4.3.2.1 With toxin A and crude culture filtrates of C. difficile strains VPI 10463 and M-1. 
Dot blot analysis (see section 2.7.4) was used to determine the binding of the polyclonal 
monospecific toxin A antiserum (see section 4.3.1) to toxin A and crude culture filtrates of 
VPI 10463 and M-1. C. difficile VPI 10463 is highly virulent and produces both toxins A 
and B. The M-1 strain, however, is avirulent and does not produce either toxin. In 
duplicate, toxin A (20pglml) was spotted onto nitrocellulose as a positive control along 
with the crude filtrates of the test strains VPI and M-1. One set was incubated with 1: 1000 
dilution of toxin A antiserum while the other was incubated with 1: 1000 dilution of pre- 
immune serum. Both blots were then incubated with 1: 1000 dilution of goat anti-rabbit 
alkaline phosphatase conjugate. 
4.3.2.2 With toxin A peptides. 
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4.3.2.2.1 By SDS-PAGE and western blotting. 
The toxin A peptides were cleaved where necessary with factor Xa (see section 2.8.3). 
Toxin A peptides A2, B, D, E, F, G and H2 were resolved on three 8% SDS-PAGE gels 
(see section 2.7.1). Two of the gels were western blotted (see section 2.7.3) whilst the 
third was stained with coomassie blue (see section 2.7.1). One of the western blots was 
probed wit4 a 1: 1000 dilution of the polyclonal monospecific toxin A antiserum whilst the 
second was probed with a 1: 1000 dilution of pre-immune serum. Both blots were then 
incubated with a 1: 1000 dilution of goat anti-rabbit alkaline phosphatase conjugate before 
being developed. 
4.3.2.2.2 By ELISA analysis. 
ELISA analysis (see section 2.15) was used to determine the binding of the toxin A 
antiserum (see section 4.3.1) to the native toxin A peptides. Toxin A peptides were 
cleaved where necessary with factor Xa. (see section 2.8.3). Each peptide (A2, B, C, D, E, 
F, G and H2) was diluted to a final concentration of 109g1ml and applied to six replica 
wells of the ELISA plate. Toxin A and MBP were included on the plate as the positive 
and negative controls respectively. Three of the six wells coated with each sample were 
incubated with a 1: 1000 dilution of toxin A antiserum with the remaining three incubated 
with a 1: 1000 dilution of pre-immune serum. The wells were then treated with a 1: 1000 
dilution of goat anti-rabbit alkaline phosphatase conjugate before being developed. The 
mean absorbances at 405nm in the pre-immune wells were deducted from the 
corresponding absorbances for the anti-toxin A treated wells and the differences plotted 
on a graph. 
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4.3.3 Cross-reactivity of the polyclonal monospecific anti-peptide A2, B, D, E, G and 
H2 antisera. 
4.3.3.1 With toxin A and crude culture filtrates of VPI and M-1. 
The cross-reactivity of the peptide antisera (see section 4.3.1) with toxin A, VPI and M-1 
were determined by dot blot analysis (see section 4.3.2.1). The peptide used to raise an 
antiserum was included as a positive control on the dot blots treated with that antiserum. 
Each nitrocellulose square also contained holotoxin A, VPI and M-1 culture filtrates. The 
first of each pair of blots was treated with a 1: 1000 dilution of the relevant polyclonal 
monospecific peptide antiserum and the second with a 1: 1000 dilution of the 
corresponding pre-immune serum. The remainder of the method has been previously 
described (see section 4.3.2.1). 
4.3.3.2 With holotoxen A 
An ELISA assay (see section 2.15) was used to determine cross-reactivity of the 
polyclonal monospecific peptide antisera (see section 4.3.1) with formaldehyde treated and 
untreated toxin A. 
Toxin A was treated with 0.4% formaldehyde solution for 36 hrs at 37°C, diluted to 
1Oggml'' then used to coat an ELISA plate. A second plate was coated with IO. tgml'' of 
untreated toxin A. Each peptide antiserum and pre-immune serum was diluted 1: 1,000 and 
applied to three replica wells on both plates. Toxin A and MBP antisera were also 
included as positive and negative controls respectively. All wells were treated with a 
1: 1,000 dilution of goat anti-rabbit alkaline phosphatase conjugate prior to being 
developed. The triplicate mean absorbance for each pre-immune serum was deducted from 
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the mean absorbance for the corresponding peptide antiserum and the differences were 
plotted on a graph. 
An ELISA plate was also coated with 10µgml-' of peptide H2 and processed as already 
described to determine the level of non-specific binding of the repeat region of toxin A to 
the different polyclonal monospecific peptide antisera. 
4.3.3.3 With the respective toxin A peptides. 
4.3.3.3.1 By E LISA analysis 
ELISA analysis (see section 2.15) was used to determine the binding of each peptide 
antiserum (see section 4.3.1) to its native toxin A peptide. The toxin A peptides were 
cleaved with factor Xa (see section 2.8.3). The peptides (A2, B, D, E, G and H2) were 
diluted to io. gml-' and each applied to six replica wells across the plate. In each case, 
three of the six wells were incubated with a 1: 1,000 dilution of the relevant peptide 
antiserum, whereas, the other three wells were incubated with a 1: 1,000 dilution of the 
corresponding pre-immune serum i. e. wells containing peptide A2 were incubated with the 
peptide A2 antiserum. All of the wells were then treated with a 1: 1,000 dilution of goat 
anti-rabbit alkaline phosphatase conjugate. The mean absorbance obtained with the pre- 
immune serum was subtracted from the mean absorbance obtained with the corresponding 
peptide antiserum and the results were plotted on a graph. 
4.3.3.3.2 By SDS-PAGE and western blot 
This method was adopted to determine the cross reactivity of each peptide antiserum with 
its own antigen. The toxin A peptides were cleaved where necessary with factor Xa (see 
section 2.8.3). One microgram of each toxin A peptide were applied to the wells of one 
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8% SDS-PAGE gel (see section 2.7.1). On a further two 8% SDS-PAGE gels lµg of each 
peptide were applied in duplicate to two adjacent wells. The three gels were resolved and 
the first was stained in coomassie blue. The other two gels were western blotted and 
stained in ponceau solution (see section 2.7.3). The different lanes were labelled and the 
nitrocellulose was cut into strips. In each case, one of the two duplicate strips was 
incubated with a 1: 1,000 dilution of the relevant peptide antiserum (see section 4.3.1), 
whereas, the second strip was incubated with 1 1: 1,000 dilution of the corresponding pre- 
immune serum. The strip containing peptide C (which contains part of the A2 fragment) 
was probed with peptide A2 antiserum and the strip containing peptide F (the C-terminal 
portion of peptide G) was probed with anti- peptide G antiserum. All of the strips were 
then treated with a 1: 1,000 dilution of goat anti-rabbit alkaline phosphatase conjugate 
before development. The bands on the western blots were compared to the protein profiles 
on the coomassie blue stained gel. 
4.3.4 Cross-reactivity of the Mabs PCG-4 and 37B5 with the toxin A peptides. 
4.3.4.1 By SDS-PAGE and western blot 
The toxin A peptides were cleaved where necessary with factor Xa (see section 2.8.3). On 
duplicate 8% SDS-PAGE gels, 1µg of each toxin A peptide (A2, B, D, E, F, G and H2) 
was applied to separate wells and the gels were resolved (see section 2.7.1). Toxin A and 
MBP were included on both gels as positive and negative controls respectively. One of the 
gels was stained in coomassie blue for reference and the second was western blotted (see 
section 2.7.3). The blot was probed with a 2pgml-' of the Mab 37B5 followed by a 
1: 1,000 dilution of goat anti-mouse alkaline phosphatase conjugate. This experiment was 
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repeated as described above with the exception that the western blot was probed with 
2µgm1"t of the Mab PCG-4. 
4.3.4.2 By ELISA analysis 
ELISA analysis was used to determine the cross-reactivity of the Mabs PCG-4 and 37B5 
with the native toxin A peptides as described in section 2.15 with the following 
exceptions. 
The toxin A peptides were cleaved where necessary with factor Xa (see section 2.8.3). 
The peptides were then diluted to l09gml"' and each applied to six wells on two duplicate 
ELISA plates. MBP and the E. coli protein sample were included as negative controls 
whilst toxin A was included as a positive control. On one ELISA plate, three of the replica 
wells for each peptide were incubated with 2µgml"' of the Mab PCG-4. On the second 
plate, three of the replica wells were incubated with 2ggml"1 of the Mab 37B5. On both 
plates, the remaining three replica wells for each peptide were incubated with antibody 
diluent only (conjugate control). Each well was treated with a 1: 1,000 dilution of goat 
anti-mouse alkaline phosphatase conjugate prior to development. In each case, the mean 
absorbance obtained at 405nm for the conjugate control was deducted from the 
corresponding mean absorbance for the wells incubated with Mab. The differences in 
absorbances were plotted on two separate graphs. 
4.35 ELISA determination of non-specific binding of the MAb IgG3. % to the toxin A 
peptides. 
This assay was based on a method described by Cooke et al, 1998. 
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Where necessary toxin A peptides were cleaved with Factor Xa to remove the MBP (see 
section 2.8.3). The wells of a Maxisorp C96 microtitre plate (Life Technologies Ltd., 
Paisley, U. K) were coated, in triplicate, with toxin A and toxin A peptides (diluted in 
0.05M carbonate buffer pH 9.6) at 4°C overnight. Toxin A was coated at 10µgml4 but the 
concentrations of the toxin A peptide fusions were adjusted to account for their relative 
size when compared to toxin A (peptide A2; 3.3 pgml"', peptide E; 3.6pgmml', peptide G; 
4.8 Lgml', MBP; 1.4pgm1"', peptide H2; 3. Opgm1"' and the E. coil sample; 3. Op. gml"'). 
Therefore for every one molecule of holotoxin A in the assay there was one molecule of a 
toxin A peptide fusion product. Wells coated with 1.4µgmr' MBP acted as a negative 
control for peptides A2, E and G, whilst wells coated with the E. coli protein sample were 
included as a negative control for peptide H2. Wells coated with toxin A acted as a 
positive control for non-specific binding to the Mab IgG3)L (Sigma). The plate was 
washed three times with PBS containing 0.05% Tween-20 (PBST) and then blocked with 
2% Bovine Serum Albumin (BSA; Sigma) in PBST for Ihr at room temperature. Fifty p1 
of the IgG3)L Mab (40pgmt') was added to each well and incubated for 2hr at 37°C. The 
plate was washed three times with PBST, and 50µI goat anti-mouse immunoglobulin G- 
alkaline phosphatase conjugate (Sigma) in 1% BSA-PBST added to each well. After an 
incubation of lhr at 37°C the plate was washed three times with PBST and twice with 
sterile distilled water. Fifty µi of pNpp alkaline phosphate substrate solution (Sigma) was 
added to each well and the absorbance at 405nm was monitored hourly for 3hr. The 
highest A4os obtained with wells that lacked primary antibody was taken as the 
background value. The absorbance values were plotted on a graph. 
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4.3.6 Non-specific binding of the MAb IgG3a. to toxin A and to peptide H2 following 
treatment of the antibody with a-galactosidase. 
The a-galactosidase treatment of the Mabs was based on a method described by Cooke et 
al, 1998. 
To determine whether or not a-galactosidase could reduce the binding of the Mab IgGA 
to toxin A or peptide H2, the ELISA procedure (section 4.3.5) was adopted with the 
following exceptions. 
One third of a Maxisorp C96 microtitre plate (Life Technologies) was coated with 5µgml"' 
of toxin A, one third with 5 tgml"' of peptide H2 and the final third with 5µgmC'of the E. 
coli negative control sample at 4°C overnight. 
Four test antibody preparations were prepared. In the first test the Mab IgG3A, was diluted 
in 1% Bovine Serum Albumin (BSA)/PBSA/0.05% Tween-20 pH 6.0 (diluent) to a final 
concentration of 40µgml-' (Mab preparation) and then pre-incubated with an equal volume 
of 30µgml' a-galactosidase (Sigma) solution (diluted in diluent) for 1 hr at 22°C. In the 
second test the Mab preparation outlined in test I was pre-incubated as above but with an 
equal volume of diluent to determine the level of non-specific binding of the untreated 
Mab to the proteins. In the third test the diluent was pre-incubated as above with an equal 
volume of the a-galactosidase solution (30µgml") to determine the direct effect, if any, of 
the a-galactosidase on the proteins. The fourth test involved the pre-incubation of diluent 
only and acted as a conjugate control. 
After blocking the wells in 2% BSA/PBS/0.05% Tween-20, each protein sample on the 
plate was incubated, in triplicate, with 50µl of each of the four test antibody preparations 
for 2 hrs at 37°C. Following this step, the ELISA proceeded as outlined in section 4.3.5. 
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This method was repeated using 2µgml-' of the specific Mab to toxin A, PCG-4, in place 
of the non-specific Mab IgG3?.. The absorbance values obtained with untreated antibody 
were plotted on a graph alongside the absorbance values obtained with a-galactosidase 
treated antibody. 
4.3.7 Statistical analysis of ELISA derived data. 
In each case, the mean absorbance value of the conjugate control wells or the pre-immune 
serum wells was compared to the mean absorbance of the test sample in a two sample T- 
test (Minitab). Where p<0.05 we reject HO (90=µ1) with 95% confidence limits. The 
alternative hypothesis HI was therefore accepted (µ0*µ l ). If p>0.05 we accept HO 
(µ0=µ1) with 95% confidence limits. This statistical analysis was carried out on all ELISA 
data. 
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4.4 RESULTS 
Statistical analyses stated in this section were performed as outlined in section 4.3.7. 
4.4.1 Titres of the polyclonal monospecific toxin A and peptide antisera 
Rabbit polyclonal monospecific antisera was raised to holotoxin A and to the toxin A 
peptides A2, B, D, E, G and H2 (see section 4.3.1). To determine an effective working 
dilution, each antiserum was diluted and directed against the antigen that it had been 
raised against in an ELISA based assay. The absorbance values obtained were plotted 
against the dilution factors on line graphs. All of the antisera recognised homologous 
antigens, suggesting that each toxin A peptide was antigenic. At a dilution of 1: 40,960 
each antiserum still detected its antigen, however, at this low dilution the line graphs 
tailed off. It was decided therefore, to use each antiserum at a dilution of 1: 1,000 - 
1: 2,000 because this dilution represented a much more sensitive area on the line graphs 
(results not shown). 
4.4.2 Cross-reactivity of toxin A antiserum 
4.4.2.1 With crude culture filtrate from strains VPI 10463 and M-1 
On the dot blots a 1: 1,000 dilution of the polyclonal toxin A antiserum recognised the 
toxin A positive control as well as the crude culture filtrate from strain VPI 10463 (see 
figure 4.1, lanes Al and A2). This strain is highly virulent and produces both toxin A and 
B, which would have been present in the filtrate. The antiserum did not however, 
recognise the crude culture filtrate from the avirulent, non-toxigenic strain M-1 (figure 
4.1, lane A3). There was a weak non-specific interaction of the conjugate with toxin A 
but this was not seen with VPI or M-1 (figure 4.1, lanes Cl, C2 and C3). 
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4.4.2.2 With the toxin A peptides 
On a western blot the polyclonal toxin A antiserum recognised peptide H2 (figure 4.2 
lanes 9 and 19) and the cleaved toxin A peptides A2, D and G (see figure 4.2 lanes 3 and 
13,5 and 15,8 and 18 respectively). The reaction with peptide H2 was far stronger than 
with peptides A2, D and G which, only reacted weakly. The antiserum did not recognise 
peptides B, E and F (see figure 4.2 lanes 4 and 14,6 and 16,7 and 17 respectively). 
Although an attempt was made to load equal concentrations of each full- length peptide, 
the proportion of each preparation represented by truncated products or MBP varied 
greatly. It would appear, however, that the reaction of the antiserum with peptides A2, D 
and G was specific and not due to a background binding caused by overloading of the 
peptides on the gel. This was shown by peptides B (35 kDa; figure 4.2 lane 4) and E (65 
kDa; figure 4.2 lane 6) which clearly did not react with the antiserum although there was 
more of these two peptides on the gel than the two reacting peptides A2 (99 kDa; figure 
4.2 lane 3) and G (105 kDa; figure 4.2 lane 8). The pre-immune serum did not react with 
any proteins on the western blot (result not shown). 
Cross-reactivity of the toxin A antiserum with the native peptides was also studied by 
ELISA analysis (see section 4.3.2.2.2). The results were plotted on a graph (see figure 
4.3). Again the antiserum was shown to bind significantly to peptides A2 (p=0.0009), D 
(p. 0.0009), G (p<0.0001) and H2 (p=0.0001). Peptide C, which was not screened in the 
western blot, was also shown to bind significantly (p=0.0034) to the toxin A antiserum. 
Binding of the polyclonal toxin A antiserum to peptides B, E and F was significant with 
95% confidence limits but not with 90% confidence limits (in each case p>0.01). For all 
three peptides the mean absorbance obtained with toxin A antiserum was less than 1.2 x 
greater than the mean absorbance obtained with the corresponding pre-immune serum. 
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MBP and the E. coli negative control sample did not bind significantly to polyclonal 
toxin A antiserum (p=0.33 and 0.42 respectively). 
4.4.3 Cross-reactivity of the polyclonal peptide antisera 
4.4.3.1 With toxin A and crude culture filtrates from strains VPI 10463 and M- I 
Toxin A peptides A2, B, D, E, G and H2 were injected into rabbits to produce polyclonal 
monospecific antisera (see section 4.3.1). Dot blot analysis was used to determine the 
Cross-reactivity of the different antisera with toxin A and crude culture filtrates of C. 
docile strains VPI 10463 and M-1 (see section 4.3.3.1). Each antiserum reacted most 
strongly with the homologous immunogen, followed by toxin A then filtrate from strain 
VPI 10463. The weak reaction with VPI was probably due to the low levels of toxin A in 
the filtrate. None of the antisera reacted with the filtrate from the non-toxigenic strain M- 
1 (see figure 4.4 blots 1,3,5,7,9 and 11). The pre-immune sera did not cross-react (or 
did so weakly) with the peptides, toxin A, VPI or M-1 suggesting that the results obtained 
with the peptide antisera were specific (see figure 4.4 blots 2,4,6,8,10 and 12). These 
results suggest that all of the peptide specific antisera recognise domains in native toxin 
A. 
4.4.3.2 With holotoxin A by ELISA and western blot 
An ELISA assay was used to demonstrate the affinity of the polyclonal peptide antisera 
to toxin A and the results were plotted on a graph (see figure 4.5). All of the peptide 
antisera bound significantly to holotoxin A (in each case p<0.05). The MBP antiserum 
however, did not bind significantly to toxin A (p=0.12). These results did not correlate 
with those obtained when toxin A antiserum was directed against the peptides (see 
216 
section 4.4.2.2) where only peptides A2, D, G and H2 were recognised. This ELISA was 
repeated therefore, using peptide H2 as the ligand instead of holotoxin A to determine 
whether or not the peptide antisera were binding nonspecifically to the repeat end- 
binding portion of the holotoxin. Polyclonal peptide H2 antiserum bound significantly to 
peptide H2 with a p-value of <0.0001. Anti-peptide B, D and E antisera did not bind 
significantly (in each case p>0.05). Anti-peptide A2 and G antisera bound significantly at 
the 5% level but not at the 10% level with p-values of 0.012 and 0.042 respectively. In 
both of the latter cases however, the level of binding of the antisera to peptide H2 was 
less than 1.5 x the level of binding of the pre-immune sera to peptide H2 (results not 
shown). 
These small differences did not account for the discrepancies seen between figures 4.3 
and 4.5. It was concluded that formaldehyde treatment of toxin A prior to rabbit 
immunisation had fixed the toxin in a certain configuration, perhaps its native state, only 
allowing antibodies to be raised to exposed epitopes. The ELISA was again repeated to 
determine whether or not the peptide antisera were able to cross-react with formalised 
toxin A. The results obtained were similar to those obtained in figure 4.3 and were 
plotted on a graph (see figure 4.6). The antisera to peptides A2, D, G and H2 bound 
significantly to formalised holotoxin A with p-values of 0.0072,0.0007,0.0013 and 
0.0061 respectively. There was no significant binding of anti-peptide B (p=0.082), anti- 
peptide E (p=0.15) or anti-MBP (p=0.62) antisera to formalised toxin A. 
4.4.3.3 With their respective immunogens 
An ELISA assay was used to determine the ability of each peptide antiserum to bind to its 
respective native peptide and the results were plotted on a graph (see figure 4.7). Each 
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polyclonal peptide antiserum bound significantly to homologous immunogen (in each 
case p<0.05). As there was a possibility that these reactions were due to cross-reactivity 
of only the MBP with the antisera, the cleaved peptides were also probed on western 
blots (see section 4.3.3.3.2). Each cleaved peptide was probed with its respective peptide 
antiserum and pre-immune serum (see figures 4.8 and 4.9). The peptide A2 antiserum had 
a high affinity for binding to the full-length peptides A2 (99 kDa) and C (123 kDa) (see 
figure 4.8, lanes 5a and 8, lanes 3a and 10). There was a weak background binding of 
each pre-immune serum to the peptides (see figure 4.8, lanes 5b and 3b). As peptides A2 
and c did not cleave to completion it was difficult to determine whether this binding was 
due to antibodies directed against MBP, peptide A2 or both. 
The polyclonal peptide B antiserum reacted with both the 43 kDa MBP and the 35 kDa 
toxin A peptide B (see figure 4.8, lanes 4a and 9). The pre-immune serum reacted weakly 
with the MBP but not with peptide B (see figure 4.8, lane 4b). 
Unfortunately there was some uncleaved peptide D in the preparation loaded onto the gel, 
which masked the western blot results to some extent. Close observation does reveal 
however, that the polyclonal peptide D antiserum recognised both the MBP and the 49 
kDa peptide D (see figure 4.9, lanes 3 and 7a). Although there was a small amount of 
background binding of the pre-immune serum to the fusion product there was no reaction 
with the 49 kDa peptide D (see figure 4.9, lane 7b). 
The polyclonal peptide E antiserum reacted with the 43 kDa MBP and the 65 kDa band 
corresponding to peptide E (see figure 4.8, lanes 2a and 11). This fusion product did not 
react with the pre-immune serum (see figure 4.8, lane 2b). 
The polyclonal peptide G antiserum reacted with both peptide F and peptide G (see figure 
4.8, lanes 1a and 12 and figure 4.9, lanes 2 and 6a). Peptide F was resistant to cleavage 
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and so it was difficult to determine whether the binding was due to antibodies recognising 
peptide F, MBP or both. The antiserum was clearly binding to the cleaved 105 kDa band 
corresponding to peptide G however (see figure 4.9, lane 6a). These proteins did not react 
significantly with the pre-immune serum (see figure 4.8, lane 1b and figure 4.9, lane 6b). 
Finally, peptide H2 (89.46 kDa) had a high affinity for binding to the polyclonal peptide 
H2 antiserum (see figure 4.9, lanes 4 and 8a). There was also a significant amount of 
non-specific binding of the pre-immune serum to this peptide (see figure 4.9, lane 8b). 
4.4.4 Cross-reactivity of the toxin A peptides with the Mabs PCG-4 and 37B5. 
The 37B5 Mab reacted only with toxin A (see figure 4.10, lanes 3 and 12) and peptide H2 
(see figure 4.10, lanes 9 and 18) on a western blot. The antibody did not cross-react with 
the IMP (see figure 4.10, lanes 2 and 11) or with the toxin A peptides A2, B, D, E and F 
(see figure 4.10, lanes 4 and 13,5 and 14,6 and 15,7 and 16,8 and 17 respectively). The 
same result was obtained when the peptides were probed with the Mab PCG-4 (results 
not shown). 
These results were confirmed by screening the native peptides in ELISA assays. Again, 
holotoxin A and peptide H2 were bound significantly by the 37B5 Mab (p-values of 
0.0065 and 0.0027 respectively) and PCG-4 Mab (p-values of 0.0028 and 0.0042 
respectively)(see figure 4.11 and 4.12). The E. coil and MBP negative controls and the 
peptides A2, B, C, D, E and G did not react with either Mab in the ELISA assays (in each 
case p>0.05). 
4.4.5 Non-specific binding of the toxin A peptides with the murine Mab IgG3),. 
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An ELISA assay was used to determine the region of the toxin A molecule responsible 
for non-specifically binding to Mabs (see section 4.3.5). Only holotoxin A and peptides 
A2, E, G and H2 were examined. These peptides represent the entire toxin A molecule. 
The antibody only bound significantly to holotoxin A and peptide H2 (see figure 4.13) 
with p-values of 0.004 and 0.0001 respectively. Binding of the antibody to the other 
protein samples was not significant at the 10% level (in each case p> 0.01). 
A second set of ELISA assays was used to determine whether or not peptide H2 binds 
non-specifically to the antibody via a galactose residue. The non-specific binding was 
significantly reduced by prior treatment of the monoclonal antibody with a-galactosidase 
(see figure 4.14), with p-values of 0.0001 and 0.0005 for toxin A and peptide H2 
respectively. With 90% confidence limits, a-galactosidase treatment had no effect on the 
binding of the E. coli negative control sample to the Mab. The ELISA was repeated using 
the specific Mab PCG-4 as a negative control. Prior treatment of the PCG-4 antibody 
with a-galactosidase failed to significantly reduce binding to holotoxin A or peptide H2 
with p-values of 0.12 and 0.34 respectively (results not shown). 
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Figure 4.1 
Dot blots showing the cross-reactivity of the polyclonal monospecific toxin A antiserum 
with toxin A and the crude culture filtrates from strains VPI 10463 and M-1. 
Samples 1, toxin A; 2, strain VPI 10463; 3, strain M-1; 4, PBSA. Dot blots were probed 
with A, polyclonal monospecific toxin A antiserum followed by anti-rabbit alkaline 
phosphatase conjugate; B, pre-immune rabbit serum followed by anti-rabbit alkaline 
phosphatase conjugate; C, anti-rabbit alkaline phosphatase conjugate only. 
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Figure 4.2 
8% SDS-PAGE gel (A) and western blot (B) showing the cleaved toxin A peptides 
probed with the polyclonal monospecific toxin A antiserum. 
Lanes I and 11, high MWT markers; lanes 2 and 12, toxin A; lanes 3 and 13, peptide A2; 
lanes 4 and 14, peptide B; lanes Sand 15, peptide D; lanes 6 and 16, peptide E; lanes 7 
and 17, peptide F; lanes 8 and 18, peptide G; lanes 9 and 19, peptide H2; lanes 10 and 20, 
low MWT markers. 
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Figure 4.3 
A graph to show the ELISA values obtained when the cleaved toxin A peptides 
were probed with the polyclonal monospecific anti-toxin A antiserum. Peptides 
shown in red bound significantly to the anti-toxin A antiserum. 
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Figure 4.4 
Dot blots to determine the cross-reactivity of the different polyclonal peptide antisera 
with toxin A and with crude culture filtrates from strains VPI 10463 and M- 1. 
Blots were probed with 1, peptide A2 antiserum; 3, peptide B antiserum; 5, peptide D 
antiserum; 7, peptide E antiserum; 9, peptide G antiserum; 11, peptide H2 antiserum; 2, 
4,6,8,10 and 12, rabbit pre-immune sera. Samples on each blot were a, holotoxin A and 
the peptide specific to the antiserum (positive control); b, culture filtrate from strains VPI 
10463 and M-1. 
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Figure 4.5 
A graph to show binding of the different polyclonal monospecific anti-peptide 
antisera to wells containing untreated holotoxin A in an ELISA assay. The 
antisera shown in red bound significantly to native holotoxin A. 
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Figure 4.6 
A graph to show binding of the different polyclonal monospecific anti-peptide 
antisera to wells containing formalised holotoxin A in an ELISA assay. The 
antisera shown in red bound significantly to formaldehyde treated toxin A. 
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Figure 4.7 
A graph to show binding of each native toxin A peptide to its respective 
polyclonal monospecific anti-peptide antiserum in an ELISA assay. Each binding 
was statistically significant. 
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Figure 4.8 
8% SDS-PAGE gel (B) and western blot (A) showing the cleaved toxin A peptides. 
Western blots labelled `a' were probed with polyclonal peptide antiserum (specified 
below) whereas those labelled `b' were probed with the corresponding pre-immune 
serum. 
Lanes 1 a, 1b and 12, peptide F (1 a probed with peptide G antiserum); lanes 2a, 2b and 
11, peptide E (2a probed with peptide E antiserum); lanes 3a, 3b and 10, peptide C (3a 
probed with peptide A2 antiserum); lanes 4a, 4b and 9, peptide B (4a probed with peptide 
B antiserum); lanes 5a, 5b and 8, peptide A2 (5a probed with peptide A2 antiserum); 
lanes 6 and 7, high MWT markers. 
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8% SDS-PAGE gel (A) and western blot (B) showing the cleaved toxin A peptides. Blots 
labelled `a' were probed with polyclonal peptide antiserum (specified below) whereas 
those labelled `b' were probed with the corresponding pre-immune rabbit serum. 
Lanes 1 and 5, high MWT markers; lanes 2,6a and 6b, peptide G (6a probed with peptide 
G antiserum); lanes 3,7a and 7b, peptide D (7a probed with peptide D antiserum); lanes 
4,8a and 8b, peptide H2 ( 8a probed with peptide H2 antiserum); lane 9, low MWT 
markers. 
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Figure 4.10 
8% SDS-PAGE gel (A) and western blot (B) showing the cleaved toxin A peptides 
probed with the monoclonal antibody 357B. 
Lanes I and 10, low MWT markers; lanes 2 and 11, MBP; lanes 3 and 12, toxin A; lanes 
4 and 13, peptide A2; lanes 5 and 14, peptide B; lanes 6 and 15, peptide D; lanes 7 and 
16, peptide E; lanes 8 and 17, peptide F; lanes 9 and 18, peptide H2. 
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Figure 4.11 
A graph to show binding of the 3785 monoclonal antibody to the toxin A peptides 
to locate an active site for enterotoxicity in the toxin A molecule. Proteins shown 
in red bound significantly to the antibody. 
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Figure 4.12 
A graph to show binding of the PCG-4 monoclonal antibody to the toxin A 
peptides to locate a binding site for the antibody in the toxin A molecule. Proteins 
shown in red bound significantly to the antibody with 95% confidence limits. 
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Figure 4.13 
A graph to show non-specific binding of the IgG3X murine monoclonal antibody 
to holotoxin A and the toxin A peptides. Protein samples shown in red bound 
significantly to the antibody with 90% confidence limits. 
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Figure 4.14 
A graph to show the effect of a-galactosidase treatment on the non-specific binding of 
toxin A, peptide H2 and the E. coli negative control to the murine monoclonal 
antibody IgG3X. Absorbance values shown in blue indicate non-specific binding of the 
antibody to the labelled peptide, whereas, those shown in yellow indicate the reduced 
non-specific binding to the protein due to pre-treatment of the antibody with a- 
galactosidase. 
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4.5 DISCUSSION 
When a given protein is expressed as small recombinant peptides, there is always the 
chance that the peptides will not fold in the correct manner to represent the corresponding 
tertiary structure of the native molecule. It was important to note therefore, that antiserum 
raised against each of the toxin A peptides not only recognised the homologous 
immunogen but also non-formalised holotoxin and crude culture filtrate from the 
toxigenic C. dif cile strain VPI 10463. None of the antisera bound significantly to the 
crude culture filtrate from the non-toxigenic C diJcile strain m-1. As MBP antiserum 
did not cross-react with toxin A, it can only be assumed that at least part of each peptide 
had folded correctly to represent the corresponding structure in the native toxin A 
molecule. 
On western blots each toxin A peptide specific antiserum reacted with both MBP and 
homologous immunogen suggesting that each peptide (A2, B, D, E, G and H2) was 
antigenic. 
To date, all that is known of the secondary or tertiary structure for either toxin is that 
toxin A is composed of 8% a-helices and 65% ß-sheets (Borriello, 1991). There may also 
be a protoxin form of toxin A which is cytotoxic but which haemagglutinates poorly 
(Borriello et al, 1990) and has double the amount of a-helices (Borriello, 1991). An 
attempt was made to learn more about the tertiary structure of toxin A using antibody 
reaction profiling. The observation that toxin A antiserum recognised only recombinant 
peptides A2, C, D, G and H2, whereas all of the peptide antisera recognised native, non- 
formalised holotoxin A was initially confusing. The first assumption was that there were 
some antibodies in the peptide antisera that were binding non-specifically to the repeat 
region of holotoxin A. The results of an ELISA assay however, did not confirm this and 
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showed (with the exception of anti-peptide H2 antiserum) that none of the antisera bound 
to peptide H2 (ie repeat region of toxin A). Another consideration was that formalised 
holotoxin was used for the production of toxin A antiserum but non formalised toxin A 
was being used for the ELISA studies. Once the ELISA assays were repeated using 
formalised holotoxin, antisera to peptides A2, D, G and H2 cross-reacted with the toxin, 
whereas antisera to peptides B and E did not. These results suggest that on an ELISA 
plate the structure of non-formalised toxin A alters, exposing different (previously 
unexposed) regions of the molecule. Formaldehyde treated toxin A however appears to 
be fixed in one configuration, possibly its native state. Another concern was that the 
formaldehyde may have altered some regions of the toxin A molecule (namely those 
represented by peptides B, E and F) causing a loss of antigenicity. Had time allowed this 
possibility could have been ruled out by formaldehyde fixing the toxin A peptides had 
time allowed. Cross-reactivity of a peptide antiserum with the untreated peptide but not 
with the formalised peptide would suggest that the formaldehyde was disrupting the 
structure of the peptide, causing a possible loss of antigenicity. 
The antibody reaction profiles suggest that peptides B (amino acids [aa] 542-859), 
truncated E (aa 542-1,161) and F (aa 1,324-1,830) are unexposed in the native toxin A 
molecule but that peptides A2 (aa 1-536), C (aa 114-859), D (aa 869-1,330), 0 (aa 869- 
1,830) and H2 (aa 1,832-2,683) are exposed. Narrowing this down further, the exposed 
regions lie between as 1-541,1,162-1,324 and 1,832-2,683. In support of these 
predictions a hydropathy plot for the toxin A protein shows that the region between as 1- 
541 is mainly hydrophilic. The region between as 1,162-1,324 also shows some 
hydrophilic domains although it is interesting to note that the only strongly hydrophobic 
region in the molecule lies just upstream between as 1,050-1,100. Finally the plot shows 
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that the repeat region of toxin A (aa 1,832-2,683) is the most hydrophilic part of the 
molecule suggesting that this portion is surface exposed (Dove et al, 1990). A 
diagrammatic representation of the predicted surface exposed regions of toxin A can be 
seen in appendix 8. These results provide the first indication of the tertiary structure of 
holotoxin A. The validity of these observations will be determined once the structure of 
the toxin A molecule has been deduced by X-ray crystallography. 
It is interesting to note that screening of C. docile genomic libraries with polyclonal 
toxin A antiserum only results in the isolation of clones containing the repeat region of 
toxin A (Price et al, 1987, von Eichel-Streiber et al 1989, Muldrow et al 1987, Wren et al 
1987) although other regions of the molecule appear to be both surface exposed and 
antigenic. Perhaps the repeat end of toxin A is the most immundominant part of the 
molecule and so the antibody response is preferentially directed against this region. This 
hypothesis is supported by the results seen in figure 4.2 which show that the toxin A 
antiserum has a high affinity for binding to peptide H2 but only binds weakly to peptides 
A2, D and G. Perhaps formaldehyde fixing the toxin reduced the immunodominance of 
the repeat region thereby allowing antibodies to be raised against other surface exposed 
regions. As previously mentioned, the repeat region of toxin A is extremely hydrophilic 
and is known to be the receptor-binding domain of the toxin (Dove et al 1990, Price et al 
1987). It is also known that epitopes of the C-terminal repeat region are surface exposed 
due to the ability of the MAb PCG-4 to precipitate toxin A. It is likely therefore, that the 
repeat region is wrapped around the remainder of the native toxin A and is therefore the 
major part of the molecule that is exposed to the immune system. It is also possible that 
native toxin A dimerises in a manner that exposes predominantly the repeat structure. 
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When peptides A2, D and G were injected into rabbits without the immundominant 
repeat region of the toxin, however, each elicited a strong antibody response. 
It has recently been reported that C. docile strains that produce toxin A which lacks the 
repeat region are not detected at all by polyclonal toxin A antiserum (Kato et al, 1999). 
Most diagnostic kits used today for the detection of toxigenic C. di, fticile strains however, 
make use of antiserum directed against the C-terminal repeat region of toxin A. Strains 
producing truncated forms of the toxin A gene that lack the C-terminal repeat region 
therefore maybe escaping these detection systems. It is possible that these strains are 
capable of causing mild disease and their detection is therefore important. It would be 
useful to use a polyclonal or monoclonal antiserum raised against peptide A2 to develop a 
more sensitive and effective diagnostic kit that would also detect these mutated but 
virulent C. docile strains. 
The 37B5 Mab, like PCG-4, recognised the C-terminal repeat end peptide H2. Although 
it is possible that the N-terminal peptides were not folded correctly to form an additional 
binding site for the 37B5 Mab, the fact that the antibody bound with such a high affmity 
to peptide H2 makes an additional site unlikely. These results were disappointing as it 
had been suggested that the 37B5 Mab was blocking an active site for enterotoxicity 
unrelated to toxin A binding (Kamiya et al, 1991). This conclusion was drawn because 
the 37B5 Mab, unlike PCG-4, was unable to block haemagglutination of rabbit red blood 
cells and therefore thought unable to block toxin A binding. Attempts to repeat the 
experiments of Lyerly et al 1986 and block haemagglutination using the PCG-4 Mab 
were unsuccessful in our laboratory (results not shown). Kamiya and co-workers did not 
use the PCG-4 Mab as a positive control in their haemagglutination neutralisation 
experiments with the 37B5 Mab and cannot therefore, draw the conclusion that the 37B5 
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antibody is not blocking enterotoxicity by blocking binding of toxin A to its target cell 
(Kamiya et al 1986). As both the PCG-4 and 37B5 Mabs bind to peptide H2, it is likely 
that both share the same binding site in the toxin A molecule and block enterotoxicity by 
blocking binding of the toxin to its target cell. 
Mabs are extremely powerful tools that are frequently used to identify the functional 
epitopes of protein molecules. It is essential therefore, that Mabs interact specifically by a 
true immune reaction with their antigen. Toxin A has been shown to bind non- 
specifically to murine Mabs raised to antigens other than toxin A (Lyerly et al 1989) and 
this function has led to many misleading results. The ability of toxin A to non- 
specifically bind to antibodies, is in keeping with the ability of a number of proteins from 
a variety of gram-positive (Forsgren et a11966, Korvall 1973, Retnoningrum et al 1994) 
and gram-negative (Forsgren et al 1979, Labbe et al 1995, Mintz et al 1994, Yarnall et al 
1988) microorganisms, to interact non-immunologically with immunoglobulins. Recent 
results have shown that unlike these other protein molecules which bind to the Fc domain 
of antibodies, toxin A binds to an IgG3? murine Mab through the Fab domain (Cooke 
and Borriello 1998). The significance of the ability of toxin A to bind non-specifically 
with immunoglobulins by interaction with the Fab component is unknown. 
It is well known that the repeats at the C-terminal end of toxin A are involved in 
carbohydrate binding (Dove et al 1990, Price et al 1987) and that they bind to the 
trisaccharide residue Gala 1-3Galß1-4GlcNac (Krivan et al 1986, Tucker et al 1991). The 
expectation was, therefore, that the repeat end peptide (H2) would be responsible for non- 
specifically binding to the Fab domain of murine monoclonal antibodies. The results in 
this section prove this to be the case and also show that binding is mediated through 
galactose residues on the antibody molecule. Carbohydrate is mainly localised on the 
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constant domain of the heavy chain of IgG Fab fragments. If it is the case, as suspected, 
that the C-terminal repeat region of toxin A is exposed over the surface of the molecule, 
there would be a maximum surface area available for toxin A to non-specifically bind to 
antibodies in vivo. At present, it is unknown whether this non-specific interaction with 
galactose residues on antibodies is purely coincidental or whether it is a function that has 
been adapted to enable toxin A to mask itself from the immune system in vivo. It has 
been suggested that this ability may promote interaction of toxin A with mucus due to the 
presence of secretory IgA, which contains more carbohydrate than other 
immunoglobulins (Cooke and Borriello 1998, Goodman 1982). 
A practical outcome of these findings was the indication that Mabs raised to toxin A 
should be treated with ac and/or ß-galactosidase to confirm specific interaction. A 
reduction in binding to toxin A following this treatment would suggest that the Mab is 
binding in a non-specific manner and not by a true immune reaction. Another important 
consideration is that the majority of Mabs raised to toxin A that appear to bind to the C- 
terminal repeat region of the molecule may be doing so in a non-specific manner. 
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SECTION 
-5 
A STUDY OF THE BIOLOGICAL ACTIVITIES EXPRESSED 
BY THE TOXIN A PEPTIDES 
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Section 5 
A Study of the Biological Activities Expressed by the Toxin A Peptides 
5.1 SUMMARY 
The eight toxin A peptides were used to localise the active sites for a range of biological 
activities associated with C. docile toxin A. All activities related to binding of 
carbohydrate i. e. cold haemagglutination of rabbit erythrocytes and binding of bovine 
thyroglobulin were restricted solely to peptide H2 (C-terminal repeat end of toxin A). 
Peptide H2 also caused a cytopathic effect (CPE) on tissue culture cells which was 
atypical of holotoxin A. None of the other peptides had an effect. In the rabbit ileal loop 
assay, none of the toxin A peptides induced a visible haemorrhagic fluid secretion, whilst 
loops that contained either holotoxin A or cholera toxin were fully distended. Polyclonal 
antisera raised against both holotoxin A and peptide H2 were shown to partially inhibit 
the toxin A induced CPE on Vero cells and the WA of rabbit erythrocytes. Polyclonal 
antisera raised against the N-terminal peptides (A2-G) however, did not protect against 
these toxin A induced biological activities. 
Immunohistochemistry and transmission electron microscopy (TEM) studies showed that 
peptide H2 bound to the surface of Vero cells in vitro and was also internalised in 
membrane bound vesicles into rabbit intestinal cells in the rabbit ileal loop assay. These 
results suggest that the C-terminal repeat region of toxin A is solely responsible for 
uptake of the holotoxin into endosome-like compartments within cells. We propose that 
peptide H2 binds to cell surface receptors and activates intracellular transmembrane 
signalling pathways, which exert cellular effects (visualised as the atypical CPE) that are 
independent of the catalytic action of the holotoxin. 
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5.2 INTRODUCTION 
The toxin A peptides produced in section 3 are important tools for increasing the limited 
knowledge on the structure-function relationships of toxin A. Various biological 
activities have been attributed to toxin A although the active sites responsible for many of 
these processes have not been identified. 
Toxin A has been shown to bind with a higher affinity to hamster ileal brush border 
membranes at 4°C than at 37°C (Krivan et al 1986, Rolfe 1991). This cold binding has 
also been demonstrated with rabbit erythrocytes, bovine thyroglobulin, rabbit ileal brush 
borders and human intestinal epithelial cells (Krivan et al 1986, Pothoulakis et al 1991, 
Krivan et al 1987, Smith et al, 1997). The trisaccharide residue Gala 1-3Galß 1-4GlcNac 
is present on rabbit erythrocytes and bovine thyroglobulin and has been revealed as the 
binding ligand (Krivan et a11986, Krivan et a11987, Clark et al 1987). This carbohydrate 
however, is not present on human cells but the findings led to the identification of the 
Lewis X, Y and I antigens as possible receptors for toxin A on human intestinal epithelial 
cells (Tucker et al 1991). Since this time Lewis X has been ruled out as a receptor for 
toxin A (Sauerborn et al, 1997). Also, a further study has pointed out that as the Lewis X, 
Y and I antigens do not possess terminal alpha-galactose units, other receptors are likely 
to be involved in toxin A binding to some human intestinal cells (Smith et al, 1997). The 
C-terminal region of toxin A is composed of repeating oligopeptides and it is this region 
of the holotoxin that has been identified as the receptor binding domain (Price et al 1987, 
Wren et al 1991). 
Toxin A is a potent cytotoxin in vitro causing a characteristic rounding up of cells due to 
disruption of the actin cytoskeleton. As well as cytotoxic activity, toxin A also exhibits 
enterotoxic activity causing destruction of the colonic epithelium which results in fluid 
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secretion into the intestine (Lima et al 1988, Lyerly et al 1985a). The active sites 
responsible for these biological activities have not yet been identified, although it is 
believed that they reside within the N-terminal two thirds of the molecule. 
The aim of this section was to determine the regions of the toxin A molecule responsible 
for H/A of rabbit erythrocytes, thyroglobulin binding, cytotoxicity and enterotoxicity. 
Peptide specific antisera would also be used in an attempt to neutralise the biological 
activities of toxin A. The protective potential of each peptide would therefore be 
determined. 
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5.3 MATERIALS AND METHODS 
5.3.1 Haemagglutination (H/A) assay 
This assay is based on a method described by Krivan et al (1986) with the slight 
modification that a 1% rabbit red blood cell (RRBC) suspension was used (Kamiya et al, 
1988), instead of a 2.5% suspension. Where necessary the toxin A peptides were cleaved 
with factor Xa (see section 2.8.3). Fifty µl of each toxin A peptide (16µgmf') was diluted 
two-fold with Tris Buffered Saline (isotonic buffer) in the wells of a v-bottom 
microtitration plate (Sero-well). Holotoxin A (320µgmf) was placed in one well as a 
positive control. MBP and the E. coli protein sample were used as negative controls (see 
sections 3.3.7.1 and 3.3.7.5). Fifty µl of a 1% RRBC suspension was added to each well 
and incubated for at least 3h at 4°C. H/A titres were expressed as the reciprocal of the 
highest dilution giving a positive HVA when viewed by eye. The experiment was repeated 
to compare the H/A titres of peptide H2 to holotoxin A. Peptide H2 (16µgm1') and toxin 
A (320µgm1"') were diluted two-fold with Tris-buffered saline in the wells of a V-bottom 
plate. RRBCs were added to each well and the reactions were then incubated as described. 
53.2 T6yroglobulin binding assay 
The ability of each toxin A peptide to bind bovine thyroglobulin was determined using an 
Enzyme Linked Immunosorbent Assay (ELISA) based technique. Bovine thyroglobulin 
(Sigma) was dissolved in 0.05M carbonate buffer pH 9.6 to a final concentration of 
10µgmr`, and applied to a 96 well ELISA plate (Life Technologies Ltd., Paisley, U. K) at 
4°C overnight. The wells were blocked with 1% gelatin / PBS / 0.05% Tween 20 for lh at 
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room temperature. Where necessary the fusion peptides were cleaved with factor Xa at 
4°C overnight (see section 2.8.3). Toxin A peptides were diluted in 0.1% gelatin / PBS / 
0.05% Tween 20 to the final concentration of 10. tgm1"', and 50gl aliquots were applied in 
triplicate to the wells and incubated at 4°C for 2h. Wells were washed with PBS / 0.05% 
Tween 20 at 4°C and incubated with a 1: 1,000 dilution of the relevant polyclonal peptide 
specific antiserum at 4°C for 2h. Following four washes with PBS / 0.05% Tween-20, 
50µ1 of goat anti-rabbit alkaline phosphatase conjugate (1: 1000 dilution; Sigma) was 
applied and incubated at 4°C for lh. Each well was washed with PBS / 0.05% Tween 20 
then sterile distilled water. 500 of pNpp alkaline phosphatase substrate solution (Sigma) 
was added and absorbance values were recorded at 405nm. Controls were included to 
determine the background level binding of each peptide antiserum to bovine thyroglobulin. 
A statistical analysis was performed (see section 4.3.7). 
5.3.3 Cytotozicity Assay 
This assay makes use of African Green Monkey Kidney (Vero) cells, as described by 
Kamiya et al (1988). Vero cells were grown in culture flasks in Medium 199 (Sigma, St 
Louis, USA) containing 5% newborn calf serum, 1% penicillin and 1% glutamine. When 
confluent, the cells were recovered from the flask by incubating with 3mls trypsin / EDTA 
solution (Sigma) for 2mins at 37°C and were resuspended in 20mis of growth medium. 
Two hundred µl aliquots of cell suspension were added to each well of a 96 well sterile 
microtitre plate (Falcon). The cells were incubated overnight at 37°C to reach confluency 
before the medium was replaced with 100µ1 of maintenance medium (Medium 199 
containing 2% newborn calf serum, 1% penicillin and 1% glutamine). Where necessary 
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toxin A peptides were cleaved with Factor Xa at 4°C overnight (see section 2.8.3). Ten- 
fold serial dilutions of the peptides (16µgm1"') were prepared in PBS, and l00µ1 of each 
sample was added to the Vero cells in the microtitre plate. Toxin A (16pgml'') was diluted 
in the same way and included in the assay as a positive control. MBP (16µgm1') was 
included as a negative control for peptides A2-G whilst the E. coli protein sample 
(16µgml') acted as a negative control for peptide H2. Following an incubation of 24h at 
37°C, cells were monitored for a CPE, commonly seen as cell rounding. The cytotoxicity 
titre (cytotoxic unit [CU]/100 µl) was expressed as the highest dilution that induced more 
than 50% CPE after an incubation of 24h. 
For toxin A and peptide H2 the dilution giving an end point in the ten-fold dilution series 
was used as a starting point for a two-fold dilution series to yield a more accurate end 
point. 
5.3.4 Enterotoxic activity of the toxin A peptides in rabbit ileal loops. 
The new loop assay was performed at Leicester University in collaboration with Dr. Julian 
Ketley. Beal loop tests were done as previously described (Evans et al, 1973 and Mitchell 
et al, 1986) with the following exceptions. 
A method was developed for constructing closed loops in rabbit ileum. The rabbit was 
fasted for 24 hr and the ileum washed through with 50m1 phosphate buffered saline (PBS: 
4.25g/l NaCl, 2.44g/l KH2PO4,8.09g11 Na2PO4 pH. 7). From the point of ligation, 5cm 
ligated loops with 5cm interloop spaces were constructed and tied with cotton. Toxin A 
peptides were cleaved where necessary (see section 2.8.3). Five hundred µl of the toxin A 
peptides A2, B, C, D, E and G (72µgnil') and 0.5m1 of peptide H2 (25µgmr') were 
248 
injected into different loops. The interloop spaces were injected with 0.5ml of PBSA. 
Toxin A (72µgm1') or cholera toxin (2pgml"') were injected and included as positive 
controls, whereas MBP (72µgml') and the E. coli protein sample (25µgml"') were 
included as negative controls. The ileal loops were returned to the rabbit, which was left 
to recover from the anaesthetic. The loops were examined after an 18hr incubation period 
and the results were recorded as the volume of fluid taken from the loop / the length of the 
loop (V/L ; mi/cm). A small section of each loop was carefully dissected and placed in 
0.5ml of glutaraldehyde for electron microscopy studies. 
5.3.5 Neutralisation of the toxin A induced CPE on Vero cells by the toxin A peptide 
polyclonal monospecific antisera. 
Using polyclonal monospecific antisera raised to toxin A and to toxin A peptides A, B, D, 
E, G and H2 (see section 4.3.1), an attempt was made to neutralise the toxin A induced 
CPE (see section 5.3.3). Vero cells were grown to confluency in 96 well tissue culture 
plates and the growth media replaced with l00µ1 of maintenance medium. 
Two sets of toxin A dilutions were prepared in PBSA. In the first set toxin A was diluted 
to 26µgm1', 2.6µ8m1', 260ngm1"', 130ngm ', 65ngml', 32.5ngmr', 16.25ngml"' and 
8.125ngmr'. In the second set toxin A was diluted to 26µgmr', 13µgml'', 6.5µgm1', 
3.25µgmt', 1.625µgmI', 812.5ngm1' and 406ngm1'. Each of the above mentioned 
polyclonal nzonospecific antisera and their respective pre-bleed sera were diluted 1: 10 in 
PBSA. 100µl aliquots of each of the toxin A dilutions in set one were mixed 1: 1, in 
separate reactions, with each of the antibody preparations. One hundred µl aliquots of 
each of the toxin A dilutions in set two were mixed 1: 1, in separate reactions, with the 
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diluted preparation of either polyclonal monospecific anti-toxin A, anti-peptide H2 or their 
respective pre-bleed sera (the original toxin A concentrations now diluted 1: 2). The tubes 
were incubated for lhr at 37°C. One hundred µl aliquots of each neutralisation reaction 
were applied to Vero cells in 96 well plates (the original toxin A concentrations now 
diluted 1: 4). Each specific antiserum was limited to one column and the samples were 
arranged down the plate in the order of decreasing toxin A concentration. 
Following an incubation of 24hr at 37°C with 5% CO2. the cells were observed for a CPE 
(commonly seen as cell rounding). The cytotoxicity titre (cytotoxic unit [CU] /100µ1) was 
expressed as the highest dilution that induced more than 50% CPE after an incubation of 
24hr. 
5.3.6 Neutralisation of the toxin A induced H/A of RRBCs by polyclonal 
monospecific toxin A and peptide H2 antisera. 
Using polyclonal monospecific antisera raised to toxin A and peptide H2 (see section 
4.3.1), an attempt was made to neutralise the toxin A induced H/A of RRBCs (see section 
5.3.1). 
Toxin A was diluted in PBSA to the final concentrations of 65µgm1'', 32.5µgm1"', 
16.251. tgm1'1,8.125µgm1"', 4.0625µgm14,2.031µgm1'', 1.015µgm1'' and 0.505µgm1"'. One 
hundred µl aliquots of each of the toxin A dilutions were mixed 1: 1, in separate reactions, 
with a neat preparation of either polyclonal monospecific toxin A antiserum, peptide H2 
antiserum or the respective pre-bleed sera (the original toxin A concentrations now diluted 
1: 2). The tubes were incubated for 1hr at 37°C. One hundred µ1 of each neutralisation 
reaction were tested for the ability to haemagglutinate RRBCs. Each specific antiserum 
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was limited to one column and the samples were arranged down the V-well plate in the 
order of decreasing toxin A concentration. 
5.3.7 Detection of binding of peptide H2 to Vero cells by immunobistochemistry 
5.3.7.1 Production of monolayers of Vero cells on glass coverslips. 
A glass coverslip was placed in the bottom of each well of a 24 well sterile tissue culture 
plate (Falcon). Confluent Vero cells were recovered from a tissue culture flask by 
trypsinisation and resuspended in 25m1s of growth medium (see section 5.3.3). One ml 
aliquots of the cell suspension were added to each well containing a glass coverslip. The 
cells were incubated at 37°C with 5% CO2 to reach confluency and the growth medium 
was then replaced with 0.3 ml of maintenance medium (see section 5.2.2.1). 
5.3.7.2 Incubation of Vero cells with peptide H2 
Monolayers of Vero cells were grown to confluency on glass coverslips in a 24 well tissue 
culture plate and the growth medium was replaced with 0.3 nil maintenance medium (see 
section 5.2.2.1). 
Peptide H2 (0.3 ml of 18µgml'' stock) was added to eight wells (A), the negative control 
E. coli protein sample (0.3 ml; directly comparable to peptide H2) was added to eight 
wells (B) and PBSA (0.3 ml; negative control) was added to four wells (C). The cells were 
incubated with the protein samples at 4°C for 20mins. Two coverslips from each of wells 
A, B and C were removed and washed with 3x1 ml of wash buffer pH 7.5 (8mM 
Na2HPO4,2.2mM NaH2PO4,140mM NaCl). These coverslips (4°C samples) were fixed 
by submerging in a glass petri-dish containing acetone for l Omins. The fixed cells were air 
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dried then placed in a fresh 24 well plate. The remaining cells were incubated at 37°C with 
5% C02 for 10mins. Again two coverslips were removed from A and B. These were 
washed, fixed and air-dried as mentioned previously (37°C, 10 min samples). The 
remaining cells were returned to the 37°C incubator. This process: was repeated with two 
coverslips from A and B after 20mins at 37°C and with two coverslips from A, B and C 
after 30mins at 37°C. Once all of the coverslips had been placed in a fresh 24 well plate, 
they were covered in foil and stored at -20°C ready for immunohistological examination. 
5.3.7.3 Immunohistochemical detection of bound peptide H2 
Iminunohistochemical detection was performed as outlined by the Vectastain ® Universal 
Elite ABC Kit (Vector Laboratories) instruction manual. A brief outline is given below. 
The prepared coverslips (section 5.3.7.2) were equilibrated to RT, air dried then washed 
with 3x0.5mis of wash buffer pH 7.5 (8mM Na2PO4,2.2mM NaH2PO4,140mM NaCI). 
One of each of the pairs of coverslips containing Vero cells treated with peptide H2 or the 
E. coli protein sample, for 20mins at 4°C, 10mins at 37°C, 20mins at 37°C and 30mins at 
37°C were incubated with 7µgml'' of the Mab PCG-4 (diluted in wash buffer) at 4°C, 
overnight with shaking. One of each of the pairs of control coverslips containing untreated 
Vero cells incubated under identical conditions was also treated with the PCG-4 Mab as 
described above. The remaining coverslip from each pair was incubated with 5O00 of 
wash buffer at 4°C overnight with shaking. 
All of the coverslips were washed with 5x iml of wash buffer and then incubated with 0.5 
ml of Biotinylated Universal Antibody (Vector Laboratories) for 30mins at RT with 
shaking. Any nonspecific binding of the biotinylated antibody to the Vero cells or the 
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protein sample was evident in the second coverslip of each pair that was not incubated 
with primary antibody. The coverslips were washed with 5xI ml of wash buffer before 
incubation with 0.5m1 of a preformed avidin and biotinylated horse radish peroxidase 
macromolecular complex (Vectastain (D Elite ABC Reagant; Vector Laboratories) for 
30mins at room temperature with shaking. Coverslips were washed with 5x1 ml of wash 
buffer before incubating in diaminobenzidine tetrahydrochloride solution (DAB; Vector 
Laboratories) for 2mins to allow the colour to develop. A summary of the Vectastain Elite 
ABC detection system can be seen in figure 5.6. 
The coverslips were rinsed in distilled water, allowed to dry then counterstained with 
Haemotoxylin (Nustain Inc. ) for 2mins. Submerging respectively in 30%, 60% then 90% 
ethanol solutions for 10secs each dehydrated the cells. The cells were rehydrated by 
submerging in xylene solution (Nustain Inc. ) for 10secs before placing on a glass slide, 
applying a drop of DPX mounting solution (Nustain) and overlaying with a glass 
coverslip. 
Each sample was viewed under a bright field microscope (Orthoplan) alongside its 
respective negative controls at magnifications of x10, x16 and x25. Results were 
photographed using a Leitz-Wild MP551 camera. 
5.3.8 Transmission electron microscopy (T. E. M. ) 
A detailed account of the methodology used in the EM studies is outlined in Powell, 1999. 
A brief outline is provided below. 
5.3.8.1 incubation and treatment of Vero cells with toxin A peptides for electron 
microscopy (E. M. ) studies. 
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Confluent Vero (monkey kidney) cells were recovered from a tissue culture flask by 
trypsinisation and resuspended in 50m1 growth medium (see section 5.3.3). One ml 
aliquots of the cell suspension were added to each well of two 24 well sterile tissue culture 
microtitration plates (Falcon). The cells were incubated at 37°C with 5% CO2 to reach 
confluency and the growth medium was then replaced with 0.5 ml of maintenance medium 
(see section 5.3.3). MBP (negative control), peptide A2, E. coli protein sample (negative 
control), peptide H2 and toxin A were each diluted to 5µgm1"' in maintenance medium and 
each sample was added in multiples of 6x0.5m1 aliquots to the cells in the microtitration 
plates. A further row of six wells was incubated with 0.5m1 TBS and was included as a 
further negative control. The microtitre plates were placed at 4°C for 30mins. The cells in 
one representative well per protein sample were washed with iml PBSA (4.25g/1 NaCl, 
2.44g/l KH2PO4,8.09gll Na2PO4 pH. 7) and then resuspended in 0.5m1 1% glutaraldehyde 
(fixative). The cells were gently removed from the microtitre plate, placed in 0.5ml 
eppendorf tubes and left to fix for lhr at RT. These represented the 4°C samples. The 
remaining cells in the plate were incubated at 37°C with 5% CO2 for 5mins. Again the cells 
in one well per protein sample were washed, transferred and fixed as above (5min 
samples) then the remaining cells returned to the 37°C incubator for a further 25mins. 
Samples were collected, washed and fixed for each protein sample after the 25mins at 
37°C, ihr at 37°C, ihrs at 37°C and overnight at 37°C. The appearance of the cells was 
monitored at each stage. After fixation the cells were gently pelleted at 6,000 xg for 2mins 
then resuspended in 0.5m1 PBS. The cells were stored in PBSA at 4°C until the unicryl 
processing procedure (see section 5.3.8.3). 
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5.3.8.2 Treatment of rabbit deal tissue with toxin A peptides 
Toxin A, peptide A2 and MBP (negative control) were diluted to 72µgm1"' in amylose 
buffer (20mM Tris-HCI, 200mM NaCI, 1mM EDTA). Peptide H2 and the E. coli protein 
sample (negative control) were diluted to 25µgml' in PBS. Cholera toxin was diluted to 
2pgmrl and was included as an additional positive control. Five hundred µl aliquots of 
each sample were injected into different ileal loops and incubated for an 18hr period (see 
section 5.3.4). The rabbit was sacrificed by injecting a lethal dose of anaesthetic drug. The 
loops were removed and small samples were taken and fixed in 1% glutaraldehyde 
overnight at 4°C. The tissue samples were removed from fixative, placed in 0.5m1 PBS and 
stored at 4°C until they were processed in unicryl resin [British Biocell International, 
Cardiff U. K. ] (see section 5.3.8.3). 
5.3.8.3 Unicryl processing schedule 
The cell monolayers and tissue samples prepared in sections 5.3.8.1 and 5.3.8.2 were 
pelleted at 6,000 xg for 2mins. They were then dehydrated by incubating in 70% ethanol 
for 3x lOmins, 90% ethanol for 3x 10mins and 100% ethanol for 3x 10mins with 
intermittent centrifugation at 6,000 xg for 2mins. The dehydrated cells were infiltrated 
with unicryl resin (British Biocell International, Cardiff U. K. ): ethanol (1: 2) for 30mins, 
unicryl resin: ethanol (2: 1) for 30mins, 100% unicryl resin for 2x ihr and finally with 
100% resin overnight. The cells were pelleted by centrifugation at 6,000 xg for 2mins to 
ensure the pellets were at the bottom of the eppendorf tube. The resin was then 
polymerised using longwave UV (360 nm) in a UV polymerisation chamber (Agar 
Scientific, U. K. ) for 1-2 days at 4°C. Ultra-thin sections (50-100 nm) were cut using a 
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Reichert OMU2 ultramicrotone. Sections were collected on Formvar coated nickel grids 
and stored at 40°C in grid boxes prior to the post-embed immunolabelling procedure (see 
section 5.3.8.4). 
5.3.8.4 Post-embed immunolabelling procedure 
The grids containing the sections were floated face down on 30µl droplets of PBSA/1% 
BSA (Bovine Serum Albumin; Sigma) for 1 Omins. The grids were then transferred without 
rinsing to 30µl droplets of the relevant primary antiserum (as described below) and 
incubated for 1-2 hrs. Sections containing toxin A, peptide H2 or the E. coif protein 
sample were incubated with 20 
. 
gm ' of the Mab PCG-4. Sections containing peptide A2 
or MBP were incubated with a 1: 10 dilution of peptide A2 antiserum (raised ` in house', 
see section 4.3.1). Sections of cells that had not been treated with any protein sample were 
incubated with both of the mentioned primary antisera to determine the level of non- 
specific binding of the antibodies to the cells. Sections were transferred to 3x 301il 
droplets of PBSA for Smins each and were then gently jet washed in PBSA. The sections 
were blotted dry and then quickly transferred to 2091 droplets of gold labelled secondary 
antibody for 1 hr. Sections treated with the PCG-4 Mab were incubated with a 1: 20 
dilution of 10 or 15nm gold labelled anti-mouse conjugate (British Biocell International). 
Sections treated with peptide A2 primary antiserum were incubated with a 1: 20 dilution of 
a lOnm gold-labelled protein A conjugate (British Biocell International). As further 
negative controls, sections were included that had been treated with each protein sample 
but not with the any primary antisera- These sections were subsequently incubated with 
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the secondary gold-labelled antibodies to determine the levels of non-specific binding of 
the gold conjugates to the cells or protein samples. Sections were transferred to 3x 30µ1 
droplets of distilled water for 2mins to remove the unbound gold conjugate. The sections 
were blotted dry, post stained with aqueous 4% uranyl acetate and Reynolds lead citrate 
(Agar Scientific U. K. ) then examined at 80 KV in a Transmission Electron Microscope 
(JEOL JEM 100C). Sections were compared to their respective negative controls and 
representative areas of each section were photographed. 
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5.4 RESULTS 
5.4.1 H/A assay 
The H/A of RRBCs is dependent on the recognition of the trisaccharide residue Gala 1- 
3Galpl-4G1ucNac. Only holotoxin A (see figure 5.1 lane IOA) and the C-terminal repeat 
end peptide, H2 (see figure 5.1 lane 8), acted as cold haemagglutinins for rabbit 
erythrocytes. The H/A titre of peptide H2 was 1: 64. The N-terminal toxin A peptides, the 
MBP and the E. coli negative control sample had no effect on the RRBCs (see figure 5.1 
lanes 1-7 and 9). 
The assay was repeated to compare the H/A titre of peptide H2 to holotoxin A. The 
holotoxin (320µgm1') had an IVA titre of 1: 512, whilst that of fragment H2 (16µgm1') 
was 1: 64. This represented effects induced by 312ngmi 
1 and 125ngm1" for toxin A and 
peptide H2 respectively. 
Further evidence that peptide H2 binds to RRBCs came from the internalisation study of 
peptide H2 into rabbit intestinal epithelial cells (see figure 5.2). At a magnification of x 
39,000 the electron micrograph shows the high affmity binding of gold labelled peptide 
H2 to an isolated RRBC. 
5.4.2 Bovine thyroglobulin binding 
Again the binding of toxin A to bovine thyroglobulin is dependant on the recognition of 
the trisaccharide residue Gala 1-3Ga1ß1-4G1ucNac. Apart from toxin A, only peptide H2 
(C-terminal repeat region of toxin A) bound significantly to bovine thyroglobulin. In the 
ELISA assay, the binding of peptide H2 to thyroglobulin showed an O. D405 of 1.723 +/- 
0.023 and was significant (p<0.001) (see figure 5.3) which was greater than that of toxin 
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A which gave an O. D4o5 of 0.426 +/_ 0.017 with ap value of <0.0001 (see figure 5.3). 
None of the other toxin A peptides or negative control samples bound significantly to 
bovine thyroglobulin (in each case p>0.2). 
5.4.3 Cytotoxicity assay 
None of the peptides covering the N-terminal region of toxin A (peptides A2-G) were 
cytotoxic to Vero cells. In each case the cell monolayer appeared unaffected (see figure 
5.4 part A). Holotoxin A (positive control) on the other hand, caused a classic CPE (see 
figure 5.4 part B) with a titre of 1: 4x103. Peptide H2, representing the C-terminal repeat 
region of toxin A, had an effect on the morphology of the cells (see (figure 5.4 part C) 
which had a titre of 1: 40. These findings represent an ability to induce morphological 
changes in cells by exposure to 2ngmt' of toxin A and 200ngmr' of peptide H2. The 
effect of peptide H2 was different to the holotoxin. The E. coli protein sample (negative 
control for peptide H2) had no effect on the Vero cell monolayer. 
5.4.4 Rabbit ileal loop assay 
Following incubation of the rabbit deal loops with the toxin A peptides, each loop was 
monitored for the presence of an enterotoxic effect in the form of fluid accumulation. The 
results are shown in table 5.1. None of the toxin A peptides (A2-H2) or the negative 
control samples induced a visible fluid secretion into the ileal loops. The fluid 
accumulations recorded for the cholera toxin and C. docile toxin A positive controls 
however, were 2.25ml/cm and 2.29m1/cm respectively. 
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5.4.5 Neutralisation of the toxin A induced CPE on Vero cells and H/A of RRBCs by 
polyclonal toxin A peptide antisera 
In the cytotoxicity assay, the holotoxin A incubated with pre-bleed rabbit sera caused a 
classic CPE with a titre of 1: 1.6x103. This represented an ability to induce morphological 
changes in Vero cells by exposure to 4ngm1'' of toxin A. 
Pre-incubation of toxin A with the different antisera raised against the N-terminal 
peptides (A2-G) failed to neutralise the CPE with the cytotoxicity titre remaining at 
1: 1.6x103 in each case. A 1: 10 dilution of the antiserum raised against the C-terminal 
repeat end peptide (H2) was successful in neutralising the toxin A induced CPE from a 
titre of 1: 1.6x103 to 1: 1.6x10'. This represented an ability to induce morphological 
changes in Vero cells by exposure to 406ngm1'' of treated toxin A. A 1: 10 dilution of the 
monospecific toxin A antiserum, however, neutralised the toxin A induced CPE causing a 
reduction from a titre of 1: 1.6x103 to 1: 4. This titre represented an end point CPE caused 
by 1.625µgm1'1 of treated toxin A (results not shown). 
The toxin A (65 pgml"') treated with neat pre-immune sera gave an IVA titre of 1: 16, 
representing an end point toxin A concentration of 2.03µgm1"' (see Figure 5.5, lanes 2 
and 4). The toxin A treated with undiluted polyclonal monospecific toxin A antiserum 
was only able to haemagglutinate RRBCs when applied at a neat concentration (final 
concentration of toxin A of 32.5ggmt) to the wells of the microtitre plate (see Figure 
5.5, lane 1). When toxin A was treated with the polyclonal peptide H2 antiserum, 
however, the WA titre was reduced to 1: 2 representing an effect induced by exposure to 
16.25µgml" of toxin A (see Figure 5.5, lane 3). 
5.4.6 Immunohistochemical detection of binding of peptide H2 to Vero cell receptors 
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The Vectastain Elite ABC Kit (Vector Laboratories) was used to detect binding of toxin 
A peptide H2 to Vero cell surface receptors (see section 5.3.7). A diagrammatic 
representation of the staining procedure is shown in figure 5.6. The cell nuclei were 
counterstained with haemotoxylin to enable easier visualisation of the cells under the 
microscope. The clearest images were achieved at a magnification of x 25. A brown 
precipitate was evident on all of the cell monolayers treated with toxin A peptide H2 
suggesting that in all conditions the peptide was binding to cell surface receptors on the 
Vero cells. The binding was greater following incubation at 37°C for 30mins (see figure 
5.7 B) than at 4°C for 20mins or 37°C for 10 or 20mins. An identical pattern was 
observed for cells treated with holotoxin A (results not shown). 
The lack of brown precipitate on all samples incubated with the E. coif negative control 
proteins (see figure 5.7 part A) suggested that the binding seen in figure 5.7 part B was 
due to peptide H2 and not to a contaminating E. coli protein or PCG-4 binding to cell 
components. These results suggest, as expected, that the C-terminal repeat region of toxin 
A is responsible for binding to cell surface receptors. 
5.4.7 Transmission electron microscopy (TEM) studies 
5.4.7.1 Internalisation of peptide H2 into cells 
The method outlined in section 5.3.8 was used to study early binding and internalisation 
of peptide H2 into Vero cells. Lowicryl resin was used in these experiments, as opposed 
to Spurs resin, in an attempt to retain the antigenicity of peptide H2. One of the 
consequences of using this resin however is that the ultrastructural preservation of the 
cell monolayers is often poor. 
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Approximately 30 x more gold particles were observed in the cell monolayers treated 
with peptide H2 than those treated with the E. coli negative control proteins (results not 
shown). The gold label was mainly concentrated on the cell membranes or just inside the 
cells and was at its greatest density in the mono layers incubated with peptide H2 for 1 hr 
at 37°C. Unfortunately there was poor ultrastructural preservation of the tissue culture 
cells treated with peptide H2 and so with no time to repeat the experiment, the results 
were deemed inconclusive. 
Peptide H2 was successfully detected however, in rabbit intestinal cells using the 
methods outlined in sections 5.3.8.2,5.3.8.3 and 5.3.8.4. A large proportion of the H2 
peptide was localised in membrane bound vesicles which were possibly late endosomes 
(see figure 5.8). The majority of the peptide was found in the late stages of internalisation 
(often close to the nucleus) because the rabbit ileal loop assay was incubated at 37°C for 
18 hrs. 
There were approximately 20 x more gold labels associated with the sections treated with 
peptide H2 than with those treated with the E. coli negative control proteins. The number 
of gold particles associated with the negative control sections was negligible and the few 
particles present did not appear to be associated with membrane bound vesicles (see 
figure 5.9). These results suggest that the PCG-4 Mab and the gold labelled conjugate 
were binding specifically to peptide H2 and not non-specifically to the E. coil negative 
control proteins or the intestinal cell components. It would appear therefore, that peptide 
H2 can bind and be internalised into endosome-like compartments within target cells. 
5.4.7.2 Internalisation of peptide A2 into cells 
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Attempts to localise peptide A2 in rabbit intestinal cells by TEM were inconclusive due 
to some non-specific binding of the polyclonal peptide A2 antiserum to the intestinal 
cells. The numbers of gold particles in the peptide A2 treated sections were similar to the 
numbers observed in the negative control sections (results not shown) suggesting that 
peptide A2 was not internalised efficiently into the intestinal cells. 
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Figure 5.1 
r 
*Neat concentration = 16pgm1"' 
A 
B 
Haemagglutination of rabbit red blood cells by the cleaved toxin A peptides and their 
respective negative controls. 
Lane 1, peptide A2; lane 2, peptide B; lane 3, peptide D; lane 4, peptide E; lane 5, peptide 
F; lane 6, peptide G; lane 7, MBP; lane 8, peptide H2; lane 9, E. coli negative control 
proteins; lane I OA, toxin A (positive control); lane I OB, PBSA. 
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Figure 5.2 
Transmission electron micrograph of a section of rabbit ileal loop tissue treated with 
toxin A peptide H2 showing high affinity binding of the peptide to a rabbit red blood cell 
(indicated by the gold particles). Taken at a magnification of x 39,000. 
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Figure 5.3 
A graph to show binding of the toxin A peptides to bovine thyroglobulin in an 
ELISA assay. Binding was significant for holotoxin A and peptide H2 only. 
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Protein sample used to coat ELISA plate wells 
A B 
C 
Figure 5.4 
Effect of the toxin A peptides on a monolayer of vero cells after a 16 hr incubation at 
37°C with 5% CO2. Images viewed under an inverted light microscope at a magnification 
of x 100. A, an unaffected monolayer; B, a toxin A treated monolayer; C, a monolayer 
treated with toxin A peptide H2. 
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Figure 5.5 
Neutralisation of the toxin A induced haemagglutination of rabbit red blood cells by pre- 
incubation of toxin A with polyclonal monospecific toxin A and peptide H2 antisera. 
Lane 1, treated with toxin A antiserum; lane 2, treated with pre-immune serum; lane 3, 
treated with peptide H2 antiserum; lane 4, treated with pre-immune serum; lane 5A, toxin 
A (positive control); lane 5B, PBSA. 
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Universal 
Biotinylated 
Antibody 
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Antibody 
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4 Vero cells 
.4 
-Class Coverslip 
Figure 5.6 
A diagrammatic representation of the Vectastain Universal Immunohistochemical 
staining procedure (Vector Laboratories) used for the detection of binding of peptide 
H2 to receptors on the surface of Vero cells. Binding of peptide H2 to Vero cells was 
detected primarily with the specific Mab PCG-4. Binding of the PCG-4 Mab to a 
biotinyated antibody followed by an avidin / biotin complex (ABC) resulted in the 
production of peroxidase. The DAB substrate then reacted with available peroxidase 
to form a brown precipitate which was visualised under a microscope. 
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Figure 5.7 
Detection of toxin A peptide H2 binding to cell surface receptors on 
Vero cells using 
immunohistochemistry. Each sample was treated with the MAb PCG-4 followed by the 
Vectastain ABC antibody system (Vector Laboratories). The cells were visualised under 
an orthoplan microscope 
(magnification x 25) and photographed with a Leitz-Wild 
MP551 camera. 
A, Vero cells incubated with the 
E. coli negative control protein sample for 30 mins at 
37°C; B, Vero cells incubated with the toxin A peptide H2 protein preparation for 30 
mins at 37°C. The brown precipitate 
in B indicates binding of peptide H2 to Vero cells. 
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SAMPLE 
INJECTED 
INTO LOOP 
FLUID ACCUMULATION 
Vol. Fluid / Length of Loop (ml / cm) 
PEPTIDE A2 NFA 
PEPTIDE B NFA 
PEPTIDE C NFA 
PEPTIDE D NFA 
PEPTIDE E NFA 
PEPTIDE G NFA 
MBP (-ve cut. ) NFA 
PEPTIDE H2 NFA 
E. coli (-ve cut) NFA 
C dßfftcik Toxin A 18 m1 /8 cm = 2.25 
CHOLERA TOXIN 16 ml /7 cm = 2.29 
PBSA NFA 
NFA 
- 
no fluid accumulation 
Table 5.1 
Table showing the fluid accumulation observed after each toxin A peptide was injected 
into a ligated rabbit ileal loop. Results are recorded as a ratio of the volume of fluid 
recovered from the loop divided by the length of the loop after an 18hr incubation period. 
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5.5 DISCUSSION 
All the activities that were dependent on carbohydrate binding i. e. H/A and binding to 
thyroglobulin were restricted solely to peptide H2. The N-terminal peptides lacked these 
biological activities. These results were expected as the carboxy-terminal region of toxin 
A, composed of domains of oligopeptides, has been shown to be the receptor binding 
region (Price et al 1987, Wren et al 1991) and to specifically bind to certain tri- 
saccharides (Krivan et al 1986, Tucker and Wilkins 1991) including Gala l 
-3Galß l- 
4NacGluc. 
It was interesting to note that 2.5 times more holotoxin A than peptide H2 was required to 
haemagglutinate rabbit erythrocytes. This can be explained by the fact that the C-terminal 
repeat end of toxin A was responsible for this function and this region is approximately 
one third the size of the holotoxin (2.6 Kb as oppose to 8.1 Kb). 
Purification of peptide H2 from inclusion bodies involved denaturing the peptide with 
guanidine hydrochloride followed by renaturation by gradual dialysis. A complication of 
this process is that some peptides will not refold properly during dialysis. It was 
reassuring to observe therefore, that peptide H2 was able to bind to these carbohydrates 
suggesting that it had retained biological activity. 
None of the toxin A peptides appeared to induce a classical CPE on Vero cells or an 
enterotoxic effect in the rabbit Real loops. It is possible that the peptide(s) containing the 
relevant active sites were not biologically active. Another, more likely explanation, is that 
more than one region of the toxin A molecule is responsible for the full CPE and that 
these regions are components of different peptides. Perhaps the N-terminal peptides, for 
example, could not be internalised into the Vero cells without the repeat end-binding 
domain. 
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It was interesting to observe that peptide H2 (repeat end of toxin A) caused a physical 
and reproducible change to Vero cells in tissue culture. The classical confluent 
mosaicism of the normal cell sheet was lost and the cells became `stringy' in appearance. 
Peptide H2 was one hundred times less potent than toxin A at inducing morphological 
changes to Vero cells. This effect was dissimilar to the classical cell rounding CPE seen 
with toxin A and was not due to the E. coli negative control proteins. These results 
contradict the findings of Price et al, 1987 who concluded that a recombinant repeat end 
peptide had no morphological effect on CHO cells in a cytotoxicity assay. 
The results obtained in this thesis do suggest that peptide H2 can have a direct effect on 
cells. It is possible that this binding peptide was simply clumping the cells giving them a 
, stringy' appearance. Alternatively a number of experiments on cells in vitro, have 
yielded results indicating that binding of toxin A to a cell surface receptor activates 
intracellular transmembrane signalling pathways which may exert cellular effects 
independent of the catalytic action of the toxin (Pothoulakis et al 1988, Castagliuolo et al 
1994). Pothoulakis et al, 1988 provided data suggesting that the binding of toxin A to a 
granulocyte membrane receptor stimulated an increase in intracellular calcium, which 
elicited a chemotactic response by granulocytes to toxin A. A later study used an anti- 
galactose antibody that binds the trisaccharide Gala1-3Galß1-4G1cNac to mimic the 
effects of toxin A in rat colon. This work concluded that binding of toxin A to receptors 
bearing this tri-saccharide caused a series of events which resulted in fluid secretion, 
increased permeability and mast cell protease II release in rat colon (Pothoulakis et al 
1996a). 
If binding alone of toxin A to an intestinal cell receptor is sufficient to stimulate fluid 
secretion, we would have expected to observe a fluid response in the ileal loop injected 
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with peptide H2. The different amounts of peptide H2 and anti-galactose antibody used in 
these two different experiments however, could explain this discrepancy. In the rat colon 
experiment a 5cm loop was injected with 250µg of the anti-galactose antibody 
(pothoulakis et al 1996a). In our experiment however, a 5cm rabbit ileal loop was 
injected with only 12.5µg of peptide H2 due to the poor concentration of peptide 
recovered by the purification procedure. It is reasonable to assume, therefore, that more 
peptide H2 may have resulted in fluid secretion into the Real loop. 
The demonstration that binding alone induced morphological changes in cells may partly 
explain why toxin A has different biological activities to toxin B although they share the 
same mechanism of action for induction of cytopathic effects. This observation causes 
concern when considering the possible use of the repeat region of toxin A as a vehicle for 
the delivery of oral vaccines against C. dWIcile disease. 
Although other workers have demonstrated that the binding of holotoxin A to cell surface 
receptors activates intracellular transmembrane signalling pathways (Pothoulakis et al 
1988, Pothoulakis et al 1996a) no work has been done focusing purely on binding of the 
C-terminal repeat region of the toxin to cells. The results in this section indicate that 
peptide H2 (corresponding to the repeat region of toxin A) can bind to Vero cells 
independently of the N-terminal portion of the holotoxin. It was interesting to observe 
that in the immunohistochemistry experiments the binding was greater at 37°C than at 
4°C. These observations contradict the theory of others that have observed that holotoxin 
A binds to certain trisaccharides more efficiently at 4°C than 37°C (Krivan et al 1986, 
Tucker et a11991, Cooke et al 1998). In our experiments however, the peptide was only 
incubated with the cells for 20mins at 4°C and so it is possible that the incubation time 
was not long enough for efficient binding. 
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It was unfortunate that the TEM studies on tissue culture cells for the detection of early 
binding and internalisation of peptide H2 were inconclusive. A high density of gold 
labelling was observed in the cells treated with peptide H2 but it was difficult to pinpoint 
label within coated pits due to poor ultrastructural preservation of the sections. The TEM 
studies performed on rabbit ileal tissue treated with peptide H2, however, did 
conclusively show that peptide H2 not only bound to cells but was also internalised into 
membrane bound vesicles. Some of the peptide was observed outside of vesicles, which 
was probably due to the way the tissue had been sectioned rather than due to the peptide 
escaping from endosomes. Other workers have suggested that a hydrophobic domain 
(amino acids 1,050-1,100), not present in peptide H2, is necessary for efficient escape of 
the holotoxin from endosomes (Dove et al 1990, von Eichel-Streiber eta! 1995). 
The low density of labelling in these peptide H2 treated sections was probably due to the 
small amount of peptide that was applied to the deal loop. Only 12.5µg of peptide H2 
was injected into a 5cm rabbit ileal loop, which has a vast surface area for binding and 
internalisation of proteins. Bearing this in mind, we were unlikely to find an area on a 
section showing more than 2 or 3 peptide H2 containing membrane bound vesicles. It 
was also possible that after incubation for 18hrs in the rabbit, a large proportion of the 
peptide had been degraded or had been destroyed by the immune system. Other workers 
that have studied internalisation of toxin A into cells by TEM have also shown a poor 
density of labelling, some micrographs showing only one or two gold labelled toxin 
molecules per endosome (Kushnaryov et al 1989, Sturgeon 1994, von Eichel-Streiber et 
al 1996). Although the density of labelling in the peptide H2 treated sections was low in 
our experiments, it was approximately 20 x greater than in the corresponding negative 
controls. Also in the peptide 112 treated sections, the gold label was often associated with 
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membrane bound vesicles suggesting uptake by a receptor mediated process, however the 
few gold labels found in the negative controls were not associated with vesicles 
suggesting non-specific binding. As a post-embed immunolabelling procedure was 
employed for the detection of peptide H2 there was no possibility that the gold labelled 
antibody seen in endosomes was taken up non-specifically by the cells. The tissue was 
incubated with peptide H2, fixed, sectioned and then probed with the PCG-4 and gold- 
labelled antibodies. 
These results, taken together, suggest that the C-terminal repeat region of toxin A is 
independently responsible for binding and internalisation of the holotoxin into membrane 
bound vesicles, and also that the N-terminal region of the molecule is not necessary for 
these processes. This adds support to the possibility that binding alone of the holotoxin 
to cell surface receptors, may activate intracellular transmembrane signalling pathways 
which result in a change in the morphology of the target cells. 
The N-terminal peptide A2, which is believed to contain the catalytic domain of the toxin 
(see section 6), was not internalised by the rabbit intestinal cells probably due to the fact 
that it was unable to associate with the cells without the receptor binding domain of the 
toxin molecule. 
The polyclonal monospecific antisera raised against the N-terminal toxin A peptides (A2- 
G) failed to neutralise the holotoxin A induced CPE on Vero cells. It is possible that the 
catalytic domain lies inside the holotoxin A molecule and is only exposed once the toxin 
is in the cell cytoplasm. It is likely therefore, that microinjection of the relevant antiserum 
into the cell prior to internalisation of the toxin could inhibit the CPE. Polyclonal 
antiserum raised against peptide H2 did neutralise the toxin A induced H/A and CPE. 
These results compare to the data published by Wren et al 1991 who also found that the 
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antiserum raised against a small 10 amino acid repeating sequence of toxin A neutralised 
both H/A and the CPE. In these cases, it was assumed that the antiserum was recognising 
the C-terminal repeat region of the holotoxin and blocking binding of the molecule to its 
receptor on the erythrocyte and Vero cell. 
It would appear that peptide H2 is both antigenic and immunogenic and as such, 
vaccination with this peptide should have a protective effect against C. docile infection 
in an animal model. These conclusions are supported by the findings of Lyerly et al 1990, 
who found that vaccination of hamsters with a recombinant C-terminal repeat end peptide 
(comprising 33 of the 38 repeating units seen in holotoxin A) partially protected them 
against C. docile disease. More recently it has also been shown that mice immunised 
with the C-terminal repeat region of toxin A were protected against a three-fold lethal 
dose of toxin A (Sauerborn et al, 1997). 
The Mab PCG-4 has been shown to bind to the repeat region of toxin A between amino 
acids 2,097 through 2,141 and 2,355 through 2,398 (Frey et al, 1992) and blocks toxin A 
induced enterotoxicity but not cytotoxicity (Lyerly et al, 1986b). These results, together 
with the fact that polyclonal monospecific anti-peptide H2 neutralises cytotoxicity, 
suggest that different domains of the C-terminal repeat region of toxin A are responsible 
for binding to different cell type receptors. 
279 
SECTION 
-6 
BIOCHEMICAL PROPERTIES OF HOLOTOXIN A 
AND THE RECOMBINANT TOXIN A PEPTIDES 
SECTION 
-6 
Biochemical Properties of Holotoxin A and the Recombinant 
Toxin A Peptides 
6.1 SUMMARY 
6.2 INTRODUCTION 
6.3 MATERIALS AND METHODS 
6.3.1 Preparation of recombinant Rho A 
6.3.2 In vitro glucosylation of recombinant Rho A 
6.3.3 Cloning, expression and purification of the first 629 bp of the toxin A gene 
6.3.3.1 PCR amplification of the first 629 bp of the toxin A gene (a') 
6.3.3.2 Cloning of the 629 bp PCR product (a') into the pCRII vector 
6.3.3.3 Sub-cloning of fragment a' into the pMal-c2 expression vector 
6.3.3.4 Induction of expression from the recombinant pMal-c2 vector 
6.3.3.5 Purification and cleavage of the peptide A' fusion product 
6.3.4 In vitro glucosylation of recombinant RhoA by peptides A2 and A' 
6.3.5 Binding of toxin A peptides to ATP-agarose 
6.4 RESULTS 
6.4.1 In vitro glucosylation of recombinant RhoA 
6.4.2 Cloning, expression and purification of the first 629 bp of the toxin A gene 
6.4.2.1 Introductory comment 
6.4.2.2 PCR amplification of the first 629 bp of the toxin A gene (a') 
6.4.2.3 Cloning of the 629 bp PCR product (a') into the pMal-c2 
expression vector 
280 
6.4.2.4 Induction of expression of fragment a' from the pMal-c2 vector 
6.4.2.5 Purification and cleavage of the peptide A' fusion product 
6.4.3 In vitro glucosylation of recombinant Rho A by peptides A2 and A' 
6.4.4 Binding of toxin A peptides to ATP-agarose 
6.5 Discussion 
281 
Section-6 
Biochemical Properties of Holotozin A and the Recombinant Toxin A 
Peptides 
6.1 SUMMARY 
Toxin A peptides A2 (aa 1-536), B (aa 542-859), C (aa 114-859), D (aa 869-1330), E (aa 
542-1161), G (aa 869-1830), H2 (aa 1832- 2683) and A' (aa 1-205) were all assayed for 
the ability to glucosylate recombinant RhoA (rRhoA) in vitro. Peptide A2 was the only 
peptide that possessed enzyme activity, this being approximately 45% of that observed 
with the holotoxin. The results obtained for peptides A', A2 and C indicate that the first 
536 amino acids contain the catalytic domain for this activity, that more than the first 
205aa alone are required for a peptide to be active, and that the first 113aa are essential 
either structurally or functionally for expression of enzymatic activity. 
Only toxin A peptides B (aa 542-859) and E (aa 542-1161) were retained on ATP- 
agarose columns whereas peptides A2, G and H2 (covering the remainder of the 
molecule) were not. This indicates that the ATP binding site resides between amino acids 
542-859 in the toxin A molecule. 
Interestingly, the peptides that bind ATP (B and E) do not glucosylate rRhoA and the 
peptide that glucosylates rRhoA (A2) lacks the nucleotide-binding site. There was no 
evidence from these studies to suggest that a proven nucleotide-binding site was required 
for in vitro glucosylation of rRhoA. 
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6.2 Introduction 
The cytotoxic effects of toxin A and B are characterised by the rounding up of cells 
which is caused by disruption of the actin cytoskeleton. Recently it has been 
demonstrated that both toxins A and B are enzymes that glucosylate low molecular 
weight GTP-binding proteins of the Rho family. Using UDP-glucose as a co-substrate, 
the toxins glucosylate Rho, Rac and Cdc42 thus inhibiting the biological activities of 
these GTPases (Just et al, 1994,1995b, c). In addition, toxin A glucosylates Rap proteins 
(Chaves-Olarte et al, 1997). Rho proteins are regulators of the actin cytoskeleton, 
therefore glucosylation leads to destruction of the cytoskeleton and the morphological 
changes observed in toxin-treated cells. 
Both toxins A (Lobban and Borriello, 1992) and B (Florin and Thelestam, 1984) have 
also been shown to bind ATP in vitro, and a putative nucleotide binding site has been 
located within the N-terminal third of toxin B based on sequence homology with an ATP 
binding motif (Barroso et al, 1994). The function of these ATP binding sites is at present 
unknown. 
The aim of this section was to determine the regions of the toxin A molecule responsible 
for glucosylation of RhoA and ATP binding. The results should give some indication as 
to whether these two functions are connected or unrelated. 
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6.3 MATERIALS AND METHODS 
6.3.1 Preparation of recombinant Rho A 
The rRho A was provided by Dr. April Roberts and was purified at CAMR, Porton Down, 
Salisbury. 
The E. coli JM101 strain containing the GST-Rho A coding sequence in the expression 
vector pGEX-2T was provided by Prof. Alan Hall, University College, London. Details of 
how the clone was produced are described by Self and Hall. (1995). The culture was 
grown in LB broth containing 50µgrnr' ampicillin (2 x 1.01) to an OD6o of 0.5. Expression 
of recombinant GST-Rho A was induced by the addition of IPTG to the final 
concentration of 1mM. Following induction, the culture was grown to stationary phase 
(A600 
- 
1.0), and the cells were recovered by centrifugation (5,000 x g, 10min, 4°C). 
Following storage at 
-70°C overnight, the cells were lysed and the GST-Rho A bound to 
glutathione-Sepharose (Pharmacia). Recombinant Rho A was released from the 
glutathione-Sepharose by treatment with thrombin (5units/1.01 culture) as described by 
Self and Ha11 (1995). Precipitation with benzamidine-agarose beads (Sigma; 10µU1.01) 
released the Rho A from the thrombin. The purified Rho A was dialysed into 50mM 
triethanolamine pH 7.5,150mM KC1,3mM MgCl2 at 4°C for 5hr and then stored at 
- 
70°C. The protein concentration of Rho A was estimated by visually comparing the 
coomassie stained band intensity of the Rho A to that of a set of albumin standards on a 4- 
20% SDS-PAGE gel. An Also value of 1.0 for Rho A was estimated to correspond to a 
protein concentration of lmgml"' 
6.3.2 In-Vrtro glucosylation of rRho A. 
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This method was adapted from the glucosylation reaction described by Just et al, (1995a). 
Glucosylation reactions were carried out by myself at C. A. M. R, Porton Down, Salisbury 
in collaboration with Dr. April Roberts. 
Briefly 33nM final concentration of toxin A and each of the toxin A peptides were assayed 
for glucosyltransferase activity in a 50µ1 reaction volume containing 50mM 
triethanolamine pH 7.5,150mM KCI, 0.3mM GDP, 3mM MgC12,10µM ZnC12,7µM 
UDP- [14C] glucose (Amersham; lOOnCi) and 11µM (250µgm1) rRho A (see section 
6.3.1). 
Prior to addition to the reaction mix, the toxin A peptides were cleaved from MBP by 
incubation with Factor Xa as already described (see section 2.8.3). The protein 
concentrations of the toxin A peptides were determined using the Coomassie Plus Protein 
Assay Reagant Kit (Pierce) and 8% SDS-PAGE analysis (see sections 2.9.1 and 2.9.2). 
The toxin A peptides were incorporated into the assay at a final concentration of 33nM 
based on the apparent protein concentration of the cleaved toxin A peptide without MBP. 
Controls were included to demonstrate that MBP and E. coli derived proteins could not 
glucosylate rRho A. Further controls were included to prove that when toxin A, toxin A 
peptides or Rho A were absent from the reaction mix, no glucosylation was observed. 
Samples were set up in quadruplet and then incubated at 37°C for Mr. Protein samples 
were precipitated by incubating on ice for 3min in the presence of 0.45ml BSA (lmgml') 
and 0.5m124% trichloroacetic acid (TCA aq; 12% final concentration). Precipitates were 
collected on Durapore membranes (Millipore, 25mm diameter, 0.21im) using a vacuum 
filtration unit (Millipore 1225 Sampling Manifold). The filters were washed twice with 5m1 
12% TCA, placed in 5m1 scintillation fluid (Sigma) and soaked for 2.5hr at room 
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temperature. The vials were transferred to a Wallac 1410 Scintillation Counter for the 
detection of the Rho A-14C-glucose product. 
P-values were determined for each test protein by comparing the quadruplet mean cpm of 
the sample to the highest quadruplet mean cpm of an appropriate negative control in a 
two-tailed T-test. Based on the percentage of Rho A that was glucosylated, counts per 
minute were converted to pico moles of product (Rho A- glucose). 
6.3.3 Cloning, expression and purification of the first 629bp of the toxin A gene. 
6.3.3.1 PCR amplification of the first 629bp of the toxin A gene (a'). 
Using the method outlined in section 2.3 primers 3 and 13 (5' 
AGATACTAGTCGACACTATATAATA 3') (see appendix 2) were used to amplify a 
629bp DNA fragment of the toxin A gene (bps 1-629; see appendix 1) from C. dijcile 
strain VPI 10463 chromosomal DNA (see section 2.2.1). The thermocycling conditions 
were denaturation for 1 min at 97°C, annealing for 1 min at 50°C and extension for 1 min 
at 72°C. The PCR product was analysed by 1.2 % agarose gel electrophoresis (see section 
2.2.3). 
6.3.3.2 Cloning of the 629bp PCR product (a') into the pCRII vector. 
The 629bp PCR product amplified in section 6.3.3.1 was purified from an agarose gel as 
outlined in section 2.2.4. The purified PCR product was ligated to the pCRII T-tailing 
vector (see section 2.4.1) and then transformed into InvaF' competent cells (see section 
2.4.2). Plasmid DNA was isolated (see section 2.2.2.1) from selected white colonies and 
was digested with BamHI and Sall (see section 2.2.6). The DNA profiles were analysed 
by 1% agarose gel electrophoresis (see section 2.2.3) in order to select a clone with a 
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629bp toxin A insert. A positive culture was mixed 1: 1 with 40% glycerol and stored at 
- 
70°C. 
6.3.3.3 Sub-cloning of fragment a' into the pMal-c2 expression vector. 
The recombinant pCRII plasmid isolated in section 6.3.3.2 and the pMal-c2 vector (New 
England Biolabs) were digested with BamHI and Sail (see section 2.2.6). Both digests 
were run on a 0.8% agarose gel (see section 2.2.3) and the 6.7Kb pMal-c2 and 629bp a' 
fragments were cut from the gel and purified (see section 2.2.4). The purified products 
were analysed by agarose gel electrophoresis to determine the concentration of DNA 
present (see section 2.2.3). The purified BamHI, Sail digested a' fragment was ligated to 
the digested pMal-c2 vector (see section 2.2.7) and the ligation was transformed into 
JM109 competent cells (see section 2.2.8). The transformation reaction was plated out 
onto LB agar plates containing 100. Lgmi'' of ampicillin (LB amp plate) and incubated 
overnight at 37°C. Colonies were selected and sub-cultured onto a master LB amp plate 
and onto a LB amp plate containing 8014gmr' of X-gal and 0.1mM IPTG. Again the plates 
were incubated overnight at 37°C. Plasmid DNA was isolated from white colonies (see 
section 2.2.2.1), digested with BamHI and Sall (see section 2.2.6) and analysed on a 0.8% 
agarose gel (see section 2.2.3). A clone containing the 629bp a' DNA insert was incubated 
overnight at 37°C, mixed 1: 1 with 40% sterile glycerol and stored at 
-70°C. 
6.3.3.4 Induction of expression from the recombinant pMal-c2 vector 
Expression of the MBP fusion product was induced from the pMal-c2 vector containing 
the a' DNA insert as outlined in section 2.8.1. The presence of the toxin A peptide (A') 
coded for by the a' DNA fragment was determined by SDS-PAGE (see section 2.7.1) and 
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probing a western blot (see section 2.7.3) with a 1: 10,000 dilution of anti-MBP serum 
(New England Biolabs). The size of the A' fusion peptide was compared to the size of the 
major truncated products (approx. 65 ma) produced when toxin A peptide A2 (aa's 1- 
536) was expressed in E. coll. 
6.3.3.5 Purification and cleavage of the peptide A' fusion product. 
The toxin A peptide A' MBP fusion product was purified by amylose affinity 
chromatography as outlined in section 2.8.2. The protein in each fraction was analysed by 
SDS-PAGE (see section 2.7.1) and the size compared to that of the major truncated 
products (approx. 65 kDa) produced from the expression of peptide A2. The 
concentration of the fusion protein was determined as outlined in section 2.9.1. The MBP 
was cleaved from peptide A' by incubation with factor Xa as outlined in section 2.8.3. 
6.3.4 In vitro glucosylation of rRho A by peptides A2 and A'. 
The in vitro glucosylation assay outlined in section 6.3.2 was used to compare the 
glucosyltransferase activity of peptide A2 to any possible activity displayed by the shorter 
peptide A' (see section 6.3.3.5). Expression of peptide A2 in E. coli also results in the 
production of a series of truncated products the most predominant of which was 
approximately 65 kDa which corresponds in size and constitution to the same region of 
the toxin A molecule as peptide A' (see section 6.4.2.4). 
Peptides A2 and A' were cleaved with factor Xa prior to addition into the glucosylation 
reaction (see section 2.8.3). The peptides were included in the assay at a final 
concentration of 33nM based on the apparent protein concentration of the full-length 
peptides only (i. e. truncated species and MBP not included in the concentration 
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estimations). As a direct comparison, an additional glucosylation assay was undertaken in 
which peptide A2 was incorporated at a final concentration of 33nM based on the 
apparent protein concentration of the peptide without MBP (i. e. truncated species 
included in concentration estimation). 
Toxin A (33nM) and MBP (33nM) were included in the assay as positive and negative 
controls respectively. Other negative controls were identical to those outlined in section 
6.3.2. BSA was also included in one assay in place of rRhoA to ensure that holotoxin A 
specifically glucosylated RhoA and not any protein. Again P-values were determined for 
each test protein by comparing the quadruplet mean cpm of the sample to the highest 
quadruplet mean cpm of an appropriate negative control in a two-tailed T-test. Based on 
the percentage of Rho A that had been glucosylated, counts per minute were converted to 
pico moles of product (Rho A- glucose). 
6.3.5 Binding of toxin A peptides to ATP 
- 
agarose. 
This method was adapted from that of Lobban et al, 1992 and Florin et al, 1984. 
Toxin A, toxin A peptides (A2, B, E, G and H2) and MBP (lml of a 20gg/ml solution) 
were each applied to one column (I cm x 2cm) of ATP-agarose (containing 1. lµmol ATP; 
Sigma), and to one of agarose without ATP, equilibrated with 10mi of 20mM Tris-HCI, 
pH 7.4. The columns were sealed and left for 30min at RT before being washed with 40m1 
of 20mM Tris-HC1 pH 7.4. The first 6m1 of wash was collected as 30 x 0.2m1 fractions for 
dot blot analysis whilst the remaining wash was discarded. Bound protein was eluted with 
IM NaCl and collected as 15 x 0.2m1 fractions. 2µl of each fraction was spotted onto a 
nitrocellulose strip for dot blotting (see section 2.7.4). The nitrocellulose was air dried 
and then blocked with 1% gelatin/PBS/Tween-20 for ihr at RT. Blots were probed with 
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either specific polyclonal anti peptide serum (1: 1,000 dilution), anti-toxin A serum 
(1: 1000 dilution) (see section 4.3.1) or anti-MBP serum (1: 10,000 dilution, New England 
Biolabs) for 2hr at RT. Blots were washed in PBS/Tween-20 and then incubated in goat 
anti-rabbit alkaline phosphatase conjugate (1: 1,000 dilution; Sigma) for lhr at RT. 
Following washing in PBS/Tween 20 and then SDW, fractions containing protein were 
highlighted by developing in BCIP/NBT alkaline phosphatase substrate solution (Sigma). 
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6.4 RESULTS 
6.4.1 In-vitro glucosylation of rRhoA 
To determine whether the PCR-generated toxin A peptides possessed glucosyltransferase 
activity holotoxin A and the toxin A peptides were assayed for their ability to glucosylate 
rRhoA in the presence of UDP-[IT'4C] glucose in vitro. Only holotoxin A and peptide A2 
(aa 1-536) possessed enzyme activity giving mean counts per minute (cpm) of 66,803.0 ± 
1761 (p< 0.00001) and 10,542 + 627 (p< 0.0001) respectively, corresponding to 
incorporation of UDP-V'4c] glucose into RhoA (see Figure 6.1). Peptides B, C, D, E, G 
and H2 lacked glucosyltransferase activity and gave an insignificant mean cpm of > 208 
(in each case p> 0.1). Other negative controls consisted of test buffer inclusive of MBP 
alone (85.8 ± 37.3), E. coli lysate alone (186.0 ± 87.9), rRhoA alone (123.1 + 68.3) and 
UDP-14C glucose alone (153.7 ± 78.1). 
Of the 567.5 pmoles of rRhoA in the 5091 reaction volume, approximately 116.3 proles 
were converted to the RhoA-glucose product by holotoxin A as opposed to 18.16 pmoles 
by peptide A2. SDS-PAGE and western blot analysis demonstrated that preparations of 
peptide A2 contained a series of truncated species the most abundant of which were 
approximately 22kDa in size (65kDa including MBP) (see Figure 3.9, lanes 8 and 10). 
These most probably resulted from poor codon usage in E. coli but may also have been 
produced by SDS-reduction. The truncated species account for a large proportion of the 
total concentration of the peptide A2 preparation. At this stage it was unclear whether the 
enzyme activity was expressed only by full-length peptide A2 or by full-length peptide 
A2 plus the 22kDa truncated species. 
6.4.2 Cloning, expression and purification of the first 629 bp of the toxin A gene 
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6.4.2.1 Introductory comment 
Preparations of peptide A2 contain large amounts of truncated species of approximately 
65kDa corresponding to the first 21-22kDa (629bp) of holotoxin A. Full length peptide 
A2 represents only about one third of the total protein concentration in the purified 
preparations. To ensure that the peptide responsible for glucosylation was incorporated 
into the assay at a final concentration of 33nM, it was important to determine whether or 
not the 22kDa truncated species expressed enzymatic activity. 
6.4.2.2 PCR amplification of the first 629bp of the toxin A gene (a') 
The primers and thermocycling conditions (see section 6.3.3.1) were successfully used to 
amplify a 629bp DNA product (bps 1-629 of the toxin A gene) corresponding to toxin A 
fragment a' (see Figure 6.2, lanes 2 and 3). 
6.4.2.3 Cloning of the 629bp PCR product (a') into the pMal-c2 expression vector 
The 629bp PCR product (a') was successfully cloned into the pCRII T-tailing vector (see 
section 6.3.3.2) (results not shown). The DNA insert was removed by digestion with 
BamHI and Sall and subsequently cloned into the pMal-c2 expression vector (see section 
6.3.3.3). Seven potential transformants were screened by digestion with BamHI and Sall, 
and resolved by agarose gel electrophoresis (see Figure 6.3). Clones 1,2,5 and 7 all 
contained the 629bp toxin A fragment. The cloned DNA was sequenced (see section 
3.3.4) shown to be correct and `in frame' with the vector malE gene (results not shown). 
6.4.2.4 Induction of expression of fragment a' from the pMal-c2 vector 
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Expression of the toxin A fragment a' was induced from the pMal-c2 vector (see section 
6.3.3.4). Clones 1,2,5, and 7 all expressed a MBP-fusion product of approximately 65 
kDa (peptide A') (see Figure 6.4, lanes 5 and 17,7 and 19,9 and 21,11 and 23). This 
peptide was not produced when IPTG was omitted from the culture (see Figure 6.4, lanes 
4and 16,6and 18,8and20,10and22). 
Full length peptide A' was only slightly larger in size than the 65 kDa major truncated 
species seen in purified preparations of peptide A2 (see Figure 6.4, lanes 12 and 24). It 
was decided that peptide A' was a good match for the 65kDa truncated species seen in 
peptide A2 preparations and was a suitable control for glucosyltransferase experiments. 
6.4.2.5 Purification and cleavage of the peptide A' fusion product 
The peptide A' fusion product was purified by amylose affinity chromatography (see 
section 6.3.3.5). The highest protein concentration for the fusion product was typically in 
the range of 0.8-1.0mgm1-'. Apart from the full-length peptide two truncated species 
were present in the peptide A' preparation (see Figure 6.5, lane 3). The first corresponded 
to the size of the MBP (see Figure 6.5, lane 5) and the second was slightly smaller than 
the full-length peptide. Full length peptide A' fusion product was cleaved by factor Xa to 
produce the 43kDa MBP and a peptide of approximately 22 kDa corresponding to the 
toxin A peptide (A'). A small proportion of the full-length fusion product remained 
uncleaved in this instance (see Figure 6.5, lane 4). 
6.4.3 In vitro glucosylation of rRhoA by peptides A2 and A' 
To determine whether the first 21kDa of holotoxin A are capable of glucosylating RhoA, 
the experiment was repeated (see section 6.3.2) using only peptides A2 and A' (see 
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section 6.3.4). Two different amounts of peptide A2 were included in the assay in 
separate reactions. The first reaction incorporated peptide A2 at a final concentration of 
33nM dependent on the estimated concentration of the full-length peptide only in the 
protein mixture (_ 65µg/ml) (A2-FL). The second reaction incorporated peptide A2 at a 
final concentration of 33nM dependent on the estimated concentration of both full-length 
peptide and truncated species in the protein mixture (_ 195µg/ml) (A2-total). 
The results (see Figure 6.6) indicated that peptide A' (aa 1-205) lacked enzyme activity 
giving mean cpm of 202.8 ± 76.4 (p= 0.12). The reaction containing holotoxin A gave 
mean cpm of 96,928 ± 3791 (p< 0.0001) corresponding to incorporation of UDP-[LT'14C ]
glucose into recombinant RhoA. Holotoxin A, however, did not glucosylate BSA proteins 
giving a mean cpm of 82.1 ± 43.3 (p= 0.18) (result not shown). In both cases, peptide A2 
showed significant levels of glucosyltransferase activity. Reactions containing peptide 
A2-FL gave mean cpm of 24,287 ± 969 (p< 0.0001) whereas those containing peptide 
A2-total gave mean cpm of 6,486 ± 316 (p< 0.0001). Other negative controls consisted of 
test buffer inclusive of MBP alone (181 ± 114), RhoA alone (115.7 ± 28.2) and UDP-14C 
alone (105.6 ± 95.0). 
Of the 567.5 pmoles of rRhoA in the 50µ1 reaction volume, approximately 168.9 pmoles 
were converted to the RhoA-glucose product by holotoxin A as opposed to 76.1 pmoles 
by peptide A2-FL and 11.3 pmoles by peptide A2-total. The relevant positions of 
peptides A2, A' and C in the holotoxin molecule are outlined in figure 6.7. 
6.4.4 Binding of toxin A peptides to ATP-agarose 
The method outlined in section 6.3.5 was used to locate the ATP-binding site within the 
holotoxin A molecule. The positive control holotoxin A was retained on an ATP-agarose 
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column following stringent washing (see Figure 6.8, panel Al row e). The negative 
control MBP, however, was not retained on either the ATP-agarose column or the 
straight agarose column (see Figure 6.8, panel A2 and B2 row e). 
The toxin A peptides A2 (see Figure 6.9 panels Al and B1 row e), G (see Figure 6.10 
panels A2 and B2 row e) and H2 (see Figure 6.11 panels A and B row e) did not bind to 
either the ATP-agarose column or the agarose column without ATP. In each case the 
positive controls reacted strongly with the specified antibodies on the dot blots (panels A 
and B, row a on the above mentioned figures). Peptides C and A' were not tested. 
The overlapping peptides B (aa 542-859) and E (aa 542-1160) were both retained on the 
ATP-agarose columns following stringent washing (see Figure 6.9 panel A2 row e and 
Figure 6.10 panels Al row e, respectively) but were not retained on agarose columns 
lacking ATP (see Figure 6.9 panel B2 row e and Figure 6.10 panels B1 row e, 
respectively). These results suggest that the ATP-binding site is situated between amino 
acids 542 and 859 in the holotoxin A molecule. 
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Figure 6.1 
Glucosyltransferase activity of holotoxin A and the toxin A peptides. MBP was 
a negative control for peptides A2-G whereas E. coli was a negative control 
for peptide H2. Holotoxin A and peptide A2 significantly glucosylated rRhoA 
in vitro. 
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TEST SAMPLE 
629 bp 
Figure 6.2 
1.2% agarose gel showing the PCR amplification of toxin A fragment a' from C. difrcile 
VPI10463 chromosomal DNA using primers 3 and 13. 
Lane 1,1Kb ladder; Lane 2 and 3, C. difficile DNA amplified with primers 3 and 13; 
Lane 4, C. difficile DNA amplified with primers 13 only; Lane 5, C. dif cile DNA 
amplified with primers 3 only; Lane 6, no template. 
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123456 
123456789 
6.65 kb 
629 bp 
Figure 6.3 
0.8% agarose gel showing the sub-cloning of toxin A fragment a' into the pMal-c2 
expression vector. 
Lane 1,1Kb ladder; Lanes 2-8, potential pMal-c2 clones (clones 1-7) containing 
fragment a' (BamHl and Sall digests); Lane 9, pMal-c2 only (BamHl and Sall digests). 
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Figure 6.4 
8% SDS-PAGE (A) and respective western blot (B) probed with MBP antiserum showing 
the induction of expression of peptide A'. 
Lanes I and 13, LMW markers; Lanes 2 and 14, uninduced JM 109 containing pMal-c2 
only; Lanes 3 and 15, induced JM 109 containing pMal-c2; Lanes 4 and 16, uninduced 
JM 109 containing pMal-c2 plus fragment a' (clone 1); Lanes 5 and 17, induced JM 109 
containing pMal-c2 plus fragment a' (clone 1); Lanes 6 and 18, as lanes 4 and 16 (clone 
2); Lanes 7 and 19, as lanes 5 and 17 (clone 2); Lanes 8 and 20, as lanes 4 and 16 (clone 
5); Lanes 9 and 21, as lanes 5 and 17 (clone 5); Lanes 10 and 22, as lanes 4 and 16 (clone 
7); Lanes 11 and 23, as lanes 5 and 17 (clone 7); Lanes 12 and 24, purified toxin A 
peptideAl 
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Figure 6.5 
10% SDS-PAGE gel showing the amylose affinity purification and factor Xa cleavage of 
the peptide A' fusion product. 
Lane 1, LMW markers; Lane 2, uncleaved peptide A2 fusion product; Lane 3, uncleaved 
peptide A' fusion product; Lane 4, factor Xa cleaved peptide A' fusion product; Lane 5, 
MBP. 
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Figure 6.6 
The glucosyltranserase activity displayed by preparations of peptide A2 is due to the full- 
length peptide and not to the 65 kDa major truncated species represented in this assay by 
peptide A'. The amount of peptide A2 added to the assay was calculated to take into 
account the concentration of full-length peptide only (Pep A2 ) or full-length peptide plus 
truncated species (Pep A2 + trunc. ) 
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Figure 6.8 
Dot blots of fractions collected after protein samples were applied to columns of (A) 
ATP-agarose and (B) agarose without ATP, probed with (1) monoclonal antibody PCG- 
4, and (2) MBP antiserum. The proteins added to the column were: 1, toxin A and 2, 
M BP. Fractions were as follows: a, positive control (i. e. Panel 1, toxin A with PCG-4, 
Panel 2, MBP with MBP antiserum) and first I ml flow through; b, c and d, 30x 0.2m1 
fractions of wash after incubation of column with protein; e and f, 15x 0.2m1 fractions 
eluted with 1M NaCl (following a further 35m1s of washing). 
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Figure 6.9 
Dot blots of fractions collected after protein samples were applied to columns of (A) 
ATP-agarose and (B) agarose without ATP, probed with MBP antiserum. 
The proteins added to the columns were 1, peptide A2 fusion product, 2, peptide B lesion 
product. Fractions were as follows: a, positive control (i. e. Panel I -peptide A2, and Panel 
2-peptide B) and first I ml flow through; b-f, as b-f in figure 6.8. 
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Figure 6.10 
Dot blots of fractions collected after protein samples were applied to columns of (A) 
ATP-agarose and (B) agarose without ATP, probed with MBP antiserum. 
The proteins added to the columns were 1, peptide E fusion product and 2, peptide G 
fusion product. Fractions were as follows: a, positive control (i. e. Panel 1-peptide E, and 
Panel 2-peptide G) and first 1 ml flow through; b-f, as b-fin figure 6.8. 
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Figure 6.11 
Dot blots of fractions collected after peptide H2 was applied to a column of (A) ATP- 
agarose and (B) agarose without ATP, probed with monoclonal antibody PCG-4. 
Fractions were as follows: a, positive control (i. e. Peptide H2) and first I ml flow through; 
b-f, as b-f in figure 6.8. 
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6.5 DISCUSSION 
One of the major breakthroughs in delineating the molecular mechanism of action of C. 
diJcile toxins A and B was the recent observation that they act as glucosyltransferases 
which monoglucosylate Rho proteins using UDP-Glucose as a co-substrate (Just et al, 
1995b, c). One of the aims of this chapter was to locate the region of the toxin A molecule 
responsible for this activity. The data presented here provide direct evidence that the 
UDP-glucose binding site, the catalytic site for glucose transfer and the Rho interaction 
site all occur within the first 536 N-terminal amino acids of toxin A (peptide A2). None 
of the other toxin A peptides exhibited the ability to glucosylate rRhoA in vitro. 
Analysis of the peptide A2 by SDS-PAGE showed that approximately 50% of the protein 
preparation consisted of a series of truncated species of about 65 kDa (inclusive of MBP) 
compared to the molecular mass of 99kDa (inclusive of MBP) of the full-length peptide. 
In order to determine whether or not this also had activity, the DNA coding for the first 
205aa of the toxin A molecule was cloned and the recombinant protein product (peptide 
A') was examined. No activity was detected. Presuming that recombinant peptide A' was 
folded correctly, this result suggests that the first 205aa of the toxin A molecule alone are 
not sufficient for full enzymatic activity. This result also suggests that peptide A2 was 
more active than first anticipated as less peptide A2 was present in the initial experiments 
than indicated by the total purified protein measurements. Once the concentration was 
adjusted to incorporate only full-length peptide A2 (A2-FL) into the assay at a final 
concentration of 33nM, the enzyme activity expressed by peptide A2 was typically about 
45% of that expressed by holotoxin A. The lower enzyme activity exhibited by peptide 
A2 could be explained by the fact that it was a recombinant protein expressed in a gram 
negative organism (i. e. not as effective as the native holotoxin). Alternatively, fit w, ps 
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possible that the glucosyltransferase molecule (peptide A2) had been truncated at the C- 
terminal end leading to a reduction in enzyme activity. 
Further adding to these results, peptide C that spans the proposed catalytic domain of the 
toxin A molecule (aa 114-859) does not glucosylate rRhoA. Again presuming that 
peptide C was folded correctly, these results suggest that although amino acids 1-113 are 
not solely responsible for glucosylation they are essential either structurally or 
functionally for full enzymatic activity. Since this work was completed, other 
investigators have also presented data to suggest that the glucosyltransferase activity of 
toxins A and B resides within the N-terminus of the molecules (Hofmann et al, 1997, 
Wagenknecht-Wiesner, et al, 1997, Soehn et al, 1998, Faust et al, 1998). 
In support of the data presented M. this chapter, Hofmann and co-workers provided 
evidence to show that the N-terminal 546aa residues of toxin B express full 
glucosyltransferase activity. The similarity of these two results is not surprising 
considering that the homology of toxins A and Bis greatest between the N-terminal two- 
thirds of the molecules (von Eichel-Streiber et al, 1992). Hofmann and co-workers also 
showed that a toxin B fragment encompassing the first 516aa residues was at least 1,000 
fold less active than fragment 1-546 and that a fragment covering 1-468aa was 
completely inactive (Hofinann et al, 1997, ). In contrast, Wagenknecht-Wiesner and co- 
workers have shown that a toxin B fragment covering as 1-467 expressed extremely 
weak enzymatic activity (Wagenknecht-Wiesner, et al, 1997). 
The results presented here on toxin A, together with published observations on toxin B, 
(Hofmann et al, 1997, ) suggest that site directed mutagenesis of the 20aa residues (517- 
536) within an N-terminal peptide (aa 1-536) of toxin A or B should further delineate the 
catalytic domain. 
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In an attempt to identify the different regions of peptide A2 important for glucosylation, 
the peptide A2 sequence data were compared to others in a computer database (Basic 
Local Alignment Search Tool, BLAST search) for regions of homology. Unfortunately 
the programme only aligned peptide A2 with clostridial toxin sequences and did not 
identify any protein sequences relating to Rho glucosylation. Recent studies have shown 
that the amino acids 364 through 516 primarily define the substrate specificity of C. 
sordellii lethal toxin (Hofmann et al, 1998). In contrast to C. docile toxins A and B, 
which exclusively modify Rho sub-family proteins, C. sordellii lethal toxin also 
glucosylates Ras sub-family proteins. The investigators showed that a chimeric fusion 
protein of C. docile toxin B, in which amino acids 364 through 516 had been exchanged 
for the same region of C. sordellii lethal toxin also glucosylated Rho sub-family proteins 
(Hofmann et al, 1998). 
A further study resulted in the identification of several amino acid residues in C. sordellii 
lethal toxin that are essential for the enzyme activity (Busch et al, 1998). Exchange of 
aspartic acid at position 286 or 288 with alanine or asparagine decreased 
glucosyltransferase activity by about 5,000 fold and blocked glucohydrolase activity. No 
enzyme activity was detected with the double mutant. Mutation of this DXD motif 
prevented radiolabelling by azido-UDP-glucose. Asparagine at positions 270 and 273 
were also shown to be important for both ghicosyltransferase and glucohydrolase activity. 
The investigators concluded that the DXD motif, which is highly conserved in all 
clostridial cytotoxins and some glucosyltransferases, is functionally essential for enzyme 
activity and may participate in the binding of UDP-glucose (Busch et al, 1998). 
Results obtained in chapter 5 showed that peptide A2, although possessing 
glucosyltransferase activity in vitro, had no effect on tissue culture cells or in rabbit ileal 
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loops. It has been shown, however, that microinjection of the same region of toxin B into 
cells caused glucosylation of Rho proteins and a full CPE (Hofmann et al, 1997). It 
appears that peptide A2 is unable to affect cells due to an inability to enter the cell 
cytoplasm. It would be interesting, therefore, to examine the effect on cells of a chimeric 
protein consisting of peptide A2 fused to a protein that would deliver the peptide into 
cells. 
Only peptides B (aa 542-859) and E (aa 542-1161) were retained on an ATP-agarose 
column suggesting that the ATP-binding site resides between amino acids 542 and 859 in 
the holotoxin molecule. These results provide the first direct identification of an ATP 
binding site within either the toxin A or B molecules. In these experiments the agarose 
was attached to the ATP via the ribose hydroxyls (Sigma cat. No. A4793). This particular 
attachment leaves the phosphate group of ATP particularly well exposed. Toxin A has 
also been shown to bind polyphosphates (Lobban and Borriello, 1992) so it is possible 
that the interaction between ATP agarose and peptides B and E is via a polyphosphate 
binding site. Based on homology with an ATP binding motif, however, a putative ATP 
binding site has also been identified in toxin B between amino acids 651 and 683 
(Barroso et al, 1994). The same conserved sequence (-IGHGKDE[25x]K-) is also present 
in holotoxin A between amino acids 653-685. This region is covered by peptides B and E 
supporting the hypothesis that both peptides encode an ATP-binding site. It is also 
possible that the polyphosphate-binding site and the ATP binding site are coded for by 
the same region of the toxin A molecule. It is of interest that the peptides containing the 
nucleotide-binding site (B and E) were the only peptides shown to possess this ability, 
but these peptides lacked glucosyltransferase activity. Further, peptide A2, which 
possessed glucosylation activity lacked a nucleotide-binding site. There was no direct 
310 
evidence that a proven nucleotide binding site was required for in vitro glucosylation of 
rRhoA by toxin A. Microinjection of a toxin B peptide (aa 1-546) into cells resulted in 
glucosylation of Rho proteins and a full CPE indicating that the putative nucleotide 
binding site in toxin B is also unnecessary for glucosyltransferase activity (Hofmann et 
al, 1997). These observations fail to identify a role for the nucleotide binding site of toxin 
A and the putative one for toxin B. It is possible that the ATP binding site is important 
for endocytosis or translocation of toxin A into the cytoplasm It would be interesting, 
therefore, to study a truncated form of toxin A, which lacked the ATP binding site but 
which retained its ability to bind to cells and to act as a glucosyltransferase molecule. 
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SECTION 
-7 
CYTOTOXIC ACTIVITY OF A TRUNCATED TOXIN CONSISTING 
OF THE GLUCOSYLTRANSFERASE AND BINDING 
DOMAINS OF TOXIN A 
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Section 7 
Cytotoxic activity of a truncated toxin consisting of the glucosyltransferase and 
binding domains of toxin A 
7.1 Summary 
Both the glucosyltransferase (bps 1-1,614) and receptor binding (bps 5,505 
- 
8,058) 
regions of the toxin A gene were successfully re-amplified by PCR from C. diIcile VPI 
10463 chromosomal DNA. The DNA fragment encoding the binding region (hT) was 
cloned into the pCR II T-tailing vector downstream of the DNA fragment encoding the 
glucosyltransferase activity (aT). The fused construct (aT + hT) was sub-cloned into the 
pET 30a expression vector and sequence data confirmed that the front portion of the 
insert (aT) was in frame' with the vectors T7 promotor. IPTG induction resulted in low 
levels of expression of a histidine fusion protein of approximately 147 kDa consisting of 
the glucosyltransferase region (AT; amino acids 1-538) fused to the binding region (HT; 
amino acids 1,835-2,686) of the holotoxin molecule. The recombinant peptide, which 
appeared to be present in both the soluble and insoluble fractions, reacted with the PCG-4 
monoclonal antibody suggesting that the C-terminal repeat region of the truncated toxin 
(HT) had remained `in frame' with peptide AT. 
Purification by histidine affinity chromatography typically yielded between 5-10 µgml` 
of soluble recombinant truncated toxin fusion protein. The truncated toxin was capable of 
haemagglutinating RRBCs as effectively as the holotoxin suggesting that the repeat 
region-binding portion (HT) of the truncated toxin was biologically active. The truncated 
toxin also demonstrated classical cytotoxicity in vitro but was approximately 1,400 fold 
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less potent to Vero cells than the holotoxin. This indicates that peptide HT (or peptide A2) 
is able to glucosylate cellular Rho proteins and induce a CPE suggesting that the 
nucleotide binding site (amino acids 651-683) is not essential for this activity. In 
conclusion, fusion of the glucosyltransferase and binding domains of toxin A forms an 
active toxin molecule. The reduced activity of the truncated toxin suggests that the central 
region (amino acids 539-1,834) of the holotoxin is probably involved in effective 
processing and / or delivery of the molecule. 
7.2 Introduction 
The results from section 6 indicated that peptide A2 (amino acids 1-536) contained all the 
structures necessary for full glucosyltransferase activity. Although this peptide was 
biologically active in vitro it was unable to induce cytotoxic effects in tissue culture cells 
or rabbit ileal loops, probably due to an inability to enter the cells. In order to 
demonstrate cytotoxic capability therefore, it would be necessary to deliver the 
glucosyltransferase molecule (peptide A2) into cells. As an alternative to microinjection 
it was decided to produce a truncated toxin consisting of peptide A2 fused to a suitable 
delivery peptide. 
The results from section 5 indicated that peptide H2 (C-terminal repeat region of toxin A) 
was both able to bind to cells and to be internalised into endosome-like compartments 
within the cells making it a suitable delivery protein for peptide A2. The ability of 
peptide H2 to escape endosomes and enter the cytoplasm was unknown. 
The aim of this section was to engineer a biologically active truncated toxin A (AT + HT) 
consisting of the glucosyltransferase molecule (amino acids 1-538) representing peptide 
A2, fused to the binding domain (amino acids 1,835-2,686) representing peptide H2. This 
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recombinant truncated toxin (see figure 7.1) would lack the central region (amino acids 
539-1,834) of the holotoxin molecule. It was hoped that the truncated toxin would be 
used to demonstrate the cytotoxic capability of peptide A2 whilst also giving some 
indication as to the importance of the central region of the holotoxin molecule. 
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7.3 Materials and Methods 
7.3.1 PCR Amplification of fragments aT and hT for construction of the truncated 
toxin construct. 
The glucosyltransferase domain of toxin A (aT) was re-amplified by PCR using the 
forward primer: 5' AGCCATGGCTATGTCTTTAATATCTAAAGAAG 3' (14; see 
appendix 2) and the reverse primer: 5' CAGAAAGAGGTCGACCAGTATAATCTCT 3' 
(15; see appendix 2) in a 500 reaction volume (see section 2.3). The binding portion of 
toxin A (hT) was re-amplified by PCR using the forward primer: 5' 
TTAGTTAAAGGTCGACTCAATATAAAT 3' (16; see appendix 2) and the reverse 
primer: 5' CAATCTCGAAGGATCCACCAGCTGCA 3' (17; see appendix 2) also in a 
5Oµ1 reaction volume (see section 2.3). Thermocycling conditions were as follows: 
FRAGMENT DENATURE ANNEAL 
aT 97°C; l min 50°C; l min 
hT 97°C; lmin 58°C; 1 min 
EXTEND 
72°C; 2min 
72°C; 3min 
In both reactions there were 35 amplification cycles with the final extension time increased 
to 9.9min. 
7.3.2 Purification of the PCR products aT and hT 
The PCR products ä (1.630Kb) and hT (2.589Kb) resulting from section 7.3.1 were 
visualised on a 0.8% agarose gel (see section 2.2.3). The DNA fragments aT and hT were 
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excised from the gel, passed through glass beads and then Spinbind purified (see section 
2.2.4). 
7.3.3 Cloning of the truncated toxin construct (aT + hT) into the expression vector 
pET30a 
The purified PCR products, aT (1.630Kb) and hT (2.598Kb), were each individually cloned 
into the pCRII T-tailing vector (see section 2.4). Plasmids containing the aT DNA insert 
(bp's 1-1,630 of the toxin A gene; see appendix 1) were digested with NcoI and BamHI 
(see section 2.2.6) and analysed on a 0.8% agarose gel (see section 2.2.3). Plasmids 
containing the hT DNA insert (bps 5,485-8,074 of the toxin A gene; see appendix 1) were 
digested with Sall and BamHI (see section 2.2.6) and analysed by 0.8% agarose gel 
electrophoresis (see section 2.2.3). It was necessary to orientate plasmids containing 
fragment aT to isolate a clone with an inverted insert. When digested with the restriction 
enzyme Ncol (see section 2.2.6), a clone with an insert in the correct orientation showed 
two fragments of 3.945 Kb and 1.555 Kb on a 0.8% agarose gel (see section 2.2.3) 
whereas a clone with an inverted insert showed two fragments of 2.345 Kb and 3.15 Kb 
on a 0.8% agarose gel (see section 2.2.3). These profiles were made possible by the 
presence of a unique NcoI site 1.88 kb into the pCRH vector. The recombinant plasmid 
with an inverted insert was linearised by digestion with the restriction enzymes Sall and 
BamHI (see section 2.2.6) to allow the hT recombinant DNA insert (removed from the 
pCRII vector by digestion with the restriction enzymes Sall and BamHI) to be ligated (see 
section 2.2.7) via the Sall site alongside the inverted aT DNA fragment in the pCRII 
vector. The fused DNA construct was removed from the pCRII vector as a 4.172 Kb 
318 
fragment by digestion with Ncol and BamHI (see section 2.2.6) and was analysed by 0.8% 
agarose gel electrophoresis (see section 2.2.3). The pET30a expression vector (Novagen 
Inc. ) was also digested with Ncol and BamHI then analysed by 0.8% agarose gel 
electrophoresis (see section 2.2.3). The fused 4.172Kb truncated toxin fragment and the 
5.4 Kb-digested pET30a fragment were purified from an agarose gel (see section 2.2.4). 
The purified 4.172 Kb fragment was ligated with the digested pET30a vector (see section 
2.2.7). Expression of constructs from the pET30a vector provides an N-terminal fusion to 
a histidine / S-tag (six amino acids and fifteen amino acids respectively). Recombinant 
plasmids were transformed (see section 2.2.9) into electrocompetent E. coli JM109 
(Novagen Inc. ) for storage at 
-70°C and into electrocompetent E. coli BL21 DE3 
(Novagen Inc. ) for expression. The DNA insert was sequenced from the pET30a vector 
using the Novagen Inc. supplied T7 promotor primer #69348-1 
(TAATACGACTCACTAT) and the T7 terminator primer #69337-1 
(CCGCTGAGCAATAACTA). A summary of the steps involved in cloning the truncated 
toxin construct can be seen in Figure 7.2 
7.3.4 Expression of the truncated toxin A peptide in E cols and determination of 
solubility 
BL21 DE3 clones containing the truncated toxin A construct (aT + hT), and a pET30a 
plasmid alone, were grown at 37°C overnight with shaking in LB broth containing 
30µgm1' kanamycin (see section 2.1.1). A 2ml aliquot of each overnight culture was 
inoculated into 100 ml of fresh LB broth (containing 30µgm1-' kanamycin) and incubated 
at 37°C with shaking until the culture reached an O. D6oo of 0.6. Samples were produced 
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corresponding to both uninduced and induced soluble fractions (see section 2.8.4) for the 
truncated toxin (AT and HT) clone and for a pET30a clone that lacked a DNA insert. 
Briefly, half of the 100ml culture was removed and pelleted at 5,000xg for 20mins 
(uninduced cells). Expression of the recombinant protein was induced from the T7 
promotor in the remaining culture by the addition of IPTG to a final concentration of 
1mM with continued incubation at 37°C for 3 hrs. These cells were pelleted at 5,000xg 
for 20mins (induced cells). Both the uninduced and induced cells were resuspended in 
lOmis PBS then sonicated in an ice-water bath for l5secs bursts at an amplitude of 10 
microns until the culture was clear. The sonicates were centrifuged at 10,000xg for 20 
mins at 4°C to pellet insoluble proteins. The 10ml supernatants (induced and uninduced 
soluble fractions) were removed and stored at 4°C until further analysis. The pellets were 
resuspended (by sonication) into 10mis of PBS (induced and uninduced insoluble 
fractions) and stored at 4°C. 
Each fraction was mixed 1: 1 with 2x SDS-PAGE gels (see section 2.7.1). Gels were 
either stained with CBB (see section 2.7.1) or transferred to nitrocellulose for western 
blotting (see section 2.7.3). The truncated toxin fusion peptide (AT and HT) was detected 
by incubating the blot with 3µg/ml of the PCG-4 Mab (specific for the repeat end of toxin 
A) followed by a 1: 1,000 dilution of a goat anti-mouse IgG alkaline phosphatase 
conjugate (Sigma). Alternatively, the truncated toxin was detected using a 1: 5,000 dilution 
of an anti-S-Tag antibody (Novagen Inc. ) followed by a 1: 1,000 dilution of a goat anti- 
rabbit IgG alkaline phosphatase conjugate (Sigma). 
7.3.5 Purification of the truncated toxin A fusion peptide 
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The truncated toxin A (fragment AT + HT) histidine fusion product was purified on a 
histidine resin affinity column using the provided buffers as outlined by manufacturers 
instructions (His. Binde Buffer Kit; Novagen, Inc). A brief outline is provided below: 
lOmis of an overnight culture (see section 2.1.1) of BL21 DE3 cells containing the 
recombinant plasmid were inoculated into 1 litre of LB broth containing 30µgmr' of 
kanamycin. The cells were incubated at 37°C, with shaking (250rpm), until reaching an 
O. D600 of 0.6. Expression of the truncated toxin was induced by incubating with IPTG to 
the final concentration of ImM at 37°C, with shaking, for a further 3 hrs. The cells were 
harvested at 5,000 xg for 5mins and then resuspended in 40mis of ice-cold lx Binding 
buffer (Novagen Inc. ). The cell sample was sonicated in an ice-water bath at amplitude of 
10 microns for bursts of 15 secs until the sample was no longer viscous. Cell debris was 
removed from the sample by centrifugation at 39,000 xg for 20mins followed by filtration 
through a 0.45micron filter (Acrodisc). A 5m1 sample of His. Bind Resin (Novagen Inc. ) 
was applied to a small polypropylene column (Biorad) and allowed to pack under gravity 
flow. Five mis of packed resin was sufficient to purify up to 40mg of histidine fusion 
protein. The resin was charged and equilibrated by washing sequentially with 3 volumes of 
SDW, 5 volumes of lx Charge buffer (Novagen Inc. ) and 3 volumes of lx Binding buffer 
(where 1 volume is equivalent to the settled bed volume). The prepared protein sample 
was applied to the column at a flow rate of 10 column volumes per hour. The column was 
washed with 10 volumes of 1x Binding buffer and 6 volumes of 1x Wash buffer (Novagen 
Inc. ). The bound protein was eluted with 4 volumes of lx Elute buffer (Novagen Inc. ) and 
collected as 15 x 0.5 ml fractions. E. coli BL21 DE3 containing pET30a without an insert 
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were treated in the same way as above and the proteins also passed down a histidine 
column. The eluted fractions were used as E. coli negative controls. 
The presence of protein in the fractions was determined by dot blotting (see section 2.7.4) 
and probing with a 1: 1,000 dilution of the Mab PCG-4 followed by a 1: 1,000 dilution of 
goat anti-mouse alkaline phosphatase conjugate (Sigma). Alternatively the dot blots were 
probed with a 1: 5,000 dilution of an anti-S-Tag antibody (Novagen Inc. ) or a 1: 1,000 
dilution of peptide A2 antiserum (see section 4.3.1) followed by a 1: 1,000 dilution of goat 
anti-rabbit alkaline phosphatase conjugate (Sigma). 
7.3.6 Determination of the concentration of purified truncated toxin (AT + HT) 
The concentration of the purified truncated toxin peptide was ' determined using the 
Coomassie Plus Protein Assay Reagent Kit (see section 2.9.1.2) and checked using the S- 
Tag Rapid Assay Kit (Novagen) as outlined by the manufacturers instructions. This latter 
detection system is based on the interaction of the 15 amino acid S-Tag with ribonuclease 
S-protein which together form an enzymatically active ribonuclease. Therefore, following 
the addition of the purified S-protein, the assay of ribonuclease activity provides a direct 
measurement of the S-Tag fusion protein. 
7.3.7 Effect of the truncated toxin on Vero cells in vitro 
Vero cells were grown to confluency in 96 well sterile microtitre plates (Falcon)(see 
section 5.3.3). The growth medium was replaced with 50µ1 of maintenance medium 
(Medium 199 containing 2% newborn calf serum, 1% penicillin and 1% glutamine). Ten- 
fold serial dilutions of the truncated toxin (7.5pg/m1), holotoxin A (260gg/ml), histidine 
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col unn elution buffer (Novagen) and E. coil negative control (see section 7.2.5) were 
prepared in PBS before 50µ1 of each were applied to the Vero cells. Two-fold serial 
dilutions of truncated toxin A, E. coli negative control and elution buffer were also 
prepared in PBS and applied to the Vero cells (i. e. 50µl). The cells were monitored for a 
CPE, commonly seen as cell rounding after incubation at 37°C for 24 hrs. The cytotoxicity 
titre (Cytotoxic unit [CU]/50µ1) was expressed as the highest dilution that induced more 
than 50% CPE after an incubation of 24 hrs. 
7.3.8 Haemagglutination of RRBCs by the truncated toxin 
The haemagglutination assay was performed as outlined in section 5.3.1. Briefly, 50µ1 of 
both the purified truncated toxin preparation (7.5µg/ml) and holotoxin A (100µg/ml) were 
diluted two-fold with TBS in the wells of a v-bottom microtitration plate (Sero-well). 
Holotoxin A (320pg/ml) was placed in one well as a positive control whilst the E. coil 
negative control (see section 7.2.5) was added to a second well as a negative control. Fifty 
µl of a 1% RRBC suspension was added to each well and incubated for at least 3 hrs at 
4°C. H/A titres were expressed as the reciprocal of the highest dilution giving a positive 
H/A when viewed by eye. 
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7.4 RESULTS 
7.4.1 PCR amplification of toxin A fragments aT and hT 
It was necessary to re-design PCR primers to amplify the glucosyltransferase (a) and the 
binding region (hT) of toxin A to enable them to be fused to eventually produce a 
truncated toxin which lacked the central portion of the holotoxin molecule (bp 1,630- 
5,485). Using the primers and thermocycling conditions outlined in section 7.3.1 both 
fragments were successfully amplified. Primers 14 and 15 (see appendix 2) were used to 
amplify the 1.630Kb product aT (bp 1-1,630) (see figure 7.3, lanes 1 and 2) while primers 
16 and 17 (see appendix 2) were used to amplify a 2.589Kb product hT (bp 5,485-8,074) 
(see figure 7.3, lanes 3 and 4). 
7.4.2 Cloning of the truncated toxin construct (aT + hT) into the pET30a expression 
vector 
The method outlined in section 7.3.3 and represented diagrammatically in figure 7.1 was 
used to clone fragments aT and hT as a fusion into the pET30a expression vector `in 
frame' with the T7 promotor. Firstly, both PCR products were cloned into the pCRII T- 
tailing vector. It was necessary to determine the orientation of pCRII clones containing 
fragment aT. Digestion with NcoI allowed selection of a clone with an inverted insert. 
The restriction pattern required was two fragments of 1.554Kb and 4.036Kb as opposed 
to 3.154Kb and 2.436Kb (results not shown). Digestion of a pCRJI clone containing an 
inverted aT insert with Ncol and Sall produced a 2.4Kb NcoI and Sall vector band, a 
1.554Kb Ncol vector band and a 1.63 Kb NcoI and Sall band corresponding to fragment 
aT (see figure 7.4, lanes 1 and 2). To visualise the cloned insert more clearly, the plasmid 
was first digested with Ncol to produce fragments of 1.554Kb and 4.036Kb. The latter 
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fragment was purified from an agarose gel (see section 2.2.4) then digested with Sall. 
This resulted in two fragments, a 2.4Kb vector band and a 1.63Kb band corresponding to 
fragment aT (see figure 7.4, lanes 3,4 and 5). 
Digestion of pCRII clones containing hT with Sall and BamHI produced two bands of 
3.9Kb (pCRII vector) and 2.589Kb (fragment hT) (see figure 7.5, lanes 1-3). 
The pCRII clone containing an inverted aT insert was linearised by digestion with Sall 
and BamHI (see section 7.3.3). The 2.589Kb hT fragment (released from the pCRII vector 
by digestion with Sall and BamHI) was then ligated into the opened pCRII clone 
containing fragment aT. In this way fragment hT fused to fragment aT via a Sall restriction 
site. Digestion of pCRII clones containing the fused truncated toxin fragment (aT+ hT) 
with BamHI and NcoI produced a 4.2Kb band (fragment aT+ hT) and two vector bands of 
1.5Kb and 2.4Kb (see figure 7.6, lanes 1-5). 
The 4.2Kb truncated toxin fragment was sub-cloned into the pET30a expression vector 
via the BamHI and NcoI restriction sites (see section 7.3.3). Digestion of pET30a clones 
containing the truncated toxin fragment with BamHI and NcoI produced a 5.4Kb vector 
band and a 4.2Kb band corresponding to the truncated toxin fragment (see figure 7.7). 
The truncated toxin DNA insert was sequenced from the pET30a vector using the primers 
described in section 7.3.3. The sequence data revealed that fragments aT and hT both 
corresponded to the correct regions of the toxin A molecule and that fragment aT was in 
frame with the T7 promotor (results not shown). 
7.4.3 Expression of the truncated toxin peptide and determination of its solubility 
The method outlined in section 7.3.4 was used to isolate induced and uninduced soluble 
and insoluble protein fractions from E. coli BL21 DE3 clones containing either the 
325 
pET30a truncated toxin clone or the pET30a vector without an insert. The protein 
fractions were resolved by 8% SDS-PAGE then visualised by CBB staining and western 
blot analysis (see section 7.3.4). CBB staining did not reveal an additional recombinant 
protein running at approximately 147 kDa in the samples that contained the truncated 
toxin insert (see figure 7.8, lanes 8-14). The gel was also western blotted and probed with 
the PCG-4 Mab (specific for the repeat region of toxin A) and an anti-S-Tag antibody 
(see section 7.3.4). The PCG-4 Mab reacted with the peptide H2 positive control (see 
figure 7.9, lane 11) as expected. A small amount of over-spill of the positive control into 
lanes 9,10 and 12 was also detected. The Mab PCG-4 did not react with the soluble or 
insoluble fractions from the induced BL21 DE3 cells containing the pET30a vector only 
(see figure 7.9, lanes 7 and 8). This further supports the theory that the weak reaction 
seen in lanes 9 and 10 (uninduced BL21 DE3 cells containing the pET30a vector only) 
was due to over-spill of lane 11 and not a specific reaction. 
Prior to IPTG induction, the PCG-4 Mab reacted weakly with a protein of approximately 
116 kDa in both the soluble and insoluble fractions originating from the BL21 DE3 cells 
which contained the truncated toxin insert (see figure 7.9, lanes 5 and 6). Following IPTG 
induction the PCG-4 reactive protein was increased in both the soluble and insoluble 
fractions although it appeared greater in the insoluble fractions (see figure 7.9, lanes 1-4). 
Although some truncated products were present the size of the full-length fusion protein 
compares well to the estimated size of 147 kDa (see figure 7.9, lanes 1-4). The fact that 
the PCG-4 Mab is highlighting full-length peptide by binding to the C-terminal repeat 
region (peptide HT) of the construct suggests that the truncated toxin has maintained the 
correct reading frame throughout. 
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Surprisingly, the S-Tag antibody bound only to the soluble fraction taken from induced 
BL21 DE3 cells containing the truncated toxin insert (see figure 7.10, lane 2) and not the 
insoluble fraction (see figure 7.10, lane 1). When half as much of the soluble induced 
fraction was applied there was no reaction (see figure 7.10, lane 3). Again the highlighted 
protein was approximately 147 kDa as predicted. An identical western blot was also 
probed with polyclonal peptide A2 antiserum but the background was too high and 
masked the true antibody reaction (result not shown). 
7.4.4 Purification of the truncated toxin A fusion peptide 
The procedure outlined in section 7.3.5 was used to purify the truncated toxin histidine 
fusion product. The fractions eluted from the histidine column with elute buffer 
(Novagen) were spotted onto nitrocellulose strips for dot blotting (see section 7.3.5). Four 
identical blots were prepared and probed with the PCG-4 Mab, polyclonal anti-peptide 
A2 serum, anti-S-Tag serum or alkaline phosphatase conjugate only (secondary antibody 
control). 
With the exception of the conjugate control, which did not react with any of the protein 
fractions (see figure 7.11, panel D), all of the antisera reacted with their positive controls 
and with the lysate before addition to the column (see figure 7.11, panels A, B and C, row 
a, columns I and 2). The positive controls were peptide H2 for the PCG-4 Mab, peptide 
A2 for the polyclonal A2 antiserum, and a purified S-Tag fusion product (Novagen) for 
the S-Tag antiserum. Only the polyclonal A2 antiserum appeared to react significantly 
with the 15m1 of wash buffer collected prior to elution of the bound protein (see figure 
7.11, panel B, row a, column 3). The results obtained with all three of the antibodies 
suggested that the first I ml fraction of 12 collected contained the highest concentration of 
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truncated toxin histidine fusion product (see figure 7.11, panels A, B and C, rows b and 
c). The protein concentration of fraction one was determined as outlined in section 7.3.6 
and was typically found to be in the range of 5- 10 µgml4. 
7.4.5 Effect of the truncated toxin on Vero cells 
The method outlined in section 7.3.7 was used to determine the effect of the recombinant 
truncated toxin on Vero cells in vitro. Cells incubated for 24 hrs with the E. coli negative 
control sample or with the column elution buffer (see section 7.3.5) remained unaffected 
(see figure 7.12 panel C). Holotoxin A (260 µgml') on the other hand caused a classic 
CPE (see figure 7.12 panel A) with a titre of 1: 1x105 which represents an ability to 
induce morphological changes in cells by exposure to 1.3 ngml'' of toxin A. The 
recombinant truncated toxin (7.5 µgml') also demonstrated classical cytotoxicity (see 
figure 7.12 panel B) but appeared much less potent than toxin A with a titre of only 1: 2 
representing activity on cells by 1.858 . tgmr' of the protein. 
7.4.6 H/A of RRBCs by the truncated toxin 
Both holotoxin A and the recombinant truncated toxin haemagglutinated RRBCs. The 
IVA titre of holotoxin A (100 µgmrl) was 1: 32 whilst that of the truncated toxin (7.5 
µgmr) was 1: 2 (see figure 7.13 wells Al-A8 and B1-B8 respectively). This represented 
effects induced by 1.563 µgml'1 and 1.858 µgml'' of holotoxin A and truncated toxin 
respectively. The E. coli negative control (see section 7.3.5) had no effect on the RRBCs. 
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Figure 7.2 
A figure to summarise cloning of the truncated toxin A construct. 
I) Cloning of fragment aT and fragment h. ' side by side into the pCRII vector. 2) Removal of 
the fused truncated toxin A construct from the pCRII vector by digestion with Ncol and Bam 
M. 3) Ligation of the fused toxin A construct to the pET30a expression vector `in frame' 
with the S-tag and His-tag fusions. 330 
12 
1.6kb 
34 
2.5 kb 
Figure 7.3 
0.8% agarose gel showing the PCR amplification of toxin A fragments aT and hT from C. 
diJcile VP110463 chromosomal DNA for construction of truncated toxin. 
Lanes 1 and 3,1 kb ladder; Lane 2, fragment aT; Lane 4, fragment hT. 
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Figure 7.4 
0.8% agarose gel showing cloning of the fragment aT PCR product in an inverted 
orientation into the pCRII T-tailing vector. 
Lanes I and 3, l kb ladder, Lane 2, pCRII containing an inverted aT insert digested with 
Ncol and Sall; Lane 3, a 4.036 kb fragment produced from a pCRII plus inverted aT insert 
digested with Ncol; Lane 5,4.036kb Ncol fragment digested with Sall. 
332 
123 
3.9kb 
2.6 kb 
Figure 7.5 
0.8% agarose gel showing cloning of the fragment hT PCR product into the pCRII T- 
tailing vector. 
Lane 1,1 kb ladder; Lane 2, pCRII containing fragment hT (Sall digest); Lane 3, pCRII 
containing fragment hT (Sall / BamHI digest). 
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Figure 7.6 
0.8% agarose gel showing fragments aT and hT fused together in the pCRUI T-tailing 
vector to produce the truncated toxin fragment. 
Lane 1,1kb ladder; Lanes 2 and 4, pCRII clones containing fused truncated toxin 
fragment (Ncol digest); Lanes 3 and 5, as 2 and 4 (Ncol and BamHt digests). 
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Figure 7.7 
0.8% agarose gel showing sub-cloning of the truncated toxin fragment into the pET30a 
expression vector. 
Lane 1,1kb ladder; Lanes 2-4, pET30a containing truncated toxin A DNA insert (Ncol 
and BamHl digest); Lane 5, pET30a only (Ncol and BamIII digest). 
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Figure 7.8 
An 8% SDS-PAGE gel stained with CBB showing induction of expression of the 
truncated toxin peptide from the pET30a vector. Insoluble and soluble fractions are 
shown. 
Lane 1, HMW markers, Lane 2, peptide A2; Lane 3, peptide H2; Lane 4, uninduced 
BL21 DE3 containing pET30a only (insoluble fraction); Lane 5, as lane 4 (soluble 
fraction); Lane 6, as lane 4 but induced; Lane 7, as lane 5 but induced; Lane 8, uninduced 
BL21 DE3 containing truncated toxin clone (insoluble fraction); Lane 9, as lane 8 
(soluble fraction); Lane 10, as lane 8 but induced; Lane 11, as lane 9 but induced; Lane 
12; as lane 9 (loading double); Lane 13, as lane 10 (loading double). 
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Figure 7.9 
Western blot of figure 7.8 probed with the PCG-4 monoclonal antibody. 
Lane 1, induced BL21 DE3 containing truncated toxin clone (insoluble fraction, 100µl); 
Lane 2, as lane 1 but soluble fraction (l00µ1); Lane 3, as lane 2 but S0µ1; Lane 4, as lane 
1 but 50µl; Lane 5, as lane 3 but uninduced; Lane 6, as lane 4 but uninduced; Lane 7, 
induced BL21 DE3 containing pET30a only (soluble fraction, 50pl); Lane 8, as lane 7 
but insoluble fraction (50µl); Lane 9, as lane 7 but uninduced; Lane 10, as lane 8 but 
uninduced; Lane 11, peptide H2; Lane 12, peptide A2; Lane 13, HMW markers. 
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Figure 7.10 
Western blot of figure 7.8 probed with the anti-S-Tag antibody (Novagen Inc. ). 
Lanes 1-13, identical to figure 7.9. 
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a 
b 
c 
a 
b 
c 
Figure 7.11 
71ý 
Dot blots probed with A) PCG-4 mAb, B) polyclonal anti-peptide A2 antiserum, C) anti- 
S. Tag antiserum and D) alkaline phosphatase conjugate only showing purification of the 
truncated toxin fusion product by histidine resin affinity chromatography. 
Samples include al, lysate before application to column; a2, positive control (peptide H2 
for panel A, peptide A2 for panel B, S. Tag fusion product [Novagen Inc. ] for panel C, all 
three proteins for panel D); a3, wash prior to elution; a4, elution buffer; rows b and c, 12 
x1 ml fractions eluted from column following washing. 
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Figure 7.12 
Effect of the recombinant truncated toxin on a monolayer of Vero cells after a 24 hr 
incubation at 37°C with 5% CO2. Images viewed under an inverted light microscope at a 
magnification of x 100. 
Panel A, holotoxin A treated monolayer; panel B, recombinant truncated toxin treated 
monolayer; panel C, an unaffected monolayer. 
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Figure 7.13 
Haemagglutination of rabbit red blood cells by the recombinant truncated toxin. Two-fold 
serial dilutions of A, holotoxin A (100µgm1"') and B, truncated toxin (7.5µgm1'1) can be 
seen going down the microtitre plate. 
Wells Al-A8,1: 2 
- 
1: 256 dilutions of holotoxin A; B1-B8, neat 
- 
1: 128 dilutions of 
truncated toxin; Cl, holotoxin A (positive control); C2, histidine column elution buffer 
(negative control). 
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7.5 Discussion 
This section was successful in constructing a biologically active truncated toxin which 
consisted of only the glucosyltransferase domain (AT) fused to the binding domain (H) 
of toxin A. The truncated toxin differed from the holotoxin by lacking the central region 
(aa 539-1834) which contains an ATP-binding site (see section 6), a hydrophobic region 
and four conserved cysteine residues (Cys597, Cys700, Cys1169, Cys1623) (Barroso et al, 
1994). 
Purification of the truncated toxin by histidine affinity chromatography typically yielded 
lml of soluble protein with a concentration ranging from 5-10µg/m1. There are several 
possible explanations for this poor yield. Firstly, expression of clostridial proteins in E. 
coil is problematic due to codon usage (see section 3-Discussion). Secondly, the results 
shown in figures 7.10,7.11 and 7.12 suggested that a proportion of the truncated toxin 
was insoluble. It is possible that this proportion of the fusion peptide had been put into 
inclusion bodies and was therefore being lost prior to purification by histidine affinity 
chromatography. Finally, the repeat end binding portion (HT) of the truncated toxin may 
have been wrapped around the rest of the molecule (as appears to occur in the native 
holotoxin) masking the histidine fusion and preventing binding to the column. 
The PCG-4 Mab bound to both the soluble and insoluble fractions of the truncated toxin 
whereas the S-Tag antibody only bound to the soluble fraction. The polyclonal peptide 
A2 antiserum, although appearing to bind to the truncated toxin, had a high level of 
background non-specific binding to other E. coif proteins. Both sequence data and the 
positive recognition of full length truncated toxin by the PCG-4 Mab indicated that the 
fusion protein was in the correct reading frame. 
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Both holotoxin A and the truncated toxin haemagglutinated RRBCs with comparable 
efficiency (ie. end points of 1.563 pgmt1 for holotoxin A and 1.858 µgml'1 for the 
truncated toxin). This suggests that the repeat end-binding portion of the truncated toxin 
(HI) was biologically active and was binding to RRBCs. 
The truncated toxin also induced a classic CPE on Vero cells in vitro but appeared 
approximately 1,400 fold less potent than native toxin A (ie. end points of 1.3 ngml"' for 
holotoxin A as oppose to 1.86 p. gml'' for truncated toxin). The truncated toxin also 
appeared less stable than holotoxin, with storage for more than one week at 4°C leading 
to complete loss of activity (results not shown). As peptide A2 alone did not cause a CPE 
and peptide H2 alone did not cause a classic CPE, it is reasonable to conclude that 
delivery of peptide A2 into the cell resulted in the classical effect seen. These results 
indicate that peptide A2 contains all of the active sites necessary for cellular 
glucosylation and encompasses the cytotoxicity of the holotoxin. As the nucleotide 
binding site, the hydrophobic region and the conserved cysteine residues are all absent 
from the truncated toxin, it would appear that these regions are not essential for induction 
of cytotoxic effects. This conclusion is supported by the observations that microinjection 
of a corresponding peptide (amino acids 1-546) of toxin B (Hofinann et al, 1997), and 
glucosylated Rho proteins per se (Just et at, 1995c), are sufficient to cause cytotoxic 
effects. 
The observed reduction in potency of the truncated toxin compared to the holotoxin 
provides important information concerning the function of the nucleotide binding site, the 
internal hydrophobic region and the concerned cysteine residues (see figure 1.1). Other 
investigators have shown that mutation of the putative nucleotide-binding site (amino 
acids 651-683) in toxin B caused a 99% reduction in cytotoxicity (Barroso et at, 1994). 
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Removal of the hydrophobic region and Cys1167 from toxin B also reduced cytotoxicity 
(Barroso et al, 1994). These results taken together with our observations on toxin A 
suggest that these conserved features are important for full expression of cytotoxic 
activity. 
It would appear that together the glucosyltransferase domain (AT) and the binding 
domain (HT) of toxin A form an active toxin with a reduced potency. The results from 
section 5 indicate that the repeat end binding portion of toxin A (peptide H2) is able to 
bind to cells and be internalised into endosome-like compartments. It is reasonable to 
assume therefore, that this is also true of the truncated toxin. The reduction in observed 
cytotoxic activity is likely to be due to the truncated toxin having a reduced efficiency at 
escaping these compartments to enter the cytoplasm. It is also possible that the truncated 
toxin is folded in such a way that the repeat end-binding portion is partially masking one 
or all of the active sites responsible for glucosyltransferase activity. It could be argued 
that the CPE seen was due to uptake of some of the truncated toxin by generalised 
pinocytosis. If this were the only route of uptake however, it is reasonable to assume that 
peptide A2 alone would have been taken up in the same way enabling it also to cause a 
CPE. No such effect was seen with peptide A2 in Vero cells. The binding portion of toxin 
A therefore, appears to be aiding the cytotoxic activity of the truncated toxin, most likely 
by delivering the glucosyltransferase molecule into the cell. Had more time been 
available it would have been interesting to study the proposed internalisation of the 
truncated toxin into endosome-like compartments using electron microscopy studies. 
The results from this section suggest that although not essential for cytotoxic activity, 
nucleotide binding and the internal hydrophobic region are important for toxin A 
stability, efficient endocytosis and / or translocation into the cytosol. The toxin B 
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hydrophobic region has tentatively been associated with translocation of the toxin into the 
cytoplasm (Barroso et al, 1994). Others have suggested that the putative toxin B ATP 
binding site may be involved with the interaction of the toxin with the cell shortly after 
the binding step (Florin and Thelestam, 1984). 
It must be remembered that all experimentation in this section has been performed in 
vitro. The fate of the active truncated toxin in vivo would be of interest, and may provide 
evidence of an important role for the nucleotide binding sites of toxins A and B. Also, 
had more time been available it would have been interesting to study the effects, if any, 
of the truncated toxin on human intestinal cells or in the rabbit ileal loop model of the 
disease. 
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SECTION-8 
GENERAL DISCUSSION 
SECTION-8 
GENERAL DISCUSSION 
When expressing a protein as a series of overlapping recombinant peptides it is important 
to remember that the peptides may not fold correctly to form an active site or, in fact, an 
active site may be split between two peptides. As such, a given peptide may not truly 
resemble its homologous region in the native protein. Results from these studies 
therefore, must be interpreted with caution. Whereas a positive result indicates that a 
peptide is responsible for a given function, a negative result only implies that a particular 
peptide is not involved. 
Having considered these points the outlined studies were successful in locating the 
regions of toxin A responsible for several functions. Together, these results support the 
three-domain model for C. docile toxin A, which appears to be common to all large 
clostridial cytotoxins (von Eichel Streiber et al, 1996). 
The C-terminal region of toxin A was shown to be responsible for all activity relating to 
carbohydrate binding, including the ability to bind non-specifically to some monoclonal 
antibodies. This ability probably promotes interaction of toxin A with secretory IgA in 
mucus or may function to mask the toxin from the immune system in vivo. This region of 
the toxin (represented by peptide 112) also demonstrated the ability to bind to cells and to 
be internalised, probably by receptor mediated endocytosis, into endosome-like 
compartments within cells. It is possible therefore, that receptor binding alone may be 
sufficient to stimulate endocytosis suggesting that the ATP binding site and catalytic 
domain of toxin A are not essential for this activity. This function makes the repeat 
region of toxin A an ideal delivery molecule for transporting peptides into cells. The 
repetitive nature of the ligand domain of toxin A allows a multipoint interaction between 
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the toxin and its cellular receptors, thus increasing the affinity of the toxin for the cells. 
Results from the antibody mapping studies suggest that native toxin A is more or less 
covered by its C-terminal repeat region. These results are supported by the observation 
that C. docile strains which produce truncated toxin A which lacks the repeat region are 
not detected by polyclonal anti-toxin A antiserum (Kato et al, 1999). It is not surprising 
therefore, that the polyclonal antiserum raised against peptide H2 in these studies 
neutralised the toxin A induced CPE on Vero cells. This protection was most likely due 
to the antiserum blocking binding of the toxin to its target cell. 
These studies were also first in locating the catalytic domain of toxin A to a 536 amino 
acid peptide (peptide A2) at the extreme N-terminus of the molecule. The first 113 amino 
acids of toxin A, although not solely responsible for glucosyltransferase activity, were 
shown to be essential for full catalytic activity. This region, in C. sordellii lethal toxin at 
least, does not appear to be involved in binding UDP-glucose (Busch et al, 1998) and 
does not define substrate specificity (Hofmann et al, 1998). It is likely therefore, that 
amino acids 1-113 of toxin A are essential for the correct folding of the catalytic domain 
and expression of its activity. 
Some of these results are in keeping with those of toxin B where the enzyme activity has 
been located to the first 546 amino acids at the N-terminus of the molecule (Hofmann et 
al, 1997). The first 517 amino acids of toxin B had exceptionally weak enzyme activity 
suggesting that amino acids 517-546 are important for glucosyltransferase activity 
(Hofmann et al, 1997). The published observations on toxin B and those presented here 
on toxin A suggest that site directed mutagenesis of the twenty amino acids 517-536 
within the N-terminal peptide A2 of toxin A would further delineate the catalytic domain. 
Polyclonal antibody mapping studies suggest that at least part of the fragment encoding 
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the catalytic domain of toxin A is exposed in the native state. The failure of peptide A2 
antiserum to neutralise the toxin A induced CPE, however, suggests that the active sites 
responsible for glucosyltransferase activity are not fully exposed in the native state. It is 
likely that intracellular processing of the toxin results in a change in the tertiary structure 
of the molecule exposing these catalytic domains. This may explain why the induction of 
a CPE by microinjection and in vitro glucosylation requires several fold higher amounts 
of toxin than does intoxication by the normal route (Popoff et al, 1996, Mueller et al, 
1992). 
These studies also provide the first localisation of the toxin A ATP-binding site to a 
peptide covering amino acids 542-859 of the holotoxin. Polyclonal antibody mapping 
studies indicate that this region is unexposed in formalised holotoxin. The binding of 
toxin A to an ATP agarose column demonstrated here, and in a previous study (Lobban 
and Borriello, 1992) however, indicates that the ATP binding site is accessible in at least 
a fraction of the toxin A preparation. Therefore, there is either differential accessibility to 
ATP and polyclonal antibodies or unfolding of the toxin A molecule under aerobic 
conditions. There is some evidence for unfolding in that antibody to peptides B and E 
(both containing the ATP binding site) reacted with unfixed but not fixed toxin A. It is 
unlikely therefore that formalised toxin A would bind to ATP agarose. 
The localisation of the ATP binding site in toxin A supports the identification of a 
putative ATP binding site in toxin B between amino acids 653-685 (Hofinann et al, 
1997). It has been suggested that this ATP binding site may be involved in co-ordinating 
the IJDp-glucose cofactor during modification (von Eichel-Streiber et al, 1996). It is of 
interest, therefore, that peptide A2, which possessed glucosyltransferase activity lacked 
the nucleotide-binding site. These observations suggest that the ATP binding site is not 
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involved in Rho glucosylation and fails to identify a role for the nucleotide-binding site. 
However, the truncated toxin A in this present study (which lacks the ATP binding site, 
hydrophobic region and conserved cysteine residues) was 1,000 fold less cytotoxic than 
the holotoxin in vitro. Mutation of the nucleotide-binding site in toxin B has also been 
shown to cause a 99% reduction in cytotoxicity (Barroso et al, 1994). These results 
suggest that the ATP binding site and the hydrophobic region are not essential for 
cytotoxicity but are required for stability and / or efficient translocation of the toxin into 
the cytosol. There are several other possible explanations that alone, or in combination, 
may explain the reduced activity of the truncated toxin. Firstly if the truncated toxin lacks 
the ability to escape endosomes, it is possible that the effect seen on Vero cells was due 
only to the toxin that had been internalised by pinocytosis. Another suggestion is that the 
glucosyltransferase domain of the recombinant truncated toxin was not as active as the 
corresponding region in the native holotoxin. Finally it is possible that the truncated toxin 
was folded in such a way that the repeat end-binding portion of the molecule was 
masking the catalytic domain and thus hindering glucosyltransferase activity. The effect 
of the truncated toxin in rabbit Real loops, on human intestinal biopsy tissue and in the 
hamster model of the disease in vivo requires further investigation. 
The major problem encountered in these studies was in producing adequate amounts of 
the toxin A peptides. Low levels of expression of some of the constructs in E. coli were a 
result of poor codon usage. Some regions of toxin A required amplification with two of 
three different sets of PCR primers before a sufficient level of expression was obtained. 
Although eventually successful, the main and most time consuming step of this PhD was 
the production of the toxin A constructs. These studies highlight the desperate need for an 
efficient cloning system for clostridial genes. Had time allowed, alternative-cloning 
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systems might have been employed for some of the more problematic regions of toxin A. 
Different hosts such as the gram positive lactococcal species or Bacillus subtilis may be 
more compatible for expression of clostridial genes. Cloning systems for these organisms 
however are far more difficult to establish than for E. coll. Alternatively insect cells or 
yeast cells are possibilities. It should be pointed out that there is no guarantee that 
expression in these systems would yield better results than in E. coli. 
The toxin A peptides provide an important tool for future research into the structure- 
function relationships of toxin A. Solving the 3-D structure of the holotoxin and the toxin 
A peptides by X-ray crystallography would clarify which regions of the molecule are 
exposed in the native state, and may be helpful in determining potential receptor binding 
sites. The data obtained should add finer detail to the preliminary tertiary structure 
predictions made in this thesis by antibody reaction profiling. 
The involvement of the ATP binding site in toxin A induced cell damage also requires 
further investigation. An isogenic deletion mutant of C. docile in which the ATP 
binding site is inactivated in the toxin A gene would be useful. Electron microscopy 
studies could then be used to directly compare uptake of the mutated toxin and the native 
holotoxin into cells. Time course studies such as these may provide data to reinforce the 
hypothesis that the ATP binding site is involved in efficient translocation of the toxin into 
the cytoplasm. 
Many investigators have provided evidence to suggest that binding of toxin A to its 
intestinal cell receptor stimulates transmembrane signalling events which trigger fluid 
secretion and immune cells prior to Rho glucosylation (Pothoulakis et al, 1988, 
Castagliuolo et al, 1994). The observation in these studies that peptide 112 (repeat end 
binding portion) is not only internalised into endosome-like compartments within cells 
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but that it also alters the morphology of the cells tends to support this theory. Recently 
published data indicates that early intracellular signalling of C. di7cile toxin A in rat 
ileum involves a protein tyrosine kinase-dependent pathway (Castagliuolo et al, 1998b). 
Protein tyrosine kinase activity in the ileal mucosa was increased three fold just 15 
minutes after toxin A administration and significant secretory and inflammatory changes 
were evident after 1 hour. It would be interesting to repeat these experiments using just 
peptide H2 to determine whether binding alone to a cell surface receptor is sufficient to 
trigger these responses. In our studies no fluid accumulation was observed in rabbit ileal 
loops treated with peptide H2. It is possible that the concentration of peptide H2 in these 
experiments was too low to cause a significant fluid response. Another possibility is that 
binding to the cell surface receptor only stimulates a mild secretory effect because the 
signal is continually being removed as the toxin is down regulated into endosomes 
allowing the receptor to be recycled back to the membrane. It would be interesting to 
determine whether binding of peptide H2 to human intestinal cells also stimulates a 
tyrosine kinase dependent pathway. The postulated signalling capacity of toxin A 
probably explains the different biological activities of toxins A and B. This raises the 
question as to whether the toxin B repeats, in isolation, have any additional biological 
activity. 
The apparent resistance of neonates to the damaging effects of toxin A may also be 
explained by intracellular signalling mechanisms. It is possible that the intestinal cell 
receptor for toxin A in neonates is immature, and Perhaps binding to this receptor does 
not trigger the intracellular signalling pathways which, in adults, result in endocytosis of 
the toxin. Recent observations have indicated that the secretor), component of secretory 
IgA in human milk binds to toxin A and may function as a receptor analogue, protecting 
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human infants from C. docile associated disease (Dallas and Rolfe, 1998). Removal of 
the carbohydrate residues from the secretory component reduced toxin A binding. It 
seems likely, however, that a combination of factors are responsible for the resistance of 
human neonates to the damaging effects of toxin A. 
There is evidence to suggest that natural immunity against toxin A does protect some 
humans and hamsters against C. docile associated diarrhoea and PMC (Kyne et al, 
1999, Giannasca et al, 1999). Antibodies to recombinant C. docile toxins have also been 
shown to be an effective treatment for preventing relapse of C docile associated disease 
in hamsters (Kink and Williams, 1998). With an increasing elderly population and an 
expanding use of broad-spectrum antimicrobials, C. docile is likely to become an 
increasing problem. The long-term control of this disease therefore relies on the 
production of an effective vaccine that protects all susceptible individuals. The vaccine 
potential of some of the toxin A peptides produced in this study therefore warrants 
investigation. Caution should be taken if considering amino acids 1-536 (peptide A2), 
which encompass the catalytic domain of the molecule, as a potential vaccine candidate. 
The C-terminal repeat-end of toxin A (peptide H2) is an obvious vaccine candidate for 
several reasons. Firstly, antiserum to this region protects against the toxin A induced 
cytopathic effect. Secondly, the repeat binding region of toxin A is known to associate 
with mucus and intestinal cells thus encouraging a localised immunity. Finally, this 
region is acid stable making it an ideal candidate for an orally delivered vaccine. This 
peptide is also likely to wrap around the outside of an attached peptide thus protecting it 
from the effects of low pH in the gut. 
Recent studies have also shown that mice immunised with the repeat region of toxin A 
were protected against a three-fold lethal dose of toxin A (Sauerborn et al, 1997). The 
352 
demonstration that the repeat region of toxin A (peptide H2) alone had an effect on cells 
in our studies raises a note of caution over the possible use of this region as a vehicle for 
the formulation and delivery of oral vaccines. Recent studies, however, have been 
successful in using the repeat region of toxin A as a vaccine candidate against C. docile 
associated disease (Ward et al, 1997,1999). In the first of these studies the repeat region 
of toxin A was cloned in-frame with fragment C of tetanus toxin and was expressed in an 
attenuated Salmonella typhimurium mutant. This mutant delivered the fusion protein to 
the intestinal mucosa inducing an anti-toxin A serum response in mice (Ward et al, 
1997). More recently the same fusion protein was expressed within attenuated Salmonella 
typhimurium BRD509 (aroA aroD). Serum from mice immunised intra-nasally or intra- 
gastrically with the vaccine candidate neutralised toxin A induced cytotoxicity (Ward et 
al, 1997). Intranasal administration appeared to induce higher serum and mucosal toxin A 
antibody responses than intragastric administration. 
These studies, in mice, are extremely encouraging and indicate that the repeat region of 
toxin A may prove to be an ideal vaccine candidate against C. dfcile disease. Before 
vaccines such as these are formulated for humans, however, it may be advisable to 
determine the exact intracellular signalling pathways that are stimulated by binding of the 
repeat region of toxin A to cell receptors. 
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APPENDICES 
APPENDIX I 
'The nucleotide sequence of the coding region of Clostridium diJcile toxin A. The toxin A gene 
was first cloned and sequenced by Dove et al., 1990. 
ATGTCTTTAATATCTAAAGAAGAGTTAATAAAACTCGCATATAGCATTAGACCAAGAGAAAATGAGTATAAAACTATACTAACTAATTTA 
90 
MSLISKEELIKLAYSIRPRENEYKTILTNL 
GACGAATATAATAAGTTAACTACAAACAATAATGAAAATAAATATTTGCAATTAAAAAAACTAAATGAATCAATTGATGTTTTTATGAAT 
180 
DEYNKLTTNNNENKYL0LKKLNES10VFMN 
AAATATAAAACTTCAAGCAGAAATAGAGCACTCTCTAATCTAAAAAAAGATATATTAAAAGAAGTAATTCTTATTAAAAATTCCAATACA 
270 
KYKTSSRNRALSNLKKDILKEVILIKNSNT 
AGCCCTGTAGAAAAAAATTTACATTTTGTATGGATAGGTGGAGAAGTCAGTGATATTGCTCTTGAATACATAAAACAATGGGCTGATATT 
360 
$pVEKNLHFVWIGGEVSDIALEYIK0WA01 
AATGCAGAATATAATATTAAACTGTGGTATGATAGTGAAGCATTCTTAGTAAATACACTAAAAAAGGCTATAGTTGAATCTTCTACCACT 
450 
NAEYNIKLWY0SEAFLVNTLKKAIVESSTT 
GAAGCATTACAGCTACTAGAGGAAGAGATTCAAAATCCTCAATTTGATAATATGAAATTTTACAAAAAAAGGATGGAATTTATATATGAT 
540 
EAL0LLEEEI0NP0FDNMKFYKKRMEFIYD 
AGACAAAAAAGGTTTATAAATTATTATAAATCTCAAATCAATAAACCTACAGTACCTACAATAGATGATATTATAAAGTCTCATCTAGTA 
630 
R0KRFINYYKS0INKPTVPTIDDIIKSHLV 
TCTGAATATAATAGAGATGAAACTGTATTAGAATCATATAGAACAAATTCTTTGAGAAAAATAAATAGTAATCATGGGATAGATATCAGG 
720 
SEYNR0ETVLESYRTNSLRKINSNHGIDIR 
GCTAATAGTTTGTTTACAGAACAAGAGTTATTAAATATTTATAGTCAGGAGTTGTTAAATCGTGGAAATTTAGCTGCAGCATCTGACATA 
810 
ANSLFT -E 0ELLNIYS0ELLNRGNLAAAS0I 
GTAAGATTATTAGCCCTAAAAAATTTTGGCGGAGTATATTTAGATGTTGATATGCTTCCAGGTATTCACTCTGATTTATTTAAAACAATA 
900 
yRLLALKN 
_F 
GGVYLDV0MLPGIHSDLFKTI 
TCTAGACCTAGCTCTATTGGACTAGACCGTTGGGAAATGATAAAATTAGAGGCTATTATGAAGTATAAAAAATATATAAATAATTATACA 
990 
SRPSSIGL0RWEMIKLEAIMKYKKYINNYT 
TCAGAAAACTTTGATAAACTTGATCAACAATTAAAAGATAATTTTAAACTCATTATAGAAAGTAAAAGTGAAAAATCTGAGATATTTTCT 
1080 
SENF0KL000LKDNFKLIIESKSEKSEIFS 
AAATTAGAAAATTTAAATGTATCTGATCTTGAAATTAAAATAGCTTTCGCTTTAGGCAGTGTTATAAATCAAGCCTTGATATCAAAACAA 
117C 
KLENLNVS0LEIKIAFALGSVIN0ALISK0 
GGTTCATATCTTACTAACCTAGTAATAGAACAAGTAAAAAATAGATATCAATTTTTAAACCAACACCTTAACCCAGCCATAGAGTCTGAT 
126C 
GSYLTNLVIE0VKNRY0FLN0HLNPAIESD 
AATAACTTCACAGATACTACTAAAATTTTTCATGATTCATTATTTAATTCAGCTACCGCAGAAAACTCTATGTTTTTAACAAAAATAGCA 
-ý--- 135C 
NNFT0TTKIFH08LFNSATAENSMFLTKIA 
CCATACTTACAAGTAGGTTTTATGCCAGAAGCTCGCTCCACAATAAGTTTAAGTGGTCCAGGAGCTTATGCGTCAGCTTACTATGATTTC 
1440 
pyL0VGFMPEARSTISLSGPGAYASAYY0F 
ATAAATTTACAAGAAAATACTATAGAAAAAACTTTAAAAGCATCAGATTTAATAGAATTTAAATTCCCAGAAAATAATCTATCTCAATTG 
1530 
[NL0ENTIEKTLKASDLIEFKFPENNLS0L 
ACAGAACAAGAAATAAATAGTCTATGGAGCTTTGATCAAGCAAGTGCAAAATATCAATTTGAGAAATATGTAAGAGATTATACTGGTGGA 
1620 
TE0EINSLWSF00ASAKY0FEKYVRDYTGG 
TCTCTTTCTGAAGACAATGGGGTAGACTTTAATAAAAATACTGCCCTCGACAAAAACTATTTATTAAATAATAAAATTCCATCAAACAAT 
i-------- 1710 
SLSEDNGV0FNKNTAL0KNYLLNNKIPSNN 
GTAGAAGAAGCTGGAAGTAAAAATTATGTTCATTATATCATACAGTTACAAGGAGATGATATAAGTTATGAAGCAACATGCAATTTATTT 
---I ,. 1800 
V' EEAGSKNYVHYII0L0G0DISYEATCNLF 
TCTAAAAATCCTAAAAATAGTATTATTATACAACGAAATATGAATGAAAGTGCAAAAAGCTACTTTTTAAGTGATGATGGAGAATCTATT 
- 
1890 
SKNPKNSIII0RNMNESAKSYFLSDDGESI 
TTAGAATTAAATAAATATAGGATACCTGAAAGATTAAAAAATAAGGAAAAAGTAAAAGTAACCTTTATTGGACATGGTAAAGATGAATTC 
1980 
LELNKYRIPERLKNKEKVKVTFIGHGKDEF 
AACACAAGCGAATTTGCTAGATTAAGTGTAGATTCACTTTCCAATGAGATAAGTTCATTTTTAGATACCATAAAATTAGATATATCACCT 
2070 
NTSEFARLSVDSLSNE1SSFLDTIKL0ISP 
AAAAATGTAGAAGTAAACTTACTTGGATGTAATATGTTTAGTTATGATTTTAATGTTGAAGAAACTTATCCTGGGAAGTTGCTATTAAGT 
2160 
KNVEVNLLGCNMFSYDFNVEETYPGKLLLS 
ATTATGGACAAAATTACTTCCACTTTACCTGATGTAAATAAAAATTCTATTACTATAGGAGCAAATCAATATGAAGTAAGAATTAATAGT 
2250 
[M0KITSTLP0VNKNSITIGAN0YEVRINS 
GAGGGAAGAAAAGAACTTCTGGCTCACTCAGGTAAATGGATAAATAAAGAAGAAGCTATTATGAGCGATTTATCTAGTAAAGAATACATT 
2340 
EGRKELLAHSGKWINKEEAIMSDLSSKEYI 
TTTTTTGATTCTATAGATAATAAGCTAAAAGCAAAGTCCAAGAATATTCCAGGATTAGCATCAATATCAGAAGATATAAAAACATTATTA 
2430 
FFDSIDNKLKAKSKNIPGLASISE01KTLL 
CTTGATGCAAGTGTTAGTCCTGATACAAAATTTATTTTAAATAATCTTAAGCTTAATATTGAATCTTCTATTGGGGATTACATTTATTAT 
2520 
LDASVSP0TKFILNNLKLNIESSIG0YIYY 
GAAAAATTAGAGCCTGTTAAAAATATAATTCACAATTCTATAGATGATTTAATAGATGAGTTCAATCTACTTGAAAATGTATCTGATGAA 
2610 
EKLEPVKNIIHNSI0DLIDEFNLLENVSDE 
TTATATGAATTAAAAAAATTAAATAATCTAGATGAGAAGTATTTAATATCTTTTGAAGATATCTCAAAAAATAATTCAACTTACTCTGTA 
--- 
2700 
LYELKKLNNLDEKYLISFEDISKNNST. Y SV 
AGATTTATTAACAAAAGTAATGGTGAGTCAGTTTATGTAGAAACAGAAAAAGAAATTTTTTCAAAATATAGCGAACATATTACAAAAGAA 
ý`ý---- 279C 
RFINKSNGESVYVETEKEIFSKYSEHITKE 
ATAAGTACTATAAAGAATAGTATAATTACAGATGTTAATGGTAATTTATTGGATAATATACAGTTAGATCATACTTCTCAAGTTAATACA 
28ßC 
[STIKNSIITDVNGNLL0NI0LDHTS0VNT 
TTAAACGCAGCATTCTTTATTCAATCATTAATAGATTATAGTAGCAATAAAGATGTACTGAATGATTTAAGTACCTCAGTTAAGGTTCAA 
ý-'-- '- 2970 
LNAAFFl0SLIDYSSNKDVLNDLSTSVKV0 
CTTTATGCTCAACTATTTAGTACAGGTTTAAATACTATATATGACTCTATCCAATTAGTAAATTTAATATCAAATGCAGTAAATGATACT 
3060 
LYA0LFSTGLNTIYDSI0LVNLISNAVNDT 
ATAAATGTACTACCTACAATAACAGAGGGGATACCTATTGTATCTACTATATTAGACGGAATAAACTTAGGTGCAGCAATTAAGGAATTA 
3150 
INVLPTITEGIPIVSTILDGINLGAAIKEL 
CTAGACGAACATGACCCATTACTAAAAAAAGAATTAGAAGCTAAGGTGGGTGTTTTAGCAATAAATATGTCATTATCTATAGCTGCAACT 
3240 
LDEHDPLLKKELEAKVGVLAINMSLSIAAT 
GTAGCTTCAATTGTTGGAATAGGTGCTGAAGTTACTATTTTCTTATTACCTATAGCTGGTATATCTGCAGGAATACCTTCATTAGTTAAT 
3330 
VASIVGIGAEVTIFLLPIAGISAGIPSLVN 
AATGAATTAATATTGCATGATAAGGCAACTTCAGTGGTAAACTATTTTAATCATTTGTCTGAATCTAAAAAATATGGCCCTCTTAAAACA 
3420 
NELILHDKATSVVNYFNHLSESKKYGPLKT 
GAAGATGATAAAATTTTAGTTCCTATTGATGATTTAGTAATATCAGAAATAGATTTTAATAATAATTCGATAAAACTAGGAACATGTAAT 
-i 3510 
E0DKILVPID0LVISEIDFNNNSIKLGTCN 
ATATTAGCAATGGAGGGGGGATCAGGACACACAGTGACTGGTAATATAGATCACTTTTTCTCATCTCCATCTATAAGTTCTCATATTCCT 
3600 
ILAMEGGSGHTVTGNIDHFFSSPSISSHIP 
TCATTATCAATTTATTCTGCAATAGGTATAGAAACAGAAAATCTAGATTTTTCAAAAAAAATAATGATGTTACCTAATGCTCCTTCAAGA 
3690 
5LS1YSAIGIETENL0FSKKIMMLPNAPSR 
GTGTTTTGGTGGGAAACTGGAGCAGTTCCAGGTTTAAGATCATTGGAAAATGACGGAACTAGATTACTTGATTCAATAAGAGATTTATAC 
3780 
VFWWETGAVPGLRSLENDGTRLL0SIR0LY 
CCAGGTAAATTTTACTGGAGATTCTATGCTTTTTTCGATTATGCAATAACTACATTAAAACCAGTTTATGAAGACACTAATATTAAAATT 
3870 
pGKFYWRFYAFFDYAITTLKPVYEDTNIKI 
AAACTAGATAAAGATACTAGAAACTTCATAATGCCAACTATAACTACTAACGAAATTAGAAACAAATTATCTTATTCATTTGATGGAGCA 
1396C 
KLDKDTRNFIMPTITTNEIRNKLSYSFDGA 
GGAGGAACTTACTCTTTATTATTATCTTCATATCCAATATCAACGAATATAAATTTATCTAAAGATGATTTATGGATATTTAATATTGAT 
405C 
GGTYSLLLSSYPISTNINLSKD0LWIFNID 
AATGAAGTAAGAGAAATATCTATAGAAAATGGTACTATTAAAAAAGGAAAGTTAATAAAAGATGTTTTAAGTAAAATTGATATAAATAAA 
4140 
NEVREI5IENGTIKKGKLIKDVLSKIDINK 
AATAAACTTATTATAGGCAATCAAACAATAGATTTTTCAGGCGATATAGATAATAAAGATAGATATATATTCTTGACTTGTGAGTTAGAT 
4230 
NKLIIGN0TIDFSGDIDNKDRYIFLTCELD 
GATAAAATTAGTTTAATAATAGAAATAAATCTTGTTGCAAAATCTTATAGTTTGTTATTGTCTGGGGATAAAAATTATTTGATATCCAAT 
4320 
DKISLIIEINLVAKSYSLLLSGDKNYLISN 
TTATCTAATACTATTGAGAAAATCAATACTTTAGGCCTAGATAGTAAAAATATAGCGTACAATTACACTGATGAATCTAATAATAAATAT 
4410 
LSNTIEKINTLGLDSKNIAYNYTDESNNKY 
TTTGGAGCTATATCTAAAACAAGTCAAAAAAGCATAATACATTATAAAAAAGACAGTAAAAATATATTAGAATTTTATAATGACAGTACA 
4500 
FGAISKTS0KSIIHYKKDSKNILEFYNDST 
TTAGAATTTAACAGTAAAGATTTTATTGCTGAAGATATAAATGTATTTATGAAAGATGATATTAATACTATAACAGGAAAATACTATGTT 
1 4590 
LEFNSKDFIAEDINVFMKDDINTITGKYYV 
GATAATAATACTGATAAAAGTATAGATTTCTCTATTTCTTTAGTTAGTAAAAATCAAGTAAAAGTAAATGGATTATATTTAAATGAATCC 
4680 
DNNTDKSIDFSISLVSKN0VKVNGLYLNES 
GTATACTCATCTTACCTTGATTTTGTGAAAAATTCAGATGGACACCATAATACTTCTAATTTTATGAATTTATTTTTGGACAATATAAGT 
4770 
VYSSYLDFVKNSDGHHNTSNFMNLFLDNIS 
TTCTGGAAATTGTTTGGGTTTGAAAATATAAATTTTGTAATCGATAAATACTTTACCCTTGTTGGTAAAACTAATCTTGGATATGTAGAA 
4860 
FWKLFGFENINFVIDKYFTLVGKTNLGYVE 
TTTATTTGTGACAATAATAAAAATATAGATATATATTTTGGTGAATGGAAAACATCGTCATCTAAAAGCACTATATTTAGCGGAAATGGT 
4950 
FICDNNKNIDIYFGEWKTSSSKSTIFSGNG 
AGAAATGTTGTAGTAGAGCCTATATATAATCCTGATACGGGTGAAGATATATCTACTTCACTAGATTTTTCCTATGAACCTCTCTATGGA 
5040 
RNVVVEPIYNPDTGEDISTSL0FSYEPLYG 
ATAGATAGATATATAAATAAAGTATTGATAGCACCTGATTTATATACAAGTTTAATAAATATTAATACCAATTATTATTCAAATGAGTAC 
5130 
IDRYINKVLIAPDLYTSLININTNYYSNEY 
TACCCTGAGATTATAGTTCTTAACCCAAATACATTCCACAAAAAAGTAAATATAAATTTAGATAGTTCTTCTTTTGAGTATAAATGGTCT 
5220 
YPEIIVLNPNTF. H KKVNINLDSSSFEYKWS 
ACAGAAGGAAGTGACTTTATTTTAGTTAGATACTTAGAAGAAAGTAATAAAAAAATATTACAAAAAATAAGAATCAAAGGTATCTTATCT 
531C 
TEGS0FILVRYLEESNKKIL0KIRIKGILS 
AATACTCAATCATTTAATAAAATGAGTATAGATTTTAAAGATATTAAAAAACTATCATTAGGATATATAATGAGTAATTTTAAATCATTT 
5400 
NT0SFNKMSIDFKDIKKLSLGYIMSNFKSF 
AATTCTGAAAATGAATTAGATAGAGATCATTTAGGATTTAAAATAATAGATAATAAAACTTATTACTATGATGAAGATAGTAAATTAGTT 
5490 
NSENELDRDHLGFKI10NKTYYYDEDSKLV 
AAAGGATTAATCAATATAAATAATTCATTATTCTATTTTGATCCTATAGAATTTAACTTAGTAACTGGATGGCAAACTATCAATGGTAAA 
5580 
KGLININNSLFYFDPIEFNLVTGWQTINGK 
AAATATTATTTTGATATAAATACTGGAGCAGCTTTAACTAGTTATAAAATTATTAATGGTAAACACTTTTATTTTAATAATGATGGTGTG 
5670 
KYYFDINTGAALTSYKIINGKHFYFNNDGV 
ATGCAGTTGGGAGTATTTAAAGGACCTGATGGATTTGAATATTTTGCACCTGCCAATACTCAAAATAATAACATAGAAGGTCAGGCTATA 
5760 
M0LGVFKGPDGFEYFAPANT0NNNIEG0AI 
GTTTATCAAAGTAAATTCTTAACTTTGAATGGCAAAAAATATTATTTTGATAATAACTCAAAAGCAGTCACTGGATGGAGAATTATTAAC 
5850 
VY0SKFLTLNGKKYYFDNNSKAVTGWRIIN 
AATGAGAAATATTACTTTAATCCTAATAATGCTATTGCTGCAGTCGGATTGCAAGTAATTGACAATAATAAGTATTATTTCAATCCTGAC 
5940 
NEKYYFNPNNAIAAVGL0VIDNNKYYFNPD 
ACTGCTATCATCTCAAAAGGTTGGCAGACTGTTAATGGTAGTAGATACTACTTTGATACTGATACCGCTATTGCCTTTAATGGTTATAAA 
6030 
TAIISKGW0TVNGSRYYFDTDTAIAFNGYK 
ACTATTGATGGTAAACACTTTTATTTTGATAGTGATTGTGTAGTGAAAATAGGTGTGTTTAGTACCTCTAATGGATTTGAATATTTTGCA 6120 
TIDGKHFYFDSDCVVKIGVFSTSNGFEYFA 
CC TGCTAATACTTATAATAATAACATAGAAGGTCAGGCTATAGTTTATCAAAGTAAATTCTTAACTTTGAATGGTAAAAAATATTACTTT 
6210 
pANTYNNNIEGQAIVY0SKFLTLNGKKYYF 
GATAATAACTCAAAAGCAGTTACCGGATTGCAAACTATTGATAGTAAAAAATATTACTTTAATACTAACACTGCTGAAGCAGCTACTGGA 6300 
0NNSKAVTGL0TIDSKKYYFNTNTAEAATG 
TGGCAAACTATTGATGGTAAAAAA"rATTACTTTAATACTAACACTGCTGAAGCAGCTACTGGATGGCAAACTATTGATGGTAAAAAATAT 
6390 
W0TIDGKKYYFNTNTAEAATGW0T10GKKY 
TACTTTAATACTAACACTGCTATAGCTTCAACTGGTTATACAATTATTAATGGTAAACATTTTTATTTTAATACTGATGGTATTATGCAG 6480 
YFNTNTAIASTGYTIINGKHFYFNTDGIMQ 
ATAGGAGTGTTTAAAGGACCTAATGGATTTGAATATTTTGCACCTGCTAATACGGATGCTAACAACATAGAAGGTCAAGCTATACTTTAC 6570 
1GVFKGPNGFEYFAPANT0ANNIEG0AILY 
CAAAATGAATTCTTAACTTTGAATGGTAAAAAATATTACTTTGGTAGTGACTCAAAAGCAGTTACTGGATGGAGAATTATTAACAATAAG 
6660 
0NEFLTLNGKKYYFGSDSKAVTGWRIINNK 
AAATATTACTTTAATCCTAATAATGCTATTGCTGCAATTCATCTATGCACTATAAATAATGACAAGTATTACTTTAGTTATGATGGAATT 
6750 
KYYFNPNNAIAAIHLCTINN0KYYFSYDGI 
CTTCAAAATGGATATATTACTATTGAAAGAAATAATTTCTATTTTGATGCTAATAATGAATCTAAAATGGTAACAGGAGTATTTAAAGGA 
6840 
L0NGYITIERNNFYFDANNESKMVTGVFKG 
CC TAATGGATTTGAGTATTTTGCACCTGCTAATACTCACAATAATAACATAGAAGGTCAGGCTATAGTTTACCAGAACAAATTCTTAACT 
6930 
pNGFEYFAPANTHNNNIEG0AIVY0NKFLT 
TTGAATGGCAAAAAATATTATTTTGATAATGACTCAAAAGCAGTTACTGGATGGCAAACCATTGATGGTAAAAAATATTACTTTAATCTT 
7020 
LNGKKYYFDNDSKAVTGW0TIDGKKYYFNL 
AACACTGCTGAAGCAGCTACTGGATGGCAAACTATTGATGGTAAAAAATATTACTTTAATCTTAACACTGCTGAAGCAGCTACTGGATGG 
7110 
NTAEAATGW0TIDGKKYYFNLNTAEAATGW 
CAAACTATTGATGGTAAAAAATATTACTTTAATACTAACACTTTCATAGCCTCAACTGGTTATACAAGTATTAATGGTAAACATTTTTAT 
7200 
TIDGKKYYFNTNTFIASTGYTSINGKHFY 
TTTAATACTGATGGTATTATGCAGATAGGAGTGTTTAAAGGACCTAATGGATTTGAATACTTTGCACCTGCTAATACGGATGCTAACAAC 
7290 
FNTDGIM0IGVFKGPNGFEYFAPANTDANN 
ATAGAAGGTCAAGCTATACTTTACCAAAATAAATTCTTAACTTTGAATGGTAAAAAATATTACTTTGGTAGTGACTCAAAAGCAGTTACC 7380 
EG0AILY0NKFLTLNGKKYYFGSDSKAVT 
GGACTGCGAACTATTGATGGTAAAAAATATTACTTTAATACTAACACTGCTGTTGCAGTTACTGGATGGCAAACTATTAATGGTAAAAAA 7470 
GLRTIDGKKYYFNTNTAVAVTGW0TINGKK 
TACTACTTTAATACTAACACTTCTATAGCTTCAACTGGTTATACAATTATTAGTGGTAAACATTTTTATTTTAATACTGATGGTATTATG 
7560 
yYFNTNTSIASTGYTIISGKHFYFNT0GIM 
CAGATAGGAGTGTTTAAAGGACCTGATGGATTTGAATACTTTGCACCTGCTAATACAGATGCTAACAATATAGAAGGTCAAGCTATACGT 7650 
0IGVFKGPDGFEYFAPANTDANNIEG0AIR 
TATCAAAATAGATTCCTATATTTACATGACAATATATATTATTTTGGTAATAATTCAAAAGCGGCTACTGGTTGGGTAACTATTGATGGT 
7740 
y0NRFLYLH0NIYVFGNNSKAATGWVT10G 
AATAGATATTACTTCGAGCCTAATACAGCTATGGGTGCGAATGGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGTTTA 7830 
NRYYFEPNTAMGANGYKTIDNKNFYFRNGL 
CC TCAGATAGGAGTGTTTAAAGGGTCTAATGGATTTGAATACTTTGCACCTGCTAATACGGATGCTAACAATATAGAAGGTCAAGCTATA 7920 
pQIGVFKGSNGFEYFAPANTDANNIEG0AI 
CGTTATCAAAATAGATTCCTACATTTACTTGGAAAAATATATTACTTTGGTAATAATTCAAAAGCAGTTACTGGATGGCAAACTATTAAT 8010 
RY0NRFLHLLGKIYYFGNNSKAVTGW0TIN 
GGTAAAGTATATTACTTTATGCCTGATACTGCTATGGCTGCAGCTGGTGGACTTTTCGAGATTGATGGTGTTATATATTTCTTTGGTGTT 
810C 
GKVYYFMPDTAMAAAGGLFE10GVIYFFGV 
GATGGAGTAAAAGCCCCTGGGATATATGGCTAAAATATATGTTTGATAAAAAATTATTCCTGTGCTACTAAGAAATTATTTTTATATAAT 8190 
pGVKAPGIYGNICLIKNYSCATKKLFLYN 
AAATATTGAG 
__ 
r _ý------ý 8200 
KY 
APPENDIX 2 
PCR Primers 
A summary of the primers used for the PCR amplification of the toxin A fragments from C. 
docile VPI 10463 chromosomal DNA. Engineered restriction endonuclease sites are typed in 
bold and stop codons are underlined. 
Primer 
No. 
Primer Sequence 
(5' 
- 
3') 
Location (bp's) in 
Toxin A Gene 
(see appendix 1) 
Used for the 
Amplification 
of Fragments 
1 TATTGCTCTTGGATTCATAAAACAA 324 
- 
348 al, c 
2 CAGAAAGAGGTCGACCAGTCTAATC 1,606 
- 
1,630 al, a2 
3 GGATCCATGTCTTTAATATCTAAAG 
AAG 
1-22 a2, a' 
4 TATACTGGTGGATCCCTTTCTGAAG 1,609 
- 
1,633 b, e 
5 CATTTTCAAGTCGACTGAACTAATC 2,575 
- 
2,599 b, c 
6 ACTTGAAAATGGATCCGATGAATTA 2,589-2,613 d, 
7 TTTATATTCGTCGACATTGGCTATG 3,989 
- 
4,013 d, e 
8 GGAGCAGGAGGATCCTACTCTTTAT 3,955 
- 
3,979 f, 
9 TATATTGATTAAGCTTTAAACTAAT 5,484 
- 
5,508 f, 
10 AATTAGTTAAAGGATCCATCAATAT 5,483 
- 
5,507 hl, 
11 CTCGAAAAGTCGACCAGCTTAAGCC 8,046 
- 
8,070 hl, h2 
12 CCATGGGATTAATCAATATAAATAA 
TTCA 
5,495 
- 
5,517 h2 
13 AGATACTAGTCGACACTATATAATA 601 
- 
633 a' 
14 AGCCATGGCTATGTCTTTAATATCT 
AAAGAA 
1- 21 aT 
15 CAGAAAGAGGTCGACCAGTATAATC 
TCT 
1,603 
- 
1,630 AT 
16 P TTAGTTAAAGGTCGACTCAATATAA 
AT 
5,485-5,511 hT 
17 CAATCTCGAAGGATCCACCAGCTGC 
A 
8,049 
- 
8,074 hT 
APPENDIX 3 
Cloning and Expression Vectors 
IacZa ATG 
M13 Reverse Primer S p6 Promoter 
CAG GAA ACA GCT ATG AC ATG ATT ACG CCA AGC IFAT TTA GGT GAC ACT ATA GAA 
GTC CTT TGT CGA TAC TG TAC TAA TGC GGT TCG PITA AAT CCA CTG TGA TAT CTT 
Nsi I Hind III Kpn I Sac I BamH I Spe I 
TAC TCA AGC TAT GCA TCA AGC TTG GTA CCG AGC TCGIGAT CCA CTA GTA ACG GCC 
ATG AGT TCG ATA CGT AGT TCG AAC CAT GGC TCG AGC CTA GGT GAT CAT TGC CGG 
BsO(I EcoR I EcoR I EcoR v 
GCC AGT GIG CTG GAA TTC GGC TT Product A GCC GAA TTC TGC AGA TAT 
CGG TCA CAC GAC CTT AAG CCG TT CGG CTT AAG ACG TCT ATA 
BstX I Not I Xho 1 Nsi I Xba I Apa I 
f 
CCA TCA CAC TGG CGG CCG CTC GAG CAT GCAI TCT AGA GGG CCC AAT TCG CCC TAT 
I 
GGT AGr GfG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC IGGG ATA 
T7 Promoter M13 
-201 Forward Primer M13(-401 Forward Primer 
AGT GAG TCG TAT TC AAT TCA CTG GCC GTC GTT TTA C AA T CGT GAC TGG GAA AAC 
TCA AGC ATA A GTTA AGT GAC CGG CAG CAA AAT t' TT GC IA GCA CTG ACC CTT TTG 
+1 
pCR®II 
3.9 kb 
Figure showing the PCRII vector used for cloning PCR products by TA cloning. The 
restriction endonuclease sites surrounding the cloning region are shown along with the 
Sp6 and T7 primer positions. (Taken and modified from the `TA Cloning Kit' instruction 
manual, Invitrogen). 
polylinker 
IacZa 
ma/E 
rmB 
Ptac 
terminator 
pMAL-c2 
pMAL-p2 qm pr 
lacl Q 
ý- 
- 
M13 on 
pBR322 on 
Xmn I &S IR I Ba mH I Xba I $81 1 Pst 1 lünd III 
malE... ATC GAG GGA AGG ATT TCA GAA TTC GGA TCC TCT AGA GTC GAC CTG CAG GCA AGC TTG... lacZa 
lie glu ply a19 ilA 
Factor Xa 
cleavage site 
Figure showing the pMal vectors along with the polylinker sequence. PMaI-c2 is 6,646 
bps and has an exact deletion of the malE signal sequence. PMa1-p2 is 6,721 bps and has 
an intact malE signal sequence allowing periplasmic expression. The arrows indicate the 
direction of transcription. Expression from the pMal vectors allows fusion to a 43 kDa 
Maltose Binding Protein. (Taken and modified from the `Protein Fusion and Purification 
System' instruction manual, New England Biolabs). 
Xho klo 
Eft k+6) 
Not Ipa) 
Mind W(173) 
102 
/ 6y1111241) 
N V Dr8111(Stam ap 
Nds k346) 
. 
ýý Xba 1(3 
l'ý 5411) SQrn 05) 
NN Sph at) 
Pvu 1(4470) ApaB 1(E60) 
S9f 1(4479) 
Sma 1(4353) 
Mpu 1(1171) 
Bd 1(ttgo) 
Nru 1(4136) 
pET-30a(+) e. tE II(, u7) (5422bp) Apa I(1w) 
E0o67 I(3ecs) BaaH II(taM 
NwN 1(3603) Hpa ((1052) 
9Y 
Bai 1( 450) j PSM 1(2021) 
BspLU11I( ' PFl11081(206.7) 
Sep 1(3161) 991 Iwo) Fop 1(22U) Bat11071(301aj/ Psp511(32e3) Tth111 1(3072) 
Bspß 1(2003) 
T7 PICT m«arm« 0034.1 
pr; m. r 06WI4" rte Im 
.. for no I The 
AGATCGATCTCGATCCCGCGAAATTAATACCACTCACTATAGGGQAATTGTQAGCGGATAACAATTCCCCTCTAGAAATAATTTTQTTTAACTTTAAGAAG"" 
AN* I NMMT1Q >l 
_ 
TATACATATGCACCATCATCATCATCATTCTTCTQQTCTQQTQCCACGCQQTTCTQGTATQAAAQAAACCQCTQCTQCTAAATTCQAACQCCACCACATQQACAQCCCAQATCTQ 
MatN+sM+iNtaNlsNlsNlsSerSerGlyLwYe1ºroAroQly3erGIyMatLyaGIYThrAIWleAIaLys/heQIvArj4lnMI*Me*AiPSerrreASPLou 
off (+) N- C-0 I 
6GTACCGACGACCACGACAAQ6CTETMT000ARC TCA TwCýºQTr 
r 
QAC CTTQCQQCCQCACTCQAQCAC ACCACCAC AC A TQAQATCCQQCTQCT 
GtYThrAsPASPA$OAIM. Y$AldlitAleA$P1 IsQIyýle 1A IYL 9aIP IaCysQlyArgihrArqAIarroºreºre/rgrreltuArq{erQlyCyib 
pET 30h(+) AtG' 
p67 3Oc(+) !! AT 
AspLYuL. uA ;; TU l aL. Q l uN I;; -i;; 7; W4 aH I N11-atnd.. . 
OINW1 
Figure showing the pET3Oa expression vector with its polylinker region. This vector 
carries an N-terminal His"Tag configuration (6 histidine residues) plus an optional C- 
terminal His"Tag sequence. The cloning / expression region of the coding strand is 
transcribed by T7 RNA polymerase. (Taken from the `pET System Manual', Novagen 
Inc. ). 
EcoR I( 
Apo N4M 
Cla I(24) 
Aat 1107) Hind 111(29) 
Ssp 1(4449) 1 
Sca 1(4125), 
PVU 1(4015) \ /ý 
ý21 
Pst 1(3N0) 
Eaml l O5 
HE 11(ße) 
pET-3a (4640bp) 
AWN 1(3168) 
BspLU11 1(2752) 
All 111(2752) 
Sap 1(2636) 
Bst11 W 1(2528) 
BsaA I(zaoa) 
ith111 If2497) 
BSRIB 1(2393) 
Pvu 11(2343) 
spul 102 1(468) 
, 
BamH 1(510) 
Nds I(550) 
Xba I(ä88) 
Bg(11(641) 
- 
SgrA 1(687) 
Sph 1(643) 
ECON 1(903) 
v-ý Sal 1(928) 
PshA 1(993) 
Eag I(121m 
-Nru 1(1251) 
Apa81(1329) 
BBpM 1(1331) 
/ eem k1e3e) 
Ava I(17oZ 
MSc ((1723) 
spul 0 I(18U) 
BscG 1(1912) 
T7 p oMwe. r of m 01034t3 
BON 
17 WOWAPOW 10- 
- 
Abe I rim 
AG A TC TC GA TCCC GC GAA AT TAA TACGAC TC AC TAT AGGGA GAC C ACAAC GGT TT CC CTC TA GAAAT AA TTT TGT TT AACTT TA AGAR GGAGA 
ýý pET-3a Bw1i I fipt/11O21 
TATACATATGGCTAGCATGAC? GGTGGACAGCAAATGGGTCGCGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCAC GCTGAGCAATAACTAGCATAA 
MetAlaSerMetThrGlyGlyGlnGlnMetGlyArgGlySerGlyCyöEnd 7712floineW oil 
pET-3b 
... 
GGTCGGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAA 
pET-34 Novi - 
G$yArgArpPrOAt I. I snLvuAlaArgLyaGl uA IcGluLeuAIaAI AI ThrAIaGIUGIfEnd 
TACCATGGCTAGC... pET-3.. d 
... 
GGTCGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAA 
MetAIaSer.. GI Ar, 41 I eAr LeuLauThrL öPr, 4IuAr L e: L suSer Tr LauLeuPr 2ProLeuSer At; nd%; nEnd 
Wwadnow 
CCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG 
PET 3a-d doning/expression region 
Figure showing the pET3a expression vector (Novagen Inc, ). The pET3d vector is the 
same as pET3a with the following exceptions. It 
is a 4637bp plasmid and 2bp have been 
subtracted from each site beyond BamHl at position 510. 
An Ncol site has also been 
substituted for the Ndel site 
in pET3a. By cloning a DNA insert into the Ncol site it is 
possible to bypass the T7 tag and produce an unfused recombinant peptide. 
APPENDIX 4 
Summary of the purified toxin A peptides 
Peptide 
Name 
Expected 
Peptide 
S' kDa 
Actual Peptide 
Size(kDa) 
Length of 
Insert 
DNA (Kb) 
Region of the 
Toxin A Gene 
Covered b 's 
Region of the 
Toxin A Protein 
Covered (aa's) 
A2 99.28* 99.28* + 
64* (truncated) 
1.616 1-1,616 1-536 
B 76.85* 76.85* 0.967 1,618-2,585 542-859 
C 121.33* 121.33* 2.25 335-2,585 114-859 
D 91.51* 91.51* 1.4 2,600-4,000 869-1,330 
E 125.85* 108* 2.382 1,618-4,000 542-(-)1,161 
F 96.24* 96.24* 1.528 3,965-5,493 1,324-1,830 
G 144.01* 144.01 * 2.893 2,600-5,493 869-1,830 
H1 132.67* 132.67* 2.562 5,495-8,057 1,834-2,683 
H2 89.46 89.46 2.568 5,489-8,057 1,832-2,683 
; A' 64.53* 64.53* + 63* 
truncated 
0.615 1-615 1-205 
II 
Truncate 
Toxin : 
56.49 
89.46 
145.95 
56.49 
89.46 
145.95 
1.614 Kb 
2.556 Kb 
4.17 Kb 
1-1,614 
5,505-8,058 
1-538 
1835-2686 
* inclusive of the 43 kDa maltose binding protein. 
A table summarising the sizes of the toxin A peptides and their locations in the toxin A 
molecule (see appendix 1). 
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APPENDIX 6 
Codon Usage Tables 
Phe F UUU 81.8 Ser S UCU 32.1 Tyr Y UAU 80.2 Cys C UGU 82.5 
Phe F UUC 18.2 Ser S UCC 2.1 Tyr Y UAC 19.8 Cys C UGC 17.5 
Leu L UUA 61.4 Ser S UCA 28.0 End 
- 
UAA 66.7 End 
- 
UGA 6.6 
Leu L UUG 11.7 Ser S UCG 0.8 End 
- 
UAG 26.7 Trp W UGG 100 
Leu L CUU 14.2 Pro P CCU 52.2 His H CAU 72.6 Arg R CGU 9.1 
Leu L CUC 1.4 Pro P CCC 0.8 His H CAC 27.4 Arg R CGC 1.7 
Leu L CUA 11.3 Pro P CCA 45.4 Gin Q CAA 83.9 Arg R CGA 5.7 
Ser S CUG 2.4 Pro P CCG 1.6 Gin Q CAG 16.1 Arg R CGG 0.4 
Ile I AUU 37.5 Thr T ACU 54.8 Asn N AAU 85.8 Ser S AGU 29.0 
Ile I AUC 6.4 Thr T ACC 4.7 Asn N AAC 14.2 Ser S AGC 5.7 
Ile I AUA 56.1 Thr T ACA 37.2 Lys K AAA 80.2 Are R AGA 75.7 
Met M AUG 100 Thr T ACG 3.3 Lys K AAG 19.8 Arg R AGG 7.4 
Val V GUU 40.1 Ala A GCU 47.5 Asp D GAU 85.2 Gly G GGU 42.0 
Val V GUC 4.2 Ala A GCC 4.9 Asp D GAC 14.8 Gly G GGC 6.1 
Val V GUA 46.8 Ala A GCA 45.6 Glu E GAA 79.6 Gly G GGA 46.6 
Val V GUG 8.9 Ala A GCG 2.0 Glu E GAG 20.4 Gly G GGG 5.3 
Fields: [amino acid] [symbol] [codon] [% frequency] 
C. dif cile codon usage table. The rarest codons in E. coli gene expression are underlined. 
Taken from NAKAMURA Yasukazu Official Netscape Site 
(httn. //www. d aa. ffrc. go jp/-nakamura/1. E-mail address: akamu cazusa. orjp 
Phe F UUU 56.5 Ser S UCU 8.2 Tyr Y UAU 56.6 Cys C UGU 44.3 
Phe F UUC 43.5 Ser S UCC 8.0 Tyr Y UAC 43.4 Cys C UGC 55.7 
Leu L UUA 25.6 Ser S UCA 6.9 End 
- 
UAA 62.5 End 
- 
UGA 28.1 
Leu L UUG 25.2 Ser S UCG 7.9 End 
- 
UAG 9.4 Trp W UGG 100 
Len L CUU 21.2 Pro P CCU 16.1 His H CAU 56.3 Arg R CGU 37.9 
Leu L CUC 20.5 Pro P CCC 15.1 His H CAC 43.7 Arg R CGC 38.6 
Leu L CUA 7.5 Pro P CCA 19.3 Gln Q CAA 33.6 Arg R CGA 6.5 
Ser S CUG 46.9 Pro P CCG 52.4 Gln Q CAG 66.4 Arg R CGG 9.9 
Ile I AUU 49.8 Thr T ACU 17.4 Asn N AAU 45.1 Ser S AGU 7.9 
Ile I AUC 42.0 Thr T ACC 42.8 Asn N AAC 54.9 Ser S AGC 14.2 
Ile I AUA 8.2 Thr T ACA 13.9 Lys K AAA 75.6 Are R AGA 4.5 
Met M AUG 100 Thr T ACG 25.9 Lys K AAG 24.4 Arg R AGG 2.7 
Val V GUU 26.8 Ala A GCU 17.0 Asp D GAU 62.2 Gly G GGU 34.3 
Val V GUC 21.0 Ala A GCC 26.7 Asp D GAC 37.8 Gly G GGC 39.6 
Val V GUA 15.8 Ala A GCA 21.6 Glu E GAA 68.4 Gly G GtA 11.2 
Val V GUG 36.4 Ala A GCG 34.7 Glu E GAG 31.6 Gly G GGG 14.9 
Fields: [amino acid] [symbol] (codon] [0/q frequency] 
E. coli codon usage table. The rarest codons in E. coli gene expression are underlined. 
Taken from NAKAMURA Yasukazu Official Netscape Site 
(http: //www. dna. affre. go. jp/-'nakamura/). E-mail address: ynakamu@kazusa. or. p. 
APPENDIX 7 
Figure showing the frequency with which the rare E. coli arginine codons AGA and AGG occur within 
toxin A fragment a2. The nucleotide sequence is shown in black, the amino acid sequence is in blue and 
the rare arginine codons are highlighted in red. 
1 ATGTCTTTAA TATCTAAAGA AGAGTTAATA AAACTCGCAT ATAGCATT7C 
MSLISKEELIKLAYSIR 
51 ACCAAGAGAA AATGAGTATA AAACTATACT AACTAATTTA GACGAATATA 
PRENEYKTILTNLDEYN 
101 ATAAGTTAAC TACAAACAAT AATGAAAATA AATATTTACA ATTAAAAAAA 
KLTTNNNENKYLQLKK 
151 CTAAATGAAT CAATTGATGT TTTTATGAAT AAATATAAAA CTTCAAGC, %G 
LNESIDVFMNKYKTSSR 
201 AAATAGAGCA CTCTCTAATC TAAAAAAAGA TATATTAAAA GAAGTAATTC 
NRALSNLKKDILKEVIL 
251 TTATTAAAAA TTCCAATACA AGCCCTGTAG AAAAAAATTT ACATTTTGTA 
IKNSNYSPVEKNLHFV 
301 TGGATAGGTG GAGAAGTCAG TGATATTGCT CTTGAATACA TAAAACAATG 
WIGGEVSDIALEYIKQW 
351 GGCTGATATT AATGCAGAAT ATAATATTAA ACTGTGGTAT GATAGTGAAG 
ADINAEYNIKLWYDSEA 
401 CATTCTTAGT AAATACACTA AAAAAGGCTA TAGTTGAATC TTCTACCACT 
FLVNTLKKAIVESSTT 
451 GAAGCATTAC AGCTACTAGA GGAAGAGATT CAAAATCCTC AATTTGATAA 
EALQLLEEEIQNPQFDN 
501 TATGAAATTT TACAAAAAAA C, GATGGAATT TATATATGAT AGACAAAAAA 
MKFYKKRMEFIYDRQKR 
551 GGTTTATAAA TTATTATAAA TCTCAAATCA ATAAACCTAC AGTACCTACA 
FINYYKSQINKPTVPT 
601 ATAGATGATA TTATAAAGTC TCATCTAGTA TCTGAATATA ATAG;,, GATGA 
IDDIIKSHLVSEYNRDE 
651 AACTGTATTA GAATCATATA GAACAAATTC TTTGAGAAAA ATAAATAGTA 
TVLESYRTNSLRKINSN 
701 ATCATGGGAT AGATATCAGG GCTAATAGTT TGTTTACAGA ACAAGAGTTA 
HGIDIRANSLFTEQEL 
751 TTAAATATTT ATAGTCAGGA GTTGTTAAAT CGTGGAAATT TAGCTGCAGC 
LNIYSQELLNRGNLAAA 
801 ATCTGACATA GTAAGATTAT TAGCCCTAAA AAATTTTGGC GGAGTATATT 
SDIVRLLALKNFGGVYL 
851 TAGATGTTGA TATGCTTCCA GGTATTCACT CTGATTTATT TAAAACAATA 
DVDMLPGIHSDLFKTI 
901 TCTAGACCTA GCTCTATTGG ACTAGACCGT TGGGAAATGA TAAAATTAGA 
SRPSSIGLDRWEMIKLE 
951 GGCTATTATG AAGTATAAAA AATATATAAA TAATTATACA TCAGAAAACT 
AIMKYKKYINNYTSENF 
1001 TTGATAAACT TGATCAACAA TTAAAAGATA ATTTTAAACT CATTATAGAA 
DKLDQQLKDNFKLIIE 
1051 AGTAAAAGTG AAAAATCTGA GATATTTTCT AAATTAGAAA ATTTAAATGT 
SKSEKSEIFSKLENLNV 
1101 ATCTGATCTT GAAATTAAAA TAGCTTTCGC TTTAGGCAGT GTTATAAATC 
SDLEIKIAFALGSVINQ 
1151 AAGCCTTGAT ATCAAAACAA GGTTCATATC TTACTAACCT AGTAATAGAA 
ALISKQGSYLTNLVIE 
1201 CAAGTAAAAA ATA'ATATCA ATTTTTAAAC CAACACCTTA ACCCAGCCAT 
QVKN.. YQFLNQHLNPAI 
1251 AGAGTCTGAT AATAACTTCA CAGATACTAC TAAAATTTTT CATGATTCAT 
ESDNNFTDTTKIFHDSL 
1301 TATTTAATTC AGCTACCGCA GAAAACTCTA TGTTTTTAAC AAAAATAGCA 
FNSATAENSMFLTKIA 
1351 CCATACTTAC AAGTAGGTTT TATGCCAGAA GCTCGCTCCA CAATAAGTTT 
PYLQVGFMPEARSTISL 
1401 AAGTGGTCCA GGAGCTTATG CGTCAGCTTA CTATGATTTC ATAAATTTAC 
SGPGAYASAYYDFINLQ 
1451 AAGAAAATAC TATAGAAAAA ACTTTAAAAG CATCAGATTT AATAGAATTT 
ENTIEKTLKASDLIEF 
1501 AAATTCCCAG AAAATAATCT ATCTCAATTG ACAGAACAAG AAATAAATAG 
KFPENNLSQLTEQEINS 
1551 TCTATGGAGC TTTGATCAAG CAAGTGCAAA ATATCAATTT GAGAAATATG 
LWSFDQASAKYQFEKYV 
1601 TAAGAGATTA TACTGGT 
RDYTG 
APPENDIX 8 
The surface exposed and hydrophobic domains of holotoxin A 
N 
KEY: 
Hydrophilic domains 
® 
Amino acids 1-541 
Hydrophobic domains 
F1 
Amino acids 542-1,161 
Amino acids 1.162-1.324 
Amino acids 1,832-2.683 
Q 
Amino acids 1,325-1,830 
A diagrammatic representation of the predicted hydrophobic domains of 
holotoxin A as determined by antibody reaction profiles. At least part of each of 
the hydrophilic domains shown above is surface exposed in the native toxin A 
molecule having cross-reacted with polyclonal anti-formalised toxin A 
antiserum. 
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